acute O
insulin O
treatment O
normalizes O
the O
resistance O
to O
the O
cardiotoxic B-NEG
effect O
of O
isoproterenol O
in O
streptozotocin O
diabetic B-NEG
rats O
. O

a O
morphometric O
study O
of O
isoproterenol O
induced O
myocardial O
fibrosis B-NEG
. O

the O
acute O
effect O
of O
insulin O
treatment O
on O
the O
earlier O
reported O
protective O
effect O
of O
streptozotocin O
diabetes B-NEG
against O
the O
cardiotoxic B-NEG
effect O
of O
high O
doses O
of O
isoproterenol O
( O
iso O
) O
was O
investigated O
in O
rats O
. O

thirty O
to O
135 O
min O
after O
the O
injection O
of O
crystalline O
insulin O
, O
iso O
was O
given O
subcutaneously O
and O
when O
iso O
induced O
fibrosis B-NEG
in O
the O
myocardium O
was O
morphometrically O
analyzed O
7 O
days O
later O
, O
a O
highly O
significant O
correlation O
(r O
= O
0.83 O
, O
2 O
p O
= O
0.006 O
) O
to O
the O
slope O
of O
the O
fall O
in O
blood O
glucose O
after O
insulin O
treatment O
appeared O
. O

the O
myocardial O
content O
of O
catecholamines O
was O
estimated O
in O
these O
8 O
day O
diabetic B-NEG
rats O
. O

the O
norepinephrine O
content O
was O
significantly O
increased O
while O
epinephrine O
remained O
unchanged O
. O

an O
enhanced O
sympathetic O
nervous O
system O
activity O
with O
a O
consequent O
down O
regulation O
of O
the O
myocardial O
beta-adrenergic O
receptors O
could O
, O
therefore O
, O
explain O
this O
catecholamine O
resistance O
. O

the O
rapid O
reversion O
after O
insulin O
treatment O
excludes O
the O
possibility O
that O
streptozotocin O
in O
itself O
causes O
the O
iso O
resistance O
and O
points O
towards O
a O
direct O
insulin O
effect O
on O
myocardial O
catecholamine O
sensitivity O
in O
diabetic B-NEG
rats O
. O

the O
phenomenon O
described O
might O
elucidate O
pathogenetic O
mechanisms O
behind O
toxic O
myocardial O
cell O
degeneration O
and O
may O
possibly O
have O
relevance O
for O
acute O
cardiovascular O
complications O
in O
diabetic B-NEG
patients O
. O

-DOCSTART- O

differential O
effects O
of O
non-steroidal O
anti-inflammatory O
drugs O
on O
seizures B-NEG
produced O
by O
pilocarpine O
in O
rats O
. O

the O
muscarinic O
cholinergic O
agonist O
pilocarpine O
induces O
in O
rats O
seizures B-NEG
and O
status B-NEG
epilepticus I-NEG
followed O
by O
widespread O
damage O
to O
the O
forebrain O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non-steroidal O
anti-inflammatory O
drugs O
, O
sodium O
salicylate O
, O
phenylbutazone O
, O
indomethacin O
, O
ibuprofen O
and O
mefenamic O
acid O
, O
on O
seizures B-NEG
produced O
by O
pilocarpine O
. O

pretreatment O
of O
rats O
with O
sodium O
salicylate O
, O
ed50 O
103 O
mg/kg O
(60-174) O
, O
and O
phenylbutazone O
, O
59 O
mg/kg O
( O
50-70 O
) O
converted O
the O
non-convulsant O
dose O
of O
pilocarpine O
, O
200 O
mg/kg O
, O
to O
a O
convulsant O
one O
. O

indomethacin O
, O
1-10 O
mg/kg O
, O
and O
ibuprofen O
, O
10-100 O
mg/kg O
, O
failed O
to O
modulate O
seizures B-NEG
produced O
by O
pilocarpine O
. O

mefenamic O
acid O
, O
26 O
( O
22-30 O
) O
mg/kg O
, O
prevented O
seizures B-NEG
and O
protected O
rats O
from O
seizure B-NEG
-related O
brain B-NEG
damage I-NEG
induced O
by O
pilocarpine O
, O
380 O
mg/kg O
. O

these O
results O
indicate O
that O
non-steroidal O
anti-inflammatory O
drugs O
differentially O
modulate O
the O
threshold O
for O
pilocarpine-induced O
seizures B-NEG
. O

-DOCSTART- O

acute B-NEG
neurologic I-NEG
dysfunction I-NEG
after O
high-dose O
etoposide O
therapy O
for O
malignant B-NEG
glioma I-NEG
. O

etoposide O
( O
vp-16-213 O
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors B-NEG
and O
hematologic B-NEG
malignancies I-NEG
. O

when O
used O
in O
high O
doses O
and O
in O
conjunction O
with O
autologous O
bone O
marrow O
transplantation O
, O
this O
agent O
has O
activity O
against O
several O
treatment-resistant O
cancers B-NEG
including O
malignant B-NEG
glioma I-NEG
. O

in O
six O
of O
eight O
patients O
( O
75% O
) O
who O
we O
treated O
for O
recurrent O
or O
resistant O
glioma B-NEG
, O
sudden O
severe O
neurologic B-NEG
deterioration I-NEG
occurred O
. O

this O
developed O
a O
median O
of O
9 O
days O
after O
initiation O
of O
high-dose O
etoposide O
therapy O
. O

significant O
clinical O
manifestations O
have O
included O
confusion B-NEG
, O
papilledema B-NEG
, O
somnolence B-NEG
, O
exacerbation O
of O
motor B-NEG
deficits I-NEG
, O
and O
sharp O
increase O
in O
seizure B-NEG
activity O
. O

these O
abnormalities O
resolved O
rapidly O
after O
initiation O
of O
high-dose O
intravenous O
dexamethasone O
therapy O
. O

in O
all O
patients O
, O
computerized O
tomographic O
( O
ct O
) O
brain O
scans O
demonstrated O
stability O
in O
tumor B-NEG
size O
and O
peritumor O
edema B-NEG
when O
compared O
with O
pretransplant O
scans O
. O

this O
complication O
appears O
to O
represent O
a O
significant O
new O
toxicity B-NEG
of O
high-dose O
etoposide O
therapy O
for O
malignant B-NEG
glioma I-NEG
. O

-DOCSTART- O

progressive O
bile B-NEG
duct I-NEG
injury I-NEG
after O
thiabendazole O
administration O
. O

a O
27-yr-old O
man O
developed O
jaundice B-NEG
2 O
wk O
after O
exposure O
to O
thiabendazole O
. O
cholestasis B-NEG
persisted O
for O
3 O
yr O
, O
at O
which O
time O
a O
liver O
transplant O
was O
performed O
. O

two O
liver O
biopsy O
specimens O
and O
the O
hepatectomy O
specimen O
were O
remarkable O
for O
almost O
complete O
disappearance O
of O
interlobular O
bile O
ducts O
. O

prominent O
fibrosis B-NEG
and O
hepatocellular O
regeneration O
were O
also O
present O
; O
however O
, O
the O
lobular O
architecture O
was O
preserved O
. O

this O
case O
represents O
an O
example O
of O
idiosyncratic O
drug-induced B-NEG
liver I-NEG
damage I-NEG
in O
which O
the O
primary O
target O
of O
injury O
is O
the O
bile O
duct O
. O

an O
autoimmune O
pathogenesis O
of O
the O
bile B-NEG
duct I-NEG
destruction I-NEG
is O
suggested O
. O

-DOCSTART- O

differential O
effects O
of O
1,4-dihydropyridine O
calcium O
channel O
blockers O
: O
therapeutic O
implications O
. O

increasing O
recognition O
of O
the O
importance O
of O
calcium O
in O
the O
pathogenesis O
of O
cardiovascular B-NEG
disease I-NEG
has O
stimulated O
research O
into O
the O
use O
of O
calcium O
channel O
blocking O
agents O
for O
treatment O
of O
a O
variety O
of O
cardiovascular B-NEG
diseases I-NEG
. O

the O
favorable O
efficacy O
and O
tolerability O
profiles O
of O
these O
agents O
make O
them O
attractive O
therapeutic O
modalities O
. O

clinical O
applications O
of O
calcium O
channel O
blockers O
parallel O
their O
tissue O
selectivity O
. O

in O
contrast O
to O
verapamil O
and O
diltiazem O
, O
which O
are O
roughly O
equipotent O
in O
their O
actions O
on O
the O
heart O
and O
vascular O
smooth O
muscle O
, O
the O
dihydropyridine O
calcium O
channel O
blockers O
are O
a O
group O
of O
potent O
peripheral O
vasodilator O
agents O
that O
exert O
minimal O
electrophysiologic O
effects O
on O
cardiac O
nodal O
or O
conduction O
tissue O
. O

as O
the O
first O
dihydropyridine O
available O
for O
use O
in O
the O
united O
states O
, O
nifedipine O
controls O
angina B-NEG
and O
hypertension B-NEG
with O
minimal O
depression O
of O
cardiac O
function O
. O

additional O
members O
of O
this O
group O
of O
calcium O
channel O
blockers O
have O
been O
studied O
for O
a O
variety O
of O
indications O
for O
which O
they O
may O
offer O
advantages O
over O
current O
therapy O
. O

once O
or O
twice O
daily O
dosage O
possible O
with O
nitrendipine O
and O
nisoldipine O
offers O
a O
convenient O
administration O
schedule O
, O
which O
encourages O
patient O
compliance O
in O
long-term O
therapy O
of O
hypertension B-NEG
. O

the O
coronary O
vasodilating O
properties O
of O
nisoldipine O
have O
led O
to O
the O
investigation O
of O
this O
agent O
for O
use O
in O
angina B-NEG
. O

selectivity O
for O
the O
cerebrovascular O
bed O
makes O
nimodipine O
potentially O
useful O
in O
the O
treatment O
of O
subarachnoid B-NEG
hemorrhage I-NEG
, O
migraine B-NEG
headache I-NEG
, O
dementia B-NEG
, O
and O
stroke B-NEG
. O

in O
general O
, O
the O
dihydropyridine O
calcium O
channel O
blockers O
are O
usually O
well O
tolerated O
, O
with O
headache B-NEG
, O
facial O
flushing B-NEG
, O
palpitations B-NEG
, O
edema B-NEG
, O
nausea B-NEG
, O
anorexia B-NEG
, O
and O
dizziness B-NEG
being O
the O
more O
common O
adverse O
effects O
. O

-DOCSTART- O

the O
enhancement O
of O
aminonucleoside O
nephrosis B-NEG
by O
the O
co-administration O
of O
protamine O
. O

an O
experimental O
model O
of O
focal B-NEG
segmental I-NEG
glomerular I-NEG
sclerosis I-NEG
( O
fsgs B-NEG
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin-aminonucleoside O
( O
amns O
) O
and O
protamine O
sulfate O
(ps) O
. O

male O
sprague-dawley O
rats O
, O
uninephrectomized O
three O
weeks O
before O
, O
received O
daily O
injections O
of O
subcutaneous O
amns O
(1 O
mg/100 O
g O
body O
wt O
) O
and O
intravenous O
ps O
(2 O
separated O
doses O
of O
2.5 O
mg/100 O
g O
body O
wt O
) O
for O
four O
days O
. O

the O
series O
of O
injections O
were O
repeated O
another O
three O
times O
at O
10 O
day O
intervals O
. O

the O
animals O
were O
sacrificed O
on O
days O
24 O
, O
52 O
, O
and O
80 O
. O

they O
developed O
nephrotic B-NEG
syndrome I-NEG
and O
finally O
renal B-NEG
failure I-NEG
. O

the O
time-course O
curve O
of O
creatinine O
clearance O
dropped O
and O
showed O
significant O
difference O
(p O
less O
than O
0.01 O
) O
from O
that O
of O
each O
control O
group O
, O
such O
as O
, O
amns O
alone O
, O
ps O
alone O
or O
saline O
injected O
. O

their O
glomeruli O
showed O
changes O
of O
progressive O
fsgs B-NEG
. O

the O
ultrastructural O
studies O
in O
the O
initial O
stage O
revealed O
significant O
lack O
of O
particles O
of O
perfused O
ruthenium O
red O
on O
the O
lamina O
rara O
externa O
and O
marked O
changes O
in O
epithelial O
cell O
cytoplasm O
. O

therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
ps O
enhances O
the O
toxicity B-NEG
of O
amns O
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
fsgs B-NEG
in O
rats O
resulting O
in O
the O
end-stage B-NEG
renal I-NEG
disease I-NEG
. O

-DOCSTART- O

theophylline O
neurotoxicity B-NEG
in O
pregnant O
rats O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
neurotoxicity B-NEG
of O
theophylline O
is O
altered O
in O
advanced O
pregnancy O
. O

sprague-dawley O
rats O
that O
were O
20 O
days O
pregnant O
and O
nonpregnant O
rats O
of O
the O
same O
age O
and O
strain O
received O
infusions O
of O
aminophylline O
until O
onset O
of O
maximal O
seizures B-NEG
which O
occurred O
after O
28 O
and O
30 O
minutes O
respectively O
. O

theophylline O
concentrations O
at O
this O
endpoint O
in O
serum O
( O
total O
) O
and O
csf O
were O
similar O
but O
serum O
( O
free O
) O
and O
brain O
concentrations O
were O
slightly O
different O
in O
pregnant O
rats O
. O

theophylline O
serum O
protein O
binding O
determined O
by O
equilibrium O
dialysis O
was O
lower O
in O
pregnant O
rats O
. O

fetal O
serum O
concentrations O
at O
onset O
of O
seizures B-NEG
in O
the O
mother O
were O
similar O
to O
maternal O
brain O
and O
csf O
concentrations O
and O
correlated O
significantly O
with O
the O
former O
. O

it O
is O
concluded O
that O
advanced O
pregnancy O
has O
a O
negligible O
effect O
on O
the O
neurotoxic B-NEG
response O
to O
theophylline O
in O
rats O
. O

-DOCSTART- O

hyperkalemia B-NEG
induced O
by O
indomethacin O
and O
naproxen O
and O
reversed O
by O
fludrocortisone O
. O

we O
have O
described O
a O
patient O
with O
severe O
rheumatoid B-NEG
arthritis I-NEG
and O
a O
history O
of O
mefenamic O
acid O
nephropathy B-NEG
in O
whom O
hyperkalemia B-NEG
and O
inappropriate O
hypoaldosteronism B-NEG
were O
caused O
by O
both O
indomethacin O
and O
naproxen O
, O
without O
major O
decline O
in O
renal O
function O
. O

it O
is O
likely O
that O
preexisting O
renal B-NEG
disease I-NEG
predisposed O
this O
patient O
to O
type B-NEG
iv I-NEG
renal I-NEG
tubular I-NEG
acidosis I-NEG
with O
prostaglandin O
synthetase O
inhibitors O
. O

because O
he O
was O
unable O
to O
discontinue O
nonsteroidal O
anti-inflammatory O
drug O
therapy O
, O
fludrocortisone O
was O
added O
, O
correcting O
the O
hyperkalemia B-NEG
and O
allowing O
indomethacin O
therapy O
to O
be O
continued O
safely O
. O

-DOCSTART- O

hypotension B-NEG
as O
a O
manifestation O
of O
cardiotoxicity B-NEG
in O
three O
patients O
receiving O
cisplatin O
and O
5-fluorouracil O
. O

cardiac O
symptoms O
, O
including O
hypotension B-NEG
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal B-NEG
carcinoma I-NEG
while O
being O
treated O
with O
cisplatin O
( O
cddp O
) O
and O
5-fluorouracil O
(5-fu) O
. O

in O
two O
patients O
, O
hypotension B-NEG
was O
associated O
with O
severe O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
. O

all O
three O
patients O
required O
therapy O
discontinuation O
. O

cardiac O
enzymes O
remained O
normal O
despite O
transient O
electrocardiographic O
( O
ekg O
) O
changes O
. O

the O
presentation O
and O
cardiac O
evaluation O
(hemodynamic O
, O
echocardiographic O
, O
and O
scintigraphic O
) O
of O
these O
patients O
suggest O
new O
manifestations O
of O
5-fu O
cardiotoxicity B-NEG
that O
may O
be O
influenced O
by O
cddp O
. O

the O
possible O
pathophysiologic O
mechanisms O
are O
discussed O
. O

-DOCSTART- O

fatal O
aplastic B-NEG
anemia I-NEG
in O
a O
patient O
treated O
with O
carbamazepine O
. O

a O
case O
of O
fatal O
aplastic B-NEG
anemia I-NEG
due O
to O
carbamazepine O
treatment O
in O
an O
epileptic B-NEG
woman O
is O
reported O
. O

despite O
concerns O
of O
fatal O
bone B-NEG
marrow I-NEG
toxicity I-NEG
due O
to O
carbamazepine O
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

carbamazepine O
is O
a O
safe O
drug O
, O
but O
physicians O
and O
patients O
should O
be O
aware O
of O
the O
exceedingly O
rare O
but O
potentially O
fatal O
side O
effects O
, O
better O
prevented O
by O
clinical O
than O
by O
laboratory O
monitoring O
. O

-DOCSTART- O

participation O
of O
a O
bulbospinal O
serotonergic O
pathway O
in O
the O
rat O
brain O
in O
clonidine-induced O
hypotension B-NEG
and O
bradycardia B-NEG
. O

the O
effects O
of O
microinjection O
of O
clonidine O
( O
1-10 O
micrograms O
in O
1 O
microliter O
) O
into O
a O
region O
adjacent O
to O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
on O
cardiovascular O
function O
were O
assessed O
in O
urethane-anesthetized O
rats O
. O

intramedullary O
administration O
of O
clonidine O
, O
but O
not O
saline O
vehicle O
, O
caused O
a O
dose-dependent O
decrease O
in O
both O
the O
mean O
arterial O
pressure O
and O
the O
heart O
rate O
. O

the O
clonidine-induced O
hypotension B-NEG
was O
antagonized O
by O
prior O
spinal O
transection O
, O
but O
not O
bilateral O
vagotomy O
. O

on O
the O
other O
hand O
, O
the O
clonidine-induced O
bradycardia B-NEG
was O
antagonized O
by O
prior O
bilateral O
vagotomy O
, O
but O
not O
spinal O
transection O
. O

furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5-ht O
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5,7-dihydroxytryptamine O
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac B-NEG
responses O
to O
clonidine O
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

the O
data O
indicate O
that O
a O
bulbospinal O
serotonergic O
pathway O
is O
involved O
in O
development O
of O
clonidine-induced O
hypotension B-NEG
and O
bradycardia B-NEG
. O

the O
induced O
hypotension B-NEG
is O
brought O
about O
by O
a O
decrease O
in O
sympathetic O
efferent O
activity O
, O
whereas O
the O
induced O
bradycardia B-NEG
was O
due O
to O
an O
increase O
in O
vagal O
efferent O
activity O
. O

-DOCSTART- O

hypertension B-NEG
in O
neuroblastoma B-NEG
induced O
by O
imipramine O
. O
hypertension B-NEG
is O
a O
well-known O
finding O
in O
some O
patients O
with O
neuroblastoma B-NEG
. O

however O
, O
it O
has O
not O
previously O
been O
described O
in O
association O
with O
the O
use O
of O
imipramine O
. O

we O
report O
the O
occurrence O
of O
severe O
hypertension B-NEG
( O
blood O
pressure O
190/160 O
) O
in O
a O
4-year-old O
girl O
with O
neuroblastoma B-NEG
who O
was O
given O
imipramine O
to O
control O
a O
behavior B-NEG
disorder I-NEG
. O

it O
was O
determined O
later O
that O
this O
patient's O
tumor B-NEG
was O
recurring O
at O
the O
time O
of O
her O
hypertensive B-NEG
episode O
. O

since O
she O
had O
no O
blood O
pressure O
elevation O
at O
initial O
diagnosis O
and O
none O
following O
discontinuation O
of O
the O
imipramine O
( O
when O
she O
was O
in O
florid O
relapse) O
, O
we O
believe O
that O
this O
drug O
rather O
than O
her O
underlying O
disease O
alone O
caused O
her O
hypertension B-NEG
. O

the O
mechanism O
for O
this O
reaction O
is O
believed O
to O
be O
increased O
levels O
of O
vasoactive O
catecholamines O
due O
to O
interference O
of O
their O
physiologic O
inactivation O
by O
imipramine O
. O

from O
this O
experience O
, O
we O
urge O
extreme O
caution O
in O
the O
use O
of O
tricyclic O
antidepressants O
in O
children O
with O
active O
neuroblastoma B-NEG
. O

-DOCSTART- O

rechallenge O
of O
patients O
who O
developed O
oral B-NEG
candidiasis I-NEG
or O
hoarseness B-NEG
with O
beclomethasone O
dipropionate O
. O

of O
158 O
asthmatic B-NEG
patients O
who O
were O
placed O
on O
inhaled O
beclomethasone O
, O
15 O
( O
9.5% O
) O
developed O
either O
hoarseness B-NEG
(8) O
, O
oral O
thrush B-NEG
(6) O
, O
or O
both O
(1) O
. O

when O
their O
adverse O
reactions O
subsided O
, O
seven O
of O
these O
15 O
patients O
were O
rechallenged O
with O
inhaled O
beclomethasone O
. O

these O
included O
five O
cases O
who O
developed O
hoarseness B-NEG
and O
three O
who O
developed O
candidiasis B-NEG
. O

one O
patient O
had O
both O
. O

oral O
thrush B-NEG
did O
not O
recur O
, O
but O
60% O
( O
3/5 O
) O
of O
patients O
with O
hoarseness B-NEG
had O
recurrence O
. O

we O
conclude O
that O
patients O
may O
be O
restarted O
on O
inhaled O
beclomethasone O
when O
clinically O
indicated O
; O
however O
, O
because O
of O
the O
high O
recurrence O
rate O
, O
patients O
who O
develop O
hoarseness B-NEG
should O
not O
be O
re-challenged O
. O

concomitant O
use O
of O
oral O
prednisone O
and O
topical O
beclomethasone O
may O
increase O
the O
risk O
of O
developing O
hoarseness B-NEG
or O
candidiasis B-NEG
. O

-DOCSTART- O

cyclophosphamide O
cardiotoxicity B-NEG
: O
an O
analysis O
of O
dosing O
as O
a O
risk O
factor O
. O

patients O
who O
undergo O
bone O
marrow O
transplantation O
are O
generally O
immunosuppressed O
with O
a O
dose O
of O
cyclophosphamide O
( O
cya O
) O
which O
is O
usually O
calculated O
based O
on O
the O
patient's O
weight O
. O

at O
these O
high O
doses O
of O
cya O
, O
serious O
cardiotoxicity B-NEG
may O
occur O
, O
but O
definitive O
risk O
factors O
for O
the O
development O
of O
such O
cardiotoxicity B-NEG
have O
not O
been O
described O
. O

since O
chemotherapeutic O
agent O
toxicity B-NEG
generally O
correlates O
with O
dose O
per O
body O
surface O
area O
, O
we O
retrospectively O
calculated O
the O
dose O
of O
cya O
in O
patients O
transplanted O
at O
our O
institution O
to O
determine O
whether O
the O
incidence O
of O
cya O
cardiotoxicity B-NEG
correlated O
with O
the O
dose O
per O
body O
surface O
area O
. O

eighty O
patients O
who O
were O
to O
receive O
cya O
50 O
mg/kg/d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic B-NEG
anemia I-NEG
, O
wiskott-aldrich B-NEG
syndrome I-NEG
, O
or O
severe B-NEG
combined I-NEG
immunodeficiency I-NEG
syndrome I-NEG
. O

fourteen O
of O
84 O
( O
17% O
) O
patients O
had O
symptoms O
and O
signs O
consistent O
with O
cya O
cardiotoxicity B-NEG
within O
ten O
days O
of O
receiving O
1 O
to O
4 O
doses O
of O
cya O
. O

six O
of O
the O
14 O
patients O
died O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

the O
dose O
of O
cya O
per O
body O
surface O
area O
was O
calculated O
for O
all O
patients O
and O
the O
patients O
were O
divided O
into O
two O
groups O
based O
on O
daily O
cya O
dose O
: O
group O
1, O
cya O
less O
than O
or O
equal O
to O
1.55 O
g/m2/d O
; O
group O
2, O
cya O
greater O
than O
1.55 O
g/m2/d O
. O
cardiotoxicity B-NEG
that O
was O
thought O
to O
be O
related O
to O
cya O
occurred O
in O
1/32 O
( O
3% O
) O
of O
patients O
in O
group O
1 O
and O
in O
13/52 O
( O
25% O
) O
patients O
in O
group O
2 O
(p O
less O
than O
0.025) O
. O
congestive B-NEG
heart I-NEG
failure I-NEG
caused O
or O
contributed O
to O
death O
in O
0/32 O
patients O
in O
group O
1 O
v O
6/52 O
( O
12% O
) O
of O
patients O
in O
group O
2 O
(p O
less O
than O
0.25) O
. O

there O
was O
no O
difference O
in O
the O
rate O
of O
engraftment O
of O
evaluable O
patients O
in O
the O
two O
groups O
(p O
greater O
than O
0.5) O
. O

we O
conclude O
that O
the O
cya O
cardiotoxicity B-NEG
correlates O
with O
cya O
dosage O
as O
calculated O
by O
body O
surface O
area O
, O
and O
that O
patients O
with O
aplastic B-NEG
anemia I-NEG
and O
immunodeficiencies B-NEG
can O
be O
effectively O
prepared O
for O
bone O
marrow O
grafting O
at O
a O
cya O
dose O
of O
1.55 O
g/m2/d O
for O
four O
days O
with O
a O
lower O
incidence O
of O
cardiotoxicity B-NEG
than O
patients O
whose O
cya O
dosage O
is O
calculated O
based O
on O
weight O
. O

this O
study O
reaffirms O
the O
principle O
that O
drug O
toxicity B-NEG
correlates O
with O
dose O
per O
body O
surface O
area O
. O

-DOCSTART- O

studies O
of O
risk O
factors O
for O
aminoglycoside O
nephrotoxicity B-NEG
. O

the O
epidemiology O
of O
aminoglycoside-induced O
nephrotoxicity B-NEG
is O
not O
fully O
understood O
. O

experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides O
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular B-NEG
or I-NEG
tubular I-NEG
dysfunction I-NEG
. O

clinical O
trials O
of O
aminoglycosides O
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute B-NEG
renal I-NEG
failure I-NEG
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70% O
to O
80% O
. O

further O
analysis O
of O
these O
data O
suggests O
that O
the O
duration O
of O
therapy O
, O
plasma O
aminoglycoside O
levels O
, O
liver B-NEG
disease I-NEG
, O
advanced O
age O
, O
high O
initial O
estimated O
creatinine O
clearance O
and O
, O
possibly O
, O
female O
gender O
all O
increase O
the O
risk O
for O
nephrotoxicity B-NEG
. O

other O
causes O
of O
acute B-NEG
renal I-NEG
failure I-NEG
, O
such O
as O
shock B-NEG
, O
appear O
to O
have O
an O
additive O
effect O
. O

predictive O
models O
have O
been O
developed O
from O
these O
analyses O
that O
should O
be O
useful O
for O
identifying O
patients O
at O
high O
risk O
. O

these O
models O
may O
also O
be O
useful O
in O
developing O
insights O
into O
the O
pathophysiology O
of O
aminoglycoside-induced O
nephrotoxicity B-NEG
. O

-DOCSTART- O

flurothyl O
seizure B-NEG
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium O
glutamate O
(msg) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl O
seizure B-NEG
testing O
. O

monosodium O
glutamate O
( O
msg O
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions B-NEG
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

these O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
msg O
produced O
permanent O
alterations O
in O
seizure B-NEG
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

a O
flurothyl O
ether O
seizure B-NEG
screening O
technique O
was O
used O
to O
evaluate O
seizure B-NEG
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
msg O
(4 O
mg/g O
and O
1 O
mg/g) O
. O

msg O
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure B-NEG
threshold O
. O

a O
naloxone O
(5 O
mg/kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure B-NEG
thresholds O
of O
either O
control O
of O
msg-treated O
mice O
. O

flurothyl O
ether O
produced O
hypothermia B-NEG
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl O
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia B-NEG
to O
seizure B-NEG
induction O
was O
unclear O
. O

flurothyl O
seizure B-NEG
testing O
proved O
to O
be O
a O
rapid O
and O
reliable O
technique O
with O
which O
to O
evaluate O
seizure B-NEG
susceptibility O
. O

-DOCSTART- O

susceptibility O
to O
seizures B-NEG
produced O
by O
pilocarpine O
in O
rats O
after O
microinjection O
of O
isoniazid O
or O
gamma-vinyl-gaba O
into O
the O
substantia O
nigra O
. O

pilocarpine O
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive B-NEG
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures B-NEG
within O
the O
forebrain O
. O

in O
the O
present O
study O
, O
the O
effects O
of O
manipulating O
the O
activity O
of O
the O
gamma-aminobutyric O
acid O
( O
gaba)-mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
on O
seizures B-NEG
produced O
by O
pilocarpine O
in O
rats O
, O
were O
investigated O
. O

in O
animals O
pretreated O
with O
microinjections O
of O
isoniazid O
, O
150 O
micrograms O
, O
an O
inhibitor O
of O
activity O
of O
the O
gaba-synthesizing O
enzyme O
, O
l-glutamic O
acid O
decarboxylase O
, O
into O
the O
substantia O
nigra O
pars O
reticulata O
(snr) O
, O
bilaterally O
, O
non-convulsant O
doses O
of O
pilocarpine O
, O
100 O
and O
200 O
mg/kg O
, O
resulted O
in O
severe O
motor O
limbic O
seizures B-NEG
and O
status B-NEG
epilepticus I-NEG
. O

electroencephalographic O
and O
behavioral O
monitoring O
revealed O
a O
profound O
reduction O
of O
the O
threshold O
for O
pilocarpine-induced O
convulsions B-NEG
. O

morphological O
analysis O
of O
frontal O
forebrain O
sections O
with O
light O
microscopy O
revealed O
seizure B-NEG
-related O
damage O
to O
the O
hippocampal O
formation O
, O
thalamus O
, O
amygdala O
, O
olfactory O
cortex O
, O
substantia O
nigra O
and O
neocortex O
, O
which O
is O
typically O
observed O
with O
pilocarpine O
in O
doses O
exceeding O
350 O
mg/kg O
. O

bilateral O
intrastriatal O
injections O
of O
isoniazid O
did O
not O
augment O
seizures B-NEG
produced O
by O
pilocarpine O
, O
200 O
mg/kg O
. O

application O
of O
an O
irreversible O
inhibitor O
of O
gaba O
transaminase O
, O
gamma-vinyl-gaba O
( O
d,l-4-amino-hex-5-enoic O
acid) O
, O
5 O
micrograms O
, O
into O
the O
snr O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures B-NEG
produced O
by O
pilocarpine O
, O
380 O
mg/kg O
. O

this O
treatment O
was O
also O
sufficient O
to O
protect O
animals O
from O
the O
occurrence O
of O
brain B-NEG
damage I-NEG
. O

microinjections O
of O
gamma-vinyl-gaba O
, O
5 O
micrograms O
, O
into O
the O
dorsal O
striatum O
, O
bilaterally O
, O
failed O
to O
prevent O
the O
development O
of O
convulsions B-NEG
produced O
by O
pilocarpine O
, O
380 O
mg/kg O
. O

the O
results O
demonstrate O
that O
the O
threshold O
for O
pilocarpine-induced O
seizures B-NEG
in O
rats O
is O
subjected O
to O
the O
regulation O
of O
the O
gaba-mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
. O

-DOCSTART- O

non-invasive O
detection O
of O
coronary B-NEG
artery I-NEG
disease I-NEG
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole O
infusion O
. O

electrocardiographic O
changes O
after O
dipyridamole O
infusion O
( O
0.568 O
mg/kg/4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B-NEG
infarction I-NEG
( O
non- O
mi B-NEG
group) O
, O
14 O
with O
anterior B-NEG
infarction I-NEG
( O
ant-mi B-NEG
) O
and O
eight O
with O
inferior B-NEG
infarction I-NEG
( O
inf-mi B-NEG
). O

eighty-seven O
unipolar O
electrocardiograms O
( O
ecgs O
) O
distributed O
over O
the O
entire O
thoracic O
surface O
were O
simultaneously O
recorded O
. O

after O
dipyridamole O
, O
ischemic B-NEG
st-segment O
depression B-NEG
( O
0.05 O
mv O
or O
more O
) O
was O
observed O
in O
84% O
of O
the O
non- O
mi B-NEG
group O
, O
29% O
of O
the O
ant-mi B-NEG
group O
, O
63% O
of O
the O
inf-mi B-NEG
group O
and O
61% O
of O
the O
total O
population O
. O

exercise-induced O
st O
depression B-NEG
was O
observed O
in O
84% O
of O
the O
non- O
mi B-NEG
group O
, O
43% O
of O
the O
ant-mi B-NEG
group O
, O
38% O
of O
the O
inf-mi B-NEG
group O
and O
61% O
of O
the O
total O
. O

for O
individual O
patients O
, O
there O
were O
no O
obvious O
differences O
between O
the O
body O
surface O
distribution O
of O
st O
depression B-NEG
in O
both O
tests O
. O

the O
increase O
in O
pressure O
rate O
product O
after O
dipyridamole O
was O
significantly O
less O
than O
that O
during O
the O
treadmill O
exercise O
. O

the O
data O
suggest O
that O
the O
dipyridamole-induced O
myocardial B-NEG
ischemia I-NEG
is O
caused O
by O
the O
inhomogenous O
distribution O
of O
myocardial O
blood O
flow O
. O

we O
conclude O
that O
the O
dipyridamole O
ecg O
test O
is O
as O
useful O
as O
the O
exercise O
ecg O
test O
for O
the O
assessment O
of O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

-DOCSTART- O

bradycardia B-NEG
after O
high-dose O
intravenous O
methylprednisolone O
therapy O
. O

in O
5 O
consecutive O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
who O
received O
intravenous O
high-dose O
methylprednisolone O
( O
mp O
) O
therapy O
(1 O
g O
daily O
for O
2 O
or O
3 O
consecutive O
days) O
, O
a O
decline O
in O
pulse O
rate O
was O
observed O
, O
most O
pronounced O
on O
day O
4. O

in O
one O
of O
the O
5 O
patients O
the O
bradycardia B-NEG
was O
associated O
with O
complaints O
of O
substernal O
pressure O
. O

reversal O
to O
normal O
heart O
rate O
was O
found O
on O
day O
7. O

electrocardiographic O
registrations O
showed O
sinus B-NEG
bradycardia I-NEG
in O
all O
cases O
. O

no O
significant O
changes O
in O
plasma O
concentrations O
of O
electrolytes O
were O
found O
. O

careful O
observation O
of O
patients O
receiving O
high-dose O
mp O
is O
recommended O
. O

high-dose O
mp O
may O
be O
contraindicated O
in O
patients O
with O
known O
heart B-NEG
disease I-NEG
. O

-DOCSTART- O

two O
cases O
of O
downbeat B-NEG
nystagmus I-NEG
and O
oscillopsia B-NEG
associated O
with O
carbamazepine O
. O
downbeat B-NEG
nystagmus I-NEG
is O
often O
associated O
with O
structural O
lesions O
at O
the O
craniocervical O
junction O
, O
but O
has O
occasionally O
been O
reported O
as O
a O
manifestation O
of O
metabolic O
imbalance O
or O
drug O
intoxication O
. O

we O
recorded O
the O
eye O
movements O
of O
two O
patients O
with O
reversible O
downbeat B-NEG
nystagmus I-NEG
related O
to O
carbamazepine O
therapy O
. O

the O
nystagmus B-NEG
of O
both O
patients O
resolved O
after O
reduction O
of O
the O
serum O
carbamazepine O
levels O
. O

neuroradiologic O
investigations O
including O
magnetic O
resonance O
imaging O
scans O
in O
both O
patients O
showed O
no O
evidence O
of O
intracranial O
abnormality O
. O

in O
patients O
with O
downbeat B-NEG
nystagmus I-NEG
who O
are O
taking O
anticonvulsant O
medications O
, O
consideration O
should O
be O
given O
to O
reduction O
in O
dose O
before O
further O
investigation O
is O
undertaken O
. O

-DOCSTART- O

improvement O
by O
denopamine O
( O
ta-064 O
) O
of O
pentobarbital-induced O
cardiac B-NEG
failure I-NEG
in O
the O
dog O
heart-lung O
preparation O
. O

the O
efficacy O
of O
denopamine O
, O
an O
orally O
active O
beta O
1-adrenoceptor O
agonist O
, O
in O
improving O
cardiac B-NEG
failure I-NEG
was O
assessed O
in O
dog O
heart-lung O
preparations O
. O

cardiac O
functions O
depressed O
by O
pentobarbital O
( O
118 O
+/- O
28 O
mg O
; O
mean O
value O
+/- O
sd O
) O
such O
that O
cardiac O
output O
and O
maximum O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
lv O
dp/dt O
max O
) O
had O
been O
reduced O
by O
about O
35% O
and O
26% O
of O
the O
respective O
controls O
were O
improved O
by O
denopamine O
( O
10-300 O
micrograms O
) O
in O
a O
dose-dependent O
manner O
. O

with O
100 O
micrograms O
denopamine O
, O
almost O
complete O
restoration O
of O
cardiac O
performance O
was O
attained O
, O
associated O
with O
a O
slight O
increase O
in O
heart O
rate O
. O

no O
arrhythmias B-NEG
were O
induced O
by O
these O
doses O
of O
denopamine O
. O

the O
results O
warrant O
clinical O
trials O
of O
denopamine O
in O
the O
treatment O
of O
cardiac B-NEG
failure I-NEG
. O

-DOCSTART- O

clonazepam O
monotherapy O
for O
epilepsy B-NEG
in O
childhood O
. O

sixty O
patients O
( O
age-range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy B-NEG
than O
infantile B-NEG
spasms I-NEG
were O
treated O
with O
clonazepam O
. O

disappearance O
of O
seizures B-NEG
and O
normalization O
of O
abnormal O
eeg O
with O
disappearance O
of O
seizures B-NEG
were O
recognized O
in O
77% O
and O
50% O
, O
respectively O
. O
seizures B-NEG
disappeared O
in O
71% O
of O
the O
patients O
with O
generalized O
seizures B-NEG
and O
89% O
of O
partial O
seizures B-NEG
. O

improvement O
of O
abnormal O
eeg O
was O
noticed O
in O
76% O
of O
diffuse O
paroxysms O
and O
in O
67% O
of O
focal O
paroxysms O
. O

in O
excellent O
cases O
, O
mean O
effective O
dosages O
were O
0.086 O
+/- O
0.021 O
mg/kg/day O
in O
infants O
and O
0.057 O
+/- O
0.022 O
mg/kg/day O
in O
schoolchildren O
, O
this O
difference O
was O
statistically O
significant O
(p O
less O
than O
0.005) O
. O

the O
incidence O
of O
side O
effects O
such O
as O
drowsiness B-NEG
and O
ataxia B-NEG
was O
only O
5% O
. O

-DOCSTART- O

postmarketing O
study O
of O
timolol-hydrochlorothiazide O
antihypertensive O
therapy O
. O

a O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed-ratio O
combination O
containing O
10 O
mg O
of O
timolol O
maleate O
and O
25 O
mg O
of O
hydrochlorothiazide O
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive B-NEG
patients O
. O

data O
on O
9,037 O
patients O
were O
collected O
by O
1,455 O
participating O
physicians O
. O

mean O
systolic O
blood O
pressure O
decreased O
25 O
mmhg O
and O
mean O
diastolic O
blood O
pressure O
declined O
15 O
mmhg O
after O
one O
month O
of O
timolol-hydrochlorothiazide O
therapy O
(p O
less O
than O
0.01 O
, O
both O
comparisons) O
. O

age O
, O
race O
, O
and O
sex O
appeared O
to O
have O
no O
influence O
on O
the O
decrease O
in O
blood O
pressure O
. O

the O
antihypertensive O
effect O
of O
the O
drug O
was O
greater O
in O
patients O
with O
more O
severe O
hypertension B-NEG
. O

overall O
, O
1,453 O
patients O
experienced O
a O
total O
of O
2,658 O
adverse O
events O
, O
the O
most O
common O
being O
fatigue B-NEG
, O
dizziness B-NEG
, O
and O
weakness B-NEG
. O

treatment O
in O
590 O
patients O
was O
discontinued O
because O
of O
adverse O
events O
. O

-DOCSTART- O

salicylate O
nephropathy B-NEG
in O
the O
gunn O
rat O
: O
potential O
role O
of O
prostaglandins O
. O

we O
examined O
the O
potential O
role O
of O
prostaglandins O
in O
the O
development O
of O
analgesic O
nephropathy B-NEG
in O
the O
gunn O
strain O
of O
rat O
. O

the O
homozygous O
gunn O
rats O
have O
unconjugated O
hyperbilirubinemia B-NEG
due O
to O
the O
absence O
of O
glucuronyl O
transferase O
, O
leading O
to O
marked O
bilirubin O
deposition O
in O
renal O
medulla O
and O
papilla O
. O

these O
rats O
are O
also O
highly O
susceptible O
to O
develop O
papillary B-NEG
necrosis I-NEG
with O
analgesic O
administration O
. O

we O
used O
homozygous O
( O
jj O
) O
and O
phenotypically O
normal O
heterozygous O
( O
jj O
) O
animals O
. O

four O
groups O
of O
rats O
(n O
= O
7) O
were O
studied O
: O
jj O
and O
jj O
rats O
treated O
either O
with O
aspirin O
300 O
mg/kg O
every O
other O
day O
or O
sham-treated O
. O

after O
one O
week O
, O
slices O
of O
cortex O
, O
outer O
and O
inner O
medulla O
from O
one O
kidney O
were O
incubated O
in O
buffer O
and O
prostaglandin O
synthesis O
was O
determined O
by O
radioimmunoassay O
. O

the O
other O
kidney O
was O
examined O
histologically O
. O

a O
marked O
corticomedullary O
gradient O
of O
prostaglandin O
synthesis O
was O
observed O
in O
all O
groups O
. O

pge2 O
synthesis O
was O
significantly O
higher O
in O
outer O
medulla O
, O
but O
not O
cortex O
or O
inner O
medulla O
, O
of O
jj O
( O
38 O
+/- O
6 O
ng/mg O
prot O
) O
than O
jj O
rats O
( O
15 O
+/- O
3) O
(p O
less O
than O
0.01) O
. O

aspirin O
treatment O
reduced O
pge2 O
synthesis O
in O
all O
regions O
, O
but O
outer O
medullary O
pge2 O
remained O
higher O
in O
jj O
( O
18 O
+/- O
3) O
than O
jj O
rats O
(9 O
+/- O
2) O
(p O
less O
than O
0.05) O
. O

pgf2 O
alpha O
was O
also O
significantly O
higher O
in O
the O
outer O
medulla O
of O
jj O
rats O
with O
and O
without O
aspirin O
administration O
(p O
less O
than O
0.05) O
. O

the O
changes O
in O
renal O
prostaglandin O
synthesis O
were O
accompanied O
by O
evidence O
of O
renal B-NEG
damage I-NEG
in O
aspirin-treated O
jj O
but O
not O
jj O
rats O
as O
evidenced O
by O
: O
increased O
incidence O
and O
severity O
of O
hematuria B-NEG
(p O
less O
than O
0.01) O
; O
increased O
serum O
creatinine O
(p O
less O
than O
0.05) O
; O
and O
increase O
in O
outer O
medullary O
histopathologic O
lesions O
(p O
less O
than O
0.005 O
compared O
to O
either O
sham-treated O
jj O
or O
aspirin-treated O
jj) O
. O

these O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B-NEG
renal I-NEG
medullary I-NEG
lesions I-NEG
and O
deterioration B-NEG
of I-NEG
renal I-NEG
function I-NEG
. O

-DOCSTART- O

prophylactic O
lidocaine O
in O
the O
early O
phase O
of O
suspected O
myocardial B-NEG
infarction I-NEG
. O

four O
hundred O
two O
patients O
with O
suspected O
myocardial B-NEG
infarction I-NEG
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double-blind O
randomized O
trial O
of O
lidocaine O
vs O
placebo O
. O

during O
the O
1 O
hour O
after O
administration O
of O
the O
drug O
the O
incidence O
of O
ventricular B-NEG
fibrillation I-NEG
or O
sustained O
ventricular B-NEG
tachycardia I-NEG
among O
the O
204 O
patients O
with O
acute O
myocardial B-NEG
infarction I-NEG
was O
low O
, O
1.5% O
. O

lidocaine O
, O
given O
in O
a O
300 O
mg O
dose O
intramuscularly O
followed O
by O
100 O
mg O
intravenously O
, O
did O
not O
prevent O
sustained O
ventricular B-NEG
tachycardia I-NEG
, O
although O
there O
was O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
warning O
arrhythmias B-NEG
between O
15 O
and O
45 O
minutes O
after O
the O
administration O
of O
lidocaine O
(p O
less O
than O
0.05) O
. O

the O
average O
plasma O
lidocaine O
level O
10 O
minutes O
after O
administration O
for O
patients O
without O
a O
myocardial B-NEG
infarction I-NEG
was O
significantly O
higher O
than O
that O
for O
patients O
with O
an O
acute O
infarction B-NEG
. O

the O
mean O
plasma O
lidocaine O
level O
of O
patients O
on O
beta-blocking O
agents O
was O
no O
different O
from O
that O
in O
patients O
not O
on O
beta O
blocking O
agents O
. O

during O
the O
1-hour O
study O
period O
, O
the O
incidence O
of O
central O
nervous O
system O
side O
effects O
was O
significantly O
greater O
in O
the O
lidocaine O
group O
, O
hypotension B-NEG
occurred O
in O
11 O
patients O
, O
nine O
of O
whom O
had O
received O
lidocaine O
, O
and O
four O
patients O
died O
from O
asystole B-NEG
, O
three O
of O
whom O
had O
had O
lidocaine O
. O

we O
cannot O
advocate O
the O
administration O
of O
lidocaine O
prophylactically O
in O
the O
early O
hours O
of O
suspected O
myocardial B-NEG
infarction I-NEG
. O

-DOCSTART- O

evidence O
for O
a O
cholinergic O
role O
in O
haloperidol-induced O
catalepsy B-NEG
. O

experiments O
in O
mice O
tested O
previous O
evidence O
that O
activation O
of O
cholinergic O
systems O
promotes O
catalepsy B-NEG
and O
that O
cholinergic O
mechanisms O
need O
to O
be O
intact O
for O
full O
expression O
of O
neuroleptic-induced O
catalepsy B-NEG
. O

large O
doses O
of O
the O
cholinomimetic O
, O
pilocarpine O
, O
could O
induce O
catalepsy B-NEG
when O
peripheral O
cholinergic O
receptors O
were O
blocked O
. O

low O
doses O
of O
pilocarpine O
caused O
a O
pronounced O
enhancement O
of O
the O
catalepsy B-NEG
that O
was O
induced O
by O
the O
dopaminergic O
blocker O
, O
haloperidol O
. O

a O
muscarinic O
receptor O
blocker O
, O
atropine O
, O
disrupted O
haloperidol-induced O
catalepsy B-NEG
. O

intracranial O
injection O
of O
an O
acetylcholine-synthesis O
inhibitor O
, O
hemicholinium O
, O
prevented O
the O
catalepsy B-NEG
that O
is O
usually O
induced O
by O
haloperidol O
. O

these O
findings O
suggest O
the O
hypothesis O
that O
the O
catalepsy B-NEG
that O
is O
produced O
by O
neuroleptics O
such O
as O
haloperidol O
is O
actually O
mediated O
by O
intrinsic O
central O
cholinergic O
systems O
. O

alternatively O
, O
activation O
of O
central O
cholinergic O
systems O
could O
promote O
catalepsy B-NEG
by O
suppression O
of O
dopaminergic O
systems O
. O

-DOCSTART- O

cardiovascular B-NEG
dysfunction I-NEG
and O
hypersensitivity B-NEG
to O
sodium O
pentobarbital O
induced O
by O
chronic O
barium O
chloride O
ingestion O
. O

barium-supplemented O
long-evans O
hooded O
rats O
were O
characterized O
by O
a O
persistent O
hypertension B-NEG
that O
was O
evident O
after O
1 O
month O
of O
barium O
( O
100 O
micrograms/ml O
mineral O
fortified O
water O
) O
treatment O
. O

analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium-induced O
disturbances B-NEG
within I-NEG
the I-NEG
cardiovascular I-NEG
system I-NEG
. O

the O
most O
distinctive O
aspect O
of O
the O
barium O
effect O
was O
a O
demonstrated O
hypersensitivity B-NEG
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
. O

under O
barbiturate O
anesthesia O
, O
virtually O
all O
of O
the O
myocardial O
contractile O
indices O
were O
depressed O
significantly O
in O
barium-exposed O
rats O
relative O
to O
the O
corresponding O
control-fed O
rats O
. O

the O
lack O
of O
a O
similar O
response O
to O
ketamine O
and O
xylazine O
anesthesia O
revealed O
that O
the O
cardiovascular O
actions O
of O
sodium O
pentobarbital O
in O
barium-treated O
rats O
were O
linked O
specifically O
to O
this O
anesthetic O
, O
and O
were O
not O
representative O
of O
a O
generalized O
anesthetic O
response O
. O

other O
myocardial O
pathophysiologic O
and O
metabolic O
changes O
induced O
by O
barium O
were O
manifest O
, O
irrespective O
of O
the O
anesthetic O
employed O
. O

the O
contractile O
element O
shortening O
velocity O
of O
the O
cardiac O
muscle O
fibers O
was O
significantly O
slower O
in O
both O
groups O
of O
barium-treated O
rats O
relative O
to O
the O
control O
groups O
, O
irrespective O
of O
the O
anesthetic O
regimen O
. O

similarly O
, O
significant O
disturbances O
in O
myocardial O
energy O
metabolism O
were O
detected O
in O
the O
barium-exposed O
rats O
which O
were O
consistent O
with O
the O
reduced O
contractile O
element O
shortening O
velocity O
. O

in O
addition O
, O
the O
excitability O
of O
the O
cardiac O
conduction O
system O
was O
depressed O
preferentially O
in O
the O
atrioventricular O
nodal O
region O
of O
hearts O
from O
barium-exposed O
rats O
. O

overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic B-NEG
disturbances I-NEG
, O
and O
the O
hypersensitivity B-NEG
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic B-NEG
disorder I-NEG
induced O
by O
chronic O
barium O
exposure O
. O

these O
experimental O
findings O
represent O
the O
first O
indication O
that O
life-long O
barium O
ingestion O
may O
have O
significant O
adverse O
effects O
on O
the O
mammalian O
cardiovascular O
system O
. O

-DOCSTART- O

propranolol O
antagonism O
of O
phenylpropanolamine-induced O
hypertension B-NEG
. O

phenylpropanolamine O
( O
ppa O
) O
overdose B-NEG
can O
cause O
severe O
hypertension B-NEG
, O
intracerebral B-NEG
hemorrhage I-NEG
, O
and O
death O
. O

we O
studied O
the O
efficacy O
and O
safety O
of O
propranolol O
in O
the O
treatment O
of O
ppa-induced O
hypertension B-NEG
. O

subjects O
received O
propranolol O
either O
by O
mouth O
for O
48 O
hours O
before O
ppa O
or O
as O
a O
rapid O
intravenous O
infusion O
after O
ppa O
. O

ppa O
, O
75 O
mg O
alone O
, O
increased O
blood O
pressure O
( O
31 O
+/- O
14 O
mm O
hg O
systolic O
, O
20 O
+/- O
5 O
mm O
hg O
diastolic) O
, O
and O
propranolol O
pretreatment O
antagonized O
this O
increase O
( O
12 O
+/- O
10 O
mm O
hg O
systolic O
, O
10 O
+/- O
7 O
mm O
hg O
diastolic) O
. O

intravenous O
propranolol O
after O
ppa O
also O
decreased O
blood O
pressure O
. O

left O
ventricular O
function O
( O
assessed O
by O
echocardiography O
) O
showed O
that O
ppa O
increased O
the O
stroke B-NEG
volume O
30% O
( O
from O
62.5 O
+/- O
20.9 O
to O
80.8 O
+/- O
22.4 O
ml) O
, O
the O
ejection O
fraction O
9% O
( O
from O
64% O
+/- O
10% O
to O
70% O
+/- O
7%) O
, O
and O
cardiac O
output O
14% O
( O
from O
3.6 O
+/- O
0.6 O
to O
4.1 O
+/- O
1.0 O
l/min) O
. O

intravenous O
propranolol O
reversed O
these O
effects O
. O

systemic O
vascular O
resistance O
was O
increased O
by O
ppa O
28% O
( O
from O
1710 O
+/- O
200 O
to O
2190 O
+/- O
700 O
dyne O
x O
sec/cm5 O
) O
and O
was O
further O
increased O
by O
propranolol O
22% O
( O
to O
2660 O
+/- O
1200 O
dyne O
x O
sec/cm5) O
. O

we O
conclude O
that O
ppa O
increases O
blood O
pressure O
by O
increasing O
systemic O
vascular O
resistance O
and O
cardiac O
output O
, O
and O
that O
propranolol O
antagonizes O
this O
increase O
by O
reversing O
the O
effect O
of O
ppa O
on O
cardiac O
output O
. O

that O
propranolol O
antagonizes O
the O
pressor O
effect O
of O
ppa O
is O
in O
contrast O
to O
the O
interaction O
in O
which O
propranolol O
enhances O
the O
pressor O
effect O
of O
norepinephrine O
. O

this O
is O
probably O
because O
ppa O
has O
less O
beta O
2 O
activity O
than O
does O
norepinephrine O
. O

-DOCSTART- O

mesangial O
function O
and O
glomerular B-NEG
sclerosis I-NEG
in O
rats O
with O
aminonucleoside O
nephrosis B-NEG
. O

the O
possible O
relationship O
between O
mesangial B-NEG
dysfunction I-NEG
and O
development O
of O
glomerular B-NEG
sclerosis I-NEG
was O
studied O
in O
the O
puromycin O
aminonucleoside O
( O
pan O
) O
model O
. O

five O
male O
wistar O
rats O
received O
repeated O
subcutaneous O
pan O
injections O
; O
five O
controls O
received O
saline O
only O
. O

after O
4 O
weeks O
the O
pan O
rats O
were O
severely O
proteinuric B-NEG
( O
190 O
+/- O
80 O
mg/24 O
hr) O
, O
and O
all O
rats O
were O
given O
colloidal O
carbon O
( O
cc O
) O
intravenously O
. O

at O
5 O
months O
glomerular B-NEG
sclerosis I-NEG
was O
found O
in O
7.6 O
+/- O
3.4% O
of O
the O
glomeruli O
of O
pan O
rats O
; O
glomeruli O
of O
the O
controls O
were O
normal O
. O

glomeruli O
of O
pan O
rats O
contained O
significantly O
more O
cc O
than O
glomeruli O
of O
controls O
. O

glomeruli O
with O
sclerosis B-NEG
contained O
significantly O
more O
cc O
than O
non-sclerotic O
glomeruli O
in O
the O
same O
kidneys O
. O

cc O
was O
preferentially O
localized O
within O
the O
sclerotic O
areas O
of O
the O
affected O
glomeruli O
. O

since O
mesangial O
cc O
clearance O
from O
the O
mesangium O
did O
not O
change O
during O
chronic O
pan O
treatment O
, O
we O
conclude O
that O
this O
preferential O
cc O
localization O
within O
the O
lesions O
is O
caused O
by O
an O
increased O
cc O
uptake O
shortly O
after O
injection O
in O
apparent O
vulnerable O
areas O
where O
sclerosis B-NEG
will O
develop O
subsequently O
. O

cluster O
analysis O
showed O
a O
random O
distribution O
of O
lesions O
in O
the O
pan O
glomeruli O
in O
concordance O
with O
the O
random O
localization O
of O
mesangial O
areas O
with O
dysfunction O
in O
this O
model O
. O

similar O
to O
the O
remnant O
kidney O
model O
in O
pan O
nephrosis B-NEG
the O
development O
of O
glomerular B-NEG
sclerosis I-NEG
may O
be O
related O
to O
mesangial O
overloading O
. O

-DOCSTART- O

relationship O
between O
nicotine-induced O
seizures B-NEG
and O
hippocampal O
nicotinic O
receptors O
. O

a O
controversy O
has O
existed O
for O
several O
years O
concerning O
the O
physiological O
relevance O
of O
the O
nicotinic O
receptor O
measured O
by O
alpha-bungarotoxin O
binding O
. O

using O
mice O
derived O
from O
a O
classical O
f2 O
and O
backcross O
genetic O
design O
, O
a O
relationship O
between O
nicotine-induced O
seizures B-NEG
and O
alpha-bungarotoxin O
nicotinic O
receptor O
concentration O
was O
found O
. O

mice O
sensitive O
to O
the O
convulsant O
effects O
of O
nicotine O
had O
greater O
alpha-bungarotoxin O
binding O
in O
the O
hippocampus O
than O
seizure B-NEG
insensitive O
mice O
. O

the O
binding O
sites O
from O
seizure B-NEG
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol O
, O
trypsin O
or O
heat O
. O

thus O
it O
appears O
that O
the O
difference O
between O
seizure B-NEG
sensitive O
and O
insensitive O
animals O
may O
be O
due O
to O
a O
difference O
in O
hippocampal O
nicotinic O
receptor O
concentration O
as O
measured O
with O
alpha-bungarotoxin O
binding O
. O

-DOCSTART- O

the O
role O
of O
p-aminophenol O
in O
acetaminophen-induced O
nephrotoxicity B-NEG
: O
effect O
of O
bis(p-nitrophenyl O
) O
phosphate O
on O
acetaminophen O
and O
p-aminophenol O
nephrotoxicity B-NEG
and O
metabolism O
in O
fischer O
344 O
rats O
. O

acetaminophen O
( O
apap O
) O
produces O
proximal O
tubular B-NEG
necrosis I-NEG
in O
fischer O
344 O
( O
f344 O
) O
rats O
. O

recently O
, O
p-aminophenol O
(pap) O
, O
a O
known O
potent O
nephrotoxicant O
, O
was O
identified O
as O
a O
metabolite O
of O
apap O
in O
f344 O
rats O
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
if O
pap O
formation O
is O
a O
requisite O
step O
in O
apap-induced O
nephrotoxicity B-NEG
. O

therefore O
, O
the O
effect O
of O
bis(p-nitrophenyl O
) O
phosphate O
(bnpp) O
, O
an O
acylamidase O
inhibitor O
, O
on O
apap O
and O
pap O
nephrotoxicity B-NEG
and O
metabolism O
was O
determined O
. O

bnpp O
(1 O
to O
8 O
mm O
) O
reduced O
apap O
deacetylation O
and O
covalent O
binding O
in O
f344 O
renal O
cortical O
homogenates O
in O
a O
concentration-dependent O
manner O
. O

pretreatment O
of O
animals O
with O
bnpp O
prior O
to O
apap O
or O
pap O
administration O
resulted O
in O
marked O
reduction O
of O
apap O
( O
900 O
mg/kg O
) O
nephrotoxicity B-NEG
but O
not O
pap O
nephrotoxicity B-NEG
. O

this O
result O
was O
not O
due O
to O
altered O
disposition O
of O
either O
apap O
or O
acetylated O
metabolites O
in O
plasma O
or O
renal O
cortical O
and O
hepatic O
tissue O
. O

rather O
, O
bnpp O
pretreatment O
reduced O
the O
fraction O
of O
apap O
excreted O
as O
pap O
by O
64 O
and O
75% O
after O
apap O
doses O
of O
750 O
and O
900 O
mg/kg O
. O

bnpp O
did O
not O
alter O
the O
excretion O
of O
apap O
or O
any O
of O
its O
non-deacetylated O
metabolites O
nor O
did O
bnpp O
alter O
excretion O
of O
pap O
or O
its O
metabolites O
after O
pap O
doses O
of O
150 O
and O
300 O
mg/kg O
. O

therefore O
, O
the O
bnpp-induced O
reduction O
in O
apap-induced O
nephrotoxicity B-NEG
appears O
to O
be O
due O
to O
inhibition O
of O
apap O
deacetylation O
. O

it O
is O
concluded O
that O
pap O
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
apap-induced O
renal B-NEG
tubular I-NEG
necrosis I-NEG
. O

-DOCSTART- O

morphine-induced O
seizures B-NEG
in O
newborn O
infants O
. O

two O
neonates O
suffered O
from O
generalized O
seizures B-NEG
during O
the O
course O
of O
intravenous O
morphine O
sulfate O
for O
post-operative O
analgesia O
. O

they O
received O
morphine O
in O
doses O
of O
32 O
micrograms/kg/hr O
and O
40 O
micrograms/kg/hr O
larger O
than O
a O
group O
of O
10 O
neonates O
who O
received O
6-24 O
micrograms/kg/hr O
and O
had O
no O
seizures B-NEG
. O

plasma O
concentrations O
of O
morphine O
in O
these O
neonates O
was O
excessive O
( O
60 O
and O
90 O
mg/ml) O
. O

other O
known O
reasons O
for O
seizures B-NEG
were O
ruled O
out O
and O
the O
convulsions B-NEG
stopped O
a O
few O
hours O
after O
cessation O
of O
morphine O
and O
did O
not O
reoccur O
in O
the O
subsequent O
8 O
months O
. O

it O
is O
suggested O
that O
post-operative O
intravenous O
morphine O
should O
not O
exceed O
20 O
micrograms/kg/ml O
in O
neonates O
. O

-DOCSTART- O

effect O
of O
vincristine O
sulfate O
on O
pseudomonas B-NEG
infections I-NEG
in O
monkeys O
. O

in O
rhesus O
monkeys O
, O
intravenous O
challenge O
with O
0.6 O
x O
10(10 O
) O
to O
2.2 O
x O
10(10)pseudomonas O
aeruginosa O
organisms O
caused O
acute O
illness O
of O
4 O
to O
5 O
days' O
duration O
with O
spontaneous O
recovery O
in O
13 O
of O
15 O
monkeys O
; O
blood O
cultures O
became O
negative O
3 O
to O
17 O
days O
after O
challenge O
. O
leukocytosis B-NEG
was O
observed O
in O
all O
monkeys O
. O

intravenous O
or O
intratracheal O
inoculation O
of O
2.0 O
to O
2.5 O
mg O
of O
vincristine O
sulfate O
was O
followed O
by O
leukopenia B-NEG
in O
4 O
to O
5 O
days O
. O

intravenous O
inoculation O
of O
4.2 O
x O
10(10 O
) O
to O
7.8 O
x O
10(10 O
) O
pyocin O
type O
6 O
pseudomonas O
organisms O
in O
monkeys O
given O
vincristine O
sulfate O
4 O
days O
previously O
resulted O
in O
fatal O
infection B-NEG
in O
11 O
of O
14 O
monkeys O
, O
whereas O
none O
of O
four O
receiving O
pseudomonas O
alone O
died O
. O

these O
studies O
suggest O
that O
an O
antimetabolite-induced O
leukopenia B-NEG
predisposes O
to O
severe O
pseudomonas O
sepsis B-NEG
and O
that O
such O
monkeys O
may O
serve O
as O
a O
biological O
model O
for O
study O
of O
comparative O
efficacy O
of O
antimicrobial O
agents O
. O

-DOCSTART- O

central O
excitatory O
actions O
of O
flurazepam O
. O

toxic O
actions O
of O
flurazepam O
( O
fzp O
) O
were O
studied O
in O
cats O
, O
mice O
and O
rats O
. O

high O
doses O
caused O
an O
apparent O
central O
excitation O
, O
most O
clearly O
seen O
as O
clonic O
convulsions B-NEG
, O
superimposed O
on O
general O
depression B-NEG
. O

following O
a O
lethal O
dose O
, O
death O
was O
always O
associated O
with O
convulsions B-NEG
. O

comparing O
the O
relative O
sensitivity O
to O
central O
depression B-NEG
and O
excitation O
revealed O
that O
rats O
were O
least O
likely O
to O
have O
convulsions B-NEG
at O
doses O
that O
did O
not O
first O
cause O
loss B-NEG
of I-NEG
consciousness I-NEG
, O
while O
cats O
most O
clearly O
showed O
marked O
central O
excitatory O
actions O
. O

signs O
of O
fzp O
toxocity B-NEG
in O
cats O
included O
excessive O
salivation B-NEG
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle B-NEG
tremors I-NEG
and O
convulsions B-NEG
. O

an O
interaction O
between O
fzp O
and O
pentylenetetrazol O
( O
ptz O
) O
was O
shown O
by O
pretreating O
mice O
with O
fzp O
before O
ptz O
challenge O
. O

as O
a O
function O
of O
dose O
, O
fzp O
first O
protected O
against O
convulsions B-NEG
and O
death O
. O

at O
higher O
doses O
, O
however O
, O
convulsions B-NEG
again O
emerged O
. O

these O
doses O
of O
fzp O
were O
lower O
than O
those O
that O
would O
alone O
cause O
convulsions B-NEG
. O

these O
results O
may O
be O
relevant O
to O
the O
use O
of O
fzp O
in O
clinical O
situations O
in O
which O
there O
is O
increased O
neural O
excitability O
, O
such O
as O
epilepsy B-NEG
or O
sedative-hypnotic O
drug O
withdrawal O
. O

-DOCSTART- O

evidence O
for O
cardiac O
beta O
2-adrenoceptors O
in O
man O
. O

we O
compared O
the O
effects O
of O
single O
doses O
of O
50 O
mg O
atenolol O
(cardioselective) O
, O
40 O
mg O
propranolol O
(nonselective) O
, O
and O
placebo O
on O
both O
exercise- O
and O
isoproterenol-induced O
tachycardia B-NEG
in O
two O
experiments O
involving O
nine O
normal O
subjects O
. O

maximal O
exercise O
heart O
rate O
was O
reduced O
from O
187 O
+/- O
4(sem O
) O
after O
placebo O
to O
146 O
+/- O
7 O
bpm O
after O
atenolol O
and O
138 O
+/- O
6 O
bpm O
after O
propranolol O
, O
but O
there O
were O
no O
differences O
between O
the O
drugs O
. O

the O
effects O
on O
isoproterenol O
tachycardia B-NEG
were O
determined O
before O
and O
after O
atropine O
( O
0.04 O
mg/kg O
iv) O
. O

isoproterenol O
sensitivity O
was O
determined O
as O
the O
intravenous O
dose O
that O
increased O
heart O
rate O
by O
25 O
bpm O
( O
cd25 O
) O
and O
this O
was O
increased O
from O
1.8 O
+/- O
0.3 O
micrograms O
after O
placebo O
to O
38.9 O
+/- O
8.3 O
micrograms O
after O
propranolol O
and O
8.3 O
+/- O
1.7 O
micrograms O
after O
atenolol O
. O

the O
difference O
in O
the O
effects O
of O
the O
two O
was O
significant O
. O

after O
atropine O
the O
cd25 O
was O
unchanged O
after O
placebo O
( O
2.3 O
+/- O
0.3 O
micrograms O
) O
and O
atenolol O
( O
7.7 O
+/- O
1.3 O
micrograms) O
; O
it O
was O
reduced O
after O
propranolol O
( O
24.8 O
+/- O
5.0 O
micrograms) O
, O
but O
remained O
different O
from O
atenolol O
. O

this O
change O
with O
propranolol O
sensitivity O
was O
calculated O
as O
the O
apparent O
ka O
, O
this O
was O
unchanged O
by O
atropine O
( O
11.7 O
+/- O
2.1 O
and O
10.1 O
+/- O
2.5 O
ml/ng) O
. O

these O
data O
are O
consistent O
with O
the O
hypothesis O
that O
exercise-induced O
tachycardia B-NEG
results O
largely O
from O
beta O
1-receptor O
activation O
that O
is O
blocked O
by O
both O
cardioselective O
and O
nonselective O
drugs O
, O
whereas O
isoproterenol O
activates O
both O
beta O
1- O
and O
beta O
2-receptors O
so O
that O
after O
cardioselective O
blockade O
there O
remains O
a O
beta O
2-component O
that O
can O
be O
blocked O
with O
a O
nonselective O
drug O
. O

while O
there O
appear O
to O
be O
beta O
2-receptors O
in O
the O
human O
heart O
, O
their O
physiologic O
or O
pathologic O
roles O
remain O
to O
be O
defined O
. O

-DOCSTART- O

hormones O
and O
risk O
of O
breast B-NEG
cancer I-NEG
. O

this O
paper O
reports O
the O
results O
of O
a O
study O
of O
50 O
menopausal O
women O
receiving O
hormonal O
replacement O
therapy O
. O

the O
majority O
( O
29 O
) O
had O
surgical O
menopause O
; O
their O
mean O
age O
was O
45.7 O
years O
. O

it O
was O
hypothesized O
that O
progestins O
could O
equilibrate O
the O
effects O
of O
the O
estrogenic O
stimulation O
on O
the O
mammary O
and O
endometrial O
target O
tissues O
of O
women O
on O
hormonal O
replacement O
therapy O
. O

the O
treatment O
schedule O
consisted O
of O
conjugated O
estrogens O
( O
premarin O
) O
1.25 O
mg/day O
for O
21 O
days O
and O
medroxyprogesterone O
acetate O
10 O
mg/day O
for O
10 O
days O
in O
each O
month O
. O

the O
mean O
treatment O
period O
was O
18 O
months O
. O

during O
the O
follow-up O
period O
, O
attention O
was O
paid O
to O
breast O
modifications O
as O
evidenced O
by O
symptomatology O
, O
physical O
examination O
, O
and O
plate O
thermography O
. O
mastodynia B-NEG
was O
reported O
by O
21 O
patients O
, O
and O
physical O
examination O
revealed O
a O
light O
increase O
in O
breast O
firmness O
in O
12 O
women O
and O
a O
moderate O
increase O
in O
breast O
nodularity O
in O
2 O
women O
. O

themography O
confirmed O
the O
existence O
of O
an O
excessive O
breast O
stimulation O
in O
1 O
women O
who O
complained O
of O
moderate O
mastodynia B-NEG
and O
in O
5 O
of O
the O
7 O
women O
who O
complained O
of O
severe O
mastodynia B-NEG
. O

normalization O
was O
obtained O
by O
halving O
the O
estrogen O
dose O
. O

these O
results O
suggest O
that O
hormonal O
replacement O
therapy O
can O
be O
safely O
prescribed O
if O
the O
following O
criteria O
are O
satisfied O
: O
1) O
preliminary O
evaluation O
of O
patients O
from O
a O
clinical O
, O
metabolic O
, O
cytologic O
, O
and O
mammographic O
perspective O
; O
2) O
cyclic O
treatment O
schedule O
, O
with O
a O
progestative O
phase O
of O
10 O
days O
; O
and O
3) O
periodic O
complete O
follow-up O
, O
with O
accurate O
thermographic O
evaluation O
of O
the O
breast O
target O
tissues O
. O

-DOCSTART- O

early O
infections B-NEG
in O
kidney O
, O
heart O
, O
and O
liver O
transplant O
recipients O
on O
cyclosporine O
. O

eighty-one O
renal O
, O
seventeen O
heart O
, O
and O
twenty-four O
liver O
transplant O
patients O
were O
followed O
for O
infection B-NEG
. O

seventeen O
renal O
patients O
received O
azathioprine O
( O
aza O
) O
and O
prednisone O
as O
part O
of O
a O
randomized O
trial O
of O
immunosuppression O
with O
21 O
cyclosporine-and-prednisone-treated O
renal O
transplant O
patients O
. O

all O
others O
received O
cyclosporine O
and O
prednisone O
. O

the O
randomized O
aza O
patients O
had O
more O
overall O
infections B-NEG
(p O
less O
than O
0.05 O
) O
and O
more O
nonviral O
infections B-NEG
(p O
less O
than O
0.02 O
) O
than O
the O
randomized O
cyclosporine O
patients O
. O

heart O
and O
liver O
patients O
had O
more O
infections B-NEG
than O
cyclosporine O
renal O
patients O
but O
fewer O
infections B-NEG
than O
the O
aza O
renal O
patients O
. O

there O
were O
no O
infectious O
deaths O
in O
renal O
transplant O
patients O
on O
cyclosporine O
or O
aza O
, O
but O
infection B-NEG
played O
a O
major O
role O
in O
3 O
out O
of O
6 O
cardiac O
transplant O
deaths O
and O
in O
8 O
out O
of O
9 O
liver O
transplant O
deaths O
. O

renal O
patients O
on O
cyclosporine O
had O
the O
fewest O
bacteremias B-NEG
. O

analysis O
of O
site O
of O
infection B-NEG
showed O
a O
preponderance O
of O
abdominal B-NEG
infections I-NEG
in O
liver O
patients O
, O
intrathoracic O
infections B-NEG
in O
heart O
patients O
, O
and O
urinary B-NEG
tract I-NEG
infections I-NEG
in O
renal O
patients O
. O

pulmonary O
infections B-NEG
were O
less O
common O
in O
cyclosporine-treated O
renal O
patients O
than O
in O
aza-treated O
patients O
(p O
less O
than O
0.05) O
. O

aza O
patients O
had O
significantly O
more O
staphylococcal B-NEG
infections I-NEG
than O
all O
other O
transplant O
groups O
(p O
less O
than O
0.005) O
, O
and O
systemic O
fungal B-NEG
infections I-NEG
occurred O
only O
in O
the O
liver O
transplant O
group O
. O

cytomegalovirus O
( O
cmv O
) O
shedding O
or O
serological O
rises O
in O
antibody O
titer O
, O
or O
both O
occurred O
in O
78% O
of O
cyclosporine O
patients O
and O
76% O
of O
aza O
patients O
. O

of O
the O
cyclosporine O
patients O
, O
15% O
had O
symptoms O
related O
to O
cmv B-NEG
infection I-NEG
. O

serological O
evidence O
for O
epstein B-NEG
barr I-NEG
virus I-NEG
infection I-NEG
was O
found O
in O
20% O
of O
65 O
cyclosporine O
patients O
studied O
. O

three O
had O
associated O
symptoms O
, O
and O
one O
developed O
a O
lymphoma B-NEG
. O

-DOCSTART- O

structure-activity O
and O
dose-effect O
relationships O
of O
the O
antagonism O
of O
picrotoxin-induced O
seizures B-NEG
by O
cholecystokinin O
, O
fragments O
and O
analogues O
of O
cholecystokinin O
in O
mice O
. O

intraperitoneal O
administration O
of O
cholecystokinin O
octapeptide O
sulphate O
ester O
( O
cck-8-se O
) O
and O
nonsulphated O
cholecystokinin O
octapeptide O
( O
cck-8-ns O
) O
enhanced O
the O
latency O
of O
seizures B-NEG
induced O
by O
picrotoxin O
in O
mice O
. O

experiments O
with O
n- O
and O
c-terminal O
fragments O
revealed O
that O
the O
c-terminal O
tetrapeptide O
( O
cck-5-8 O
) O
was O
the O
active O
centre O
of O
the O
cck O
octapeptide O
molecule O
. O

the O
analogues O
cck-8-se O
and O
cck-8-ns O
( O
dose O
range O
0.2-6.4 O
mumol/kg O
) O
and O
caerulein O
dose O
range O
0.1-0.8 O
mumol/kg O
) O
showed O
bell-shaped O
dose-effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
cck-8-ns O
. O

the O
peptide O
cck-5-8 O
had O
weak O
anticonvulsant O
activity O
in O
comparison O
to O
the O
octapeptides O
, O
3.2 O
mumol/kg O
and O
larger O
doses O
of O
the O
reference O
drug O
, O
diazepam O
, O
totally O
prevented O
picrotoxin-induced O
seizures B-NEG
and O
mortality O
. O

the O
maximum O
effect O
of O
the O
peptides O
tested O
was O
less O
than O
that O
of O
diazepam O
. O

experiments O
with O
analogues O
and O
derivatives O
of O
cck-5-8 O
demonstrated O
that O
the O
effectiveness O
of O
the O
beta-alanyl O
derivatives O
of O
cck-5-8 O
were O
enhanced O
and O
that O
they O
were O
equipotent O
with O
cck-8-se O
. O

of O
the O
cck-2-8 O
analogues O
, O
ser(so3h)7-ac-cck-2-8-se O
and O
thr(so3h)7-ac-cck-2-8-se O
and O
hyp(so3h)-ac-cck-2-8-se O
were O
slightly O
more O
active O
than O
cck-8-se O
. O

-DOCSTART- O

vasopressin O
as O
a O
possible O
contributor O
to O
hypertension B-NEG
. O

the O
role O
of O
vasopressin O
as O
a O
pressor O
agent O
to O
the O
hypertensive B-NEG
process O
was O
examined O
. O

vasopressin O
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
doca-salt O
hypertension B-NEG
, O
since O
the O
elevation O
of O
blood O
pressure O
was O
not O
substantial O
in O
the O
rats O
with O
lithium-treated O
diabetes B-NEG
insipidus I-NEG
after O
doca-salt O
treatment O
. O

administration O
of O
ddavp O
which O
has O
antidiuretic O
action O
but O
minimal O
vasopressor O
effect O
failed O
to O
increase O
blood O
pressure O
to O
the O
levels O
observed O
after O
administration O
of O
avp O
. O

furthermore O
, O
the O
pressor O
action O
of O
vasopressin O
appears O
to O
be O
important O
in O
the O
development O
of O
this O
model O
of O
hypertension B-NEG
, O
since O
the O
enhanced O
pressor O
responsiveness O
to O
the O
hormone O
was O
observed O
in O
the O
initial O
stage O
of O
hypertension B-NEG
. O

increased O
secretion O
of O
vasopressin O
from O
neurohypophysis O
also O
promotes O
the O
function O
of O
the O
hormone O
as O
a O
pathogenetic O
factor O
in O
hypertension B-NEG
. O

an O
unproportional O
release O
of O
vasopressin O
compared O
to O
plasma O
osmolality O
may O
be O
induced O
by O
the O
absence O
of O
an O
adjusting O
control O
of O
angiotensin O
ii O
forming O
and O
receptor O
binding O
capacity O
for O
sodium O
balance O
in O
the O
brain O
. O

however O
, O
the O
role O
of O
vasopressin O
remains O
to O
be O
determined O
in O
human O
essential O
hypertension B-NEG
. O

-DOCSTART- O

toxic B-NEG
hepatitis I-NEG
induced O
by O
disulfiram O
in O
a O
non-alcoholic O
. O

a O
reversible O
toxic B-NEG
liver I-NEG
damage I-NEG
was O
observed O
in O
a O
non-alcoholic O
woman O
treated O
with O
disulfiram O
. O

the O
causative O
relationship O
was O
proven O
by O
challenge O
. O

-DOCSTART- O

atrial B-NEG
thrombosis I-NEG
involving O
the O
heart O
of O
f-344 O
rats O
ingesting O
quinacrine O
hydrochloride O
. O

quinacrine O
hydrochloride O
is O
toxic O
for O
the O
heart O
of O
f-344 O
rats O
. O

rats O
treated O
with O
500 O
ppm O
quinacrine O
hydrochloride O
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial B-NEG
thrombosis I-NEG
. O

the O
lesion O
was O
associated O
with O
cardiac B-NEG
hypertrophy I-NEG
and O
dilatation O
and O
focal O
myocardial B-NEG
degeneration I-NEG
. O

rats O
died O
from O
cardiac B-NEG
hypertrophy I-NEG
with O
severe O
acute O
and O
chronic O
congestion O
of O
the O
lungs O
, O
liver O
, O
and O
other O
organs O
. O

seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine O
hydrochloride O
and O
1,000 O
ppm O
sodium O
nitrite O
simultaneously O
in O
the O
diet O
had O
thrombosis B-NEG
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial B-NEG
thrombosis I-NEG
. O

sodium O
nitrite O
in O
combination O
with O
quinacrine O
hydrochloride O
appeared O
to O
have O
no O
additional O
effect O
. O

-DOCSTART- O

alternating B-NEG
sinus I-NEG
rhythm I-NEG
and O
intermittent O
sinoatrial B-NEG
block I-NEG
induced O
by O
propranolol O
. O
alternating B-NEG
sinus I-NEG
rhythm I-NEG
and O
intermittent O
sinoatrial B-NEG
( O
s-a I-NEG
) O
block I-NEG
was O
observed O
in O
a O
57-year-old O
woman O
, O
under O
treatment O
for O
angina B-NEG
with O
80 O
mg O
propranolol O
daily O
. O

the O
electrocardiogram O
showed O
alternation O
of O
long O
and O
short O
p-p O
intervals O
and O
occasional O
pauses O
. O

these O
pauses O
were O
always O
preceded O
by O
the O
short O
p-p O
intervals O
and O
were O
usually O
followed O
by O
one O
or O
two O
p-p O
intervals O
of O
0.92-0.95 O
s O
representing O
the O
basic O
sinus O
cycle O
. O

following O
these O
basic O
sinus O
cycles O
, O
alternating B-NEG
rhythm I-NEG
started O
with O
the O
longer O
p-p O
interval O
. O

the O
long O
p-p O
intervals O
ranged O
between O
1.04-1.12 O
s O
and O
the O
short O
p-p O
intervals O
between O
0.80-0.84 O
s, O
respectively O
. O

the O
duration O
of O
the O
pauses O
were O
equal O
or O
almost O
equal O
to O
one O
short O
plus O
one O
long O
p-p O
interval O
or O
to O
twice O
the O
basic O
sinus O
cycle O
. O

in O
one O
recording O
a O
short O
period O
of O
regular O
sinus O
rhythm O
with O
intermittent O
2/1 O
s-a B-NEG
block I-NEG
was O
observed O
. O

this O
short O
period O
of O
sinus O
rhythm O
was O
interrupted O
by O
sudden O
prolongation O
of O
the O
p-p O
interval O
starting O
the O
alternative O
rhythm O
. O

there O
were O
small O
changes O
in O
the O
shape O
of O
the O
p O
waves O
and O
p-r O
intervals O
. O

s-a O
conduction O
through O
two O
pathways O
, O
the O
first O
with O
2/1 O
block O
the O
second O
having O
0.12-0.14 O
s O
longer O
conduction O
time O
and O
with O
occasional O
2/1 O
block O
was O
proposed O
for O
the O
explanation O
of O
the O
alternating O
p-p O
interval O
and O
other O
electrocardiographic O
features O
seen O
. O

atropine O
1 O
mg O
given O
intravenously O
resulted O
in O
shortening O
of O
all O
p-p O
intervals O
without O
changing O
the O
rhythm O
. O

the O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol O
and O
when O
the O
drug O
was O
restarted O
a O
2/1 O
s-a B-NEG
block I-NEG
was O
seen O
. O

this O
was O
accepted O
as O
evidence O
for O
propranolol O
being O
the O
cause O
of O
this O
conduction B-NEG
disorder I-NEG
. O

-DOCSTART- O

antitumor O
effect O
, O
cardiotoxicity B-NEG
, O
and O
nephrotoxicity B-NEG
of O
doxorubicin O
in O
the O
igm O
solid O
immunocytoma B-NEG
-bearing O
lou/m/wsl O
rat O
. O

antitumor O
activity O
, O
cardiotoxicity B-NEG
, O
and O
nephrotoxicity B-NEG
induced O
by O
doxorubicin O
were O
studied O
in O
lou/m/wsl O
inbred O
rats O
each O
bearing O
a O
transplantable O
solid O
igm O
immunocytoma B-NEG
. O

animals O
with O
a O
tumor B-NEG
(diameter O
, O
15.8 O
+/- O
3.3 O
mm O
) O
were O
treated O
with O
iv O
injections O
of O
doxorubicin O
on O
5 O
consecutive O
days O
, O
followed O
by O
1 O
weekly O
injection O
for O
7 O
weeks O
( O
dose O
range O
, O
0.015-4.0 O
mg/kg O
body O
wt) O
. O
tumor B-NEG
regression O
was O
observed O
with O
0.5 O
mg O
doxorubicin/kg O
. O

complete O
disappearance O
of O
the O
tumor B-NEG
was O
induced O
with O
1.0 O
mg O
doxorubicin/kg O
. O

histologic O
evidence O
of O
cardiotoxicity B-NEG
scored O
as O
grade O
iii O
was O
only O
observed O
at O
a O
dose O
of O
1.0 O
mg O
doxorubicin/kg O
. O

light O
microscopic O
evidence O
of O
renal B-NEG
damage I-NEG
was O
seen O
above O
a O
dose O
of O
0.5 O
mg O
doxorubicin/kg O
, O
which O
resulted O
in O
albuminuria B-NEG
and O
very O
low O
serum O
albumin O
levels O
. O

in O
the O
group O
that O
received O
1.0 O
mg O
doxorubicin/kg O
, O
the O
serum O
albumin O
level O
decreased O
from O
33.6 O
+/- O
4.1 O
to O
1.5 O
+/- O
0.5 O
g/liter O
. O
ascites B-NEG
and O
hydrothorax B-NEG
were O
observed O
simultaneously O
. O

the O
same O
experiments O
were O
performed O
with O
non- O
tumor B-NEG
-bearing O
rats O
, O
in O
which O
no O
major O
differences O
were O
observed O
. O

in O
conclusion O
, O
antitumor O
activity O
, O
cardiotoxicity B-NEG
, O
and O
nephrotoxicity B-NEG
were O
studied O
simultaneously O
in O
the O
same O
lou/m/wsl O
rat O
. O
albuminuria B-NEG
due O
to O
renal B-NEG
damage I-NEG
led O
to O
extremely O
low O
serum O
albumin O
levels O
, O
so O
ascites B-NEG
and O
hydrothorax B-NEG
were O
not O
necessarily O
a O
consequence O
of O
the O
observed O
cardiomyopathy B-NEG
. O

-DOCSTART- O

intraoperative O
bradycardia B-NEG
and O
hypotension B-NEG
associated O
with O
timolol O
and O
pilocarpine O
eye O
drops O
. O

a O
69-yr-old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine O
nitrate O
and O
timolol O
maleate O
eye O
drops O
, O
developed O
a O
bradycardia B-NEG
and O
became O
hypotensive B-NEG
during O
halothane O
anaesthesia O
. O

both O
timolol O
and O
pilocarpine O
were O
subsequently O
identified O
in O
a O
24-h O
collection O
of O
urine O
. O

timolol O
( O
but O
not O
pilocarpine O
) O
was O
detected O
in O
a O
sample O
of O
plasma O
removed O
during O
surgery O
; O
the O
plasma O
concentration O
of O
timolol O
( O
2.6 O
ng O
ml-1 O
) O
was O
consistent O
with O
partial O
beta-adrenoceptor O
blockade O
. O

it O
is O
postulated O
that O
this O
action O
may O
have O
been O
enhanced O
during O
halothane O
anaesthesia O
with O
resultant O
bradycardia B-NEG
and O
hypotension B-NEG
. O

pilocarpine O
may O
have O
had O
a O
contributory O
effect O
. O

-DOCSTART- O

succinylcholine O
apnoea B-NEG
: O
attempted O
reversal O
with O
anticholinesterases O
. O

anticholinesterases O
were O
administered O
in O
an O
attempt O
to O
antagonize O
prolonged O
neuromuscular B-NEG
blockade I-NEG
following O
the O
administration O
of O
succinylcholine O
in O
a O
patient O
later O
found O
to O
be O
homozygous O
for O
atypical O
plasma O
cholinesterase O
. O

edrophonium O
10 O
mg O
, O
given O
74 O
min O
after O
succinylcholine O
, O
when O
train-of-four O
stimulation O
was O
characteristic O
of O
phase O
ii O
block O
, O
produced O
partial O
antagonism O
which O
was O
not O
sustained O
. O

repeated O
doses O
of O
edrophonium O
to O
70 O
mg O
and O
neostigmine O
to O
2.5 O
mg O
did O
not O
antagonize O
or O
augment O
the O
block O
. O

spontaneous O
respiration O
recommenced O
200 O
min O
after O
succinylcholine O
administration O
. O

it O
is O
concluded O
that O
anticholinesterases O
are O
only O
partially O
effective O
in O
restoring O
neuromuscular O
function O
in O
succinylcholine O
apnoea B-NEG
despite O
muscle O
twitch O
activity O
typical O
of O
phase O
ii O
block O
. O

-DOCSTART- O

effect O
of O
doxorubicin O
on O
[omega-i-131]heptadecanoic O
acid O
myocardial O
scintigraphy O
and O
echocardiography O
in O
dogs O
. O

the O
effects O
of O
serial O
treatment O
with O
doxorubicin O
on O
dynamic O
myocardial O
scintigraphy O
with O
[omega-i-131]heptadecanoic O
acid O
( O
i-131 O
ha) O
, O
and O
on O
global O
left-ventricular O
function O
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group O
of O
nine O
mongrel O
dogs O
. O

total O
extractable O
myocardial O
lipid O
was O
compared O
postmortem O
between O
a O
group O
of O
control O
dogs O
and O
doxorubicin-treated O
dogs O
. O

a O
significant O
and O
then O
progressive O
fall O
in O
global O
lv O
function O
was O
observed O
at O
a O
cumulative O
doxorubicin O
dose O
of O
4 O
mg/kg O
. O

a O
significant O
increase O
in O
the O
myocardial O
t1/2 O
of O
the O
i-131 O
ha O
was O
observed O
only O
at O
a O
higher O
cumulative O
dose O
, O
10 O
mg/kg O
. O

no O
significant O
alteration O
in O
total O
extractable O
myocardial O
lipids O
was O
observed O
between O
control O
dogs O
and O
those O
treated O
with O
doxorubicin O
. O

our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
i-131 O
ha O
are O
not O
the O
initiating O
factor O
in O
doxorubicin O
cardiotoxicity B-NEG
. O

-DOCSTART- O

hemodynamics O
and O
myocardial O
metabolism O
under O
deliberate O
hypotension B-NEG
. O

an O
experimental O
study O
in O
dogs O
. O

coronary O
blood O
flow O
, O
cardiac O
work O
and O
metabolism O
were O
studied O
in O
dogs O
under O
sodium O
nitroprusside O
( O
snp O
) O
and O
trimetaphan O
( O
tmp O
) O
deliberate O
hypotension B-NEG
( O
20% O
and O
40% O
mean O
pressure O
decrease O
from O
baseline) O
. O

regarding O
the O
effects O
of O
drug-induced O
hypotension B-NEG
on O
coronary O
blood O
flow O
, O
aortic O
and O
coronary O
sinus O
metabolic O
data O
(ph O
, O
po2 O
, O
pco2 O
) O
we O
could O
confirm O
that O
nitroprusside O
hypotension B-NEG
could O
be O
safely O
used O
to O
30% O
mean O
blood O
pressure O
decrease O
from O
control O
, O
trimetaphan O
hypotension B-NEG
to O
20% O
mean O
blood O
pressure O
decrease O
. O

cardiac O
work O
was O
significantly O
reduced O
during O
snp O
hypotension B-NEG
. O

myocardial O
o2 O
consumption O
and O
o2 O
availability O
were O
directly O
dependent O
on O
the O
coronary O
perfusion O
. O

careful O
invasive O
monitoring O
of O
the O
blood O
pressure O
, O
blood O
gases O
and O
of O
the O
ecg O
st-t O
segment O
is O
mandatory O
. O

-DOCSTART- O

evidence O
for O
a O
selective O
brain O
noradrenergic O
involvement O
in O
the O
locomotor O
stimulant O
effects O
of O
amphetamine O
in O
the O
rat O
. O

male O
rats O
received O
the O
noradrenaline O
neurotoxin O
dsp4 O
( O
50 O
mg/kg O
) O
7 O
days O
prior O
to O
injection O
of O
d-amphetamine O
( O
10 O
or O
40 O
mumol/kg O
i.p.) O
. O

the O
hyperactivity B-NEG
induced O
by O
d-amphetamine O
( O
10 O
mumol/kg O
) O
was O
significantly O
reduced O
by O
dsp4 O
pretreatment O
. O

however O
, O
the O
increased O
rearings O
and O
the O
amphetamine-induced O
stereotypies B-NEG
were O
not O
blocked O
by O
pretreatment O
with O
dsp4 O
. O

the O
reduction O
of O
amphetamine O
hyperactivity B-NEG
induced O
by O
dsp4 O
was O
blocked O
by O
pretreatment O
with O
the O
noradrenaline-uptake O
blocking O
agent O
, O
desipramine O
, O
which O
prevents O
the O
neurotoxic B-NEG
action O
of O
dsp4 O
. O

the O
present O
results O
suggest O
a O
selective O
involvement O
of O
central O
noradrenergic O
neurones O
in O
the O
locomotor O
stimulant O
effect O
of O
amphetamine O
in O
the O
rat O
. O

-DOCSTART- O

accelerated B-NEG
junctional I-NEG
rhythms I-NEG
during O
oral O
verapamil O
therapy O
. O

this O
study O
examined O
the O
frequency O
of O
atrioventricular O
( O
av O
) O
dissociation O
and O
accelerated B-NEG
junctional I-NEG
rhythms I-NEG
in O
59 O
patients O
receiving O
oral O
verapamil O
. O
accelerated B-NEG
junctional I-NEG
rhythms I-NEG
and O
av O
dissociation O
were O
frequent O
in O
patients O
with O
supraventricular B-NEG
tachyarrhythmias I-NEG
, O
particularly O
av O
nodal O
reentry O
. O

verapamil O
administration O
to O
these O
patients O
led O
to O
an O
asymptomatic O
increase O
in O
activity O
of O
these O
junctional O
pacemakers O
. O

in O
patients O
with O
various O
chest B-NEG
pain I-NEG
syndromes O
, O
verapamil O
neither O
increased O
the O
frequency O
of O
junctional O
rhythms O
nor O
suppressed O
their O
role O
as O
escape O
rhythms O
under O
physiologically O
appropriate O
circumstances O
. O

-DOCSTART- O

treatment O
of O
ovarian B-NEG
cancer I-NEG
with O
a O
combination O
of O
cis-platinum O
, O
adriamycin O
, O
cyclophosphamide O
and O
hexamethylmelamine O
. O

during O
the O
last O
2 O
1/2 O
years O
, O
38 O
patients O
with O
ovarian B-NEG
cancer I-NEG
were O
treated O
with O
a O
combination O
of O
cisplatinum O
(cpdd) O
, O
50 O
mg/m2 O
, O
adriamycin O
, O
30 O
mg/m2 O
, O
cyclophosphamide O
, O
300 O
mg/m2 O
, O
on O
day O
1; O
and O
hexamethylmelamine O
(hmm) O
, O
6 O
mg/kg O
daily O
, O
for O
14 O
days O
. O

each O
course O
was O
repeated O
monthly O
. O

2 O
patients O
had O
stage O
ii O
, O
14 O
stage O
iii O
and O
22 O
stage O
iv O
disease O
. O

14 O
of O
the O
38 O
patients O
were O
previously O
treated O
with O
chemotherapy O
, O
1 O
with O
radiation O
, O
6 O
with O
both O
chemotherapy O
and O
radiation O
, O
and O
17 O
did O
not O
have O
any O
treatment O
before O
cpdd O
combination O
. O

31 O
of O
the O
38 O
cases O
( O
81.5% O
) O
demonstrated O
objective O
responses O
lasting O
for O
2 O
months O
or O
more O
. O

these O
responses O
were O
partial O
in O
19 O
and O
complete O
in O
12 O
cases O
. O
hematologic B-NEG
toxicity I-NEG
was O
moderate O
and O
with O
reversible O
anemia B-NEG
developing O
in O
71% O
of O
patients O
. O

gastrointestinal O
side O
effects O
from O
cpdd O
were O
universal O
. O

hmm O
gastrointestinal B-NEG
toxicity I-NEG
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

severe O
nephrotoxicity B-NEG
was O
observed O
in O
2 O
patients O
but O
was O
reversible O
. O

there O
were O
no O
drug-related O
deaths O
. O

-DOCSTART- O

nontraumatic O
dissecting B-NEG
aneurysm I-NEG
of O
the O
basilar O
artery O
. O

a O
case O
of O
nontraumatic O
dissecting B-NEG
aneurysm I-NEG
of O
the O
basilar O
artery O
in O
association O
with O
hypertension B-NEG
, O
smoke O
, O
and O
oral O
contraceptives O
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked-in B-NEG
syndrome I-NEG
. O

-DOCSTART- O

propylthiouracil-induced O
hepatic B-NEG
damage I-NEG
. O

two O
cases O
of O
propylthiouracil-induced O
liver B-NEG
damage I-NEG
have O
been O
observed O
. O

the O
first O
case O
is O
of O
an O
acute O
type O
of O
damage O
, O
proven O
by O
rechallenge O
; O
the O
second O
presents O
a O
clinical O
and O
histologic O
picture O
resembling O
chronic B-NEG
active I-NEG
hepatitis I-NEG
, O
with O
spontaneous O
remission O
. O

-DOCSTART- O

studies O
on O
the O
bradycardia B-NEG
induced O
by O
bepridil O
. O

bepridil O
, O
a O
novel O
active O
compound O
for O
prophylactic O
treatment O
of O
anginal B-NEG
attacks I-NEG
, O
induced O
persistent O
bradycardia B-NEG
and O
a O
non-specific O
anti- O
tachycardial B-NEG
effect O
, O
the O
mechanisms O
of O
which O
were O
investigated O
in O
vitro O
and O
in O
vivo O
. O

in O
vitro O
perfusion O
of O
bepridil O
in O
the O
life-support O
medium O
for O
isolated O
sino-atrial O
tissue O
from O
rabbit O
heart O
, O
caused O
a O
reduction O
in O
action O
potential O
( O
ap O
) O
spike O
frequency O
( O
recorded O
by O
kcl O
microelectrodes O
) O
starting O
at O
doses O
of O
5 O
x O
10(-6 O
) O
m. O

this O
effect O
was O
dose-dependent O
up O
to O
concentrations O
of O
5 O
x O
10(-5 O
) O
m, O
whereupon O
blockade O
of O
sinus O
activity O
set O
in O
. O

bepridil O
at O
a O
dose O
of O
5 O
x O
10(-6 O
) O
m, O
induced O
a O
concomitant O
reduction O
in O
ap O
amplitude O
( O
falling O
from O
71 O
+/- O
8 O
mv O
to O
47 O
+/- O
6 O
mv) O
, O
maximum O
systolic O
depolarization O
velocity O
( O
phase O
0) O
which O
fell O
from O
1.85 O
+/- O
0.35 O
v/s O
to O
0.84 O
+/- O
0.28 O
v/s O
, O
together O
with O
maximum O
diastolic O
depolarization O
velocity O
( O
phase O
4) O
which O
fell O
from O
38 O
+/- O
3 O
mv/s O
to O
24 O
+/- O
5 O
mv/s O
. O

in O
vivo O
injection O
of O
bepridil O
at O
a O
dose O
of O
5 O
mg/kg O
( O
i.v. O
) O
into O
6 O
anaesthetized O
dogs O
which O
had O
undergone O
ablation O
of O
all O
the O
extrinsic O
cardiac O
afferent O
nerve O
supply O
, O
together O
with O
a O
bilateral O
medullo-adrenalectomy O
, O
caused O
a O
marked O
reduction O
in O
heart O
rate O
which O
fell O
from O
98.7 O
+/- O
4.2 O
beats/min O
to O
76 O
+/- O
5.3 O
beats/min O
sustained O
for O
more O
than O
45 O
min O
. O

it O
is O
concluded O
that O
bepridil O
reduces O
heart O
rate O
by O
acting O
directly O
on O
the O
sinus O
node O
. O

this O
effect O
, O
which O
results O
in O
a O
flattening O
of O
the O
phase O
0 O
and O
phase O
4 O
slope O
, O
together O
with O
a O
longer O
ap O
duration O
, O
may O
be O
due O
to O
an O
increase O
in O
the O
time O
constants O
of O
slow O
inward O
ionic O
currents O
( O
already O
demonstrated O
elsewhere) O
, O
but O
also O
to O
an O
increased O
time O
constant O
for O
deactivation O
of O
the O
outward O
potassium O
current O
(ip) O
. O

-DOCSTART- O

hepatitis B-NEG
and O
renal B-NEG
tubular I-NEG
acidosis I-NEG
after O
anesthesia O
with O
methoxyflurane O
. O

a O
69-year-old O
man O
operated O
for O
acute B-NEG
cholecystitis I-NEG
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B-NEG
insufficiency I-NEG
syndrome I-NEG
and O
renal B-NEG
tubular I-NEG
acidosis I-NEG
. O

massive O
bleeding B-NEG
appeared O
during O
surgery O
which O
lasted O
for O
six O
hours O
. O

postoperative O
evolution O
under O
supportive O
therapy O
was O
favourable O
. O

complete O
recovery O
was O
confirmed O
by O
repeated O
controls O
performed O
over O
a O
period O
of O
one O
year O
after O
surgery O
. O

-DOCSTART- O

pituitary O
response O
to O
luteinizing O
hormone-releasing O
hormone O
during O
haloperidol-induced O
hyperprolactinemia B-NEG
. O

the O
effects O
of O
a O
6-hour O
infusion O
with O
haloperidol O
on O
serum O
prolactin O
and O
luteinizing O
hormone O
( O
lh O
) O
levels O
was O
studied O
in O
a O
group O
of O
male O
subjects O
. O

five O
hours O
after O
starting O
the O
infusions O
, O
a O
study O
of O
the O
pituitary O
responses O
to O
lh-releasing O
hormone O
( O
lh-rh O
) O
was O
carried O
out O
. O

control O
patients O
received O
infusions O
of O
0.9% O
nacl O
solution O
. O

during O
the O
course O
of O
haloperidol O
infusions O
, O
significant O
hyperprolactinemia B-NEG
was O
found O
, O
together O
with O
an O
abolished O
pituitary O
response O
to O
lh-rh O
, O
as O
compared O
with O
responses O
of O
control O
subjects O
. O

-DOCSTART- O

antirifampicin O
antibodies O
in O
acute O
rifampicin-associated O
renal B-NEG
failure I-NEG
. O

5 O
patients O
with O
acute B-NEG
renal I-NEG
failure I-NEG
(3 O
with O
thrombopenia B-NEG
and O
hemolysis B-NEG
) O
induced O
by O
the O
reintroduction O
of O
rifampicin O
are O
described O
. O

no O
correlation O
was O
found O
between O
the O
severity O
of O
clinical O
manifestations O
and O
the O
total O
dose O
taken O
by O
the O
patients O
. O

in O
all O
but O
1 O
patient O
, O
antirifampicin O
antibodies O
were O
detected O
. O

antibodies O
suggested O
to O
be O
of O
the O
igm O
class O
were O
detected O
in O
all O
3 O
patients O
with O
hematological B-NEG
disorders I-NEG
. O

the O
pattern O
of O
non-specific O
acute B-NEG
tubular I-NEG
necrosis I-NEG
found O
in O
the O
2 O
biopsied O
patients O
, O
indistinguishable O
from O
that O
of O
ischemic O
origin O
, O
raised O
the O
possibility O
of O
a O
vascular-mediated O
damage O
. O

in O
3 O
patients O
, O
the O
possibility O
of O
a O
triggering O
immunoallergic O
mechanism O
is O
discussed O
. O

-DOCSTART- O

cardiovascular O
effects O
of O
hypotension B-NEG
induced O
by O
adenosine O
triphosphate O
and O
sodium O
nitroprusside O
on O
dogs O
with O
denervated O
hearts O
. O

adenosine O
triphosphate O
( O
atp O
) O
and O
sodium O
nitroprusside O
( O
snp O
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension B-NEG
during O
anesthesia O
. O

snp O
is O
authorized O
for O
clinical O
use O
in O
usa O
and O
uk O
, O
and O
atp O
is O
clinically O
used O
in O
other O
countries O
such O
as O
japan O
. O

we O
investigated O
how O
these O
two O
drugs O
act O
on O
the O
cardiovascular O
systems O
of O
20 O
dogs O
whose O
hearts O
had O
been O
denervated O
by O
a O
procedure O
we O
had O
devised O
. O

atp O
( O
10 O
dogs O
) O
or O
snp O
( O
10 O
dogs O
) O
was O
administered O
to O
reduce O
mean O
arterial O
pressure O
by O
30% O
to O
70% O
of O
control O
. O

before O
, O
during O
and O
after O
induced O
hypotension B-NEG
, O
we O
measured O
major O
cardiovascular O
parameters O
. O
hypotension B-NEG
induced O
by O
atp O
was O
accompanied O
by O
significant O
decreases O
in O
mean O
pulmonary O
arterial O
pressure O
(p O
less O
than O
0.001) O
, O
central O
venous O
pressure O
(p O
less O
than O
0.001) O
, O
left O
ventricular O
end-diastolic O
pressure O
(p O
less O
than O
0.001) O
, O
total O
peripheral O
resistance O
(p O
less O
than O
0.001) O
, O
rate O
pressure O
product O
(p O
less O
than O
0.001) O
, O
total O
body O
oxygen O
consumption O
(p O
less O
than O
0.05) O
, O
and O
heart O
rate O
(p O
less O
than O
0.001) O
; O
all O
these O
variables O
returned O
normal O
within O
30 O
min O
after O
atp O
was O
stopped O
. O

cardiac O
output O
did O
not O
change O
. O

during O
hypotension B-NEG
produced O
by O
snp O
similar O
decreases O
were O
observed O
in O
mean O
pulmonary O
arterial O
pressure O
(p O
less O
than O
0.01) O
, O
central O
venous O
pressure O
(p O
less O
than O
0.001) O
, O
left O
ventricular O
end-diastolic O
pressure O
(p O
less O
than O
0.01) O
, O
total O
peripheral O
resistance O
(p O
less O
than O
0.001) O
, O
rate O
pressure O
product O
(p O
less O
than O
0.001) O
, O
and O
oxygen O
content O
difference O
between O
arterial O
and O
mixed O
venous O
blood O
(p O
less O
than O
0.05) O
, O
while O
heart O
rate O
(p O
less O
than O
0.001 O
) O
and O
cardiac O
output O
(p O
less O
than O
0.05 O
) O
were O
increased O
. O

recoveries O
of O
heart O
rate O
and O
left O
ventricular O
end-diastolic O
pressure O
were O
not O
shown O
within O
60 O
min O
after O
snp O
had O
been O
stopped O
. O

both O
atp O
and O
snp O
should O
act O
on O
the O
pacemaker O
tissue O
of O
the O
heart O
. O

-DOCSTART- O

comparative O
study O
: O
endografine O
(diatrizoate) O
, O
vasurix O
polyvidone O
(acetrizoate) O
, O
dimer-x O
( O
iocarmate O
) O
and O
hexabrix O
( O
ioxaglate O
) O
in O
hysterosalpingography O
. O

side O
effects O
of O
hysterosalpingography O
with O
dimer-x O
, O
hexabrix O
, O
vasurix O
polyvidone O
and O
endografine O
in O
142 O
consecutive O
patients O
, O
receiving O
one O
of O
the O
four O
tested O
media O
were O
evaluated O
from O
replies O
to O
postal O
questionnaires O
. O

the O
dimer-x O
group O
had O
a O
higher O
incidence O
of O
nausea B-NEG
and O
dizziness B-NEG
. O

the O
endografine O
group O
had O
a O
higher O
incidence O
of O
abdominal B-NEG
pain I-NEG
. O

these O
differences O
occur O
especially O
in O
the O
age O
groups O
under O
30 O
years O
. O

hexabrix O
and O
vasurix O
polyvidone O
are O
considered O
the O
best O
contrast O
media O
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity B-NEG
hexabrix O
should O
be O
preferred O
. O

-DOCSTART- O

post-suxamethonium O
pains B-NEG
in O
nigerian O
surgical O
patients O
. O

contrary O
to O
an O
earlier O
report O
by O
coxon O
, O
scoline O
pain B-NEG
occurs O
in O
african O
negroes O
. O

its O
incidence O
was O
determined O
in O
a O
prospective O
study O
involving O
a O
total O
of O
100 O
nigerian O
patients O
( O
50 O
out-patients O
and O
50 O
in-patients) O
. O

about O
62% O
of O
the O
out-patients O
developed O
scoline O
pain B-NEG
as O
compared O
with O
about O
26% O
among O
the O
in-patients O
. O

the O
abolition O
of O
muscle O
fasciculations B-NEG
( O
by O
0.075mg/kg O
dose O
of O
fazadinium O
) O
did O
not O
influence O
the O
occurrence O
of O
scoline O
pain B-NEG
. O

neither O
the O
type O
of O
induction O
agent O
( O
althesin O
or O
thiopentone O
) O
nor O
the O
salt O
preparation O
of O
suxamethonium O
used O
( O
chloride O
or O
bromide) O
, O
affected O
the O
incidence O
of O
scoline O
pain B-NEG
. O

-DOCSTART- O

medial O
changes O
in O
arterial O
spasm B-NEG
induced O
by O
l-norepinephrine O
. O

in O
normal O
rats O
, O
the O
media O
of O
small O
arteries O
( O
0.4--0.2 O
mm O
in O
diameter O
) O
previously O
was O
shown O
to O
contain O
intracellular O
vacuoles O
, O
identified O
ultrastructurally O
as O
herniations O
of O
one O
smooth O
muscle O
cell O
into O
another O
. O

the O
hypothesis O
that O
intense O
vasoconstriction O
would O
increase O
the O
number O
of O
such O
vacuoles O
has O
been O
tested O
. O

in O
the O
media O
of O
the O
saphenous O
artery O
and O
its O
distal O
branch O
, O
vasoconstriction O
induced O
by O
l-norepinephrine O
produced O
many O
cell-to-cell O
hernias B-NEG
within O
15 O
minutes O
. O

at O
1 O
day O
their O
number O
was O
reduced O
to O
about O
1/10 O
of O
the O
original O
number O
. O

by O
7 O
days O
the O
vessel O
was O
almost O
restored O
to O
normal O
. O

triple O
stimulation O
over O
1 O
day O
induced O
more O
severe O
changes O
in O
the O
media O
. O

these O
findings O
suggest O
that O
smooth O
muscle O
cells O
are O
susceptible O
to O
damage O
in O
the O
course O
of O
their O
specific O
function O
. O

the O
experimental O
data O
are O
discussed O
in O
relation O
to O
medial O
changes O
observed O
in O
other O
instances O
of O
arterial O
spasm B-NEG
. O

endothelial O
changes O
that O
developed O
in O
the O
same O
experimental O
model O
were O
described O
in O
a O
previous O
paper O
. O

-DOCSTART- O

abnormalities O
of O
the O
pupil O
and O
visual-evoked O
potential O
in O
quinine O
amblyopia B-NEG
. O

total O
blindness B-NEG
with O
a O
transient O
tonic B-NEG
pupillary I-NEG
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual-evoked O
potentials O
developed O
in O
a O
54-year-old O
man O
after O
the O
use O
of O
quinine O
sulfate O
for O
leg B-NEG
cramps I-NEG
. O

he O
later O
recovered O
normal O
visual O
acuity O
. O

a O
transient O
tonic B-NEG
pupillary I-NEG
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual-evoked O
potentials O
in O
quinine O
toxicity B-NEG
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O
. O

-DOCSTART- O

suxamethonium-induced O
jaw B-NEG
stiffness I-NEG
and O
myalgia B-NEG
associated O
with O
atypical O
cholinesterase O
: O
case O
report O
. O

an O
11-year-old O
boy O
was O
given O
halothane O
, O
nitrous O
oxide O
and O
oxygen O
, O
pancuronium O
0.4 O
mg O
and O
suxamethonium O
100 O
mg O
for O
induction O
of O
anaesthesia O
. O

in O
response O
to O
this O
a O
marked O
jaw B-NEG
stiffness I-NEG
occurred O
which O
lasted O
for O
two O
minutes O
and O
the O
anaesthesia O
were O
terminated O
. O

four O
hours O
of O
apnoea B-NEG
ensued O
and O
he O
suffered O
generalized O
severe O
myalgia B-NEG
lasting O
for O
one O
week O
. O

he O
was O
found O
to O
have O
atypical O
plasma O
cholinesterase O
with O
a O
dibucaine O
number O
of O
12 O
, O
indicating O
homozygocity O
. O

this O
was O
verified O
by O
study O
of O
the O
family O
. O

the O
case O
shows O
that O
prolonged B-NEG
jaw I-NEG
rigidity I-NEG
and O
myalgia B-NEG
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium O
. O

-DOCSTART- O

indomethacin-induced O
hyperkalemia B-NEG
in O
three O
patients O
with O
gouty B-NEG
arthritis I-NEG
. O

we O
describe O
three O
patients O
in O
whom O
severe O
, O
life-threatening O
hyperkalemia B-NEG
and O
renal B-NEG
insufficiency I-NEG
developed O
after O
treatment O
of O
acute O
gouty B-NEG
arthritis I-NEG
with O
indomethacin O
. O

this O
complication O
may O
result O
from O
an O
inhibition O
of O
prostaglandin O
synthesis O
and O
consequent O
hyporeninemic B-NEG
hypoaidosteronism I-NEG
. O

careful O
attention O
to O
renal O
function O
and O
potassium O
balance O
in O
patients O
receiving O
indomethacin O
or O
other O
nonsteroidal O
anti-inflammatory O
agents O
, O
particularly O
in O
those O
patients O
with O
diabetes B-NEG
mellitus I-NEG
or O
preexisting O
renal B-NEG
disease I-NEG
, O
will O
help O
prevent O
this O
potentially O
serious O
complication O
. O

-DOCSTART- O

etomidate O
: O
a O
foreshortened O
clinical O
trial O
. O

a O
clinical O
evaluation O
of O
etomidate O
for O
outpatient O
cystoscopy O
was O
embarked O
upon O
. O

unpremedicated O
patients O
were O
given O
fentanyl O
1 O
microgram/kg O
followed O
by O
etomidate O
0.3 O
mg/kg O
. O

anaesthesia O
was O
maintained O
with O
intermittent O
etomidate O
in O
2-4 O
mg O
doses O
. O

patients O
were O
interviewed O
personally O
later O
the O
same O
day O
, O
and O
by O
questionnaire O
three O
to O
four O
weeks O
later O
. O

the O
trial O
was O
discontinued O
after O
20 O
cases O
because O
of O
an O
unacceptable O
incidence O
of O
side O
effects O
. O

venous O
pain B-NEG
occurred O
in O
68% O
of O
patients O
and O
50% O
had O
redness O
, O
pain B-NEG
or O
swelling B-NEG
related O
to O
the O
injection O
site O
, O
in O
some O
cases O
lasting O
up O
to O
three O
weeks O
after O
anaesthesia O
. O

skeletal O
movements O
occurred O
in O
50% O
of O
patients O
; O
30% O
experienced O
respiratory B-NEG
upset I-NEG
, O
one O
sufficiently O
severe O
to O
necessitate O
abandoning O
the O
technique O
. O
nausea B-NEG
and O
vomiting B-NEG
occurred O
in O
40% O
and O
25% O
had O
disturbing O
emergence O
psychoses B-NEG
. O

-DOCSTART- O

levodopa-induced O
dyskinesias B-NEG
are O
improved O
by O
fluoxetine O
. O

we O
evaluated O
the O
severity O
of O
motor B-NEG
disability I-NEG
and O
dyskinesias B-NEG
in O
seven O
levodopa-responsive O
patients O
with O
parkinson's B-NEG
disease I-NEG
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine O
agonist O
, O
apomorphine O
, O
before O
and O
after O
the O
administration O
of O
fluoxetine O
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+/- O
1 O
days O
. O

after O
fluoxetine O
treatment O
, O
there O
was O
a O
significant O
47% O
improvement O
(p O
< O
0.05 O
) O
of O
apomorphine-induced O
dyskinesias B-NEG
without O
modification O
of O
parkinsonian B-NEG
motor B-NEG
disability I-NEG
. O

the O
dyskinesias B-NEG
were O
reduced O
predominantly O
in O
the O
lower O
limbs O
during O
the O
onset O
and O
disappearance O
of O
dystonic B-NEG
dyskinesias I-NEG
( O
onset- O
and O
end-of-dose O
dyskinesias B-NEG
) O
and O
in O
the O
upper O
limbs O
during O
choreic B-NEG
mid-dose I-NEG
dyskinesias I-NEG
. O

the O
results O
suggest O
that O
increased O
brain O
serotoninergic O
transmission O
with O
fluoxetine O
may O
reduce O
levodopa- O
or O
dopamine O
agonist-induced O
dyskinesias B-NEG
without O
aggravating O
parkinsonian B-NEG
motor B-NEG
disability I-NEG
. O

-DOCSTART- O

a O
large O
population-based O
follow-up O
study O
of O
trimethoprim-sulfamethoxazole O
, O
trimethoprim O
, O
and O
cephalexin O
for O
uncommon O
serious O
drug B-NEG
toxicity I-NEG
. O

we O
conducted O
a O
population-based O
45-day O
follow-up O
study O
of O
232,390 O
people O
who O
were O
prescribed O
trimethoprim-sulfamethoxazole O
(tmp-smz) O
, O
266,951 O
prescribed O
trimethoprim O
alone O
, O
and O
196,397 O
prescribed O
cephalexin O
, O
to O
estimate O
the O
risk O
of O
serious O
liver B-NEG
, O
blood I-NEG
, O
skin I-NEG
, O
and I-NEG
renal I-NEG
disorders I-NEG
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

the O
results O
were O
based O
on O
information O
recorded O
on O
office O
computers O
by O
selected O
general O
practitioners O
in O
the O
united O
kingdom O
, O
together O
with O
a O
review O
of O
clinical O
records O
. O

the O
risk O
of O
clinically O
important O
idiopathic O
liver B-NEG
disease I-NEG
was O
similar O
for O
persons O
prescribed O
tmp-smz O
( O
5.2/100,000 O
) O
and O
those O
prescribed O
trimethoprim O
alone O
(3.8/100,000) O
. O

the O
risk O
for O
those O
prescribed O
cephalexin O
was O
somewhat O
lower O
(2.0/100,000) O
. O

only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
tmp-smz O
; O
of O
seven O
with O
erythema B-NEG
multiforme I-NEG
and O
stevens-johnson B-NEG
syndrome I-NEG
, O
four O
were O
exposed O
to O
tmp-smz O
. O

the O
one O
case O
of O
toxic B-NEG
epidermal I-NEG
necrolysis I-NEG
occurred O
in O
a O
patient O
who O
took O
cephalexin O
. O

finally O
, O
only O
five O
cases O
of O
acute O
parenchymal O
renal B-NEG
disease I-NEG
occurred O
, O
none O
likely O
to O
be O
caused O
by O
a O
study O
drug O
. O

we O
conclude O
that O
the O
risk O
of O
the O
serious O
diseases O
studied O
is O
small O
for O
the O
three O
agents O
, O
and O
compares O
reasonably O
with O
the O
risk O
for O
many O
other O
antibiotics O
. O

-DOCSTART- O

clinical O
safety O
of O
lidocaine O
in O
patients O
with O
cocaine-associated O
myocardial B-NEG
infarction I-NEG
. O

study O
objective O
: O
to O
evaluate O
the O
safety O
of O
lidocaine O
in O
the O
setting O
of O
cocaine-induced O
myocardial B-NEG
infarction I-NEG
( O
mi B-NEG
). O

design O
: O
a O
retrospective O
, O
multicenter O
study O
. O

setting O
: O
twenty-nine O
university O
, O
university-affiliated O
, O
or O
community O
hospitals O
during O
a O
6-year O
period O
( O
total O
of O
117 O
cumulative O
hospital-years) O
. O

participants O
: O
patients O
with O
cocaine-associated O
mi B-NEG
who O
received O
lidocaine O
in O
the O
emergency O
department O
. O

results O
: O
of O
29 O
patients O
who O
received O
lidocaine O
in O
the O
setting O
of O
cocaine-associated O
mi B-NEG
, O
no O
patient O
died O
; O
exhibited O
bradydysrhythmias B-NEG
, O
ventricular B-NEG
tachycardia I-NEG
, O
or O
ventricular B-NEG
fibrillation I-NEG
; O
or O
experienced O
seizures B-NEG
after O
administration O
of O
lidocaine O
( O
95% O
confidence O
interval O
, O
0% O
to O
11%) O
. O

conclusion O
: O
despite O
theoretical O
concerns O
that O
lidocaine O
may O
enhance O
cocaine O
toxicity B-NEG
, O
the O
use O
of O
lidocaine O
in O
patients O
with O
cocaine-associated O
mi B-NEG
was O
not O
associated O
with O
significant O
cardiovascular B-NEG
or I-NEG
central I-NEG
nervous I-NEG
system I-NEG
toxicity I-NEG
. O

-DOCSTART- O

paclitaxel O
3-hour O
infusion O
given O
alone O
and O
combined O
with O
carboplatin O
: O
preliminary O
results O
of O
dose-escalation O
trials O
. O

paclitaxel O
(taxol O
; O
bristol-myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
by O
3-hour O
infusion O
was O
combined O
with O
carboplatin O
in O
a O
phase O
i/ii O
study O
directed O
to O
patients O
with O
non-small B-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
. O

carboplatin O
was O
given O
at O
a O
fixed O
target O
area O
under O
the O
concentration-time O
curve O
of O
6.0 O
by O
the O
calvert O
formula O
, O
whereas O
paclitaxel O
was O
escalated O
in O
patient O
cohorts O
from O
150 O
mg/m2 O
( O
dose O
level O
i) O
to O
175 O
, O
200 O
, O
225 O
, O
and O
250 O
mg/m2 O
. O

the O
225 O
mg/m2 O
level O
was O
expanded O
for O
the O
phase O
ii O
study O
since O
the O
highest O
level O
achieved O
( O
250 O
mg/m2 O
) O
required O
modification O
because O
of O
nonhematologic O
toxicities B-NEG
( O
arthralgia B-NEG
and O
sensory B-NEG
neuropathy I-NEG
). O

therapeutic O
effects O
were O
noted O
at O
all O
dose O
levels O
, O
with O
objective O
responses O
in O
17 O
( O
two O
complete O
and O
15 O
partial O
regressions O
) O
of O
41 O
previously O
untreated O
patients O
. O
toxicities B-NEG
were O
compared O
with O
a O
cohort O
of O
patients O
in O
a O
phase O
i O
trial O
of O
paclitaxel O
alone O
at O
identical O
dose O
levels O
. O

carboplatin O
did O
not O
appear O
to O
add O
to O
the O
hematologic B-NEG
toxicities I-NEG
observed O
, O
and O
the O
paclitaxel/carboplatin O
combination O
could O
be O
dosed O
every O
3 O
weeks O
. O

-DOCSTART- O

the O
dose-dependent O
effect O
of O
misoprostol O
on O
indomethacin-induced O
renal B-NEG
dysfunction I-NEG
in O
well O
compensated O
cirrhosis B-NEG
. O

misoprostol O
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin-induced O
renal B-NEG
dysfunction I-NEG
in O
well O
compensated O
cirrhotic B-NEG
patients O
. O

the O
aim O
of O
this O
study O
was O
to O
determine O
if O
the O
prophylactic O
value O
of O
misoprostol O
was O
dose-dependent O
. O

parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium O
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic B-NEG
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin O
and O
various O
doses O
of O
misoprostol O
. O

the O
200-micrograms O
dose O
was O
able O
to O
totally O
abolish O
the O
deleterious O
renal O
effects O
of O
indomethacin O
, O
whereas O
the O
800-micrograms O
dose O
resulted O
in O
significant O
worsening O
of O
renal O
hemodynamics O
and O
sodium O
retention O
. O

these O
changes O
were O
maximal O
in O
the O
hour O
immediately O
after O
medications O
and O
slowly O
returned O
toward O
base-line O
levels O
thereafter O
. O

these O
results O
suggest O
that O
the O
renal O
protective O
effects O
of O
misoprostol O
is O
dose-dependent O
. O

however O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol O
to O
prevent O
the O
adverse O
effects O
of O
indomethacin O
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti-inflammatory O
therapy O
in O
patients O
with O
cirrhosis B-NEG
. O

-DOCSTART- O

increased O
frequency O
and O
severity O
of O
angio-oedema B-NEG
related O
to O
long-term O
therapy O
with O
angiotensin-converting O
enzyme O
inhibitor O
in O
two O
patients O
. O

adverse O
reactions O
to O
drugs O
are O
well O
recognized O
as O
a O
cause O
of O
acute O
or O
chronic O
urticaria B-NEG
, O
and O
angio-oedema B-NEG
. O

angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitors O
, O
used O
to O
treat O
hypertension B-NEG
and O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
were O
introduced O
in O
europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

soon O
after O
the O
introduction O
of O
ace O
inhibitors O
, O
acute O
bouts O
of O
angio-oedema B-NEG
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

we O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ace O
inhibitors O
after O
long-term O
use O
and O
in O
patients O
with O
pre-existing O
angio-oedema B-NEG
. O

-DOCSTART- O

myoclonus B-NEG
associated O
with O
lorazepam O
therapy O
in O
very-low-birth-weight O
infants O
. O

lorazepam O
is O
being O
used O
with O
increasing O
frequency O
as O
a O
sedative O
in O
the O
newborn O
and O
the O
young O
infant O
. O

concern O
has O
been O
raised O
with O
regard O
to O
the O
safety O
of O
lorazepam O
in O
this O
age O
group O
, O
especially O
in O
very-low-birth-weight O
(vlbw O
; O
< O
1,500 O
g) O
infants O
. O

three O
young O
infants O
, O
all O
of O
birth O
weight O
< O
1,500 O
g, O
experienced O
myoclonus B-NEG
following O
the O
intravenous O
administration O
of O
lorazepam O
. O

the O
potential O
neurotoxic B-NEG
effects O
of O
the O
drug O
( O
and O
its O
vehicle O
) O
in O
this O
population O
are O
discussed O
. O

injectable O
lorazepam O
should O
be O
used O
with O
caution O
in O
vlbw O
infants O
. O

-DOCSTART- O

transvenous O
right O
ventricular O
pacing O
during O
cardiopulmonary O
resuscitation O
of O
pediatric O
patients O
with O
acute O
cardiomyopathy B-NEG
. O

we O
describe O
the O
cardiopulmonary O
resuscitation O
efforts O
on O
five O
patients O
who O
presented O
in O
acute O
circulatory B-NEG
failure I-NEG
from O
myocardial B-NEG
dysfunction I-NEG
. O

three O
patients O
had O
acute O
viral O
myocarditis B-NEG
, O
one O
had O
a O
carbamazepine-induced O
acute O
eosinophilic B-NEG
myocarditis I-NEG
, O
and O
one O
had O
cardiac O
hemosiderosis O
resulting O
in O
acute O
cardiogenic B-NEG
shock I-NEG
. O

all O
patients O
were O
continuously O
monitored O
with O
central O
venous O
and O
arterial O
catheters O
in O
addition O
to O
routine O
noninvasive O
monitoring O
. O

an O
introducer O
sheath O
, O
a O
pacemaker O
, O
and O
sterile O
pacing O
wires O
were O
made O
readily O
available O
for O
the O
patients O
, O
should O
the O
need O
arise O
to O
terminate O
resistant O
cardiac O
dysrhythmias B-NEG
. O

all O
patients O
developed O
cardiocirculatory O
arrest O
associated O
with O
extreme O
hypotension B-NEG
and O
dysrhythmias B-NEG
within O
the O
first O
48 O
hours O
of O
their O
admission O
to O
the O
pediatric O
intensive O
care O
unit O
(picu) O
. O

right O
ventricular O
pacemaker O
wires O
were O
inserted O
in O
all O
of O
them O
during O
cardiopulmonary O
resuscitation O
(cpr) O
. O

in O
four O
patients O
, O
cardiac O
pacing O
was O
used O
, O
resulting O
in O
a O
temporary O
captured O
rhythm O
and O
restoration O
of O
their O
cardiac O
output O
. O

these O
patients O
had O
a O
second O
event O
of O
cardiac B-NEG
arrest I-NEG
, O
resulting O
in O
death O
, O
within O
10 O
to O
60 O
minutes O
. O

in O
one O
patient O
, O
cardiac O
pacing O
was O
not O
used O
, O
because O
he O
converted O
to O
normal O
sinus O
rhythm O
by O
electrical O
defibrillation O
within O
three O
minutes O
of O
initiating O
cpr O
. O

we O
conclude O
that O
cardiac O
pacing O
during O
resuscitative O
efforts O
in O
pediatric O
patients O
suffering O
from O
acute O
myocardial B-NEG
dysfunction I-NEG
may O
not O
have O
long-term O
value O
in O
and O
of O
itself O
; O
however O
, O
if O
temporary O
hemodynamic O
stability O
is O
achieved O
by O
this O
procedure O
, O
it O
may O
provide O
additional O
time O
needed O
to O
institute O
other O
therapeutic O
modalities O
. O

-DOCSTART- O

efficacy O
and O
safety O
of O
granisetron O
, O
a O
selective O
5-hydroxytryptamine-3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea B-NEG
and O
vomiting B-NEG
induced O
by O
high-dose O
cisplatin O
. O

purpose O
: O
to O
assess O
the O
antiemetic O
effects O
and O
safety O
profile O
of O
four O
different O
doses O
of O
granisetron O
(kytril O
; O
smithkline O
beecham O
pharmaceuticals O
, O
philadelphia O
, O
pa O
) O
when O
administered O
as O
a O
single O
intravenous O
( O
iv O
) O
dose O
for O
prophylaxis O
of O
cisplatin-induced O
nausea B-NEG
and O
vomiting B-NEG
. O

patients O
and O
methods O
: O
one O
hundred O
eighty-four O
chemotherapy-naive O
patients O
receiving O
high-dose O
cisplatin O
( O
81 O
to O
120 O
mg/m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron O
doses O
(5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms/kg O
) O
administered O
before O
chemotherapy O
. O

patients O
were O
observed O
on O
an O
inpatient O
basis O
for O
18 O
to O
24 O
hours O
, O
and O
vital O
signs O
, O
nausea B-NEG
, O
vomiting B-NEG
, O
retching O
, O
and O
appetite O
were O
assessed O
. O

safety O
analyses O
included O
incidence O
of O
adverse O
experiences O
and O
laboratory O
parameter O
changes O
. O

results O
: O
after O
granisetron O
doses O
of O
5, O
10 O
, O
20 O
, O
and O
40 O
micrograms/kg O
, O
a O
major O
response O
(< O
or O
= O
two O
vomiting B-NEG
or O
retching O
episodes O
, O
and O
no O
antiemetic O
rescue O
) O
was O
recorded O
in O
23% O
, O
57% O
, O
58% O
, O
and O
60% O
of O
patients O
, O
respectively O
, O
and O
a O
complete O
response O
( O
no O
vomiting B-NEG
or O
retching O
, O
and O
no O
antiemetic O
rescue O
) O
in O
18% O
, O
41% O
, O
40% O
, O
and O
47% O
of O
patients O
, O
respectively O
. O

there O
was O
a O
statistically O
longer O
time O
to O
first O
episode O
of O
nausea B-NEG
(p O
= O
.0015 O
) O
and O
vomiting B-NEG
(p O
= O
.0001) O
, O
and O
fewer O
patients O
were O
administered O
additional O
antiemetic O
medication O
in O
the O
10-micrograms/kg O
dosing O
groups O
than O
in O
the O
5-micrograms/kg O
dosing O
group O
. O

as O
granisetron O
dose O
increased O
, O
appetite O
return O
increased O
(p O
= O
.040) O
. O
headache B-NEG
was O
the O
most O
frequently O
reported O
adverse O
event O
(20%) O
. O

conclusion O
: O
a O
single O
10- O
, O
20- O
, O
or O
40-micrograms/kg O
dose O
of O
granisetron O
was O
effective O
in O
controlling O
vomiting B-NEG
in O
57% O
to O
60% O
of O
patients O
who O
received O
cisplatin O
at O
doses O
greater O
than O
81 O
mg/m2 O
and O
totally O
prevented O
vomiting B-NEG
in O
40% O
to O
47% O
of O
patients O
. O

there O
were O
no O
statistically O
significant O
differences O
in O
efficacy O
between O
the O
10-micrograms/kg O
dose O
and O
the O
20- O
and O
40-micrograms/kg O
doses O
. O

granisetron O
was O
well O
tolerated O
at O
all O
doses O
. O

-DOCSTART- O

adverse O
interaction O
between O
clonidine O
and O
verapamil O
. O

objective O
: O
to O
report O
two O
cases O
of O
a O
possible O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
resulting O
in O
atrioventricular B-NEG
( O
av I-NEG
) O
block I-NEG
in O
both O
patients O
and O
severe O
hypotension B-NEG
in O
one O
patient O
. O

case O
summaries O
: O
a O
54-year-old O
woman O
with O
hyperaldosteronism B-NEG
was O
treated O
with O
verapamil O
480 O
mg/d O
and O
spironolactone O
100 O
mg/d O
. O

after O
the O
addition O
of O
a O
minimal O
dose O
of O
clonidine O
( O
0.15 O
mg O
bid) O
, O
she O
developed O
complete O
av B-NEG
block I-NEG
and O
severe O
hypotension B-NEG
, O
which O
resolved O
upon O
cessation O
of O
all O
medications O
. O

a O
65-year-old O
woman O
was O
treated O
with O
extended-release O
verapamil O
240 O
mg/d O
. O

after O
the O
addition O
of O
clonidine O
0.15 O
mg O
bid O
she O
developed O
complete O
av B-NEG
block I-NEG
, O
which O
resolved O
after O
all O
therapy O
was O
stopped O
. O

discussion O
: O
an O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
has O
not O
been O
reported O
previously O
. O

we O
describe O
two O
such O
cases O
and O
discuss O
the O
various O
mechanisms O
that O
might O
cause O
such O
an O
interaction O
. O

clinicians O
should O
be O
acquainted O
with O
this O
possibly O
fatal O
interaction O
between O
two O
commonly O
used O
antihypertensive O
drugs O
. O

conclusions O
: O
caution O
is O
recommended O
in O
combining O
clonidine O
and O
verapamil O
therapy O
, O
even O
in O
patients O
who O
do O
not O
have O
sinus O
or O
av O
node O
dysfunction O
. O

the O
two O
drugs O
may O
act O
synergistically O
on O
both O
the O
av O
node O
and O
the O
peripheral O
circulation O
. O

-DOCSTART- O

pharmacological O
studies O
on O
a O
new O
dihydrothienopyridine O
calcium O
antagonist O
, O
s-312-d O
. O

5th O
communication O
: O
anticonvulsant O
effects O
in O
mice O
. O

s-312 O
, O
s-312-d O
, O
but O
not O
s-312-l O
, O
l-type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic B-NEG
tonic I-NEG
convulsions I-NEG
in O
dba/2 O
mice O
; O
and O
their O
ed50 O
values O
were O
18.4 O
( O
12.8-27.1 O
) O
mg/kg O
, O
p.o O
. O
and O
15.0 O
( O
10.2-23.7 O
) O
mg/kg O
, O
p.o. O
, O
respectively O
, O
while O
that O
of O
flunarizine O
was O
34.0 O
( O
26.0-44.8 O
) O
mg/kg O
, O
p.o O
. O

although O
moderate O
anticonvulsant O
effects O
of O
s-312-d O
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions B-NEG
induced O
by O
pentylenetetrazole O
( O
85 O
mg/kg O
, O
s.c. O
) O
or O
bemegride O
( O
40 O
mg/kg O
, O
s.c.) O
, O
no O
effects O
were O
observed O
in O
convulsions B-NEG
induced O
by O
n-methyl-d-aspartate O
, O
picrotoxin O
, O
or O
electroshock O
in O
slc:ddy O
mice O
. O

s-312-d O
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy B-NEG
. O

-DOCSTART- O

transmural O
myocardial B-NEG
infarction I-NEG
with O
sumatriptan O
. O

for O
sumatriptan O
, O
tightness O
in O
the O
chest O
caused O
by O
an O
unknown O
mechanism O
has O
been O
reported O
in O
3-5% O
of O
users O
. O

we O
describe O
a O
47-year-old O
woman O
with O
an O
acute O
myocardial B-NEG
infarction I-NEG
after O
administration O
of O
sumatriptan O
6 O
mg O
subcutaneously O
for O
cluster B-NEG
headache I-NEG
. O

the O
patient O
had O
no O
history O
of O
underlying O
ischaemic B-NEG
heart I-NEG
disease I-NEG
or O
prinzmetal's B-NEG
angina I-NEG
. O

she O
recovered O
without O
complications O
. O

-DOCSTART- O

flumazenil O
induces O
seizures B-NEG
and O
death O
in O
mixed O
cocaine-diazepam O
intoxications O
. O

study O
hypothesis O
: O
administration O
of O
the O
benzodiazepine O
antagonist O
flumazenil O
may O
unmask O
seizures B-NEG
in O
mixed O
cocaine-benzodiazepine O
intoxication O
. O

design O
: O
male O
sprague-dawley O
rats O
received O
100 O
mg/kg O
cocaine O
ip O
alone O
, O
5 O
mg/kg O
diazepam O
alone O
, O
or O
a O
combination O
of O
diazepam O
and O
cocaine O
. O

three O
minutes O
later O
, O
groups O
were O
challenged O
with O
vehicle O
or O
flumazenil O
5 O
or O
10 O
mg/kg O
ip O
. O

animal O
behavior O
, O
seizures B-NEG
( O
time O
to O
and O
incidence) O
, O
death O
( O
time O
to O
and O
incidence) O
, O
and O
cortical O
eeg O
tracings O
were O
recorded O
. O

interventions O
: O
administration O
of O
flumazenil O
to O
animals O
after O
they O
had O
received O
a O
combination O
dose O
of O
cocaine O
and O
diazepam O
. O

results O
: O
in O
group O
1, O
animals O
received O
cocaine O
followed O
by O
vehicle O
. O

this O
resulted O
in O
100% O
developing O
seizures B-NEG
and O
death O
. O

group O
2 O
received O
diazepam O
alone O
followed O
by O
vehicle O
. O

animals O
became O
somnolent O
and O
none O
died O
. O

group O
3 O
received O
diazepam O
followed O
by O
5 O
mg/kg O
flumazenil O
. O

animals O
became O
somnolent O
after O
diazepam O
and O
then O
active O
after O
flumazenil O
administration O
. O

in O
group O
4, O
a O
combination O
of O
cocaine O
and O
diazepam O
was O
administered O
simultaneously O
. O

this O
resulted O
in O
no O
overt O
or O
eeg-detectable O
seizures B-NEG
and O
a O
50% O
incidence O
of O
death O
. O

group O
5 O
received O
a O
similar O
combination O
of O
cocaine O
and O
diazepam O
, O
followed O
later O
by O
5 O
mg/kg O
flumazenil O
. O

this O
resulted O
in O
an O
increased O
incidence O
of O
seizures B-NEG
, O
90% O
(p O
< O
.01) O
, O
and O
death O
, O
100% O
(p O
< O
or O
= O
.01) O
, O
compared O
with O
group O
4. O

group O
6 O
received O
cocaine O
and O
diazepam O
followed O
by O
10 O
mg/kg O
flumazenil O
. O

this O
also O
resulted O
in O
an O
increased O
incidence O
of O
seizures B-NEG
, O
90% O
(p O
< O
or O
= O
.01) O
, O
and O
death O
, O
90% O
(p O
< O
or O
= O
.05) O
, O
compared O
with O
group O
4. O

conclusion O
: O
flumazenil O
can O
unmask O
seizures B-NEG
and O
increase O
the O
incidence O
of O
death O
in O
a O
model O
of O
combined O
cocaine-diazepam O
intoxications O
. O

-DOCSTART- O

mechanisms O
for O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin-mediated O
nephropathy B-NEG
in O
rats O
. O

studies O
were O
performed O
to O
examine O
the O
mechanisms O
for O
the O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
( O
gm)-mediated O
nephropathy B-NEG
. O

administration O
of O
gm O
at O
40 O
mg/kg O
sc O
for O
13 O
days O
to O
rats O
induced O
a O
significant O
reduction O
in O
renal O
blood O
flow O
( O
rbf O
) O
and O
inulin O
clearance O
( O
cin O
) O
as O
well O
as O
marked O
tubular B-NEG
damage I-NEG
. O

a O
significant O
reduction O
in O
urinary O
guanosine O
3',5'-cyclic O
monophosphate O
( O
cgmp O
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin-1 O
contents O
were O
also O
observed O
in O
gm-mediated O
nephropathy B-NEG
. O

superoxide O
dismutase O
( O
sod O
) O
or O
dimethylthiourea O
( O
dmtu O
) O
significantly O
lessened O
the O
gm-induced O
decrement O
in O
cin O
. O

the O
sod-induced O
increase O
in O
glomerular O
filtration O
rate O
was O
associated O
with O
a O
marked O
improvement O
in O
rbf O
, O
an O
increase O
in O
urinary O
cgmp O
excretion O
, O
and O
a O
decrease O
in O
renal O
renin O
and O
endothelin-1 O
content O
. O

sod O
did O
not O
attenuate O
the O
tubular B-NEG
damage I-NEG
. O

in O
contrast O
, O
dmtu O
significantly O
reduced O
the O
tubular B-NEG
damage I-NEG
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

neither O
sod O
nor O
dmtu O
affected O
the O
renal O
cortical O
gm O
content O
in O
gm-treated O
rats O
. O

these O
results O
suggest O
that O
1) O
both O
sod O
and O
dmtu O
have O
protective O
effects O
on O
gm-mediated O
nephropathy B-NEG
, O
2) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
sod O
and O
dmtu O
, O
and O
3) O
superoxide O
anions O
play O
a O
critical O
role O
in O
gm-induced O
renal O
vasoconstriction O
. O

-DOCSTART- O

assessment O
of O
cardiomyocyte O
dna O
synthesis O
during O
hypertrophy B-NEG
in O
adult O
mice O
. O

the O
ability O
of O
cardiomyocytes O
to O
synthesize O
dna O
in O
response O
to O
experimentally O
induced O
cardiac B-NEG
hypertrophy I-NEG
was O
assessed O
in O
adult O
mice O
. O

isoproterenol O
delivered O
by O
osmotic O
minipump O
implantation O
in O
adult O
c3heb/fej O
mice O
resulted O
in O
a O
46% O
increase O
in O
heart O
weight O
and O
a O
19.3% O
increase O
in O
cardiomyocyte O
area O
. O

no O
dna O
synthesis O
, O
as O
assessed O
by O
autoradiographic O
analysis O
of O
isolated O
cardiomyocytes O
, O
was O
observed O
in O
control O
or O
hypertrophic B-NEG
hearts I-NEG
. O

a O
survey O
of O
15 O
independent O
inbred O
strains O
of O
mice O
revealed O
that O
ventricular O
cardiomyocyte O
nuclear O
number O
ranged O
from O
3 O
to O
13% O
mononucleate O
, O
suggesting O
that O
cardiomyocyte O
terminal O
differentiation O
is O
influenced O
directly O
or O
indirectly O
by O
genetic O
background O
. O

to O
determine O
whether O
the O
capacity O
for O
reactive O
dna O
synthesis O
was O
also O
subject O
to O
genetic O
regulation O
, O
cardiac B-NEG
hypertrophy I-NEG
was O
induced O
in O
the O
strains O
of O
mice O
comprising O
the O
extremes O
of O
the O
nuclear O
number O
survey O
. O

these O
data O
indicate O
that O
adult O
mouse O
atrial O
and O
ventricular O
cardiomyocytes O
do O
not O
synthesize O
dna O
in O
response O
to O
isoproterenol-induced O
cardiac B-NEG
hypertrophy I-NEG
. O

-DOCSTART- O

central O
cardiovascular O
effects O
of O
avp O
and O
anp O
in O
normotensive O
and O
spontaneously O
hypertensive B-NEG
rats O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
compare O
influence O
of O
central O
arginine O
vasopressin O
( O
avp O
) O
and O
of O
atrial O
natriuretic O
peptide O
( O
anp O
) O
on O
control O
of O
arterial O
blood O
pressure O
( O
map O
) O
and O
heart O
rate O
( O
hr O
) O
in O
normotensive O
( O
wky O
) O
and O
spontaneously O
hypertensive B-NEG
( O
shr O
) O
rats O
. O

three O
series O
of O
experiments O
were O
performed O
on O
30 O
wky O
and O
30 O
shr O
, O
chronically O
instrumented O
with O
guide O
tubes O
in O
the O
lateral O
ventricle O
( O
lv O
) O
and O
arterial O
and O
venous O
catheters O
. O

map O
and O
hr O
were O
monitored O
before O
and O
after O
i.v O
. O
injections O
of O
either O
vehicle O
or O
1, O
10 O
and O
50 O
ng O
of O
avp O
and O
25 O
, O
125 O
and O
500 O
ng O
of O
anp O
. O

sensitivity O
of O
cardiac O
component O
of O
baroreflex O
(ccb) O
, O
expressed O
as O
a O
slope O
of O
the O
regression O
line O
was O
determined O
from O
relationships O
between O
systolic O
arterial O
pressure O
( O
sap O
) O
and O
hr O
period O
( O
hrp O
) O
during O
phenylephrine O
( O
phe)-induced O
hypertension B-NEG
and O
sodium O
nitroprusside O
( O
sn)-induced O
hypotension B-NEG
. O

ccb O
was O
measured O
before O
and O
after O
administration O
of O
either O
vehicle O
, O
avp O
, O
anp O
, O
or O
both O
peptides O
together O
. O

increases O
of O
map O
occurred O
after O
lv O
administration O
of O
1, O
10 O
and O
50 O
ng O
of O
avp O
in O
wky O
and O
of O
10 O
and O
50 O
ng O
in O
shr O
. O

anp O
did O
not O
cause O
significant O
changes O
in O
map O
in O
both O
strains O
as O
compared O
to O
vehicle O
, O
but O
it O
abolished O
avp-induced O
map O
increase O
in O
wky O
and O
shr O
. O

ccb O
was O
reduced O
in O
wky O
and O
shr O
after O
lv O
administration O
of O
avp O
during O
sn-induced O
hypotension B-NEG
. O

in O
shr O
but O
not O
in O
wky O
administration O
of O
anp O
, O
avp O
and O
anp O
+ O
avp O
decreased O
ccb O
during O
phe-induced O
map O
elevation O
. O

the O
results O
indicate O
that O
centrally O
applied O
avp O
and O
anp O
exert O
differential O
effects O
on O
blood O
pressure O
and O
baroreflex O
control O
of O
heart O
rate O
in O
wky O
and O
shr O
and O
suggest O
interaction O
of O
these O
two O
peptides O
in O
blood O
pressure O
regulation O
at O
the O
level O
of O
central O
nervous O
system O
. O

-DOCSTART- O

cutaneous O
exposure O
to O
warfarin-like O
anticoagulant O
causing O
an O
intracerebral B-NEG
hemorrhage I-NEG
: O
a O
case O
report O
. O

a O
case O
of O
intercerebral O
hematoma B-NEG
due O
to O
warfarin-induced O
coagulopathy B-NEG
is O
presented O
. O

the O
39-year-old O
woman O
had O
spread O
a O
warfarin-type O
rat O
poison O
around O
her O
house O
weekly O
using O
her O
bare O
hands O
, O
with O
no O
washing O
post O
application O
. O

percutaneous O
absorption O
of O
warfarin O
causing O
coagulopathy B-NEG
, O
reported O
three O
times O
in O
the O
past O
, O
is O
a O
significant O
risk O
if O
protective O
measures O
, O
such O
as O
gloves O
, O
are O
not O
used O
. O

an O
adverse O
drug O
interaction O
with O
piroxicam O
, O
which O
she O
took O
occasionally O
, O
may O
have O
exacerbated O
the O
coagulopathy B-NEG
. O

-DOCSTART- O

pediatric O
heart O
transplantation O
without O
chronic O
maintenance O
steroids O
. O

from O
1986 O
to O
february O
1993 O
, O
40 O
children O
aged O
2 O
months O
to O
18 O
years O
( O
average O
age O
10.4 O
+/- O
5.8 O
years O
) O
underwent O
heart O
transplantation O
. O

indications O
for O
transplantation O
were O
idiopathic B-NEG
cardiomyopathy I-NEG
(52%) O
, O
congenital B-NEG
heart I-NEG
disease I-NEG
( O
35% O
) O
with O
and O
without O
prior O
repair O
( O
71% O
and O
29% O
, O
respectively) O
, O
hypertrophic B-NEG
cardiomyopathy I-NEG
(5%) O
, O
valvular B-NEG
heart I-NEG
disease I-NEG
(3%) O
, O
and O
doxorubicin O
cardiomyopathy B-NEG
(5%) O
. O

patients O
were O
managed O
with O
cyclosporine O
and O
azathioprine O
. O

no O
prophylaxis O
with O
antilymphocyte O
globulin O
was O
used O
. O

steroids O
were O
given O
to O
39% O
of O
patients O
for O
refractory O
rejection O
, O
but O
weaning O
was O
always O
attempted O
and O
generally O
successful O
(64%) O
. O

five O
patients O
( O
14% O
) O
received O
maintenance O
steroids O
. O

four O
patients O
died O
in O
the O
perioperative O
period O
and O
one O
died O
4 O
months O
later O
. O

there O
have O
been O
no O
deaths O
related O
to O
rejection O
or O
infection B-NEG
. O

average O
follow-up O
was O
36 O
+/- O
19 O
months O
( O
range O
1 O
to O
65 O
months) O
. O

cumulative O
survival O
is O
88% O
at O
5 O
years O
. O

in O
patients O
less O
than O
7 O
years O
of O
age O
, O
rejection O
was O
monitored O
noninvasively O
. O

in O
the O
first O
postoperative O
month O
, O
89% O
of O
patients O
were O
treated O
for O
rejection O
. O

freedom O
from O
serious O
infections B-NEG
was O
83% O
at O
1 O
month O
and O
65% O
at O
1 O
year O
. O
cytomegalovirus B-NEG
infections I-NEG
were O
treated O
successfully O
with O
ganciclovir O
in O
11 O
patients O
. O

no O
impairment O
of O
growth O
was O
observed O
in O
children O
who O
underwent O
transplantation O
compared O
with O
a O
control O
population O
. O

twenty-one O
patients O
( O
60% O
) O
have O
undergone O
annual O
catheterizations O
and O
no O
sign O
of O
graft O
atherosclerosis B-NEG
has O
been O
observed O
. O
seizures B-NEG
occurred O
in O
five O
patients O
( O
14% O
) O
and O
hypertension B-NEG
was O
treated O
in O
10 O
patients O
(28%) O
. O

no O
patient O
was O
disabled O
and O
no O
lymphoproliferative B-NEG
disorder I-NEG
was O
observed.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

delirium B-NEG
during O
fluoxetine O
treatment O
. O

a O
case O
report O
. O

the O
correlation O
between O
high O
serum O
tricyclic O
antidepressant O
concentrations O
and O
central O
nervous O
system O
side O
effects O
has O
been O
well O
established O
. O

only O
a O
few O
reports O
exist O
, O
however O
, O
on O
the O
relationship O
between O
the O
serum O
concentrations O
of O
selective O
serotonin O
reuptake O
inhibitors O
( O
ssris O
) O
and O
their O
toxic O
effects O
. O

in O
some O
cases O
, O
a O
high O
serum O
concentration O
of O
citalopram O
(> O
600 O
nmol/l O
) O
in O
elderly O
patients O
has O
been O
associated O
with O
increased O
somnolence B-NEG
and O
movement B-NEG
difficulties I-NEG
. O

widespread O
cognitive B-NEG
disorders I-NEG
, O
such O
as O
delirium B-NEG
, O
have O
not O
been O
previously O
linked O
with O
high O
blood O
levels O
of O
ssris O
. O

in O
this O
report O
, O
we O
describe O
a O
patient O
with O
acute O
hyperkinetic B-NEG
delirium B-NEG
connected O
with O
a O
high O
serum O
total O
fluoxetine O
( O
fluoxetine O
plus O
desmethylfluoxetine O
) O
concentration O
. O

-DOCSTART- O

pulmonary B-NEG
edema I-NEG
and O
shock B-NEG
after O
high-dose O
aracytine-c O
for O
lymphoma B-NEG
; O
possible O
role O
of O
tnf-alpha O
and O
paf O
. O

four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high-dose O
ara-c O
for O
lymphomas B-NEG
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

it O
was O
characterized O
by O
the O
onset O
of O
fever B-NEG
, O
diarrhea B-NEG
, O
shock B-NEG
, O
pulmonary B-NEG
edema I-NEG
, O
acute B-NEG
renal I-NEG
failure I-NEG
, O
metabolic B-NEG
acidosis I-NEG
, O
weight B-NEG
gain I-NEG
and O
leukocytosis B-NEG
. O

thorough O
bacteriological O
screening O
failed O
to O
provide O
evidence O
of O
infection B-NEG
. O

sequential O
biological O
assays O
of O
il-1 O
, O
il-2 O
, O
tnf O
and O
paf O
were O
performed O
during O
ara-c O
infusion O
to O
ten O
patients O
, O
including O
the O
four O
who O
developed O
the O
syndrome O
. O

tnf O
and O
paf O
activity O
was O
found O
in O
the O
serum O
of O
respectively O
two O
and O
four O
of O
the O
cases O
, O
but O
not O
in O
the O
six O
controls O
. O

as O
tnf O
and O
paf O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock B-NEG
and O
adult B-NEG
respiratory I-NEG
distress I-NEG
syndrome I-NEG
, O
we O
hypothesize O
that O
high-dose O
ara-c O
may O
be O
associated O
with O
cytokine O
release O
. O

-DOCSTART- O

protective O
effect O
of O
clentiazem O
against O
epinephrine-induced O
cardiac B-NEG
injury I-NEG
in O
rats O
. O

we O
investigated O
the O
effects O
of O
clentiazem O
, O
a O
1,5-benzothiazepine O
calcium O
antagonist O
, O
on O
epinephrine-induced O
cardiomyopathy B-NEG
in O
rats O
. O

with O
2-week O
chronic O
epinephrine O
infusion O
, O
16 O
of O
30 O
rats O
died O
within O
4 O
days O
, O
and O
severe O
ischemic B-NEG
lesions I-NEG
and O
fibrosis B-NEG
of O
the O
left O
ventricles O
were O
observed O
. O

in O
epinephrine-treated O
rats O
, O
left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol O
were O
reduced O
, O
but O
responses O
to O
calcium O
were O
normal O
or O
enhanced O
compared O
to O
controls O
. O

left O
ventricular O
alpha O
and O
beta O
adrenoceptor O
densities O
were O
also O
reduced O
compared O
to O
controls O
. O

treatment O
with O
clentiazem O
prevented O
epinephrine-induced O
death O
(p O
< O
.05) O
, O
and O
attenuated O
the O
ventricular O
ischemic B-NEG
lesions I-NEG
and O
fibrosis B-NEG
, O
in O
a O
dose-dependent O
manner O
. O

left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol O
were O
reduced O
compared O
to O
controls O
in O
groups O
treated O
with O
clentiazem O
alone O
, O
but O
combined O
with O
epinephrine O
, O
clentiazem O
restored O
left O
atrial O
responses O
and O
enhanced O
left O
ventricular O
papillary O
responses O
to O
isoproterenol O
. O

on O
the O
other O
hand O
clentiazem O
did O
not O
prevent O
epinephrine-induced O
down-regulation O
of O
alpha O
and O
beta O
adrenoceptors O
. O

interestingly O
, O
clentiazem O
, O
infused O
alone O
, O
resulted O
in O
decreased O
adrenergic O
receptor O
densities O
in O
the O
left O
ventricle O
. O

clentiazem O
also O
did O
not O
prevent O
the O
enhanced O
responses O
to O
calcium O
seen O
in O
the O
epinephrine-treated O
animals O
, O
although O
the O
high O
dose O
of O
clentiazem O
partially O
attenuated O
the O
maximal O
response O
to O
calcium O
compared O
to O
epinephrine-treated O
animals O
. O

in O
conclusion O
, O
clentiazem O
attenuated O
epinephrine-induced O
cardiac B-NEG
injury I-NEG
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

-DOCSTART- O

cocaine O
induced O
myocardial B-NEG
ischemia I-NEG
. O

we O
report O
a O
case O
of O
myocardial B-NEG
ischemia I-NEG
induced O
by O
cocaine O
. O

the O
ischemia B-NEG
probably O
induced O
by O
coronary B-NEG
artery I-NEG
spasm I-NEG
was O
reversed O
by O
nitroglycerin O
and O
calcium O
blocking O
agents O
. O

-DOCSTART- O

doxorubicin-induced O
cardiotoxicity B-NEG
monitored O
by O
ecg O
in O
freely O
moving O
mice O
. O

a O
new O
model O
to O
test O
potential O
protectors O
. O

in O
laboratory O
animals O
, O
histology O
is O
most O
commonly O
used O
to O
study O
doxorubicin-induced O
cardiotoxicity B-NEG
. O

however O
, O
for O
monitoring O
during O
treatment O
, O
large O
numbers O
of O
animals O
are O
needed O
. O

recently O
we O
developed O
a O
new O
method O
to O
measure O
ecg O
values O
in O
freely O
moving O
mice O
by O
telemetry O
. O

with O
this O
model O
we O
investigated O
the O
effect O
of O
chronic O
doxorubicin O
administration O
on O
the O
ecg O
of O
freely O
moving O
balb/c O
mice O
and O
the O
efficacy O
of O
icrf-187 O
as O
a O
protective O
agent O
. O

the O
st O
interval O
significantly O
widened O
from O
15.0 O
+/- O
1.5 O
to O
56.8 O
+/- O
11.8 O
ms O
in O
week O
10 O
(7 O
weekly O
doses O
of O
4 O
mg/kg O
doxorubicin O
given O
i.v O
. O
plus O
3 O
weeks O
of O
observation) O
. O

the O
ecg O
of O
the O
control O
animals O
did O
not O
change O
during O
the O
entire O
study O
. O

after O
sacrifice O
the O
hearts O
of O
doxorubicin-treated O
animals O
were O
enlarged O
and O
the O
atria O
were O
hypertrophic B-NEG
. O

as O
this O
schedule O
exerted O
more O
toxicity B-NEG
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
icrf-187 O
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity B-NEG
(6 O
weekly O
doses O
of O
4 O
mg/kg O
doxorubicin O
given O
i.v O
. O
plus O
2 O
weeks O
of O
observation) O
. O

on O
this O
schedule O
, O
the O
animals' O
hearts O
appeared O
normal O
after O
sacrifice O
and O
icrf-187 O
( O
50 O
mg/kg O
given O
i.p O
. O
1 O
h O
before O
doxorubicin O
) O
provided O
almost O
full O
protection O
. O

these O
data O
were O
confirmed O
by O
histology O
. O

the O
results O
indicate O
that O
this O
new O
model O
is O
very O
sensitive O
and O
enables O
monitoring O
of O
the O
development O
of O
cardiotoxicity B-NEG
with O
time O
. O

these O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin-induced O
cardiotoxicity B-NEG
as O
demonstrated O
by O
the O
protection O
provided O
by O
icrf-187 O
. O

-DOCSTART- O

epinephrine O
dysrhythmogenicity O
is O
not O
enhanced O
by O
subtoxic O
bupivacaine O
in O
dogs O
. O

since O
bupivacaine O
and O
epinephrine O
may O
both O
precipitate O
dysrhythmias B-NEG
, O
circulating O
bupivacaine O
during O
regional O
anesthesia O
could O
potentiate O
dysrhythmogenic O
effects O
of O
epinephrine O
. O

we O
therefore O
examined O
whether O
bupivacaine O
alters O
the O
dysrhythmogenicity O
of O
subsequent O
administration O
of O
epinephrine O
in O
conscious O
, O
healthy O
dogs O
and O
in O
anesthetized O
dogs O
with O
myocardial B-NEG
infarction I-NEG
. O

forty-one O
conscious O
dogs O
received O
10 O
micrograms.kg-1.min-1 O
epinephrine O
. O

seventeen O
animals O
responded O
with O
ventricular B-NEG
tachycardia I-NEG
( O
vt B-NEG
) O
within O
3 O
min O
. O

after O
3 O
h, O
these O
responders O
randomly O
received O
1 O
or O
2 O
mg/kg O
bupivacaine O
or O
saline O
over O
5 O
min O
, O
followed O
by O
10 O
micrograms.kg-1.min-1 O
epinephrine O
. O

in O
the O
bupivacaine O
groups O
, O
epinephrine O
caused O
fewer O
prodysrhythmic O
effects O
than O
without O
bupivacaine O
. O
vt B-NEG
appeared O
in O
fewer O
dogs O
and O
at O
a O
later O
time O
, O
and O
there O
were O
more O
sinoatrial O
beats O
and O
less O
ectopies O
. O

epinephrine O
shortened O
qt O
less O
after O
bupivacaine O
than O
in O
control O
animals O
. O

one O
day O
after O
experimental O
myocardial B-NEG
infarction I-NEG
, O
six O
additional O
halothane-anesthetized O
dogs O
received O
4 O
micrograms.kg-1.min-1 O
epinephrine O
until O
vt B-NEG
appeared O
. O

after O
45 O
min O
, O
1 O
mg/kg O
bupivacaine O
was O
injected O
over O
5 O
min O
, O
again O
followed O
by O
4 O
micrograms.kg-1.min-1 O
epinephrine O
. O

in O
these O
dogs O
, O
the O
prodysrhythmic O
response O
to O
epinephrine O
was O
also O
mitigated O
by O
preceding O
bupivacaine O
. O

bupivacaine O
antagonizes O
epinephrine O
dysrhythmogenicity O
in O
conscious O
dogs O
susceptible O
to O
vt B-NEG
and O
in O
anesthetized O
dogs O
with O
spontaneous O
postinfarct O
dysrhythmias B-NEG
. O

there O
is O
no O
evidence O
that O
systemic O
subtoxic O
bupivacaine O
administration O
enhances O
the O
dysrhythmogenicity O
of O
subsequent O
epinephrine O
. O

-DOCSTART- O

milk-alkali B-NEG
syndrome I-NEG
induced O
by O
1,25(oh)2d O
in O
a O
patient O
with O
hypoparathyroidism B-NEG
. O
milk-alkali B-NEG
syndrome I-NEG
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B-NEG
ulcer I-NEG
disease I-NEG
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

although O
with O
current O
ulcer B-NEG
therapy O
( O
h-2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate) O
, O
the O
frequency O
of O
milk-alkali B-NEG
syndrome I-NEG
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia B-NEG
, O
alkalosis B-NEG
, O
and O
renal B-NEG
impairment I-NEG
remains O
the O
hallmark O
of O
the O
syndrome O
. O
milk-alkali B-NEG
syndrome I-NEG
can O
present O
serious O
and O
occasionally O
life-threatening O
illness O
unless O
diagnosed O
and O
treated O
appropriately O
. O

this O
article O
presents O
a O
patient O
with O
hypoparathyroidism B-NEG
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk-alkali B-NEG
syndrome I-NEG
. O

the O
patient O
was O
successfully O
treated O
with O
intravenous O
pamidronate O
on O
his O
first O
admission O
and O
with O
hydrocortisone O
on O
the O
second O
. O

this O
illustrates O
intravenous O
pamidronate O
as O
a O
valuable O
therapeutic O
tool O
when O
milk-alkali B-NEG
syndrome I-NEG
presents O
as O
hypercalcemic B-NEG
emergency I-NEG
. O

-DOCSTART- O

encephalopathy B-NEG
during O
amitriptyline O
therapy O
: O
are O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
and O
serotonin B-NEG
syndrome I-NEG
spectrum O
disorders? O

this O
report O
describes O
a O
case O
of O
encephalopathy B-NEG
developed O
in O
the O
course O
of O
amitriptyline O
therapy O
, O
during O
a O
remission O
of O
unipolar B-NEG
depression I-NEG
. O

this O
patient O
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
( O
nms B-NEG
) O
or O
serotonin B-NEG
syndrome I-NEG
( O
ss B-NEG
). O

the O
major O
determinant O
of O
the O
symptoms O
may O
have O
been O
dopamine/serotonin O
imbalance O
in O
the O
central O
nervous O
system O
. O

the O
nms B-NEG
-like O
encephalopathy B-NEG
that O
develops O
in O
association O
with O
the O
use O
of O
antidepressants O
indicates O
that O
nms B-NEG
and O
ss B-NEG
are O
spectrum O
disorders O
induced O
by O
drugs O
with O
both O
antidopaminergic O
and O
serotonergic O
effects O
. O

-DOCSTART- O

genetic O
separation O
of O
tumor B-NEG
growth O
and O
hemorrhagic B-NEG
phenotypes O
in O
an O
estrogen-induced O
tumor B-NEG
. O

chronic O
administration O
of O
estrogen O
to O
the O
fischer O
344 O
( O
f344 O
) O
rat O
induces O
growth O
of O
large O
, O
hemorrhagic B-NEG
pituitary B-NEG
tumors I-NEG
. O

ten O
weeks O
of O
diethylstilbestrol O
( O
des O
) O
treatment O
caused O
female O
f344 O
rat O
pituitaries O
to O
grow O
to O
an O
average O
of O
109.2 O
+/- O
6.3 O
mg O
( O
mean O
+/- O
se O
) O
versus O
11.3 O
+/- O
1.4 O
mg O
for O
untreated O
rats O
, O
and O
to O
become O
highly O
hemorrhagic B-NEG
. O

the O
same O
des O
treatment O
produced O
no O
significant O
growth O
( O
8.9 O
+/- O
0.5 O
mg O
for O
treated O
females O
versus O
8.7 O
+/- O
1.1 O
for O
untreated O
females O
) O
or O
morphological O
changes O
in O
brown O
norway O
( O
bn O
) O
rat O
pituitaries O
. O

an O
f1 O
hybrid O
of O
f344 O
and O
bn O
exhibited O
significant O
pituitary O
growth O
after O
10 O
weeks O
of O
des O
treatment O
with O
an O
average O
mass O
of O
26.3 O
+/- O
0.7 O
mg O
compared O
with O
8.6 O
+/- O
0.9 O
mg O
for O
untreated O
rats O
. O

surprisingly O
, O
the O
f1 O
hybrid O
tumors B-NEG
were O
not O
hemorrhagic B-NEG
and O
had O
hemoglobin O
content O
and O
outward O
appearance O
identical O
to O
that O
of O
bn O
. O

expression O
of O
both O
growth O
and O
morphological O
changes O
is O
due O
to O
multiple O
genes O
. O

however O
, O
while O
des-induced O
pituitary O
growth O
exhibited O
quantitative O
, O
additive O
inheritance O
, O
the O
hemorrhagic B-NEG
phenotype O
exhibited O
recessive O
, O
epistatic O
inheritance O
. O

only O
5 O
of O
the O
160 O
f2 O
pituitaries O
exhibited O
the O
hemorrhagic B-NEG
phenotype O
; O
36 O
of O
the O
160 O
f2 O
pituitaries O
were O
in O
the O
f344 O
range O
of O
mass O
, O
but O
31 O
of O
these O
were O
not O
hemorrhagic B-NEG
, O
indicating O
that O
the O
hemorrhagic B-NEG
phenotype O
is O
not O
merely O
a O
consequence O
of O
extensive O
growth O
. O

the O
hemorrhagic B-NEG
f2 O
pituitaries O
were O
all O
among O
the O
most O
massive O
, O
indicating O
that O
some O
of O
the O
genes O
regulate O
both O
phenotypes O
. O

-DOCSTART- O

increased O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder B-NEG
irritation I-NEG
. O

immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
( O
nos O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation B-NEG
of I-NEG
the I-NEG
urinary I-NEG
tract I-NEG
of O
the O
rat O
. O

chemical O
cystitis B-NEG
was O
induced O
by O
cyclophosphamide O
( O
cyp O
) O
which O
is O
metabolized O
to O
acrolein O
, O
an O
irritant O
eliminated O
in O
the O
urine O
. O

injection O
of O
cyp O
(n O
= O
10 O
, O
75 O
mg/kg O
, O
i.p. O
) O
2 O
hours O
prior O
to O
perfusion O
( O
acute O
treatment O
) O
of O
the O
animals O
increased O
fos-immunoreactivity O
( O
ir O
) O
in O
neurons O
in O
the O
dorsal O
commissure O
, O
dorsal O
horn O
, O
and O
autonomic O
regions O
of O
spinal O
segments O
( O
l1-l2 O
and O
l6-s1 O
) O
which O
receive O
afferent O
inputs O
from O
the O
bladder O
, O
urethra O
, O
and O
ureter O
. O

fos-ir O
in O
the O
spinal O
cord O
was O
not O
changed O
in O
rats O
receiving O
chronic O
cyp O
treatment O
(n O
= O
15 O
, O
75 O
mg/kg O
, O
i.p. O
, O
every O
3rd O
day O
for O
2 O
weeks) O
. O

in O
control O
animals O
and O
in O
animals O
treated O
acutely O
with O
cyp O
, O
only O
small O
numbers O
of O
nos-ir O
cells O
( O
0.5-0.7 O
cell O
profiles/sections O
) O
were O
detected O
in O
the O
l6-s1 O
dorsal O
root O
ganglia O
(drg) O
. O

chronic O
cyp O
administration O
significantly O
(p O
< O
or O
= O
.002 O
) O
increased O
bladder O
weight O
by O
60% O
and O
increased O
( O
7- O
to O
11-fold O
) O
the O
numbers O
of O
nos-immunoreactive O
( O
ir O
) O
afferent O
neurons O
in O
the O
l6-s1 O
drg O
. O

a O
small O
increase O
( O
1.5-fold O
) O
also O
occurred O
in O
the O
l1 O
drg O
, O
but O
no O
change O
was O
detected O
in O
the O
l2 O
and O
l5 O
drg O
. O

bladder O
afferent O
cells O
in O
the O
l6-s1 O
drg O
labeled O
by O
fluorogold O
( O
40 O
microliters O
) O
injected O
into O
the O
bladder O
wall O
did O
not O
exhibit O
nos-ir O
in O
control O
animals O
; O
however O
, O
following O
chronic O
cyp O
administration O
, O
a O
significant O
percentage O
of O
bladder O
afferent O
neurons O
were O
nos-ir O
: O
l6 O
( O
19.8 O
+/- O
4.6% O
) O
and O
s1 O
( O
25.3 O
+/- O
2.9%) O
. O

these O
results O
indicate O
that O
neuronal O
gene O
expression O
in O
visceral O
sensory O
pathways O
can O
be O
upregulated O
by O
chemical O
irritation O
of O
afferent O
receptors O
in O
the O
urinary O
tract O
and/or O
that O
pathological O
changes O
in O
the O
urinary O
tract O
can O
initiate O
chemical O
signals O
that O
alter O
the O
chemical O
properties O
of O
visceral O
afferent O
neurons O
. O

-DOCSTART- O

effects O
of O
a O
new O
calcium O
antagonist O
, O
cd-832 O
, O
on O
isoproterenol-induced O
myocardial B-NEG
ischemia I-NEG
in O
dogs O
with O
partial O
coronary B-NEG
stenosis I-NEG
. O

effects O
of O
cd-832 O
on O
isoproterenol O
( O
iso)-induced O
myocardial B-NEG
ischemia I-NEG
were O
studied O
in O
dogs O
with O
partial O
coronary B-NEG
stenosis I-NEG
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine O
or O
diltiazem O
. O

in O
the O
presence O
of O
coronary B-NEG
artery I-NEG
stenosis I-NEG
, O
3-min O
periods O
of O
intracoronary O
iso O
infusion O
( O
10 O
ng/kg/min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
st-segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

after O
the O
control O
iso O
infusion O
with O
stenosis B-NEG
was O
performed O
, O
equihypotensive O
doses O
of O
cd-832 O
(3 O
and O
10 O
micrograms/kg/min O
, O
n O
= O
7) O
, O
nifedipine O
(1 O
and O
3 O
micrograms/kg/min O
, O
n O
= O
9) O
or O
diltiazem O
( O
10 O
and O
30 O
micrograms/kg/min O
, O
n O
= O
7) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
iso O
infusion O
. O

both O
cd-832 O
and O
diltiazem O
, O
but O
not O
nifedipine O
, O
significantly O
reduced O
the O
increase O
in O
heart O
rate O
induced O
by O
iso O
infusion O
. O

in O
contrast O
to O
nifedipine O
, O
cd-832 O
( O
10 O
micrograms/kg/min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+/- O
12% O
to O
115 O
+/- O
26% O
of O
the O
control O
value O
(p O
< O
.01 O
) O
and O
st-segment O
elevation O
from O
5.6 O
+/- O
1.0 O
mv O
to O
1.6 O
+/- O
1.3 O
mv O
(p O
< O
.01 O
) O
at O
3 O
min O
after O
iso O
infusion O
with O
stenosis B-NEG
. O

diltiazem O
( O
30 O
micrograms/kg/min O
) O
also O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
34 O
+/- O
14% O
to O
63 O
+/- O
18% O
of O
the O
control O
value O
(p O
< O
.05 O
) O
and O
st-segment O
elevation O
from O
4.7 O
+/- O
0.7 O
mv O
to O
2.1 O
+/- O
0.7 O
mv O
(p O
< O
.01 O
) O
at O
3 O
min O
after O
iso O
infusion O
with O
stenosis B-NEG
. O

these O
data O
show O
that O
cd-832 O
improves O
myocardial B-NEG
ischemia I-NEG
during O
iso O
infusion O
with O
stenosis B-NEG
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
cd-832 O
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
cd-832 O
. O

-DOCSTART- O

the O
effect O
of O
recombinant O
human O
insulin-like O
growth O
factor-i O
on O
chronic O
puromycin O
aminonucleoside O
nephropathy B-NEG
in O
rats O
. O

we O
recently O
demonstrated O
that O
recombinant O
hgh O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
nephropathy B-NEG
, O
an O
experimental O
model O
of O
glomerular B-NEG
disease I-NEG
. O

therefore O
, O
we O
examined O
whether O
recombinant O
human O
( O
rh O
) O
igf-i O
is O
a O
safer O
alternative O
for O
the O
treatment O
of O
growth B-NEG
failure I-NEG
in O
rats O
with O
chronic O
pan O
nephropathy B-NEG
. O

the O
glomerulopathy B-NEG
was O
induced O
by O
seven O
serial O
injections O
of O
pan O
over O
12 O
wk O
. O

experimental O
animals O
(n O
= O
6) O
received O
rhigf-i O
, O
400 O
micrograms/d O
, O
whereas O
control O
rats O
(n O
= O
6) O
received O
the O
vehicle O
. O

rhigf-i O
improved O
weight O
gain O
by O
14% O
(p O
< O
0.05) O
, O
without O
altering O
hematocrit O
or O
blood O
pressure O
in O
rats O
with O
renal B-NEG
disease I-NEG
. O

urinary O
protein O
excretion O
was O
unaltered O
by O
rhigf-i O
treatment O
in O
rats O
with O
chronic O
pan O
nephropathy B-NEG
. O

after O
12 O
wk O
, O
the O
inulin O
clearance O
was O
higher O
in O
rhigf-i-treated O
rats O
, O
0.48 O
+/- O
0.08 O
versus O
0.24 O
+/- O
0.06 O
ml/min/100 O
g O
of O
body O
weight O
in O
untreated O
pan O
nephropathy B-NEG
animals O
, O
p O
< O
0.05 O
. O

the O
improvement O
in O
gfr O
was O
not O
associated O
with O
enhanced O
glomerular B-NEG
hypertrophy I-NEG
or O
increased O
segmental O
glomerulosclerosis B-NEG
, O
tubulointerstitial B-NEG
injury I-NEG
, O
or O
renal O
cortical O
malondialdehyde O
content O
. O

in O
rats O
with O
pan O
nephropathy B-NEG
, O
administration O
of O
rhigf-i O
increased O
igf-i O
and O
gh O
receptor O
gene O
expression O
, O
without O
altering O
the O
steady O
state O
level O
of O
igf-i O
receptor O
mrna O
. O

in O
normal O
rats O
with O
intact O
kidneys O
, O
rhigf-i O
administration O
(n O
= O
4) O
did O
not O
alter O
weight O
gain O
, O
blood O
pressure O
, O
proteinuria B-NEG
, O
gfr O
, O
glomerular O
planar O
area O
, O
renal O
cortical O
malondialdehyde O
content O
, O
or O
glomerular O
or O
tubulointerstitial B-NEG
damage I-NEG
, O
compared O
with O
untreated O
animals O
(n O
= O
4) O
. O

rhigf-i O
treatment O
reduced O
the O
steady O
state O
renal O
igf-i O
mrna O
level O
but O
did O
not O
modify O
gene O
expression O
of O
the O
igf-i O
or O
gh O
receptors O
. O

we O
conclude O
that O
: O
1) O
administration O
of O
rhigf-i O
improves O
growth O
and O
gfr O
in O
rats O
with O
chronic O
pan O
nephropathy B-NEG
and O
2) O
unlike O
rhgh O
, O
long-term O
use O
of O
rhigf-i O
does O
not O
worsen O
renal O
functional O
and O
structural O
injury O
in O
this O
disease O
model O
. O

-DOCSTART- O

nefiracetam O
( O
dm-9384 O
) O
reverses O
apomorphine-induced O
amnesia B-NEG
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

nefiracetam O
is O
a O
novel O
pyrrolidone O
derivative O
which O
attenuates O
scopolamine-induced O
learning B-NEG
and I-NEG
post-training I-NEG
consolidation I-NEG
deficits I-NEG
. O

given O
that O
apomorphine O
inhibits O
passive O
avoidance O
retention O
when O
given O
during O
training O
or O
in O
a O
defined O
10-12h O
post-training O
period O
, O
we O
evaluated O
the O
ability O
of O
nefiracetam O
to O
attenuate O
amnesia B-NEG
induced O
by O
dopaminergic O
agonism O
. O

a O
step-down O
passive O
avoidance O
paradigm O
was O
employed O
and O
nefiracetam O
(3 O
mg/kg O
) O
and O
apomorphine O
( O
0.5 O
mg/kg O
) O
were O
given O
alone O
or O
in O
combination O
during O
training O
and O
at O
the O
10-12h O
post-training O
period O
of O
consolidation O
. O

co-administration O
of O
nefiracetam O
and O
apomorphine O
during O
training O
or O
10h O
thereafter O
produced O
no O
significant O
anti-amnesic O
effect O
. O

however O
, O
administration O
of O
nefiracetam O
during O
training O
completely O
reversed O
the O
amnesia B-NEG
induced O
by O
apomorphine O
at O
the O
10h O
post-training O
time O
and O
the O
converse O
was O
also O
true O
. O

these O
effects O
were O
not O
mediated O
by O
a O
dopaminergic O
mechanism O
as O
nefiracetam O
, O
at O
millimolar O
concentrations O
, O
failed O
to O
displace O
either O
[3h]sch O
23390 O
or O
[3h]spiperone O
binding O
from O
d1 O
or O
d2 O
dopamine O
receptor O
subtypes O
, O
respectively O
. O

it O
is O
suggested O
that O
nefiracetam O
augments O
molecular O
processes O
in O
the O
early O
stages O
of O
events O
which O
ultimately O
lead O
to O
consolidation O
of O
memory O
. O

-DOCSTART- O

human O
corticotropin-releasing O
hormone O
and O
thyrotropin-releasing O
hormone O
modulate O
the O
hypercapnic B-NEG
ventilatory O
response O
in O
humans O
. O

human O
corticotropin-releasing O
hormone O
( O
hcrh O
) O
and O
thyrotropin-releasing O
hormone O
( O
trh O
) O
are O
known O
to O
stimulate O
ventilation O
after O
i.v O
. O
administration O
in O
humans O
. O

in O
a O
placebo-controlled O
, O
single-blind O
study O
we O
aimed O
to O
clarify O
if O
both O
peptides O
act O
by O
altering O
central O
chemosensitivity O
. O

two O
subsequent O
co2-rebreathing O
tests O
were O
performed O
in O
healthy O
young O
volunteers O
. O

during O
the O
first O
test O
0.9% O
nacl O
was O
given O
i.v. O
; O
during O
the O
second O
test O
200 O
micrograms O
of O
hcrh O
(n O
= O
12 O
) O
or O
400 O
micrograms O
of O
trh O
(n O
= O
6) O
was O
administered O
i.v O
. O

nine O
subjects O
received O
0.9% O
nacl O
i.v O
. O
during O
both O
rebreathing O
manoeuvres O
. O

the O
co2-response O
curves O
for O
the O
two O
tests O
were O
compared O
within O
the O
same O
subject O
. O

in O
the O
hcrh O
group O
a O
marked O
parallel O
shift O
of O
the O
co2-response O
curve O
to O
the O
left O
was O
observed O
after O
hcrh O
(p O
< O
0.01) O
. O

the O
same O
effect O
occurred O
following O
trh O
but O
was O
less O
striking O
(p O
= O
0.05) O
. O

hcrh O
and O
trh O
caused O
a O
reduction O
in O
the O
co2 O
threshold O
. O

the O
co2-response O
curves O
in O
the O
control O
group O
were O
nearly O
identical O
. O

the O
results O
indicate O
an O
additive O
effect O
of O
both O
releasing O
hormones O
on O
the O
hypercapnic B-NEG
ventilatory O
response O
in O
humans O
, O
presumably O
independent O
of O
central O
chemosensitivity O
. O

-DOCSTART- O

lamivudine O
is O
effective O
in O
suppressing O
hepatitis B-NEG
b I-NEG
virus O
dna O
in O
chinese O
hepatitis O
b O
surface O
antigen O
carriers O
: O
a O
placebo-controlled O
trial O
. O

lamivudine O
is O
a O
novel O
2',3'-dideoxy O
cytosine O
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis B-NEG
b I-NEG
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

we O
performed O
a O
single-blind O
, O
placebo-controlled O
study O
to O
assess O
its O
effectiveness O
and O
safety O
in O
chinese O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
carriers O
. O

forty-two O
chinese O
hbsag O
carriers O
were O
randomized O
to O
receive O
placebo O
(6 O
patients O
) O
or O
lamivudine O
orally O
in O
dosages O
of O
25 O
mg O
, O
100 O
mg O
, O
or O
300 O
mg O
daily O
( O
12 O
patients O
for O
each O
dosage) O
. O

the O
drug O
was O
given O
for O
4 O
weeks O
. O

the O
patients O
were O
closely O
monitored O
clinically O
, O
biochemically O
, O
and O
serologically O
up O
to O
4 O
weeks O
after O
drug O
treatment O
. O

all O
36 O
patients O
receiving O
lamivudine O
had O
a O
decrease O
in O
hepatitis B-NEG
b I-NEG
virus O
( O
hbv O
) O
dna O
values O
of O
>90% O
(p O
< O
.001 O
compared O
with O
placebo) O
. O

although O
25 O
mg O
of O
lamivudine O
was O
slightly O
less O
effective O
than O
100 O
mg O
(p O
= O
.011 O
) O
and O
300 O
mg O
(p O
= O
.005) O
, O
it O
still O
induced O
94% O
suppression O
of O
hbv O
dna O
after O
the O
fourth O
week O
of O
therapy O
. O

hbv O
dna O
values O
returned O
to O
pretreatment O
levels O
within O
4 O
weeks O
of O
cessation O
of O
therapy O
. O

there O
was O
no O
change O
in O
the O
hepatitis B-NEG
b I-NEG
e O
antigen O
status O
or O
in O
aminotransferase O
levels O
. O

no O
serious O
adverse O
events O
were O
observed O
. O

in O
conclusion O
, O
a O
4-week O
course O
of O
lamivudine O
was O
safe O
and O
effective O
in O
suppression O
of O
hbv O
dna O
in O
chinese O
hbsag O
carriers O
. O

the O
suppression O
was O
>90% O
but O
reversible O
. O

studies O
with O
long-term O
lamivudine O
administration O
should O
be O
performed O
to O
determine O
if O
prolonged O
suppression O
of O
hbv O
dna O
can O
be O
achieved O
. O

-DOCSTART- O

population-based O
study O
of O
risk O
of O
venous B-NEG
thromboembolism I-NEG
associated O
with O
various O
oral O
contraceptives O
. O

background O
: O
four O
studies O
published O
since O
december O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous B-NEG
thromboembolism I-NEG
( O
vte B-NEG
) O
was O
higher O
in O
women O
who O
used O
oral O
contraceptives O
( O
ocs O
) O
containing O
the O
third-generation O
progestagens O
gestodene O
or O
desogestrel O
than O
in O
users O
of O
ocs O
containing O
second-generation O
progestagens O
. O

however O
, O
confounding O
and O
bias O
in O
the O
design O
of O
these O
studies O
may O
have O
affected O
the O
findings O
. O

the O
aim O
of O
our O
study O
was O
to O
re-examine O
the O
association O
between O
risk O
of O
vte B-NEG
and O
oc O
use O
with O
a O
different O
study O
design O
and O
analysis O
to O
avoid O
some O
of O
the O
bias O
and O
confounding O
of O
the O
earlier O
studies O
. O

methods O
: O
we O
used O
computer O
records O
of O
patients O
from O
143 O
general O
practices O
in O
the O
uk O
. O

the O
study O
was O
based O
on O
the O
medical O
records O
of O
about O
540,000 O
women O
born O
between O
1941 O
and O
1981 O
. O

all O
women O
who O
had O
a O
recorded O
diagnosis O
of O
deep-vein B-NEG
thrombosis I-NEG
, O
venous B-NEG
thrombosis I-NEG
not O
otherwise O
specified O
, O
or O
pulmonary O
embolus O
during O
the O
study O
period O
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant O
were O
identified O
as O
potential O
cases O
of O
vte B-NEG
. O

we O
did O
a O
cohort O
analysis O
to O
estimate O
and O
compare O
incidence O
of O
vte B-NEG
in O
users O
of O
the O
main O
oc O
preparations O
, O
and O
a O
nested O
case-control O
study O
to O
calculate O
the O
odds O
ratios O
of O
vte B-NEG
associated O
with O
use O
of O
different O
types O
of O
oc O
, O
after O
adjustment O
for O
potential O
confounding O
factors O
. O

in O
the O
case-control O
study O
, O
we O
matched O
cases O
to O
controls O
by O
exact O
year O
of O
birth O
, O
practice O
, O
and O
current O
use O
of O
ocs O
. O

we O
used O
a O
multiple O
logistic O
regression O
model O
that O
included O
body-mass O
index O
, O
number O
of O
cycles O
, O
change O
in O
type O
of O
oc O
prescribed O
within O
3 O
months O
of O
the O
event O
, O
previous O
pregnancy O
, O
and O
concurrent O
disease O
. O

findings O
: O
85 O
women O
met O
the O
inclusion O
criteria O
for O
vte B-NEG
, O
two O
of O
whom O
were O
users O
of O
progestagen-only O
ocs O
. O

of O
the O
83 O
cases O
of O
vte B-NEG
associated O
with O
use O
of O
combined O
ocs O
, O
43 O
were O
recorded O
as O
deep-vein B-NEG
thrombosis I-NEG
, O
35 O
as O
pulmonary O
thrombosis B-NEG
, O
and O
five O
as O
venous B-NEG
thrombosis I-NEG
not O
otherwise O
specified O
. O

the O
crude O
rate O
of O
vte B-NEG
per O
10,000 O
woman-years O
was O
4.10 O
in O
current O
users O
of O
any O
oc O
, O
3.10 O
in O
users O
of O
second-generation O
ocs O
, O
and O
4.96 O
in O
users O
of O
third-generation O
preparations O
. O

after O
adjustment O
for O
age O
, O
the O
rate O
ratio O
of O
vte B-NEG
in O
users O
of O
third-generation O
relative O
to O
second-generation O
ocs O
was O
1.68 O
( O
95% O
ci O
1.04-2.75) O
. O

logistic O
regression O
showed O
no O
significant O
difference O
in O
the O
risk O
of O
vte B-NEG
between O
users O
of O
third-generation O
and O
second-generation O
ocs O
. O

among O
users O
of O
third-generation O
progestagens O
, O
the O
risk O
of O
vte B-NEG
was O
higher O
in O
users O
of O
desogestrel O
with O
20 O
g O
ethinyloestradiol O
than O
in O
users O
of O
gestodene O
or O
desogestrel O
with O
30 O
g O
ethinyloestradiol O
. O

with O
all O
second-generation O
ocs O
as O
the O
reference O
, O
the O
odds O
ratios O
for O
vte B-NEG
were O
3.49 O
( O
1.21-10.12 O
) O
for O
desogestrel O
plus O
20 O
g O
ethinyloestradiol O
and O
1.18 O
( O
0.66-2.17 O
) O
for O
the O
other O
third-generation O
progestagens O
. O

interpretation O
: O
the O
previously O
reported O
increase O
in O
odds O
ratio O
associated O
with O
third-generation O
ocs O
when O
compared O
with O
second-generation O
products O
is O
likely O
to O
have O
been O
the O
result O
of O
residual O
confounding O
by O
age O
. O

the O
increased O
odds O
ratio O
associated O
with O
products O
containing O
20 O
micrograms O
ethinyloestradiol O
and O
desogestrel O
compared O
with O
the O
30 O
micrograms O
product O
is O
biologically O
implausible O
, O
and O
is O
likely O
to O
be O
the O
result O
of O
preferential O
prescribing O
and O
, O
thus O
, O
confounding O
. O

-DOCSTART- O

mk-801 O
augments O
pilocarpine-induced O
electrographic O
seizure B-NEG
but O
protects O
against O
brain B-NEG
damage I-NEG
in O
rats O
. O

1. O

the O
authors O
examined O
the O
anticonvulsant O
effects O
of O
mk-801 O
on O
the O
pilocarpine-induced O
seizure B-NEG
model O
. O

intraperitoneal O
injection O
of O
pilocarpine O
( O
400 O
mg/kg O
) O
induced O
tonic B-NEG
and I-NEG
clonic I-NEG
seizure I-NEG
. O

scopolamine O
( O
10 O
mg/kg O
) O
and O
pentobarbital O
(5 O
mg/kg O
) O
prevented O
development O
of O
pilocarpine-induced O
behavioral O
seizure B-NEG
but O
mk-801 O
( O
0.5 O
mg/kg O
) O
did O
not O
. O

2. O

an O
electrical O
seizure B-NEG
measured O
with O
hippocampal O
eeg O
appeared O
in O
the O
pilocarpine-treated O
group O
. O

scopolamine O
and O
pentobarbital O
blocked O
the O
pilocarpine-induced O
electrographic O
seizure B-NEG
, O
mk-801 O
treatment O
augmented O
the O
electrographic O
seizure B-NEG
induced O
by O
pilocarpine O
. O

3. O
brain B-NEG
damage I-NEG
was O
assessed O
by O
examining O
the O
hippocampus O
microscopically O
. O

pilocarpine O
produced O
neuronal B-NEG
death I-NEG
in O
the O
hippocampus O
, O
which O
showed O
pyknotic O
changes O
. O

pentobarbital O
, O
scopolamine O
and O
mk-801 O
protected O
the O
brain B-NEG
damage I-NEG
by O
pilocarpine O
, O
though O
in O
the O
mk-801-treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

in O
all O
treatments O
, O
granule O
cells O
of O
the O
dentate O
gyrus O
were O
not O
affected O
. O

4. O

these O
results O
indicate O
that O
status B-NEG
epilepticus I-NEG
induced O
by O
pilocarpine O
is O
initiated O
by O
cholinergic O
overstimulation O
and O
propagated O
by O
glutamatergic O
transmission O
, O
the O
elevation O
of O
which O
may O
cause O
brain B-NEG
damage I-NEG
through O
an O
excitatory O
nmda O
receptor-mediated O
mechanism O
. O

-DOCSTART- O

paclitaxel O
, O
5-fluorouracil O
, O
and O
folinic O
acid O
in O
metastatic O
breast B-NEG
cancer I-NEG
: O
bre-26 O
, O
a O
phase O
ii O
trial O
. O

5-fluorouracil O
plus O
folinic O
acid O
and O
paclitaxel O
(taxol O
; O
bristol-myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast B-NEG
cancer I-NEG
patients O
. O

paclitaxel O
and O
5-fluorouracil O
have O
additive O
cytotoxicity B-NEG
in O
mcf-7 O
cell O
lines O
. O

we O
performed O
a O
phase O
ii O
trial O
of O
paclitaxel O
175 O
mg/m2 O
over O
3 O
hours O
on O
day O
i O
followed O
by O
folinic O
acid O
300 O
mg O
over O
1 O
hour O
before O
5-fluorouracil O
350 O
mg/m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
tfl O
) O
in O
women O
with O
metastatic O
breast B-NEG
cancer I-NEG
. O

analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow-up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
tfl O
: O
nine O
cycles O
( O
5% O
) O
were O
associated O
with O
grade O
3/4 O
neutropenia B-NEG
requiring O
hospitalization O
; O
seven O
( O
4% O
) O
cycles O
in O
two O
patients O
required O
granulocyte O
colony-stimulating O
factor O
due O
to O
neutropenia B-NEG
; O
no O
patient O
required O
platelet O
transfusions O
. O

grade O
3/4 O
nonhematologic O
toxicities B-NEG
were O
uncommon O
. O

among O
the O
34 O
patients O
evaluable O
for O
response O
, O
there O
were O
three O
complete O
responses O
( O
9% O
) O
and O
18 O
partial O
responses O
( O
53% O
) O
for O
an O
overall O
response O
rate O
of O
62% O
. O

of O
the O
19 O
evaluable O
patients O
with O
prior O
doxorubicin O
exposure O
, O
11 O
( O
58% O
) O
responded O
compared O
with O
nine O
of O
15 O
( O
60% O
) O
without O
prior O
doxorubicin O
. O

plasma O
paclitaxel O
concentrations O
were O
measured O
at O
the O
completion O
of O
paclitaxel O
infusion O
and O
at O
24 O
hours O
in O
19 O
patients O
. O

tfl O
is O
an O
active O
, O
well-tolerated O
regimen O
in O
metastatic O
breast B-NEG
cancer I-NEG
. O

-DOCSTART- O

efficacy O
and O
proarrhythmia B-NEG
with O
the O
use O
of O
d,l-sotalol O
for O
sustained O
ventricular B-NEG
tachyarrhythmias I-NEG
. O

this O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades B-NEG
de I-NEG
pointes I-NEG
, O
and O
the O
presumable O
risk O
factors O
for O
torsades B-NEG
de I-NEG
pointes I-NEG
in O
patients O
treated O
with O
d,l-sotalol O
for O
sustained O
ventricular B-NEG
tachyarrhythmias I-NEG
. O

eighty-one O
consecutive O
patients O
( O
54 O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
and O
20 O
with O
dilated B-NEG
cardiomyopathy I-NEG
) O
with O
inducible O
sustained O
ventricular B-NEG
tachycardia I-NEG
or O
ventricular B-NEG
fibrillation I-NEG
received O
oral O
d,l-sotalol O
to O
prevent O
induction O
of O
the O
ventricular B-NEG
tachyarrhythmia I-NEG
. O

during O
oral O
loading O
with O
d,l-sotalol O
, O
continuous O
electrocardiographic O
( O
ecg O
) O
monitoring O
was O
performed O
. O

those O
patients O
in O
whom O
d,l-sotalol O
prevented O
induction O
of O
ventricular B-NEG
tachycardia I-NEG
or O
ventricular B-NEG
fibrillation I-NEG
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+/- O
18 O
months O
. O

induction O
of O
the O
ventricular B-NEG
tachyarrhythmia I-NEG
was O
prevented O
by O
oral O
d,l-sotalol O
in O
35 O
( O
43% O
) O
patients O
; O
the O
ventricular B-NEG
tachyarrhythmia I-NEG
remained O
inducible O
in O
40 O
( O
49% O
) O
patients O
; O
and O
two O
( O
2.5% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d,l-sotalol O
once O
daily O
. O

four O
( O
5% O
) O
patients O
had O
from O
torsades B-NEG
de I-NEG
pointes I-NEG
during O
the O
initial O
oral O
treatment O
with O
d,l-sotalol O
. O

neither O
ecg O
[sinus-cycle O
length O
(scl) O
, O
qt O
or O
qtc O
interval O
, O
or O
u O
wave] O
nor O
clinical O
parameters O
identified O
patients O
at O
risk O
for O
torsades B-NEG
de I-NEG
pointes I-NEG
. O

however O
, O
the O
oral O
dose O
of O
d,l-sotalol O
was O
significantly O
lower O
in O
patients O
with O
torsades B-NEG
de I-NEG
pointes I-NEG
( O
200 O
+/- O
46 O
vs O
. O
328 O
+/- O
53 O
mg/day O
; O
p O
= O
0.0017) O
. O

risk O
factors O
associated O
with O
the O
development O
of O
torsades B-NEG
de I-NEG
pointes I-NEG
were O
the O
appearance O
of O
an O
u O
wave O
(p O
= O
0.049) O
, O
female O
gender O
(p O
= O
0.015) O
, O
and O
significant O
dose-corrected O
changes O
of O
scl O
, O
qt O
interval O
, O
and O
qtc O
interval O
(p O
< O
0.05) O
. O

during O
follow-up O
, O
seven O
( O
20% O
) O
patients O
had O
a O
nonfatal O
ventricular B-NEG
tachycardia I-NEG
recurrence O
, O
and O
two O
( O
6% O
) O
patients O
died O
suddenly O
. O

one O
female O
patient O
with O
stable O
cardiac B-NEG
disease I-NEG
had O
recurrent O
torsades B-NEG
de I-NEG
pointes I-NEG
after O
2 O
years O
of O
successful O
treatment O
with O
d,l-sotalol O
. O
torsades B-NEG
de I-NEG
pointes I-NEG
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d,l-sotalol O
. O

pronounced O
changes O
in O
the O
surface O
ecg O
( O
cycle O
length O
, O
qt O
, O
and O
qtc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d,l-sotalol O
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades B-NEG
de I-NEG
pointes I-NEG
. O

other O
ecg O
parameters O
before O
the O
application O
of O
d,l-sotalol O
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades B-NEG
de I-NEG
pointes I-NEG
. O

recurrence O
rates O
of O
ventricular B-NEG
tachyarrhythmias I-NEG
are O
high O
despite O
complete O
suppression O
of O
the O
arrhythmia B-NEG
during O
programmed O
stimulation O
. O

therefore O
programmed O
electrical O
stimulation O
in O
the O
case O
of O
d,l-sotalol O
seems O
to O
be O
of O
limited O
prognostic O
value O
. O

-DOCSTART- O

chronic O
hyperprolactinemia B-NEG
and O
changes O
in O
dopamine O
neurons O
. O

the O
tuberoinfundibular O
dopaminergic O
( O
tida O
) O
system O
is O
known O
to O
inhibit O
prolactin O
( O
prl O
) O
secretion O
. O

in O
young O
animals O
this O
system O
responds O
to O
acute O
elevations O
in O
serum O
prl O
by O
increasing O
its O
activity O
. O

however O
, O
this O
responsiveness O
is O
lost O
in O
aging O
rats O
with O
chronically O
high O
serum O
prl O
levels O
. O

the O
purpose O
of O
this O
study O
was O
to O
induce O
hyperprolactinemia B-NEG
in O
rats O
for O
extended O
periods O
of O
time O
and O
examine O
its O
effects O
on O
dopaminergic O
systems O
in O
the O
brain O
. O
hyperprolactinemia B-NEG
was O
induced O
by O
treatment O
with O
haloperidol O
, O
a O
dopamine O
receptor O
antagonist O
, O
and O
palkovits' O
microdissection O
technique O
in O
combination O
with O
high-performance O
liquid O
chromatography O
was O
used O
to O
measure O
neurotransmitter O
concentrations O
in O
several O
areas O
of O
the O
brain O
. O

after O
6 O
months O
of O
hyperprolactinemia B-NEG
, O
dopamine O
( O
da O
) O
concentrations O
in O
the O
median O
eminence O
( O
me O
) O
increased O
by O
84% O
over O
the O
control O
group O
. O

nine O
months O
of O
hyperprolactinemia B-NEG
produced O
a O
50% O
increase O
in O
da O
concentrations O
in O
the O
me O
over O
the O
control O
group O
. O

however O
, O
da O
response O
was O
lost O
if O
a O
9-month O
long O
haloperidol-induced O
hyperprolactinemia B-NEG
was O
followed O
by O
a O
1 O
1/2 O
month-long O
extremely O
high O
increase O
in O
serum O
prl O
levels O
produced O
by O
implantation O
of O
mmq O
cells O
under O
the O
kidney O
capsule O
. O

there O
was O
no O
change O
in O
the O
levels O
of O
da O
, O
norepinephrine O
(ne) O
, O
serotonin O
(5-ht) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
(an) O
, O
medial O
preoptic O
area O
(mpa) O
, O
caudate O
putamen O
(cp) O
, O
substantia O
nigra O
(sn) O
, O
and O
zona O
incerta O
(zi) O
, O
except O
for O
a O
decrease O
in O
5-hydroxyindoleacetic O
acid O
( O
5-hiaa O
) O
in O
the O
an O
after O
6-months O
of O
hyperprolactinemia B-NEG
and O
an O
increase O
in O
da O
concentrations O
in O
the O
an O
after O
9-months O
of O
hyperprolactinemia B-NEG
. O

these O
results O
demonstrate O
that O
hyperprolactinemia B-NEG
specifically O
affects O
tida O
neurons O
and O
these O
effects O
vary O
, O
depending O
on O
the O
duration O
and O
intensity O
of O
hyperprolactinemia B-NEG
. O

the O
age-related O
decrease O
in O
hypothalamic O
dopamine O
function O
may O
be O
associated O
with O
increases O
in O
prl O
secretion O
. O

-DOCSTART- O

treatment-related O
disseminated O
necrotizing O
leukoencephalopathy B-NEG
with O
characteristic O
contrast O
enhancement O
of O
the O
white O
matter O
. O

this O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
t1-weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy B-NEG
, O
which O
developed O
from O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
treated O
with O
high-dose O
methotrexate O
. O

in O
both O
patients O
, O
the O
enhancement O
was O
more O
pronounced O
near O
the O
base O
of O
the O
brain O
than O
at O
the O
vertex O
. O

necropsy O
of O
the O
first O
case O
revealed O
loss B-NEG
of I-NEG
myelination I-NEG
and O
necrosis B-NEG
of O
the O
white O
matter O
. O

possible O
mechanisms O
causing O
such O
a O
leukoencephalopathy B-NEG
are O
discussed O
. O

-DOCSTART- O

thrombotic B-NEG
complications O
in O
acute B-NEG
promyelocytic I-NEG
leukemia I-NEG
during O
all-trans-retinoic O
acid O
therapy O
. O

a O
case O
of O
acute B-NEG
renal I-NEG
failure I-NEG
, O
due O
to O
occlusion B-NEG
of I-NEG
renal I-NEG
vessels I-NEG
in O
a O
patient O
with O
acute B-NEG
promyelocytic I-NEG
leukemia I-NEG
( O
apl B-NEG
) O
treated O
with O
all-trans-retinoic O
acid O
( O
atra O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

we O
report O
a O
case O
of O
acute B-NEG
renal I-NEG
failure I-NEG
in O
an O
apl B-NEG
patient O
treated O
with O
atra O
alone O
. O

this O
case O
further O
supports O
the O
concern O
about O
thromboembolic B-NEG
complications O
associated O
with O
atra O
therapy O
in O
apl B-NEG
patients O
. O

the O
patients O
, O
a O
43-year-old O
man O
, O
presented O
all O
the O
signs O
and O
symptoms O
of O
apl B-NEG
and O
was O
included O
in O
a O
treatment O
protocol O
with O
atra O
. O

after O
10 O
days O
of O
treatment O
, O
he O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
that O
was O
completely O
reversible O
after O
complete O
remission O
of O
apl B-NEG
was O
achieved O
and O
therapy O
discontinued O
. O

we O
conclude O
that O
atra O
is O
a O
valid O
therapeutic O
choice O
for O
patients O
with O
apl B-NEG
, O
although O
the O
procoagulant O
tendency O
is O
not O
completely O
corrected O
. O
thrombotic B-NEG
events O
, O
however O
, O
could O
be O
avoided O
by O
using O
low-dose O
heparin O
. O

-DOCSTART- O

pupillary O
changes O
associated O
with O
the O
development O
of O
stimulant-induced O
mania B-NEG
: O
a O
case O
report O
. O

a O
30-year-old O
cocaine-dependent O
man O
who O
was O
a O
subject O
in O
a O
study O
evaluating O
the O
anticraving O
efficacy O
of O
the O
stimulant O
medication O
diethylpropion O
( O
dep O
) O
became O
manic B-NEG
during O
his O
second O
week O
on O
the O
study O
drug O
. O

pupillometric O
changes O
while O
on O
dep O
, O
especially O
changes O
in O
the O
total O
power O
of O
pupillary B-NEG
oscillation I-NEG
, O
were O
dramatically O
different O
than O
those O
observed O
in O
the O
eight O
other O
study O
subjects O
who O
did O
not O
become O
manic B-NEG
. O

the O
large O
changes O
in O
total O
power O
of O
pupillary B-NEG
oscillation I-NEG
occurred O
a O
few O
days O
before O
the O
patient O
became O
fully O
manic B-NEG
. O

such O
medication-associated O
changes O
in O
the O
total O
power O
of O
pupillary B-NEG
oscillation I-NEG
might O
be O
of O
utility O
in O
identifying O
persons O
at O
risk O
for O
manic B-NEG
-like O
adverse O
effects O
during O
the O
medical O
use O
of O
psychomotor O
stimulants O
or O
sympathomimetic O
agents O
. O

-DOCSTART- O

the O
negative O
mucosal O
potential O
: O
separating O
central O
and O
peripheral O
effects O
of O
nsaids O
in O
man O
. O

objective O
: O
we O
wanted O
to O
test O
whether O
assessment O
of O
both O
a O
central O
pain B-NEG
-related O
signal O
( O
chemo-somatosensory O
evoked O
potential O
, O
cssep O
) O
and O
a O
concomitantly O
recorded O
peripheral O
signal O
( O
negative O
mucosal O
potential O
, O
nmp O
) O
allows O
for O
separation O
of O
central O
and O
peripheral O
effects O
of O
nsaids O
. O

for O
this O
purpose O
, O
experimental O
conditions O
were O
created O
in O
which O
nsaids O
had O
previously O
been O
observed O
to O
produce O
effects O
on O
phasic O
and O
tonic O
pain B-NEG
by O
either O
central O
or O
peripheral O
mechanisms O
. O

methods O
: O
according O
to O
a O
double-blind O
, O
randomised O
, O
controlled O
, O
threefold O
cross-over O
design O
, O
18 O
healthy O
subjects O
( O
11 O
males O
, O
7 O
females O
; O
mean O
age O
26 O
years O
) O
received O
either O
placebo O
, O
400 O
mg O
ibuprofen O
, O
or O
800 O
mg O
ibuprofen O
. O

phasic O
pain B-NEG
was O
applied O
by O
means O
of O
short O
pulses O
of O
co2 O
to O
the O
nasal O
mucosa O
( O
stimulus O
duration O
500 O
ms O
, O
interval O
approximately O
60 O
s) O
, O
and O
tonic O
pain B-NEG
was O
induced O
in O
the O
nasal O
cavity O
by O
means O
of O
dry O
air O
of O
controlled O
temperature O
, O
humidity O
and O
flow O
rate O
( O
22 O
degrees O
c, O
0% O
relative O
humidity O
, O
145 O
ml.s-1) O
. O

both O
csseps O
as O
central O
and O
nmps O
as O
peripheral O
correlates O
of O
pain B-NEG
were O
obtained O
in O
response O
to O
the O
co2 O
stimuli O
. O

additionally O
, O
the O
subjects O
rated O
the O
intensity O
of O
both O
phasic O
and O
tonic O
pain B-NEG
by O
means O
of O
visual O
analogue O
scales O
. O

results O
: O
as O
described O
earlier O
, O
administration O
of O
ibuprofen O
was O
followed O
by O
a O
decrease O
in O
tonic O
pain B-NEG
but-relative O
to O
placebo-an O
increase O
in O
correlates O
of O
phasic O
pain B-NEG
, O
indicating O
a O
specific O
effect O
of O
ibuprofen O
on O
the O
interaction O
between O
the O
pain B-NEG
stimuli O
under O
these O
special O
experimental O
conditions O
. O

based O
on O
the O
similar O
behaviour O
of O
cssep O
and O
nmp O
, O
it O
was O
concluded O
that O
the O
pharmacological O
process O
underlying O
this O
phenomenon O
was O
localised O
in O
the O
periphery O
. O

by O
means O
of O
the O
simultaneous O
recording O
of O
interrelated O
peripheral O
and O
central O
electrophysiologic O
correlates O
of O
nociception O
, O
it O
was O
possible O
to O
separate O
central O
and O
peripheral O
effects O
of O
an O
nsaid O
. O

the O
major O
advantage O
of O
this O
pain B-NEG
model O
is O
the O
possibility O
of O
obtaining O
peripheral O
pain B-NEG
-related O
activity O
directly O
using O
a O
non-invasive O
technique O
in O
humans O
. O

-DOCSTART- O

acute O
severe O
depression B-NEG
following O
peri-operative O
ondansetron O
. O

a O
41-year-old O
woman O
with O
a O
strong O
history O
of O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron O
prophylaxis O
had O
been O
used O
. O

she O
had O
developed O
a O
severe O
acute O
major B-NEG
depression I-NEG
disorder I-NEG
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin O
antagonist O
. O

nine O
years O
before O
she O
had O
experienced O
a O
self-limited O
puerperal O
depressive B-NEG
episode I-NEG
. O

anaesthesia O
with O
a O
propofol O
infusion O
and O
avoidance O
of O
serotonin O
antagonists O
provided O
a O
nausea B-NEG
-free O
postoperative O
course O
without O
exacerbation O
of O
the O
depression B-NEG
disorder I-NEG
. O

-DOCSTART- O

hypertensive B-NEG
response O
during O
dobutamine O
stress O
echocardiography O
. O

among O
3,129 O
dobutamine O
stress O
echocardiographic O
studies O
, O
a O
hypertensive B-NEG
response O
, O
defined O
as O
systolic O
blood O
pressure O
( O
bp O
) O
> O
or O
= O
220 O
mm O
hg O
and/or O
diastolic O
bp O
> O
or O
= O
110 O
mm O
hg O
, O
occurred O
in O
30 O
patients O
(1%) O
. O

patients O
with O
this O
response O
more O
often O
had O
a O
history O
of O
hypertension B-NEG
and O
had O
higher O
resting O
systolic O
and O
diastolic O
bp O
before O
dobutamine O
infusion O
. O

-DOCSTART- O

continuously O
nebulized O
albuterol O
in O
severe O
exacerbations O
of O
asthma B-NEG
in O
adults O
: O
a O
case-controlled O
study O
. O

a O
retrospective O
, O
case-controlled O
analysis O
comparing O
patients O
admitted O
to O
a O
medical O
intensive O
care O
unit O
with O
severe O
exacerbations O
of O
asthma B-NEG
who O
received O
continuously O
nebulized O
albuterol O
( O
cna O
) O
versus O
intermittent O
albuterol O
( O
ina O
) O
treatments O
is O
reported O
. O

forty O
matched O
pairs O
of O
patients O
with O
asthma B-NEG
are O
compared O
. O

cna O
was O
administered O
for O
a O
mean O
of O
11 O
+/- O
10 O
hr O
. O

the O
incidence O
of O
cardiac B-NEG
dysrhythmias I-NEG
was O
similar O
between O
groups O
. O

symptomatic O
hypokalemia B-NEG
did O
not O
occur O
. O

cna O
patients O
had O
higher O
heart O
rates O
during O
treatment O
, O
which O
may O
reflect O
severity O
of O
illness O
. O

the O
incidence O
of O
intubation O
was O
similar O
. O

we O
conclude O
that O
cna O
and O
ina O
demonstrated O
similar O
profiles O
with O
regard O
to O
safety O
, O
morbidity O
, O
and O
mortality O
. O

-DOCSTART- O

hyperosmolar B-NEG
nonketotic I-NEG
coma I-NEG
precipitated O
by O
lithium-induced O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
. O

a O
45-year-old O
man O
, O
with O
a O
10-year O
history O
of O
manic B-NEG
depression I-NEG
treated O
with O
lithium O
, O
was O
admitted O
with O
hyperosmolar B-NEG
, O
nonketotic I-NEG
coma I-NEG
. O

he O
gave O
a O
five-year O
history O
of O
polyuria B-NEG
and O
polydipsia B-NEG
, O
during O
which O
time O
urinalysis O
had O
been O
negative O
for O
glucose O
. O

after O
recovery O
from O
hyperglycaemia B-NEG
, O
he O
remained O
polyuric B-NEG
despite O
normal O
blood O
glucose O
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
, O
likely O
to O
be O
lithium-induced O
. O

we O
hypothesize O
that O
when O
this O
man O
developed O
type B-NEG
2 I-NEG
diabetes I-NEG
, O
chronic O
polyuria B-NEG
due O
to O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B-NEG
. O

-DOCSTART- O

effects O
of O
the O
intracoronary O
infusion O
of O
cocaine O
on O
left O
ventricular O
systolic O
and O
diastolic O
function O
in O
humans O
. O

background O
: O
in O
dogs O
, O
a O
large O
amount O
of O
intravenous O
cocaine O
causes O
a O
profound O
deterioration B-NEG
of I-NEG
left I-NEG
ventricular I-NEG
( O
lv I-NEG
) O
systolic I-NEG
function I-NEG
and O
an O
increase O
in O
lv O
end-diastolic O
pressure O
. O

this O
study O
was O
done O
to O
assess O
the O
influence O
of O
a O
high O
intracoronary O
cocaine O
concentration O
on O
lv O
systolic O
and O
diastolic O
function O
in O
humans O
. O

methods O
and O
results O
: O
in O
20 O
patients O
( O
14 O
men O
and O
6 O
women O
aged O
39 O
to O
72 O
years O
) O
referred O
for O
cardiac O
catheterization O
for O
the O
evaluation O
of O
chest B-NEG
pain I-NEG
, O
we O
measured O
heart O
rate O
, O
systemic O
arterial O
pressure O
, O
lv O
pressure O
and O
its O
first O
derivative O
(dp/dt) O
, O
and O
lv O
volumes O
and O
ejection O
fraction O
before O
and O
during O
the O
final O
2 O
to O
3 O
minutes O
of O
a O
15-minute O
intracoronary O
infusion O
of O
saline O
(n=10 O
, O
control O
subjects O
) O
or O
cocaine O
hydrochloride O
1 O
mg/min O
(n=10) O
. O

no O
variable O
changed O
with O
saline O
. O

with O
cocaine O
, O
the O
drug O
concentration O
in O
blood O
obtained O
from O
the O
coronary O
sinus O
was O
3.0+/-0.4 O
( O
mean+/-sd O
) O
mg/l O
, O
similar O
in O
magnitude O
to O
the O
blood O
cocaine O
concentration O
reported O
in O
abusers O
dying O
of O
cocaine O
intoxication O
. O

cocaine O
induced O
no O
significant O
change O
in O
heart O
rate O
, O
lv O
dp/dt O
( O
positive O
or O
negative) O
, O
or O
lv O
end-diastolic O
volume O
, O
but O
it O
caused O
an O
increase O
in O
systolic O
and O
mean O
arterial O
pressures O
, O
lv O
end-diastolic O
pressure O
, O
and O
lv O
end-systolic O
volume O
, O
as O
well O
as O
a O
decrease O
in O
lv O
ejection O
fraction O
. O

conclusions O
: O
in O
humans O
, O
the O
intracoronary O
infusion O
of O
cocaine O
sufficient O
in O
amount O
to O
achieve O
a O
high O
drug O
concentration O
in O
coronary O
sinus O
blood O
causes O
a O
deterioration B-NEG
of I-NEG
lv I-NEG
systolic I-NEG
and I-NEG
diastolic I-NEG
performance I-NEG
. O

-DOCSTART- O

heparin-induced O
thrombocytopenia B-NEG
, O
paradoxical O
thromboembolism B-NEG
, O
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin O
remains O
the O
drug O
of O
choice O
for O
most O
anticoagulation O
needs O
. O

the O
clinical O
effects O
of O
heparin O
are O
meritorious O
, O
but O
side O
effects O
do O
exist O
. O

important O
untoward O
effects O
of O
heparin O
therapy O
including O
heparin-induced O
thrombocytopenia B-NEG
, O
heparin-associated O
osteoporosis B-NEG
, O
eosinophilia B-NEG
, O
skin B-NEG
reactions I-NEG
, O
allergic B-NEG
reactions I-NEG
other O
than O
thrombocytopenia B-NEG
and O
alopecia B-NEG
will O
be O
discussed O
in O
this O
article O
. O

-DOCSTART- O

nonopaque O
crystal O
deposition O
causing O
ureteric B-NEG
obstruction I-NEG
in O
patients O
with O
hiv O
undergoing O
indinavir O
therapy O
. O

objective O
: O
we O
describe O
the O
unique O
ct O
features O
of O
ureteric B-NEG
calculi I-NEG
in O
six O
hiv-infected B-NEG
patients O
receiving O
indinavir O
, O
the O
most O
commonly O
used O
hiv O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis B-NEG
. O

conclusion O
: O
ureteric B-NEG
obstruction I-NEG
caused O
by O
precipitated O
indinavir O
crystals O
may O
be O
difficult O
to O
diagnose O
with O
unenhanced O
ct O
. O

the O
calculi O
are O
not O
opaque O
, O
and O
secondary O
signs O
of O
obstruction O
may O
be O
absent O
or O
minimal O
and O
should O
be O
sought O
carefully O
. O

images O
may O
need O
to O
be O
obtained O
using O
i.v O
. O
contrast O
material O
to O
enable O
diagnosis O
of O
ureteric B-NEG
stones I-NEG
or I-NEG
obstruction I-NEG
in O
patients O
with O
hiv B-NEG
infection I-NEG
who O
receive O
indinavir O
therapy O
. O

-DOCSTART- O

ischemic B-NEG
colitis I-NEG
and O
sumatriptan O
use O
. O

sumatriptan O
succinate O
, O
a O
serotonin-1 O
( O
5-hydroxytryptamine-1 O
) O
receptor O
agonist O
, O
is O
an O
antimigraine O
drug O
that O
is O
reported O
to O
act O
by O
selectively O
constricting O
intracranial O
arteries O
. O

recently O
, O
vasopressor O
responses O
that O
are O
distinct O
from O
the O
cranial O
circulation O
have O
been O
demonstrated O
to O
occur O
in O
the O
systemic O
, O
pulmonary O
, O
and O
coronary O
circulations O
. O

cases O
have O
been O
published O
of O
coronary B-NEG
vasospasm I-NEG
, O
myocardial B-NEG
ischemia I-NEG
, O
and O
myocardial B-NEG
infarction I-NEG
occurring O
after O
sumatriptan O
use O
. O

we O
report O
on O
the O
development O
of O
8 O
serious O
cases O
of O
ischemic B-NEG
colitis I-NEG
in O
patients O
with O
migraine B-NEG
treated O
with O
sumatriptan O
. O

-DOCSTART- O

pallidotomy O
with O
the O
gamma O
knife O
: O
a O
positive O
experience O
. O

51 O
patients O
with O
medically O
refractory O
parkinson's B-NEG
disease I-NEG
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
august O
1993 O
and O
february O
1997 O
for O
treatment O
of O
bradykinesia B-NEG
, O
rigidity B-NEG
, O
and O
l-dopa-induced O
dyskinesias B-NEG
. O

in O
29 O
patients O
, O
the O
pallidotomies O
were O
performed O
with O
the O
leksell O
gamma O
knife O
and O
in O
22 O
they O
were O
performed O
with O
the O
standard O
radiofrequency O
( O
rf O
) O
method O
. O

clinical O
assessment O
as O
well O
as O
blinded O
ratings O
of O
unified O
parkinson's B-NEG
disease I-NEG
rating O
scale O
( O
updrs O
) O
scores O
were O
carried O
out O
pre- O
and O
postoperatively O
. O

mean O
follow-up O
time O
is O
20.6 O
months O
( O
range O
6-48 O
) O
and O
all O
except O
4 O
patients O
have O
been O
followed O
more O
than O
one O
year O
. O

85 O
percent O
of O
patients O
with O
dyskinesias B-NEG
were O
relieved O
of O
symptoms O
, O
regardless O
of O
whether O
the O
pallidotomies O
were O
performed O
with O
the O
gamma O
knife O
or O
radiofrequency O
methods O
. O

about O
2/3 O
of O
the O
patients O
in O
both O
gamma O
knife O
and O
radiofrequency O
groups O
showed O
improvements O
in O
bradykinesia B-NEG
and O
rigidity B-NEG
, O
although O
when O
considered O
as O
a O
group O
neither O
the O
gamma O
knife O
nor O
the O
radiofrequency O
group O
showed O
statistically O
significant O
improvements O
in O
updrs O
scores O
. O

one O
patient O
in O
the O
gamma O
knife O
group O
( O
3.4% O
) O
developed O
a O
homonymous B-NEG
hemianopsia I-NEG
9 O
months O
following O
treatment O
and O
5 O
patients O
( O
27.7% O
) O
in O
the O
radiofrequency O
group O
became O
transiently O
confused O
postoperatively O
. O

no O
other O
complications O
were O
seen O
. O

gamma O
knife O
pallidotomy O
is O
as O
effective O
as O
radiofrequency O
pallidotomy O
in O
controlling O
certain O
of O
the O
symptoms O
of O
parkinson's B-NEG
disease I-NEG
. O

it O
may O
be O
the O
only O
practical O
technique O
available O
in O
certain O
patients O
, O
such O
as O
those O
who O
take O
anticoagulants O
, O
have O
bleeding B-NEG
diatheses O
or O
serious O
systemic O
medical O
illnesses O
. O

it O
is O
a O
viable O
option O
for O
other O
patients O
as O
well O
. O

-DOCSTART- O

neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
and O
methylphenidate O
. O

a O
1-year-old O
female O
presented O
with O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
probably O
caused O
by O
methylphenidate O
. O

she O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B-NEG
encephalomalacia I-NEG
) O
due O
to O
severe O
perinatal O
hypoxic-ischemic B-NEG
encephalopathy I-NEG
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
. O

a O
dopaminergic O
blockade O
mechanism O
generally O
is O
accepted O
as O
the O
pathogenesis O
of O
this O
syndrome O
. O

however O
, O
methylphenidate O
is O
a O
dopamine O
agonist O
via O
the O
inhibition O
of O
uptake O
of O
dopamine O
, O
and O
therefore O
dopaminergic O
systems O
in O
the O
brainstem O
( O
mainly O
the O
midbrain O
) O
and O
the O
spinal O
cord O
were O
unlikely O
to O
participate O
in O
the O
onset O
of O
this O
syndrome O
. O

a O
relative O
gamma-aminobutyric O
acid-ergic O
deficiency O
might O
occur O
because O
diazepam O
, O
a O
gamma-aminobutyric O
acid-mimetic O
agent O
, O
was O
strikingly O
effective O
. O

this O
is O
the O
first O
reported O
patient O
with O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
probably O
caused O
by O
methylphenidate O
. O

-DOCSTART- O

differential O
effects O
of O
17alpha-ethinylestradiol O
on O
the O
neutral O
and O
acidic O
pathways O
of O
bile O
salt O
synthesis O
in O
the O
rat O
. O

effects O
of O
17alpha-ethinylestradiol O
( O
ee O
) O
on O
the O
neutral O
and O
acidic O
biosynthetic O
pathways O
of O
bile O
salt O
( O
bs O
) O
synthesis O
were O
evaluated O
in O
rats O
with O
an O
intact O
enterohepatic O
circulation O
and O
in O
rats O
with O
long-term O
bile O
diversion O
to O
induce O
bs O
synthesis O
. O

for O
this O
purpose O
, O
bile O
salt O
pool O
composition O
, O
synthesis O
of O
individual O
bs O
in O
vivo O
, O
hepatic O
activities O
, O
and O
expression O
levels O
of O
cholesterol O
7alpha-hydroxylase O
(cyp7a) O
, O
and O
sterol O
27-hydroxylase O
(cyp27) O
, O
as O
well O
as O
of O
other O
enzymes O
involved O
in O
bs O
synthesis O
, O
were O
analyzed O
in O
rats O
treated O
with O
ee O
(5 O
mg/kg O
, O
3 O
days O
) O
or O
its O
vehicle O
. O

bs O
pool O
size O
was O
decreased O
by O
27% O
but O
total O
bs O
synthesis O
was O
not O
affected O
by O
ee O
in O
intact O
rats O
. O

synthesis O
of O
cholate O
was O
reduced O
by O
68% O
in O
ee-treated O
rats O
, O
while O
that O
of O
chenodeoxycholate O
was O
increased O
by O
60% O
. O

the O
recently O
identified O
delta22-isomer O
of O
beta-muricholate O
contributed O
for O
5.4% O
and O
18.3 O
% O
(p O
< O
0.01 O
) O
to O
the O
pool O
in O
control O
and O
ee-treated O
rats O
, O
respectively O
, O
but O
could O
not O
be O
detected O
in O
bile O
after O
exhaustion O
of O
the O
pool O
. O

a O
clear O
reduction O
of O
bs O
synthesis O
was O
found O
in O
bile-diverted O
rats O
treated O
with O
ee O
, O
yet O
biliary O
bs O
composition O
was O
only O
minimally O
affected O
. O

activity O
of O
cyp7a O
was O
decreased O
by O
ee O
in O
both O
intact O
and O
bile-diverted O
rats O
, O
whereas O
the O
activity O
of O
the O
cyp27 O
was O
not O
affected O
. O

hepatic O
mrna O
levels O
of O
cyp7a O
were O
significantly O
reduced O
by O
ee O
in O
bile-diverted O
rats O
only O
; O
cyp27 O
mrna O
levels O
were O
not O
affected O
by O
ee O
. O

in O
addition O
, O
mrna O
levels O
of O
sterol O
12alpha-hydroxylase O
and O
lithocholate O
6beta-hydroxylase O
were O
increased O
by O
bile O
diversion O
and O
suppressed O
by O
ee O
. O

this O
study O
shows O
that O
17alpha-ethinylestradiol O
( O
ee)-induced O
intrahepatic B-NEG
cholestasis I-NEG
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile O
salt O
( O
bs O
) O
synthesis O
. O

simultaneous O
impairment O
of O
other O
enzymes O
in O
the O
bs O
biosynthetic O
pathways O
may O
contribute O
to O
overall O
effects O
of O
ee O
on O
bs O
synthesis O
. O

-DOCSTART- O

glibenclamide-sensitive O
hypotension B-NEG
produced O
by O
helodermin O
assessed O
in O
the O
rat O
. O

the O
effects O
of O
helodermin O
, O
a O
basic O
35-amino O
acid O
peptide O
isolated O
from O
the O
venom O
of O
a O
lizard O
salivary O
gland O
, O
on O
arterial O
blood O
pressure O
and O
heart O
rate O
were O
examined O
in O
the O
rat O
, O
focusing O
on O
the O
possibility O
that O
activation O
of O
atp O
sensitive O
k+ O
( O
k(atp) O
) O
channels O
is O
involved O
in O
the O
responses O
. O

the O
results O
were O
also O
compared O
with O
those O
of O
vasoactive O
intestinal O
polypeptide O
(vip) O
. O

helodermin O
produced O
hypotension B-NEG
in O
a O
dose-dependent O
manner O
with O
approximately O
similar O
potency O
and O
duration O
to O
vip O
. O
hypotension B-NEG
induced O
by O
both O
peptides O
was O
significantly O
attenuated O
by O
glibenclamide O
, O
which O
abolished O
a O
levcromakalim-produced O
decrease O
in O
arterial O
blood O
pressure O
. O

oxyhemoglobin O
did O
not O
affect O
helodermin-induced O
hypotension B-NEG
, O
whereas O
it O
shortened O
the O
duration O
of O
acetylcholine O
( O
ach)-produced O
hypotension B-NEG
. O

these O
findings O
suggest O
that O
helodermin-produced O
hypotension B-NEG
is O
partly O
attributable O
to O
the O
activation O
of O
glibenclamide-sensitive O
k+ O
channels O
( O
k(atp O
) O
channels) O
, O
which O
presumably O
exist O
on O
arterial O
smooth O
muscle O
cells O
. O

edrf O
( O
endothelium-derived O
relaxing O
factor)/nitric O
oxide O
does O
not O
seem O
to O
play O
an O
important O
role O
in O
the O
peptide-produced O
hypotension B-NEG
. O

-DOCSTART- O

long-term O
efficacy O
and O
adverse O
event O
of O
nifedipine O
sustained-release O
tablets O
for O
cyclosporin O
a-induced O
hypertension B-NEG
in O
patients O
with O
psoriasis B-NEG
. O

thirteen O
psoriatic B-NEG
patients O
with O
hypertension B-NEG
during O
the O
course O
of O
cyclosporin O
a O
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium O
channel O
blocker O
, O
sustained-release O
nifedipine O
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

seven O
of O
the O
13 O
patients O
had O
exhibited O
a O
subclinical O
hypertensive B-NEG
state O
before O
cyclosporin O
a O
therapy O
. O

both O
systolic O
and O
diastolic O
blood O
pressures O
of O
these O
13 O
patients O
were O
decreased O
significantly O
after O
4 O
weeks O
of O
nifedipine O
therapy O
, O
and O
blood O
pressure O
was O
maintained O
within O
the O
normal O
range O
thereafter O
for O
25 O
months O
. O

the O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin O
a O
and O
nifedipine O
included O
an O
increase O
in O
blood O
urea O
nitrogen O
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival B-NEG
hyperplasia I-NEG
in O
2 O
of O
the O
13 O
patients O
. O

our O
findings O
indicate O
that O
sustained-release O
nifedipine O
is O
useful O
for O
hypertensive B-NEG
psoriatic B-NEG
patients O
under O
long-term O
treatment O
with O
cyclosporin O
a, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival B-NEG
hyperplasia I-NEG
. O

-DOCSTART- O

torsade B-NEG
de I-NEG
pointes I-NEG
ventricular B-NEG
tachycardia I-NEG
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B-NEG
cardiomyopathy I-NEG
and O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

the O
authors O
describe O
the O
case O
of O
a O
56-year-old O
woman O
with O
chronic O
, O
severe O
heart B-NEG
failure I-NEG
secondary O
to O
dilated B-NEG
cardiomyopathy I-NEG
and O
absence O
of O
significant O
ventricular B-NEG
arrhythmias I-NEG
who O
developed O
qt B-NEG
prolongation I-NEG
and O
torsade B-NEG
de I-NEG
pointes I-NEG
ventricular B-NEG
tachycardia I-NEG
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2.5 O
mcg/kg O
per O
min O
) O
dobutamine O
. O

this O
report O
of O
torsade B-NEG
de I-NEG
pointes I-NEG
ventricular B-NEG
tachycardia I-NEG
during O
intermittent O
dobutamine O
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
arrhythmias B-NEG
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbances O
. O

the O
mechanisms O
of O
proarrhythmic O
effects O
of O
dubutamine O
are O
discussed O
. O

-DOCSTART- O

positive O
skin O
tests O
in O
late O
reactions O
to O
radiographic O
contrast O
media O
. O

in O
the O
last O
few O
years O
delayed O
reactions O
several O
hours O
after O
the O
injection O
of O
radiographic O
and O
contrast O
materials O
( O
prc O
) O
have O
been O
described O
with O
increasing O
frequency O
. O

the O
authors O
report O
two O
observations O
on O
patients O
with O
delayed O
reactions O
in O
whom O
intradermoreactions O
( O
idr O
) O
and O
patch O
tests O
to O
a O
series O
of O
ionic O
and O
non O
ionic O
prc O
were O
studied O
. O

after O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B-NEG
, O
loss B-NEG
of I-NEG
consciousness I-NEG
) O
and O
delayed O
macro-papular B-NEG
rash I-NEG
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B-NEG
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro-papular O
reaction O
after O
24 O
hours O
. O

the O
skin O
tests O
revealed O
positive O
delayed O
reactions O
of O
24 O
hours O
and O
48 O
hours O
by O
idr O
and O
patch O
tests O
to O
only O
some O
prc O
with O
common O
chains O
in O
their O
structures O
. O

the O
positive O
skin O
tests O
are O
in O
favour O
of O
immunological O
reactions O
and O
may O
help O
in O
diagnosis O
of O
allergy B-NEG
in O
the O
patients O
. O

-DOCSTART- O

risk O
of O
transient O
hyperammonemic B-NEG
encephalopathy I-NEG
in O
cancer B-NEG
patients O
who O
received O
continuous O
infusion O
of O
5-fluorouracil O
with O
the O
complication O
of O
dehydration B-NEG
and O
infection B-NEG
. O

from O
1986 O
to O
1998 O
, O
29 O
cancer B-NEG
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic B-NEG
encephalopathy I-NEG
related O
to O
continuous O
infusion O
of O
5-fluorouracil O
( O
5-fu O
) O
were O
identified O
. O

none O
of O
the O
patients O
had O
decompensated O
liver B-NEG
disease I-NEG
. O

onset O
of O
hyperammonemic B-NEG
encephalopathy I-NEG
varied O
from O
0.5 O
to O
5 O
days O
(mean O
: O
2.6 O
+/- O
1.3 O
days O
) O
after O
the O
initiation O
of O
chemotherapy O
. O

plasma O
ammonium O
level O
ranged O
from O
248 O
to O
2387 O
microg% O
(mean O
: O
626 O
+/- O
431 O
microg%) O
. O

among O
the O
32 O
episodes O
, O
26 O
( O
81% O
) O
had O
various O
degrees O
of O
azotemia B-NEG
, O
18 O
( O
56% O
) O
occurred O
during O
bacterial B-NEG
infections I-NEG
and O
14 O
( O
44% O
) O
without O
infection B-NEG
occurred O
during O
periods O
of O
dehydration B-NEG
. O

higher O
plasma O
ammonium O
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia B-NEG
were O
seen O
in O
18 O
patients O
with O
bacterial B-NEG
infections I-NEG
( O
p=0.003 O
and O
0.0006 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg/m2 O
) O
of O
5-fu O
( O
p=0.0001 O
and O
< O
0.0001 O
, O
respectively) O
. O

in O
25 O
out O
of O
32 O
episodes O
(78%) O
, O
plasma O
ammonium O
levels O
and O
mental O
status O
returned O
to O
normal O
within O
2 O
days O
after O
adequate O
management O
. O

in O
conclusion O
, O
hyperammonemic B-NEG
encephalopathy I-NEG
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5-fu O
. O
azotemia B-NEG
, O
body O
fluid O
insufficiency O
and O
bacterial B-NEG
infections I-NEG
were O
frequently O
found O
in O
these O
patients O
. O

it O
is O
therefore O
important O
to O
recognize O
this O
condition O
in O
patients O
receiving O
continuous O
infusion O
of O
5-fu O
. O

-DOCSTART- O

the O
effects O
of O
quinine O
and O
4-aminopyridine O
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
morphine O
in O
rats O
. O

1. O

the O
effects O
of O
two O
unselective O
potassium O
( O
k(+)- O
) O
channel O
blockers O
, O
quinine O
(12.5 O
, O
25 O
and O
50 O
mg/kg O
) O
and O
4-aminopyridine O
(1 O
and O
2 O
mg/kg) O
, O
on O
conditioned O
place O
preference O
and O
biphasic O
changes O
in O
motor O
activity O
induced O
by O
morphine O
( O
10 O
mg/kg O
) O
were O
tested O
in O
wistar O
rats O
. O

quinine O
is O
known O
to O
block O
voltage- O
, O
calcium- O
and O
atp-sensitive O
k(+)-channels O
while O
4-aminopyridine O
is O
known O
to O
block O
voltage-sensitive O
k(+)-channels O
. O

2. O

in O
the O
counterbalanced O
method O
, O
quinine O
attenuated O
morphine-induced O
place O
preference O
, O
whereas O
4-aminopyridine O
was O
ineffective O
. O

in O
the O
motor O
activity O
test O
measured O
with O
an O
animex-activity O
meter O
neither O
of O
the O
k(+)-channel O
blockers O
affected O
morphine-induced O
hypoactivity B-NEG
, O
but O
both O
k(+)-channel O
blockers O
prevented O
morphine-induced O
secondary O
hyperactivity B-NEG
. O

3. O

these O
results O
suggest O
the O
involvement O
of O
quinine-sensitive O
but O
not O
4-aminopyridine-sensitive O
k(+)-channels O
in O
morphine O
reward O
. O

it O
is O
also O
suggested O
that O
the O
blockade O
of O
k(+)-channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine-induced O
hypoactivity B-NEG
whereas O
morphine-induced O
hyperactivity B-NEG
seems O
to O
be O
connected O
to O
both O
quinine- O
and O
4-aminopyridine-sensitive O
k(+)-channels O
. O

-DOCSTART- O

nociceptin/orphanin O
fq O
and O
nocistatin O
on O
learning B-NEG
and I-NEG
memory I-NEG
impairment I-NEG
induced O
by O
scopolamine O
in O
mice O
. O

1. O

nociceptin O
, O
also O
known O
as O
orphanin O
fq O
, O
is O
an O
endogenous O
ligand O
for O
the O
orphan O
opioid O
receptor-like O
receptor O
1 O
( O
orl1 O
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
(cns) O
. O

on O
the O
other O
hand O
, O
nocistatin O
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
nociceptin O
and O
blocks O
nociceptin-induced O
allodynia B-NEG
and O
hyperalgesia B-NEG
. O

2. O

although O
orl1 O
receptors O
which O
display O
a O
high O
degree O
of O
sequence O
homology O
with O
classical O
opioid O
receptors O
are O
abundant O
in O
the O
hippocampus O
, O
little O
is O
known O
regarding O
their O
role O
in O
learning O
and O
memory O
. O

3. O

the O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin/orphanin O
fq O
and O
nocistatin O
could O
modulate O
impairment B-NEG
of I-NEG
learning I-NEG
and I-NEG
memory I-NEG
induced O
by O
scopolamine O
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
y-maze O
and O
step-down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

4. O

while O
nocistatin O
( O
0.5-5.0 O
nmol O
mouse-1 O
, O
i.c.v. O
) O
administered O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
had O
no O
effect O
on O
spontaneous O
alternation O
or O
passive O
avoidance O
behaviours O
, O
a O
lower O
per O
cent O
alternation O
and O
shorter O
median O
step-down O
latency O
in O
the O
retention O
test O
were O
obtained O
in O
nociceptin O
( O
1.5 O
and/or O
5.0 O
nmol O
mouse-1 O
, O
i.c.v.)-treated O
normal O
mice O
. O

5. O

administration O
of O
nocistatin O
( O
1.5 O
and/or O
5.0 O
nmol O
mouse-1 O
, O
i.c.v. O
) O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
attenuated O
the O
scopolamine-induced O
impairment O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
behaviours O
. O

6. O

these O
results O
indicated O
that O
nocistatin O
, O
a O
new O
biologically O
active O
peptide O
, O
ameliorates O
impairments O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
induced O
by O
scopolamine O
, O
and O
suggested O
that O
these O
peptides O
play O
opposite O
roles O
in O
learning O
and O
memory O
. O

-DOCSTART- O

meloxicam-induced O
liver B-NEG
toxicity I-NEG
. O

we O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid B-NEG
arthritis I-NEG
who O
developed O
acute O
cytolytic O
hepatitis B-NEG
due O
to O
meloxicam O
. O

recently O
introduced O
in O
belgium O
, O
meloxicam O
is O
the O
first O
nonsteroidal O
antiinflammatory O
drug O
with O
selective O
action O
on O
the O
inducible O
form O
of O
cyclooxygenase O
2. O

the O
acute O
cytolytic O
hepatitis B-NEG
occurred O
rapidly O
after O
meloxicam O
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity B-NEG
mechanism O
. O

this O
first O
case O
of O
meloxicam O
related O
liver B-NEG
toxicity I-NEG
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic B-NEG
damage I-NEG
. O

-DOCSTART- O

induction O
of O
apoptosis O
by O
remoxipride O
metabolites O
in O
hl60 O
and O
cd34+/cd19- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride-induced O
aplastic B-NEG
anemia I-NEG
. O

the O
antipsychotic O
agent O
, O
remoxipride O
[(s)-(-)-3-bromo-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz O
amide] O
has O
been O
associated O
with O
acquired O
aplastic B-NEG
anemia I-NEG
. O

we O
have O
examined O
the O
ability O
of O
remoxipride O
, O
three O
pyrrolidine O
ring O
metabolites O
and O
five O
aromatic O
ring O
metabolites O
of O
the O
parent O
compound O
to O
induce O
apoptosis O
in O
hl60 O
cells O
and O
human O
bone O
marrow O
progenitor O
( O
hbmp O
) O
cells O
. O

cells O
were O
treated O
for O
0-24 O
h O
with O
each O
compound O
( O
0-200 O
microm) O
. O

apoptosis O
was O
assessed O
by O
fluorescence O
microscopy O
in O
hoechst O
33342- O
and O
propidium O
iodide O
stained O
cell O
samples O
. O

results O
were O
confirmed O
by O
determination O
of O
internucleosomal O
dna O
fragmentation O
using O
gel O
electrophoresis O
for O
hl60 O
cell O
samples O
and O
terminal O
deoxynucleotidyl O
transferase O
assay O
in O
hbmp O
cells O
. O

the O
catechol O
and O
hydroquinone O
metabolites O
, O
ncq436 O
and O
ncq344 O
, O
induced O
apoptosis O
in O
hl60 O
and O
hbmp O
cells O
in O
a O
time- O
and O
concentration O
dependent O
manner O
, O
while O
the O
phenols O
, O
ncr181 O
, O
fla873 O
, O
and O
fla797 O
, O
and O
the O
derivatives O
formed O
by O
oxidation O
of O
the O
pyrrolidine O
ring O
, O
fla838 O
, O
ncm001 O
, O
and O
ncl118 O
, O
had O
no O
effect O
. O

no O
necrosis B-NEG
was O
observed O
in O
cells O
treated O
with O
ncq436 O
but O
ncq344 O
had O
a O
biphasic O
effect O
in O
both O
cell O
types O
, O
inducing O
apoptosis O
at O
lower O
concentrations O
and O
necrosis B-NEG
at O
higher O
concentrations O
. O

these O
data O
show O
that O
the O
catechol O
and O
hydroquinone O
metabolites O
of O
remoxipride O
have O
direct O
toxic O
effects O
in O
hl60 O
and O
hbmp O
cells O
, O
leading O
to O
apoptosis O
, O
while O
the O
phenol O
metabolites O
were O
inactive O
. O

similarly O
, O
benzene-derived O
catechol O
and O
hydroquinone O
, O
but O
not O
phenol O
, O
induce O
apoptosis O
in O
hbmp O
cells O
[moran O
et O
al. O
, O
mol O
. O
pharmacol. O
, O
50 O
( O
1996 O
) O
610-615] O
. O

we O
propose O
that O
remoxipride O
and O
benzene O
may O
induce O
aplastic B-NEG
anemia I-NEG
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
ncq436 O
and O
ncq344 O
to O
induce O
apoptosis O
in O
hbmp O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic B-NEG
anemia I-NEG
that O
has O
been O
associated O
with O
remoxipride O
. O

-DOCSTART- O

synthesis O
and O
preliminary O
pharmacological O
investigations O
of O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine O
derivatives O
as O
potential O
atypical O
antipsychotic O
agents O
in O
mice O
. O

in O
research O
towards O
the O
development O
of O
new O
atypical O
antipsychotic O
agents O
, O
one O
strategy O
is O
that O
the O
dopaminergic O
system O
can O
be O
modulated O
through O
manipulation O
of O
the O
serotonergic O
system O
. O

the O
synthesis O
and O
preliminary O
pharmacological O
evaluation O
of O
a O
series O
of O
potential O
atypical O
antipsychotic O
agents O
based O
on O
the O
structure O
of O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine O
( O
7 O
) O
is O
described O
. O

compound O
7e O
, O
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy O
dro-1h- O
indol-2-one O
, O
from O
this O
series O
showed O
significant O
affinities O
at O
the O
5-ht1a O
and O
5-ht2a O
receptors O
and O
moderate O
affinity O
at O
the O
d2 O
receptor O
. O

7e O
exhibits O
a O
high O
reversal O
of O
catalepsy B-NEG
induced O
by O
haloperidol O
indicating O
its O
atypical O
antipsychotic O
nature O
. O

-DOCSTART- O

sub-chronic O
inhibition O
of O
nitric-oxide O
synthesis O
modifies O
haloperidol-induced O
catalepsy B-NEG
and O
the O
number O
of O
nadph-diaphorase O
neurons O
in O
mice O
. O

rationale O
: O
ng-nitro-l-arginine O
(l-noarg) O
, O
an O
inhibitor O
of O
nitric-oxide O
synthase O
(nos) O
, O
induces O
catalepsy B-NEG
in O
mice O
. O

this O
effect O
undergoes O
rapid O
tolerance O
, O
showing O
a O
significant O
decrease O
after O
2 O
days O
of O
sub-chronic O
l-noarg O
treatment O
. O

nitric O
oxide O
( O
no O
) O
has O
been O
shown O
to O
influence O
dopaminergic O
neurotransmission O
in O
the O
striatum O
. O

neuroleptic O
drugs O
such O
as O
haloperidol O
, O
which O
block O
dopamine O
receptors O
, O
also O
cause O
catalepsy B-NEG
in O
rodents O
. O

objectives O
: O
to O
investigate O
the O
effects O
of O
subchronic O
l-noarg O
treatment O
in O
haloperidol-induced O
catalepsy B-NEG
and O
the O
number O
of O
nos O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

methods O
: O
male O
albino O
swiss O
mice O
were O
treated O
sub-chronically O
( O
twice O
a O
day O
for O
4 O
days O
) O
with O
l-noarg O
( O
40 O
mg/kg O
i.p. O
) O
or O
haloperidol O
(1 O
mg/kg O
i.p.) O
. O
catalepsy B-NEG
was O
evaluated O
at O
the O
beginning O
and O
the O
end O
of O
the O
treatments O
. O

reduced O
nicotinamide O
adenine O
dinucleotide O
phosphate-diaphorase O
( O
nadph-d O
) O
histochemistry O
was O
also O
employed O
to O
visualize O
nos O
as O
an O
index O
of O
enzyme O
expression O
in O
mice O
brain O
regions O
related O
to O
motor O
control O
. O

results O
: O
l-noarg O
sub-chronic O
administration O
produced O
tolerance O
of O
l-noarg O
and O
of O
haloperidol-induced O
catalepsy B-NEG
. O

it O
also O
induced O
an O
increase O
in O
the O
number O
of O
nadph-d-positive O
cells O
in O
the O
dorsal O
part O
of O
the O
caudate O
and O
accumbens O
nuclei O
compared O
with O
haloperidol O
and O
in O
the O
pedunculopontine O
tegmental O
nucleus O
compared O
with O
saline O
. O

in O
contrast O
, O
there O
was O
a O
decrease O
in O
nadph-d O
neuron O
number O
in O
the O
substantia O
nigra O
, O
pars O
compacta O
in O
both O
haloperidol-treated O
and O
l-noarg-treated O
animals O
. O

conclusions O
: O
the O
results O
give O
further O
support O
to O
the O
hypothesis O
that O
no O
plays O
a O
role O
in O
motor O
behavior O
control O
and O
suggest O
that O
it O
may O
take O
part O
in O
the O
synaptic O
changes O
produced O
by O
antipsychotic O
treatment O
. O

-DOCSTART- O

prolonged O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
occurs O
in O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B-NEG
ischaemia I-NEG
. O

objective O
: O
to O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
in O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
similar O
to O
that O
seen O
after O
exercise O
. O

design O
: O
a O
randomised O
crossover O
study O
of O
recovery O
time O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
after O
exercise O
and O
dobutamine O
induced O
ischaemia B-NEG
. O

subjects O
: O
10 O
patients O
with O
stable B-NEG
angina I-NEG
, O
angiographically O
proven O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
and O
normal O
left O
ventricular O
function O
. O

interventions O
: O
treadmill O
exercise O
and O
dobutamine O
stress O
were O
performed O
on O
different O
days O
. O

quantitative O
assessment O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
was O
performed O
using O
transthoracic O
echocardiography O
at O
baseline O
and O
at O
regular O
intervals O
after O
each O
test O
. O

results O
: O
both O
forms O
of O
stress O
led O
to O
prolonged O
but O
reversible O
systolic O
and O
diastolic O
dysfunction O
. O

there O
was O
no O
difference O
in O
the O
maximum O
double O
product O
(p O
= O
0.53 O
) O
or O
st O
depression B-NEG
(p O
= O
0.63 O
) O
with O
either O
form O
of O
stress O
. O

after O
exercise O
, O
ejection O
fraction O
was O
reduced O
at O
15 O
and O
30 O
minutes O
compared O
with O
baseline O
( O
mean O
(sem) O
, O
-5.6 O
(1.5)% O
, O
p O
< O
0.05 O
; O
and O
-6.1 O
(2.2)% O
, O
p O
< O
0. O

01) O
, O
and O
at O
30 O
and O
45 O
minutes O
after O
dobutamine O
( O
-10.8 O
( O
1.8)% O
and O
-5 O
. O

5 O
(1.8)% O
, O
both O
p O
< O
0.01) O
. O

regional O
analysis O
showed O
a O
reduction O
in O
the O
worst O
affected O
segment O
15 O
and O
30 O
minutes O
after O
exercise O
( O
-27.9 O
( O
7.2)% O
and O
-28.6 O
(5.7)% O
, O
both O
p O
< O
0.01) O
, O
and O
at O
30 O
minutes O
after O
dobutamine O
( O
-32 O
(5.3)% O
, O
p O
< O
0.01) O
. O

the O
isovolumic O
relaxation O
period O
was O
prolonged O
45 O
minutes O
after O
each O
form O
of O
stress O
(p O
< O
0.05) O
. O

conclusions O
: O
in O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
dobutamine O
induced O
ischaemia B-NEG
results O
in O
prolonged O
reversible O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
, O
presumed O
to O
be O
myocardial B-NEG
stunning I-NEG
, O
similar O
to O
that O
seen O
after O
exercise O
. O

dobutamine O
induced O
ischaemia B-NEG
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

-DOCSTART- O

anorexigens O
and O
pulmonary B-NEG
hypertension I-NEG
in O
the O
united O
states O
: O
results O
from O
the O
surveillance O
of O
north O
american O
pulmonary B-NEG
hypertension I-NEG
. O

background O
: O
the O
use O
of O
appetite O
suppressants O
in O
europe O
has O
been O
associated O
with O
the O
development O
of O
primary B-NEG
pulmonary I-NEG
hypertension I-NEG
( O
pph B-NEG
). O

recently O
, O
fenfluramine O
appetite O
suppressants O
became O
widely O
used O
in O
the O
united O
states O
but O
were O
withdrawn O
in O
september O
1997 O
because O
of O
concerns O
over O
adverse O
effects O
. O

materials O
and O
methods O
: O
we O
conducted O
a O
prospective O
surveillance O
study O
on O
patients O
diagnosed O
with O
pulmonary B-NEG
hypertension I-NEG
at O
12 O
large O
referral O
centers O
in O
north O
america O
. O

data O
collected O
on O
patients O
seen O
from O
september O
1, O
1996 O
, O
to O
december O
31 O
, O
1997 O
, O
included O
the O
cause O
of O
the O
pulmonary B-NEG
hypertension I-NEG
and O
its O
severity O
. O

patients O
with O
no O
identifiable O
cause O
of O
pulmonary B-NEG
hypertension I-NEG
were O
classed O
as O
pph B-NEG
. O

a O
history O
of O
drug O
exposure O
also O
was O
taken O
with O
special O
attention O
on O
the O
use O
of O
antidepressants O
, O
anorexigens O
, O
and O
amphetamines O
. O

results O
: O
five O
hundred O
seventy-nine O
patients O
were O
studied O
, O
205 O
with O
pph B-NEG
and O
374 O
with O
pulmonary B-NEG
hypertension I-NEG
from O
other O
causes O
( O
secondary O
pulmonary B-NEG
hypertension I-NEG
[sph]) O
. O

the O
use O
of O
anorexigens O
was O
common O
in O
both O
groups O
. O

however O
, O
of O
the O
medications O
surveyed O
, O
only O
the O
fenfluramines O
had O
a O
significant O
preferential O
association O
with O
pph B-NEG
as O
compared O
with O
sph O
( O
adjusted O
odds O
ratio O
for O
use O
> O
6 O
months O
, O
7.5 O
; O
95% O
confidence O
interval O
, O
1.7 O
to O
32.4) O
. O

the O
association O
was O
stronger O
with O
longer O
duration O
of O
use O
when O
compared O
to O
shorter O
duration O
of O
use O
and O
was O
more O
pronounced O
in O
recent O
users O
than O
in O
remote O
users O
. O

an O
unexpectedly O
high O
( O
11.4% O
) O
number O
of O
patients O
with O
sph O
had O
used O
anorexigens O
. O

conclusion O
: O
the O
magnitude O
of O
the O
association O
with O
pph B-NEG
, O
the O
increase O
of O
association O
with O
increasing O
duration O
of O
use O
, O
and O
the O
specificity O
for O
fenfluramines O
are O
consistent O
with O
previous O
studies O
indicating O
that O
fenfluramines O
are O
causally O
related O
to O
pph B-NEG
. O

the O
high O
prevalence O
of O
anorexigen O
use O
in O
patients O
with O
sph O
also O
raises O
the O
possibility O
that O
these O
drugs O
precipitate O
pulmonary B-NEG
hypertension I-NEG
in O
patients O
with O
underlying O
conditions O
associated O
with O
sph O
. O

-DOCSTART- O

clinical O
aspects O
of O
heparin-induced O
thrombocytopenia B-NEG
and O
thrombosis B-NEG
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

heparin O
, O
first O
used O
to O
prevent O
the O
clotting O
of O
blood O
in O
vitro O
, O
has O
been O
clinically O
used O
to O
treat O
thrombosis B-NEG
for O
more O
than O
50 O
years O
. O

although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin O
remains O
the O
anticoagulant O
of O
choice O
to O
treat O
acute O
thrombotic B-NEG
episodes O
. O

the O
clinical O
effects O
of O
heparin O
are O
meritorious O
, O
but O
side O
effects O
do O
exist O
. O
bleeding B-NEG
is O
the O
primary O
untoward O
effect O
of O
heparin O
. O

major O
bleeding B-NEG
is O
of O
primary O
concern O
in O
patients O
receiving O
heparin O
therapy O
. O

however O
, O
additional O
important O
untoward O
effects O
of O
heparin O
therapy O
include O
heparin-induced O
thrombocytopenia B-NEG
, O
heparin-associated O
osteoporosis B-NEG
, O
eosinophilia B-NEG
, O
skin B-NEG
reactions I-NEG
, O
allergic B-NEG
reactions I-NEG
other O
than O
thrombocytopenia B-NEG
, O
alopecia B-NEG
, O
transaminasemia O
, O
hyperkalemia B-NEG
, O
hypoaldosteronism B-NEG
, O
and O
priapism B-NEG
. O

these O
side O
effects O
are O
relatively O
rare O
in O
a O
given O
individual O
, O
but O
given O
the O
extremely O
widespread O
use O
of O
heparin O
, O
some O
are O
quite O
common O
, O
particularly O
hitt B-NEG
and O
osteoporosis B-NEG
. O

although O
reasonable O
incidences O
of O
many O
of O
these O
side O
effects O
can O
be O
softly O
deduced O
from O
current O
reports O
dealing O
with O
unfractionated O
heparin O
, O
at O
present O
the O
incidences O
of O
these O
side O
effects O
with O
newer O
low O
molecular O
weight O
heparins O
appear O
to O
be O
much O
less O
common O
. O

however O
, O
only O
longer O
experience O
will O
more O
clearly O
define O
the O
incidence O
of O
each O
side O
effect O
with O
low O
molecular O
weight O
preparations O
. O

-DOCSTART- O

a O
case O
of O
bilateral O
optic B-NEG
neuropathy I-NEG
in O
a O
patient O
on O
tacrolimus O
( O
fk506 O
) O
therapy O
after O
liver O
transplantation O
. O

purpose O
: O
to O
report O
a O
case O
of O
bilateral O
optic B-NEG
neuropathy I-NEG
in O
a O
patient O
receiving O
tacrolimus O
( O
fk O
506 O
, O
prograf O
; O
fujisawa O
usa O
, O
inc O
, O
deerfield O
, O
illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transplantation O
. O

method O
: O
case O
report O
. O

in O
a O
58-year-old O
man O
receiving O
tacrolimus O
after O
orthotropic O
liver O
transplantation O
, O
serial O
neuro-ophthalmologic O
examinations O
and O
laboratory O
studies O
were O
performed O
. O

results O
: O
the O
patient O
had O
episodic O
deterioration O
of O
vision O
in O
both O
eyes O
, O
with O
clinical O
features O
resembling O
ischemic B-NEG
optic I-NEG
neuropathies I-NEG
. O
deterioration B-NEG
of I-NEG
vision I-NEG
occurred O
despite O
discontinuation O
of O
the O
tacrolimus O
. O

conclusion O
: O
tacrolimus O
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic B-NEG
nerve I-NEG
toxicity I-NEG
. O

-DOCSTART- O

hypercalcemia B-NEG
, O
arrhythmia B-NEG
, O
and O
mood O
stabilizers O
. O

recent O
findings O
in O
a O
bipolar B-NEG
patient O
receiving O
maintenance O
lithium O
therapy O
who O
developed O
hypercalcemia B-NEG
and O
severe O
bradyarrhythmia B-NEG
prompted O
the O
authors O
to O
conduct O
a O
retrospective O
study O
of O
bipolar B-NEG
patients O
with O
lithium-associated O
hypercalcemia B-NEG
. O

a O
printout O
of O
all O
cases O
of O
hypercalcemia B-NEG
that O
presented O
during O
a O
1-year O
period O
was O
generated O
. O

after O
eliminating O
spurious O
hypercalcemias B-NEG
or O
those O
associated O
with O
intravenous O
fluids O
, O
the O
authors O
identified O
18 O
non-lithium-treated O
patients O
with O
hypercalcemias B-NEG
related O
to O
malignancies B-NEG
and O
other O
medical O
conditions O
( O
group O
a) O
and O
12 O
patients O
with O
lithium-associated O
hypercalcemia B-NEG
( O
group O
b) O
. O

patients O
in O
group O
b O
were O
not O
comparable O
to O
those O
in O
group O
a, O
as O
the O
latter O
were O
medically O
compromised O
and O
were O
receiving O
multiple O
pharmacotherapies O
. O

thus O
, O
two O
control O
groups O
were O
generated O
: O
group O
c1 O
, O
which O
included O
age- O
and O
sex-comparable O
lithium-treated O
bipolar B-NEG
normocalcemic O
patients O
, O
and O
group O
c2 O
, O
which O
included O
bipolar B-NEG
normocalcemic O
patients O
treated O
with O
anticonvulsant O
mood O
stabilizers O
. O

the O
electrocardiographic O
( O
ecg O
) O
findings O
for O
patients O
in O
group O
b O
were O
compared O
with O
those O
of O
patients O
in O
groups O
c1 O
and O
c2 O
. O

it O
was O
found O
that O
these O
groups O
did O
not O
differ O
in O
their O
overall O
frequency O
of O
ecg O
abnormalities O
; O
however O
, O
there O
were O
significant O
differences O
in O
the O
frequency O
of O
conduction O
defects O
. O

patients O
with O
hypercalcemia B-NEG
resulting O
from O
medical O
diseases O
and O
bipolar B-NEG
patients O
with O
lithium-associated O
hypercalcemia B-NEG
had O
significantly O
higher O
frequencies O
of O
conduction O
defects O
. O

patients O
in O
group O
a O
had O
significant O
mortality O
at O
2-year O
follow-up O
(28%) O
, O
in O
contrast O
to O
zero O
mortality O
in O
the O
other O
three O
groups O
. O

the O
clinical O
implications O
of O
these O
findings O
are O
discussed O
. O

-DOCSTART- O

attenuation O
of O
nephrotoxicity B-NEG
by O
a O
novel O
lipid O
nanosphere O
( O
ns-718 O
) O
incorporating O
amphotericin O
b. O

ns-718 O
, O
a O
lipid O
nanosphere O
incorporating O
amphotericin O
b, O
is O
effective O
against O
pathogenic O
fungi O
and O
has O
low O
toxicity B-NEG
. O

we O
compared O
the O
toxicity B-NEG
of O
ns-718 O
with O
that O
of O
fungizone O
( O
amphotericin O
b-sodium O
deoxycholate O
; O
d-amb O
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin O
b O
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

incubation O
with O
ns-718 O
resulted O
in O
significantly O
less O
damage O
of O
cultured O
human O
renal O
proximal O
tubular O
epithelial O
cells O
compared O
with O
d-amb O
. O

serum O
blood O
urea O
and O
creatinine O
concentrations O
increased O
significantly O
in O
rats O
given O
an O
iv O
infusion O
of O
d-amb O
3 O
mg/kg O
but O
not O
in O
those O
given O
the O
same O
dose O
of O
ns-718 O
. O

histopathological O
examination O
of O
the O
kidney O
showed O
tubular B-NEG
necrosis I-NEG
in O
d-amb-treated O
rats O
but O
no O
change O
in O
ns-718-treated O
rats O
. O

amphotericin O
b O
concentrations O
in O
the O
kidney O
in O
ns-718-treated O
rats O
were O
higher O
than O
those O
in O
d-amb-treated O
rats O
. O

our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin O
b O
into O
lipid O
nanospheres O
of O
ns-718 O
attenuates O
the O
nephrotoxicity B-NEG
of O
amphotericin O
b. O

-DOCSTART- O

patterns O
of O
sulfadiazine O
acute B-NEG
nephrotoxicity I-NEG
. O

sulfadiazine O
acute B-NEG
nephrotoxicity I-NEG
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis B-NEG
in O
hiv-positive O
patients O
. O

we O
report O
4 O
cases O
, O
one O
of O
them O
in O
a O
previously O
healthy O
person O
. O

under O
treatment O
with O
sulfadiazine O
they O
developed O
oliguria B-NEG
, O
abdominal B-NEG
pain I-NEG
, O
renal B-NEG
failure I-NEG
and O
showed O
multiple O
radiolucent O
renal B-NEG
calculi I-NEG
in O
echography O
. O

all O
patients O
recovered O
their O
previous O
normal O
renal O
function O
after O
adequate O
hydration O
and O
alcalinization O
. O

a O
nephrostomy O
tube O
had O
to O
be O
placed O
in O
one O
of O
the O
patients O
for O
ureteral B-NEG
lithiasis I-NEG
in O
a O
single O
functional O
kidney O
. O

none O
of O
them O
needed O
dialysis O
or O
a O
renal O
biopsy O
because O
of O
a O
typical O
benign O
course O
. O

treatment O
with O
sulfadiazine O
requires O
exquisite O
control O
of O
renal O
function O
, O
an O
increase O
in O
water O
ingestion O
and O
possibly O
the O
alcalinization O
of O
the O
urine O
. O

we O
communicate O
a O
case O
in O
a O
previously O
healthy O
person O
, O
a O
fact O
not O
found O
in O
the O
recent O
literature O
. O

probably O
many O
more O
cases O
are O
not O
detected O
. O

we O
think O
that O
a O
prospective O
study O
would O
be O
useful O
. O

-DOCSTART- O

downbeat B-NEG
nystagmus I-NEG
associated O
with O
intravenous O
patient-controlled O
administration O
of O
morphine O
. O

implications O
: O
this O
case O
documents O
a O
patient O
who O
developed O
dizziness B-NEG
with O
downbeating B-NEG
nystagmus I-NEG
while O
receiving O
a O
relatively O
large O
dose O
of O
iv O
patient-controlled O
analgesia O
morphine O
. O

although O
there O
have O
been O
case O
reports O
of O
epidural O
morphine O
with O
these O
symptoms O
and O
signs O
, O
this O
has O
not O
been O
previously O
documented O
with O
iv O
or O
patient-controlled O
analgesia O
morphine O
. O

-DOCSTART- O

hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
and O
amiodarone O
in O
animals O
with O
a O
healed O
myocardial B-NEG
infarction I-NEG
. O

the O
hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
, O
a O
noniodinated O
compound O
structurally O
related O
to O
amiodarone O
, O
were O
compared O
with O
those O
of O
amiodarone O
after O
prolonged O
oral O
administration O
, O
both O
at O
rest O
and O
during O
sympathetic O
stimulation O
in O
conscious O
dogs O
with O
a O
healed O
myocardial B-NEG
infarction I-NEG
. O

all O
dogs O
(n O
= O
6) O
randomly O
received O
orally O
dronedarone O
( O
10 O
and O
30 O
mg/kg) O
, O
amiodarone O
( O
10 O
and O
30 O
mg/kg) O
, O
and O
placebo O
twice O
daily O
for O
7 O
days O
, O
with O
a O
3-week O
washout O
between O
consecutive O
treatments O
. O

heart O
rate O
(hr) O
, O
mean O
arterial O
pressure O
(mbp) O
, O
positive O
rate O
of O
increase O
of O
left O
ventricular O
pressure O
(+lvdp/dt) O
, O
echocardiographically O
assessed O
left O
ventricular O
ejection O
fraction O
(lvef) O
, O
and O
fractional O
shortening O
(fs) O
, O
as O
well O
as O
chronotropic O
response O
to O
isoproterenol O
and O
exercise-induced O
sympathetic O
stimulation O
were O
evaluated O
under O
baseline O
and O
posttreatment O
conditions O
. O

resting O
values O
of O
lvef O
, O
fs O
, O
+lvdp/dt O
, O
and O
mbp O
remained O
unchanged O
whatever O
the O
drug O
and O
the O
dosing O
regimen O
, O
whereas O
resting O
hr O
was O
significantly O
and O
dose-dependently O
lowered O
after O
dronedarone O
and O
to O
a O
lesser O
extent O
after O
amiodarone O
. O

both O
dronedarone O
and O
amiodarone O
significantly O
reduced O
the O
exercise-induced O
tachycardia B-NEG
and O
, O
at O
the O
highest O
dose O
, O
decreased O
the O
isoproterenol-induced O
tachycardia B-NEG
. O

thus O
, O
dronedarone O
and O
amiodarone O
displayed O
a O
similar O
level O
of O
antiadrenergic O
effect O
and O
did O
not O
impair O
the O
resting O
left O
ventricular O
function O
. O

consequently O
, O
dronedarone O
might O
be O
particularly O
suitable O
for O
the O
treatment O
and O
prevention O
of O
various O
clinical O
arrhythmias B-NEG
, O
without O
compromising O
the O
left O
ventricular O
function O
. O

-DOCSTART- O

phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg/m(2) O
) O
in O
platinum/paclitaxel-refractory O
ovarian B-NEG
and I-NEG
fallopian I-NEG
tube I-NEG
cancers I-NEG
and O
primary O
carcinoma B-NEG
of I-NEG
the I-NEG
peritoneum I-NEG
. O

background O
: O
several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum-resistant O
ovarian B-NEG
cancer I-NEG
, O
with O
dose O
limiting O
toxicity B-NEG
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg/m(2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia B-NEG
( O
hand-foot B-NEG
syndrome I-NEG
) O
and O
stomatitis B-NEG
. O

we O
wished O
to O
develop O
a O
more O
tolerable O
liposomal O
doxorubicin O
treatment O
regimen O
and O
document O
its O
level O
of O
activity O
in O
a O
well-defined O
patient O
population O
with O
platinum/paclitaxel-refractory O
disease O
. O

methods O
and O
materials O
: O
patients O
with O
ovarian B-NEG
or I-NEG
fallopian I-NEG
tube I-NEG
cancers I-NEG
or O
primary O
peritoneal B-NEG
carcinoma I-NEG
with O
platinum/paclitaxel-refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
<3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin O
at O
a O
dose O
of O
40 O
mg/m(2 O
) O
q O
4 O
weeks O
. O

results O
: O
a O
total O
of O
49 O
patients O
( O
median O
age O
: O
60 O
; O
range O
41-81 O
) O
entered O
this O
phase O
2 O
trial O
. O

the O
median O
number O
of O
prior O
regimens O
was O
2 O
(range O
: O
1-6) O
. O

six O
( O
12% O
) O
and O
4 O
( O
8% O
) O
patients O
experienced O
grade O
2 O
hand-foot B-NEG
syndrome I-NEG
and O
stomatitis B-NEG
, O
respectively O
( O
no O
episodes O
of O
grade O
3) O
. O

one O
patient O
developed O
grade O
3 O
diarrhea B-NEG
requiring O
hospitalization O
for O
hydration O
. O

six O
( O
12% O
) O
individuals O
required O
dose O
reductions O
. O

the O
median O
number O
of O
courses O
of O
liposomal O
doxorubicin O
administered O
on O
this O
protocol O
was O
2 O
(range O
: O
1-12) O
. O

four O
of O
44 O
patients O
( O
9% O
) O
evaluable O
for O
response O
exhibited O
objective O
and O
subjective O
evidence O
of O
an O
antineoplastic O
effect O
of O
therapy O
. O

conclusion O
: O
this O
modified O
liposomal O
doxorubicin O
regimen O
results O
in O
less O
toxicity B-NEG
( O
stomatitis B-NEG
, O
hand-foot B-NEG
syndrome I-NEG
) O
than O
the O
standard O
fda-approved O
dose O
schedule O
. O

definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well-defined O
platinum- O
and O
paclitaxel-refractory O
ovarian B-NEG
cancer I-NEG
. O

-DOCSTART- O

efficacy O
of O
olanzapine O
in O
acute O
bipolar B-NEG
mania I-NEG
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O

the O
olanzipine O
hggw O
study O
group O
. O

background O
: O
we O
compared O
the O
efficacy O
and O
safety O
of O
olanzapine O
vs O
placebo O
for O
the O
treatment O
of O
acute O
bipolar B-NEG
mania I-NEG
. O

methods O
: O
four-week O
, O
randomized O
, O
double-blind O
, O
parallel O
study O
. O

a O
total O
of O
115 O
patients O
with O
a O
dsm-iv O
diagnosis O
of O
bipolar B-NEG
disorder I-NEG
, O
manic B-NEG
or O
mixed O
, O
were O
randomized O
to O
olanzapine O
, O
5 O
to O
20 O
mg/d O
(n O
= O
55) O
, O
or O
placebo O
(n O
= O
60) O
. O

the O
primary O
efficacy O
measure O
was O
the O
young- O
mania B-NEG
rating O
scale O
( O
y-mrs O
) O
total O
score O
. O

response O
and O
euthymia O
were O
defined O
, O
a O
priori O
, O
as O
at O
least O
a O
50% O
improvement O
from O
baseline O
to O
end O
point O
and O
as O
a O
score O
of O
no O
less O
than O
12 O
at O
end O
point O
in O
the O
y-mrs O
total O
score O
, O
respectively O
. O

safety O
was O
assessed O
using O
adverse O
events O
, O
extrapyramidal B-NEG
symptom I-NEG
( O
eps B-NEG
) O
rating O
scales O
, O
laboratory O
values O
, O
electrocardiograms O
, O
vital O
signs O
, O
and O
weight O
change O
. O

results O
: O
olanzapine-treated O
patients O
demonstrated O
a O
statistically O
significant O
greater O
mean O
( O
+/- O
sd O
) O
improvement O
in O
y-mrs O
total O
score O
than O
placebo-treated O
patients O
( O
-14.8 O
+/- O
12.5 O
and O
-8.1 O
+/- O
12.7 O
, O
respectively O
; O
p<.001) O
, O
which O
was O
evident O
at O
the O
first O
postbaseline O
observation O
1 O
week O
after O
randomization O
and O
was O
maintained O
throughout O
the O
study O
( O
last O
observation O
carried O
forward) O
. O

olanzapine-treated O
patients O
demonstrated O
a O
higher O
rate O
of O
response O
( O
65% O
vs O
43% O
, O
respectively O
; O
p O
=.02 O
) O
and O
euthymia O
( O
61% O
vs O
36% O
, O
respectively O
; O
p O
=. O
01 O
) O
than O
placebo-treated O
patients O
. O

there O
were O
no O
statistically O
significant O
differences O
in O
epss B-NEG
between O
groups O
. O

however O
, O
olanzapine-treated O
patients O
had O
a O
statistically O
significant O
greater O
mean O
( O
+/- O
sd O
) O
weight B-NEG
gain I-NEG
than O
placebo-treated O
patients O
( O
2.1 O
+/- O
2.8 O
vs O
0.45 O
+/- O
2.3 O
kg O
, O
respectively O
) O
and O
also O
experienced O
more O
treatment-emergent O
somnolence B-NEG
( O
21 O
patients O
[38.2%] O
vs O
5 O
[8.3% O
], O
respectively) O
. O

conclusion O
: O
olanzapine O
demonstrated O
greater O
efficacy O
than O
placebo O
in O
the O
treatment O
of O
acute O
bipolar B-NEG
mania I-NEG
and O
was O
generally O
well O
tolerated O
. O

-DOCSTART- O

the O
effect O
of O
pupil B-NEG
dilation I-NEG
with O
tropicamide O
on O
vision O
and O
driving O
simulator O
performance O
. O

purpose O
: O
to O
assess O
the O
effect O
of O
pupil B-NEG
dilation I-NEG
on O
vision O
and O
driving O
ability O
. O

methods O
: O
a O
series O
of O
tests O
on O
various O
parameters O
of O
visual O
function O
and O
driving O
simulator O
performance O
were O
performed O
on O
12 O
healthy O
drivers O
, O
before O
and O
after O
pupil B-NEG
dilation I-NEG
using O
guttae O
tropicamide O
1% O
. O

a O
driving O
simulator O
( O
transport O
research O
laboratory O
) O
was O
used O
to O
measure O
reaction O
time O
(rt) O
, O
speed O
maintenance O
and O
steering O
accuracy O
. O

tests O
of O
basic O
visual O
function O
included O
high- O
and O
low-contrast O
visual O
acuity O
( O
hcva O
and O
lcva) O
, O
pelli-robson O
contrast O
threshold O
( O
ct O
) O
and O
goldmann O
perimetry O
(fields) O
. O

useful O
field O
of O
view O
( O
ufov--a O
test O
of O
visual O
attention O
) O
was O
also O
undertaken O
. O

the O
mean O
differences O
in O
the O
pre- O
and O
post-dilatation O
measurements O
were O
tested O
for O
statistical O
significance O
at O
the O
95% O
level O
using O
one-tail O
paired O
t-tests O
. O

results O
: O
pupillary B-NEG
dilation I-NEG
resulted O
in O
a O
statistically O
significant O
deterioration O
in O
ct O
and O
hcva O
only O
. O

five O
of O
12 O
drivers O
also O
exhibited O
deterioration O
in O
lcva O
, O
ct O
and O
rt O
. O

little O
evidence O
emerged O
for O
deterioration O
in O
fields O
and O
ufov O
. O

also O
, O
7 O
of O
12 O
drivers O
appeared O
to O
adjust O
their O
driving O
behaviour O
by O
reducing O
their O
speed O
on O
the O
driving O
simulator O
, O
leading O
to O
improved O
steering O
accuracy O
. O

conclusions O
: O
pupillary B-NEG
dilation I-NEG
may O
lead O
to O
a O
decrease O
in O
vision O
and O
daylight O
driving O
performance O
in O
young O
people O
. O

a O
larger O
study O
, O
including O
a O
broader O
spectrum O
of O
subjects O
, O
is O
warranted O
before O
guidelines O
can O
be O
recommended O
. O

-DOCSTART- O

a O
case O
of O
isotretinoin B-NEG
embryopathy I-NEG
with O
bilateral O
anotia B-NEG
and O
taussig-bing B-NEG
malformation I-NEG
. O

we O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia B-NEG
and O
taussig-bing B-NEG
malformation I-NEG
) O
due O
to O
exposure O
to O
isotretinoin O
within O
the O
first O
trimester O
. O

in O
this O
paper O
we O
aim O
to O
draw O
to O
the O
fact O
that O
caution O
is O
needed O
when O
prescribing O
vitamin O
a-containing O
drugs O
to O
women O
of O
childbearing O
years O
. O

-DOCSTART- O

effect O
of O
methoxamine O
on O
maximum O
urethral O
pressure O
in O
women O
with O
genuine O
stress B-NEG
incontinence I-NEG
: O
a O
placebo-controlled O
, O
double-blind O
crossover O
study O
. O

the O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
potential O
role O
for O
a O
selective O
alpha1-adrenoceptor O
agonist O
in O
the O
treatment O
of O
urinary B-NEG
stress I-NEG
incontinence I-NEG
. O

a O
randomised O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
design O
was O
employed O
. O

half O
log O
incremental O
doses O
of O
intravenous O
methoxamine O
or O
placebo O
( O
saline O
) O
were O
administered O
to O
a O
group O
of O
women O
with O
genuine O
stress B-NEG
incontinence I-NEG
while O
measuring O
maximum O
urethral O
pressure O
(mup) O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
symptomatic O
side O
effects O
. O

methoxamine O
evoked O
non-significant O
increases O
in O
mup O
and O
diastolic O
blood O
pressure O
but O
caused O
a B-NEG
significant I-NEG
rise I-NEG
in I-NEG
systolic I-NEG
blood I-NEG
pressure I-NEG
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

systemic O
side O
effects O
including O
piloerection O
, O
headache B-NEG
, O
and O
cold O
extremities O
were O
experienced O
in O
all O
subjects O
. O

the O
results O
indicate O
that O
the O
clinical O
usefulness O
of O
direct O
, O
peripherally O
acting O
sub-type-selective O
alpha1-adrenoceptor O
agonists O
in O
the O
medical O
treatment O
of O
stress B-NEG
incontinence I-NEG
may O
be O
limited O
by O
associated O
piloerection O
and O
cardiovascular O
side O
effects O
. O

-DOCSTART- O

toleration O
of O
high O
doses O
of O
angiotensin-converting O
enzyme O
inhibitors O
in O
patients O
with O
chronic O
heart B-NEG
failure I-NEG
: O
results O
from O
the O
atlas O
trial O
. O

the O
assessment O
of O
treatment O
with O
lisinopril O
and O
survival O
. O

background O
: O
treatment O
with O
angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitors O
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart B-NEG
failure I-NEG
( O
chf B-NEG
), O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

the O
present O
study O
examines O
the O
safety O
and O
tolerability O
of O
high- O
compared O
with O
low-dose O
lisinopril O
in O
chf B-NEG
. O

methods O
: O
the O
assessment O
of O
lisinopril O
and O
survival O
study O
was O
a O
multicenter O
, O
randomized O
, O
double-blind O
trial O
in O
which O
patients O
with O
or O
without O
previous O
ace O
inhibitor O
treatment O
were O
stabilized O
receiving O
medium-dose O
lisinopril O
( O
12.5 O
or O
15.0 O
mg O
once O
daily O
[od] O
) O
for O
2 O
to O
4 O
weeks O
and O
then O
randomized O
to O
high- O
( O
35.0 O
or O
32.5 O
mg O
od O
) O
or O
low-dose O
( O
5.0 O
or O
2.5 O
mg O
od O
) O
groups O
. O

patients O
with O
new O
york O
heart O
association O
classes O
ii O
to O
iv O
chf B-NEG
and O
left O
ventricular O
ejection O
fractions O
of O
no O
greater O
than O
0.30 O
(n O
= O
3164 O
) O
were O
randomized O
and O
followed O
up O
for O
a O
median O
of O
46 O
months O
. O

we O
examined O
the O
occurrence O
of O
adverse O
events O
and O
the O
need O
for O
discontinuation O
and O
dose O
reduction O
during O
treatment O
, O
with O
a O
focus O
on O
hypotension B-NEG
and O
renal B-NEG
dysfunction I-NEG
. O

results O
: O
of O
405 O
patients O
not O
previously O
receiving O
an O
ace O
inhibitor O
, O
doses O
in O
only O
4.2% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension B-NEG
( O
2.0% O
) O
or O
because O
of O
renal B-NEG
dysfunction I-NEG
or O
hyperkalemia B-NEG
(2.3%) O
. O

doses O
in O
more O
than O
90% O
of O
randomized O
patients O
in O
the O
high- O
and O
low-dose O
groups O
were O
titrated O
to O
their O
assigned O
target O
, O
and O
the O
mean O
doses O
of O
blinded O
medication O
in O
both O
groups O
remained O
similar O
throughout O
the O
study O
. O

withdrawals O
occurred O
in O
27.1% O
of O
the O
high- O
and O
30.7% O
of O
the O
low-dose O
groups O
. O

subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ace O
inhibitor O
intolerance O
( O
blood O
pressure O
, O
<120 O
mm O
hg O
; O
creatinine O
, O
> O
or O
=132.6 O
micromol/l O
[> O
or O
=1.5 O
mg/dl] O
; O
age O
, O
> O
or O
=70 O
years O
; O
and O
patients O
with O
diabetes B-NEG
) O
generally O
tolerated O
the O
high-dose O
strategy O
. O

conclusions O
: O
these O
findings O
demonstrate O
that O
ace O
inhibitor O
therapy O
in O
most O
patients O
with O
chf B-NEG
can O
be O
successfully O
titrated O
to O
and O
maintained O
at O
high O
doses O
, O
and O
that O
more O
aggressive O
use O
of O
these O
agents O
is O
warranted O
. O

-DOCSTART- O

cocaine O
, O
ethanol O
, O
and O
cocaethylene O
cardiotoxity B-NEG
in O
an O
animal O
model O
of O
cocaine B-NEG
and I-NEG
ethanol I-NEG
abuse I-NEG
. O

objectives O
: O
simultaneous O
abuse B-NEG
of I-NEG
cocaine I-NEG
and I-NEG
ethanol I-NEG
affects O
12 O
million O
americans O
annually O
. O

in O
combination O
, O
these O
substances O
are O
substantially O
more O
toxic O
than O
either O
drug O
alone O
. O

their O
combined O
cardiac B-NEG
toxicity I-NEG
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene O
(ce) O
, O
a O
cocaine O
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol O
. O

the O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
ce O
in O
the O
combined O
cardiotoxicity B-NEG
of O
cocaine O
and O
ethanol O
in O
a O
model O
simulating O
their O
abuse O
. O

methods O
: O
twenty-three O
dogs O
were O
randomized O
to O
receive O
either O
1) O
three O
intravenous O
( O
iv O
) O
boluses O
of O
cocaine O
7.5 O
mg/kg O
with O
ethanol O
(1 O
g/kg O
) O
as O
an O
iv O
infusion O
(c+e O
, O
n O
= O
8) O
, O
2) O
three O
cocaine O
boluses O
only O
(c O
, O
n O
= O
6) O
, O
3) O
ethanol O
infusion O
only O
(e O
, O
n O
= O
5) O
, O
or O
4) O
placebo O
boluses O
and O
infusion O
(n O
= O
4) O
. O

hemodynamic O
measurements O
, O
electrocardiograms O
, O
and O
serum O
drug O
concentrations O
were O
obtained O
at O
baseline O
, O
and O
then O
at O
fixed O
time O
intervals O
after O
each O
drug O
was O
administered O
. O

results O
: O
two O
of O
eight O
dogs O
in O
the O
c+e O
group O
experienced O
cardiovascular B-NEG
collapse I-NEG
. O

the O
most O
dramatic O
hemodynamic O
changes O
occurred O
after O
each O
cocaine O
bolus O
in O
the O
c+e O
and O
c O
only O
groups O
; O
however O
, O
persistent O
hemodynamic O
changes O
occurred O
in O
the O
c+e O
group O
. O

peak O
ce O
levels O
were O
associated O
with O
a O
45% O
( O
sd O
+/- O
22% O
, O
95% O
ci O
= O
22% O
to O
69% O
) O
decrease B-NEG
in I-NEG
cardiac I-NEG
output I-NEG
(p O
< O
0.05) O
, O
a O
56% O
( O
sd O
+/- O
23% O
, O
95% O
ci O
= O
32% O
to O
80% O
) O
decrease O
in O
dp/dt(max O
) O
(p O
<.006) O
, O
and O
a O
23% O
( O
sd O
+/- O
15% O
, O
95% O
ci O
= O
7% O
to O
49% O
) O
decrease O
in O
svo(2 O
) O
(p O
< O
0.025) O
. O
ventricular B-NEG
arrhythmias I-NEG
were O
primarily O
observed O
in O
the O
c+e O
group O
, O
in O
which O
four O
of O
eight O
dogs O
experienced O
ventricular B-NEG
tachycardia I-NEG
. O

conclusions O
: O
cocaine O
and O
ethanol O
in O
combination O
were O
more O
toxic O
than O
either O
substance O
alone O
. O

co-administration O
resulted O
in O
prolonged O
cardiac B-NEG
toxicity I-NEG
and O
was O
dysrhythmogenic O
. O

peak O
serum O
cocaethylene O
concentrations O
were O
associated O
with O
prolonged O
myocardial B-NEG
depression I-NEG
. O

-DOCSTART- O

worsening O
of O
parkinsonism B-NEG
after O
the O
use O
of O
veralipride O
for O
treatment O
of O
menopause O
: O
case O
report O
. O

we O
describe O
a O
female O
patient O
with O
stable O
parkinson's B-NEG
disease I-NEG
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride O
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

we O
emphasize O
the O
anti-dopaminergic O
effect O
of O
veralipride O
. O

-DOCSTART- O

viracept O
and O
irregular B-NEG
heartbeat I-NEG
warning O
. O

a O
group O
of O
doctors O
in O
boston O
warn O
that O
the O
protease O
inhibitor O
viracept O
may O
cause O
an O
irregular B-NEG
heart I-NEG
beat I-NEG
, O
known O
as O
bradycardia B-NEG
, O
in O
people O
with O
hiv O
. O
bradycardia B-NEG
occurred O
in O
a O
45-year-old O
male O
patient O
who O
was O
viracept O
in O
combination O
with O
other O
anti-hiv O
drugs O
. O

the O
symptoms O
ceased O
after O
switching O
to O
another O
drug O
combination O
. O

-DOCSTART- O

frequency O
of O
appearance O
of O
myeloperoxidase-antineutrophil O
cytoplasmic O
antibody O
( O
mpo-anca O
) O
in O
graves' B-NEG
disease I-NEG
patients O
treated O
with O
propylthiouracil O
and O
the O
relationship O
between O
mpo-anca O
and O
clinical O
manifestations O
. O

objective O
: O
myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
mpo-anca)-positive O
vasculitis B-NEG
has O
been O
reported O
in O
patients O
with O
graves' B-NEG
disease I-NEG
who O
were O
treated O
with O
propylthiouracil O
(ptu) O
. O

the O
appearance O
of O
mpo-anca O
in O
these O
cases O
was O
suspected O
of O
being O
related O
to O
ptu O
because O
the O
titres O
of O
mpo-anca O
decreased O
when O
ptu O
was O
stopped O
. O

nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
mpo-anca O
and O
vasculitis B-NEG
during O
ptu O
therapy O
, O
or O
on O
the O
incidence O
of O
mpo-anca O
in O
untreated O
graves' B-NEG
disease I-NEG
patients O
. O

therefore O
, O
we O
sought O
to O
address O
these O
parameters O
in O
patients O
with O
graves' B-NEG
disease I-NEG
. O

patients O
: O
we O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism B-NEG
due O
to O
graves' B-NEG
disease I-NEG
for O
the O
presence O
of O
mpo-anca O
, O
and O
for O
the O
development O
vasculitis B-NEG
after O
starting O
ptu O
therapy O
. O

twenty-nine O
of O
them O
were O
later O
excluded O
because O
of O
adverse O
effects O
of O
ptu O
or O
because O
the O
observation O
period O
was O
less O
than O
3 O
months O
. O

the O
remaining O
73 O
patients O
( O
55 O
women O
and O
18 O
men) O
, O
all O
of O
whom O
were O
examined O
for O
more O
than O
3 O
months O
, O
were O
adopted O
as O
the O
subjects O
of O
the O
investigation O
. O

the O
median O
observation O
period O
was O
23.6 O
months O
(range O
: O
3-37 O
months) O
. O

measurements O
: O
mpo-anca O
was O
measured O
at O
intervals O
of O
2-6 O
months O
. O

results O
: O
before O
treatment O
, O
the O
mpo-anca O
titres O
of O
all O
102 O
untreated O
graves' B-NEG
disease I-NEG
patients O
were O
within O
the O
reference O
range O
( O
below O
10 O
u/ml) O
. O

three O
( O
4.1% O
) O
of O
the O
73 O
patients O
were O
positive O
for O
mpo-anca O
at O
13 O
, O
16 O
and O
17 O
months O
, O
respectively O
, O
after O
the O
start O
of O
ptu O
therapy O
. O

in O
two O
of O
them O
, O
the O
mpo-anca O
titres O
transiently O
increased O
to O
12.8 O
and O
15.0 O
u/ml O
, O
respectively O
, O
despite O
continued O
ptu O
therapy O
, O
but O
no O
vasculitic B-NEG
disorders I-NEG
developed O
. O

in O
the O
third O
patient O
, O
the O
mpo-anca O
titre O
increased O
to O
204 O
u/ml O
and O
she O
developed O
a O
higher O
fever B-NEG
, O
oral B-NEG
ulcers I-NEG
and O
polyarthralgia B-NEG
, O
but O
the O
symptoms O
resolved O
2 O
weeks O
after O
stopping O
ptu O
therapy O
, O
and O
the O
mpo-anca O
titre O
decreased O
to O
20.7 O
u/ml O
by O
4 O
months O
after O
discontinuing O
ptu O
. O

conclusions O
: O
ptu O
therapy O
may O
be O
related O
to O
the O
appearance O
of O
mpo-anca O
, O
but O
mpo-anca O
does O
not O
appear O
to O
be O
closely O
related O
to O
vasculitis B-NEG
. O

-DOCSTART- O

prevalence O
of O
heart B-NEG
disease I-NEG
in O
asymptomatic O
chronic O
cocaine O
users O
. O

to O
determine O
the O
prevalence O
of O
heart B-NEG
disease I-NEG
in O
outpatient O
young O
asymptomatic O
chronic O
cocaine O
users O
, O
35 O
cocaine O
users O
and O
32 O
age-matched O
controls O
underwent O
resting O
and O
exercise O
electrocardiography O
( O
ecg O
) O
and O
doppler O
echocardiography O
. O

findings O
consistent O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
were O
detected O
in O
12 O
( O
34% O
) O
patients O
and O
3 O
( O
9% O
) O
controls O
(p O
= O
0.01) O
. O

decreased O
left O
ventricular O
systolic O
function O
was O
demonstrated O
in O
5 O
( O
14% O
) O
patients O
, O
but O
in O
none O
of O
the O
controls O
(p O
= O
0.055) O
. O

finally O
, O
resting O
and O
peak O
exercise O
abnormal B-NEG
left I-NEG
ventricular I-NEG
filling I-NEG
was O
detected O
in O
38 O
and O
35% O
of O
patients O
as O
compared O
to O
19 O
and O
9% O
of O
controls O
, O
respectively O
(p O
= O
0.11 O
and O
0.02 O
, O
respectively) O
. O

we O
conclude O
that O
coronary B-NEG
artery I-NEG
or I-NEG
myocardial I-NEG
disease I-NEG
is O
common O
( O
38% O
) O
in O
young O
asymptomatic O
chronic O
cocaine O
users O
. O

therefore O
, O
screening O
ecg O
and O
echocardiography O
may O
be O
warranted O
in O
these O
patients O
. O

-DOCSTART- O

cardioprotective O
effects O
of O
picrorrhiza O
kurroa O
against O
isoproterenol-induced O
myocardial O
stress O
in O
rats O
. O

the O
cardioprotective O
effect O
of O
the O
ethanol O
extract O
of O
picrorrhiza O
kurroa O
rhizomes O
and O
roots O
( O
pk O
) O
on O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
with O
respect O
to O
lipid O
metabolism O
in O
serum O
and O
heart O
tissue O
has O
been O
investigated O
. O

oral O
pre-treatment O
with O
pk O
( O
80 O
mg O
kg(-1 O
) O
day(-1 O
) O
for O
15 O
days O
) O
significantly O
prevented O
the O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
and O
maintained O
the O
rats O
at O
near O
normal O
status O
. O

-DOCSTART- O

phase O
2 O
early O
afterdepolarization O
as O
a O
trigger O
of O
polymorphic O
ventricular B-NEG
tachycardia I-NEG
in O
acquired O
long-qt B-NEG
syndrome I-NEG
: O
direct O
evidence O
from O
intracellular O
recordings O
in O
the O
intact O
left O
ventricular O
wall O
. O

background O
: O
this O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
ead O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
with O
qt B-NEG
prolongation I-NEG
induced O
by O
dl-sotalol O
and O
azimilide O
. O

the O
contribution O
of O
transmural O
dispersion O
of O
repolarization O
( O
tdr O
) O
to O
transmural O
propagation O
of O
ead O
and O
the O
maintenance O
of O
tdp B-NEG
was O
also O
evaluated O
. O

methods O
and O
results O
: O
transmembrane O
action O
potentials O
from O
epicardium O
, O
midmyocardium O
, O
and O
endocardium O
were O
recorded O
simultaneously O
, O
together O
with O
a O
transmural O
ecg O
, O
in O
arterially O
perfused O
canine O
and O
rabbit O
left O
ventricular O
preparations O
. O

dl-sotalol O
preferentially O
prolonged O
action O
potential O
duration O
( O
apd O
) O
in O
m O
cells O
dose-dependently O
(1 O
to O
100 O
micromol/l) O
, O
leading O
to O
qt B-NEG
prolongation I-NEG
and O
an O
increase O
in O
tdr O
. O

azimilide O
, O
however O
, O
significantly O
prolonged O
apd O
and O
qt O
interval O
at O
concentrations O
from O
0.1 O
to O
10 O
micromol/l O
but O
shortened O
them O
at O
30 O
micromol/l O
. O

unlike O
dl-sotalol O
, O
azimilide O
( O
>3 O
micromol/l O
) O
increased O
epicardial O
apd O
markedly O
, O
causing O
a O
diminished O
tdr O
. O

although O
both O
dl-sotalol O
and O
azimilide O
rarely O
induced O
eads O
in O
canine O
left O
ventricles O
, O
they O
produced O
frequent O
eads O
in O
rabbits O
, O
in O
which O
more O
pronounced O
qt B-NEG
prolongation I-NEG
was O
seen O
. O

an O
increase O
in O
tdr O
by O
dl-sotalol O
facilitated O
transmural O
propagation O
of O
eads O
that O
initiated O
multiple O
episodes O
of O
spontaneous O
tdp B-NEG
in O
3 O
of O
6 O
rabbit O
left O
ventricles O
. O

of O
note O
, O
although O
azimilide O
(3 O
to O
10 O
micromol/l O
) O
increased O
apd O
more O
than O
dl-sotalol O
, O
its O
eads O
often O
failed O
to O
propagate O
transmurally O
, O
probably O
because O
of O
a O
diminished O
tdr O
. O

conclusions O
: O
this O
study O
provides O
the O
first O
direct O
evidence O
from O
intracellular O
action O
potential O
recordings O
that O
phase O
2 O
ead O
can O
be O
generated O
from O
intact O
ventricular O
wall O
and O
produce O
a O
trigger O
to O
initiate O
the O
onset O
of O
tdp B-NEG
under O
qt B-NEG
prolongation I-NEG
. O

-DOCSTART- O

prenatal O
cocaine O
exposure O
and O
cranial O
sonographic O
findings O
in O
preterm B-NEG
infants I-NEG
. O

purpose O
: O
prenatal O
cocaine O
exposure O
has O
been O
linked O
with O
subependymal O
hemorrhage B-NEG
and O
the O
formation O
of O
cysts B-NEG
that O
are O
detectable O
on O
cranial O
sonography O
in O
neonates O
born O
at O
term O
. O

we O
sought O
to O
determine O
if O
prenatal O
cocaine O
exposure O
increases O
the O
incidence O
of O
subependymal B-NEG
cysts I-NEG
in O
preterm B-NEG
infants I-NEG
. O

methods O
: O
we O
retrospectively O
reviewed O
the O
medical O
records O
and O
cranial O
sonograms O
obtained O
during O
a O
1-year O
period O
on O
122 O
premature B-NEG
( O
< I-NEG
36 I-NEG
weeks I-NEG
of I-NEG
gestation I-NEG
) O
infants I-NEG
. O

infants O
were O
categorized O
into O
1 O
of O
2 O
groups O
: O
those O
exposed O
to O
cocaine O
and O
those O
not O
exposed O
to O
cocaine O
. O

infants O
were O
assigned O
to O
the O
cocaine-exposed O
group O
if O
there O
was O
a O
maternal O
history O
of O
cocaine B-NEG
abuse I-NEG
during O
pregnancy O
or O
if O
maternal O
or O
neonatal O
urine O
toxicology O
results O
were O
positive O
at O
the O
time O
of O
delivery O
. O

results O
: O
five O
of O
the O
122 O
infants O
were O
excluded O
from O
the O
study O
because O
of O
insufficient O
medical O
and O
drug O
histories O
. O

the O
incidence O
of O
subependymal B-NEG
cysts I-NEG
in O
the O
117 O
remaining O
infants O
was O
14% O
( O
16 O
of O
117) O
. O

the O
incidence O
of O
subependymal B-NEG
cysts I-NEG
in O
infants O
exposed O
to O
cocaine O
prenatally O
was O
44% O
(8 O
of O
18 O
) O
compared O
with O
8% O
(8 O
of O
99 O
) O
in O
the O
unexposed O
group O
(p O
< O
0.01) O
. O

conclusions O
: O
we O
found O
an O
increased O
incidence O
of O
subependymal B-NEG
cyst I-NEG
formation O
in O
preterm B-NEG
infants I-NEG
who O
were O
exposed O
to O
cocaine O
prenatally O
. O

this O
result O
is O
consistent O
with O
results O
of O
similar O
studies O
in O
term O
infants O
. O

-DOCSTART- O

thalidomide O
neuropathy B-NEG
in O
patients O
treated O
for O
metastatic O
prostate B-NEG
cancer I-NEG
. O

we O
prospectively O
evaluated O
thalidomide-induced O
neuropathy B-NEG
using O
electrodiagnostic O
studies O
. O

sixty-seven O
men O
with O
metastatic O
androgen-independent O
prostate B-NEG
cancer I-NEG
in O
an O
open-label O
trial O
of O
oral O
thalidomide O
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
ncs O
) O
prior O
to O
and O
at O
3-month O
intervals O
during O
treatment O
. O

ncs O
included O
recording O
of O
sensory O
nerve O
action O
potentials O
( O
snaps O
) O
from O
median O
, O
radial O
, O
ulnar O
, O
and O
sural O
nerves O
. O

snap O
amplitudes O
for O
each O
nerve O
were O
expressed O
as O
the O
percentage O
of O
its O
baseline O
, O
and O
the O
mean O
of O
the O
four O
was O
termed O
the O
snap O
index O
. O

a O
40% O
decline O
in O
the O
snap O
index O
was O
considered O
clinically O
significant O
. O

thalidomide O
was O
discontinued O
in O
55 O
patients O
for O
lack O
of O
therapeutic O
response O
. O

of O
67 O
patients O
initially O
enrolled O
, O
24 O
remained O
on O
thalidomide O
for O
3 O
months O
, O
8 O
remained O
at O
6 O
months O
, O
and O
3 O
remained O
at O
9 O
months O
. O

six O
patients O
developed O
neuropathy B-NEG
. O

clinical O
symptoms O
and O
a O
decline O
in O
the O
snap O
index O
occurred O
concurrently O
. O

older O
age O
and O
cumulative O
dose O
were O
possible O
contributing O
factors O
. O
neuropathy B-NEG
may O
thus O
be O
a O
common O
complication O
of O
thalidomide O
in O
older O
patients O
. O

the O
snap O
index O
can O
be O
used O
to O
monitor O
peripheral B-NEG
neuropathy I-NEG
, O
but O
not O
for O
early O
detection O
. O

-DOCSTART- O

overexpression O
of O
copper/zinc-superoxide O
dismutase O
protects O
from O
kanamycin-induced O
hearing B-NEG
loss I-NEG
. O

the O
participation O
of O
reactive O
oxygen O
species O
in O
aminoglycoside-induced O
ototoxicity B-NEG
has O
been O
deduced O
from O
observations O
that O
aminoglycoside-iron O
complexes O
catalyze O
the O
formation O
of O
superoxide O
radicals O
in O
vitro O
and O
that O
antioxidants O
attenuate O
ototoxicity B-NEG
in O
vivo O
. O

we O
therefore O
hypothesized O
that O
overexpression O
of O
cu/zn-superoxide O
dismutase O
( O
h-sod1 O
) O
should O
protect O
transgenic O
mice O
from O
ototoxicity B-NEG
. O

immunocytochemistry O
confirmed O
expression O
of O
h-sod1 O
in O
inner O
ear O
tissues O
of O
transgenic O
c57bl/6-tgn[sod1]3cje O
mice O
. O

transgenic O
and O
nontransgenic O
littermates O
received O
kanamycin O
( O
400 O
mg/kg O
body O
weight/day O
) O
for O
10 O
days O
beginning O
on O
day O
10 O
after O
birth O
. O

auditory O
thresholds O
were O
tested O
by O
evoked O
auditory O
brain O
stem O
responses O
at O
1 O
month O
after O
birth O
. O

in O
nontransgenic O
animals O
, O
the O
threshold O
in O
the O
kanamycin-treated O
group O
was O
45-50 O
db O
higher O
than O
in O
saline-injected O
controls O
. O

in O
the O
transgenic O
group O
, O
kanamycin O
increased O
the O
threshold O
by O
only O
15 O
db O
over O
the O
respective O
controls O
. O

the O
effects O
were O
similar O
at O
12 O
and O
24 O
khz O
. O

the O
protection O
by O
overexpression O
of O
superoxide O
dismutase O
supports O
the O
hypothesis O
that O
oxidant O
stress O
plays O
a O
significant O
role O
in O
aminoglycoside-induced O
ototoxicity B-NEG
. O

the O
results O
also O
suggest O
transgenic O
animals O
as O
suitable O
models O
to O
investigate O
the O
underlying O
mechanisms O
and O
possible O
strategies O
for O
prevention O
. O

-DOCSTART- O

prednisone O
induces O
anxiety B-NEG
and O
glial O
cerebral O
changes O
in O
rats O
. O

objective O
: O
to O
assess O
whether O
prednisone O
( O
pdn O
) O
produces O
anxiety B-NEG
and/or O
cerebral O
glial O
changes O
in O
rats O
. O

methods O
: O
male O
wistar O
rats O
were O
studied O
and O
3 O
groups O
were O
formed O
(8 O
rats O
per O
group) O
. O

the O
moderate-dose O
group O
received O
5 O
mg/kg/day O
pdn O
released O
from O
a O
subcutaneous O
implant O
. O

in O
the O
high-dose O
group O
, O
implants O
containing O
pdn O
equivalent O
to O
60 O
mg/kg/day O
were O
applied O
. O

in O
the O
control O
group O
implants O
contained O
no O
pdn O
. O
anxiety B-NEG
was O
assessed O
using O
an O
open O
field O
and O
elevated O
plus-maze O
devices O
. O

the O
number O
of O
cells O
and O
cytoplasmic O
transformation O
of O
astrocytes O
and O
microglia O
cells O
were O
assessed O
by O
immunohistochemical O
analyses O
. O

results O
: O
anxiety B-NEG
was O
documented O
in O
both O
groups O
of O
pdn O
treated O
rats O
compared O
with O
controls O
. O

the O
magnitude O
of O
transformation O
of O
the O
microglia O
assessed O
by O
the O
number O
of O
intersections O
was O
significantly O
higher O
in O
the O
pdn O
groups O
than O
in O
controls O
in O
the O
prefrontal O
cortex O
(moderate-dose O
, O
24.1 O
; O
high-dose O
, O
23.6 O
; O
controls O
18.7 O
; O
p O
< O
0.01 O
) O
and O
striatum O
( O
moderate-dose O
25.6 O
; O
high-dose O
26.3 O
; O
controls O
18.9 O
; O
p O
< O
0.01) O
, O
but O
not O
in O
hippocampus O
. O

the O
number O
of O
stained O
microglia O
cells O
was O
significantly O
higher O
in O
the O
pdn O
treated O
groups O
in O
the O
prefrontal O
cortex O
than O
in O
controls O
(moderate-dose O
, O
29.1 O
; O
high-dose O
, O
28.4 O
; O
control O
, O
17.7 O
cells O
per O
field O
; O
p O
< O
0.01) O
. O

stained O
microglia O
cells O
were O
significantly O
more O
numerous O
striatum O
and O
hippocampus O
in O
the O
high-dose O
group O
compared O
to O
controls O
. O

conclusion O
: O
subacute O
exposure O
to O
pdn O
induced O
anxiety B-NEG
and O
reactivity O
of O
microglia O
. O

the O
relevance O
of O
these O
features O
for O
patients O
using O
pdn O
remains O
to O
be O
elucidated O
. O

-DOCSTART- O

phase O
ii O
study O
of O
carboplatin O
and O
liposomal O
doxorubicin O
in O
patients O
with O
recurrent O
squamous B-NEG
cell I-NEG
carcinoma I-NEG
of I-NEG
the I-NEG
cervix I-NEG
. O

background O
: O
the O
activity O
of O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
was O
tested O
in O
a O
phase O
ii O
study O
of O
patients O
with O
recurrent O
cervical B-NEG
carcinoma I-NEG
. O

methods O
: O
the O
combination O
of O
carboplatin O
( O
area O
under O
the O
concentration O
curve O
[auc] O
, O
5) O
and O
liposomal O
doxorubicin O
(doxil O
; O
starting O
dose O
, O
40 O
mg/m(2) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous B-NEG
cell I-NEG
cervical I-NEG
carcinoma I-NEG
to O
determine O
antitumor O
activity O
and O
toxicity B-NEG
profile O
. O

results O
: O
twenty-nine O
patients O
were O
assessable O
for O
response O
, O
and O
35 O
patients O
were O
assessable O
for O
toxicity B-NEG
. O

the O
overall O
response O
rate O
was O
38% O
, O
the O
median O
time O
to O
response O
was O
10 O
weeks O
, O
the O
median O
duration O
of O
response O
was O
26 O
weeks O
, O
and O
the O
median O
survival O
was O
37 O
weeks O
. O

the O
main O
toxic O
effect O
was O
myelosuppression B-NEG
, O
with O
grade O
3 O
and O
4 O
neutropenia B-NEG
in O
16 O
patients O
, O
anemia B-NEG
in O
12 O
patients O
, O
thrombocytopenia B-NEG
in O
11 O
patients O
, O
and O
neutropenic B-NEG
fever I-NEG
in O
3 O
patients O
. O

four O
patients O
had O
five O
infusion-related O
reactions O
during O
the O
infusion O
of O
liposomal O
doxorubicin O
, O
leading O
to O
treatment O
discontinuation O
in O
three O
patients O
. O

grade O
> O
or O
= O
2 O
nonhematologic O
toxicity B-NEG
included O
nausea B-NEG
in O
17 O
patients O
, O
emesis B-NEG
in O
14 O
patients O
, O
fatigue B-NEG
in O
9 O
patients O
, O
mucositis B-NEG
and/or O
stomatitis B-NEG
in O
8 O
patients O
, O
constipation B-NEG
in O
6 O
patients O
, O
weight B-NEG
loss I-NEG
in O
5 O
patients O
, O
hand-foot B-NEG
syndrome I-NEG
in O
2 O
patients O
, O
and O
skin B-NEG
reactions I-NEG
in O
3 O
patients O
. O

conclusions O
: O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
has O
modest O
activity O
in O
patients O
with O
recurrent O
cervical B-NEG
carcinoma I-NEG
. O

-DOCSTART- O

antimicrobial-induced O
mania B-NEG
( O
antibiomania B-NEG
): O
a O
review O
of O
spontaneous O
reports O
. O

the O
authors O
reviewed O
reported O
cases O
of O
antibiotic-induced O
manic B-NEG
episodes O
by O
means O
of O
a O
medline O
and O
psychlit O
search O
for O
reports O
of O
antibiotic-induced O
mania B-NEG
. O

unpublished O
reports O
were O
requested O
from O
the O
world O
health O
organization O
( O
who O
) O
and O
the O
food O
and O
drug O
administration O
(fda) O
. O

twenty-one O
reports O
of O
antimicrobial-induced O
mania B-NEG
were O
found O
in O
the O
literature O
. O

there O
were O
6 O
cases O
implicating O
clarithromycin O
, O
13 O
implicating O
isoniazid O
, O
and O
1 O
case O
each O
implicating O
erythromycin O
and O
amoxicillin O
. O

the O
who O
reported O
82 O
cases O
. O

of O
these O
, O
clarithromycin O
was O
implicated O
in O
23 O
( O
27.6% O
) O
cases O
, O
ciprofloxacin O
in O
12 O
( O
14.4% O
) O
cases O
, O
and O
ofloxacin O
in O
10 O
( O
12% O
) O
cases O
. O

cotrimoxazole O
, O
metronidazole O
, O
and O
erythromycin O
were O
involved O
in O
15 O
reported O
manic B-NEG
episodes O
. O

cases O
reported O
by O
the O
fda O
showed O
clarithromycin O
and O
ciprofloxacin O
to O
be O
the O
most O
frequently O
associated O
with O
the O
development O
of O
mania B-NEG
. O

statistical O
analysis O
of O
the O
data O
would O
not O
have O
demonstrated O
a O
significant O
statistical O
correlative O
risk O
and O
was O
therefore O
not O
undertaken O
. O

patients O
have O
an O
increased O
risk O
of O
developing O
mania B-NEG
while O
being O
treated O
with O
antimicrobials O
. O

although O
this O
is O
not O
a O
statistically O
significant O
risk O
, O
physicians O
must O
be O
aware O
of O
the O
effect O
and O
reversibility O
. O

further O
research O
clearly O
is O
required O
to O
determine O
the O
incidence O
of O
antimicrobial-induced O
mania B-NEG
, O
the O
relative O
risk O
factors O
of O
developing O
an O
antimicrobial-induced O
manic B-NEG
episode O
among O
various O
demographic O
populations O
, O
and O
the O
incidence O
of O
patients O
who O
continue O
to O
have O
persistent O
affective O
disorders O
once O
the O
initial O
episode O
, O
which O
occurs O
while O
the O
patient O
is O
taking O
antibiotics O
, O
subsides O
. O

the O
authors O
elected O
to O
name O
this O
syndrome O
antibiomania B-NEG
. O

-DOCSTART- O

levodopa-induced O
ocular B-NEG
dyskinesias I-NEG
in O
parkinson's B-NEG
disease I-NEG
. O

levodopa-induced O
ocular B-NEG
dyskinesias I-NEG
are O
very O
uncommon O
. O

usually O
they O
occur O
simultaneously O
with O
limb O
peak-dose O
choreatic B-NEG
dyskinesias I-NEG
. O

we O
report O
on O
a O
patient O
with O
leftward O
and O
upward O
deviations O
of O
gaze O
during O
the O
peak O
effect O
of O
levodopa O
, O
and O
hypothesize O
that O
a O
severe O
dopaminergic O
denervation O
in O
the O
caudate O
nucleus O
is O
needed O
for O
the O
appearance O
of O
these O
levodopa-induce O
ocular B-NEG
dyskinesias I-NEG
. O

-DOCSTART- O

a O
comparison O
of O
glyceryl O
trinitrate O
with O
diclofenac O
for O
the O
treatment O
of O
primary O
dysmenorrhea B-NEG
: O
an O
open O
, O
randomized O
, O
cross-over O
trial O
. O

primary O
dysmenorrhea B-NEG
is O
a O
syndrome O
characterized O
by O
painful O
uterine O
contractility O
caused O
by O
a O
hypersecretion O
of O
endometrial O
prostaglandins O
; O
non-steroidal O
anti-inflammatory O
drugs O
are O
the O
first O
choice O
for O
its O
treatment O
. O

however O
, O
in O
vivo O
and O
in O
vitro O
studies O
have O
demonstrated O
that O
myometrial O
cells O
are O
also O
targets O
of O
the O
relaxant O
effects O
of O
nitric O
oxide O
(no) O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
efficacy O
of O
glyceryl O
trinitrate O
(gtn) O
, O
an O
no O
donor O
, O
in O
the O
resolution O
of O
primary O
dysmenorrhea B-NEG
in O
comparison O
with O
diclofenac O
(dcf) O
. O

a O
total O
of O
24 O
patients O
with O
the O
diagnosis O
of O
severe O
primary O
dysmenorrhea B-NEG
were O
studied O
during O
two O
consecutive O
menstrual O
cycles O
. O

in O
an O
open O
, O
cross-over O
, O
controlled O
design O
, O
patients O
were O
randomized O
to O
receive O
either O
dcf O
per O
os O
or O
gtn O
patches O
the O
first O
days O
of O
menses O
, O
when O
menstrual O
cramps O
became O
unendurable O
. O

in O
the O
subsequent O
cycle O
the O
other O
treatment O
was O
used O
. O

patients O
received O
up O
to O
3 O
doses/day O
of O
50 O
mg O
dcf O
or O
2.5 O
mg/24 O
h O
transdermal O
gtn O
for O
the O
first O
3 O
days O
of O
the O
cycle O
, O
according O
to O
their O
needs O
. O

the O
participants O
recorded O
menstrual O
symptoms O
and O
possible O
side-effects O
at O
different O
times O
(0 O
, O
30 O
, O
60 O
, O
120 O
minutes O
) O
after O
the O
first O
dose O
of O
medication O
on O
the O
first O
day O
of O
the O
cycle O
, O
with O
both O
drugs O
. O

the O
difference O
in O
pain B-NEG
intensity O
score O
( O
dpi O
) O
was O
the O
main O
outcome O
variable O
. O

both O
treatments O
significantly O
reduced O
dpi O
by O
the O
30th O
minute O
(gtn O
, O
-12.8 O
+/- O
17.9 O
; O
dcf O
, O
-18.9 O
+/- O
16.6) O
. O

however O
, O
dcf O
continued O
to O
be O
effective O
in O
reducing O
pelvic B-NEG
pain I-NEG
for O
two O
hours O
, O
whereas O
gtn O
scores O
remained O
more O
or O
less O
stable O
after O
30 O
min O
and O
significantly O
higher O
than O
those O
for O
dfc O
( O
after O
one O
hour O
: O
gtn O
, O
-12.8 O
+/- O
17.9 O
; O
dfc O
, O
-18.9 O
+/- O
16.6 O
and O
after O
two O
hours O
: O
gtn O
, O
-23.7 O
+/- O
20.5 O
; O
dfc O
, O
-59.7 O
+/- O
17.9 O
, O
p O
= O
0.0001) O
. O
low B-NEG
back I-NEG
pain I-NEG
was O
also O
relieved O
by O
both O
drugs O
. O
headache B-NEG
was O
significantly O
increased O
by O
gtn O
but O
not O
by O
dcf O
. O

eight O
patients O
stopped O
using O
gtn O
because O
headache B-NEG
--attributed O
to O
its O
use--became O
intolerable O
. O

these O
findings O
indicate O
that O
gtn O
has O
a O
reduced O
efficacy O
and O
tolerability O
by O
comparison O
with O
dcf O
in O
the O
treatment O
of O
primary O
dysmenorrhea B-NEG
. O

-DOCSTART- O

temocapril O
, O
a O
long-acting O
non-sh O
group O
angiotensin O
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular B-NEG
injury I-NEG
in O
chronic O
puromycin O
aminonucleoside O
nephrosis B-NEG
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril O
, O
a O
long-acting O
non-sh O
group O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitor O
, O
reduced O
proteinuria B-NEG
, O
inhibited O
glomerular O
hypertrophy B-NEG
and O
prevented O
glomerulosclerosis B-NEG
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
- O
induced O
nephrotic B-NEG
rats O
. O
nephrosis B-NEG
was O
induced O
by O
injection O
of O
pan O
( O
15mg/100g O
body O
weight O
) O
in O
male O
sprague-dawley O
( O
sd O
) O
rats O
. O

four O
groups O
were O
used O
, O
i) O
the O
pan O
group O
(14) O
, O
ii O
) O
pan/temocapril O
(13) O
, O
iii O
) O
temocapril O
( O
14 O
) O
and O
iv O
) O
untreated O
controls O
(15) O
. O

temocapril O
(8 O
mg/kg/day O
) O
was O
administered O
to O
the O
rats O
which O
were O
killed O
at O
weeks O
4, O
14 O
or O
20 O
. O

at O
each O
time O
point O
, O
systolic O
blood O
pressure O
(bp) O
, O
urinary O
protein O
excretion O
and O
renal O
histopathological O
findings O
were O
evaluated O
, O
and O
morphometric O
image O
analysis O
was O
done O
. O

systolic O
bp O
in O
the O
pan O
group O
was O
significantly O
high O
at O
4, O
14 O
and O
20 O
weeks O
, O
but O
was O
normal O
in O
the O
pan/temocapril O
group O
. O

urinary O
protein O
excretion O
in O
the O
pan O
group O
increased O
significantly O
, O
peaking O
at O
8 O
days O
, O
then O
decreased O
at O
4 O
weeks O
, O
but O
rose O
again O
significantly O
at O
14 O
and O
20 O
weeks O
. O

temocapril O
did O
not O
attenuate O
proteinuria B-NEG
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

the O
glomerulosclerosis B-NEG
index O
( O
gsi O
) O
was O
6.21 O
% O
at O
4 O
weeks O
and O
respectively O
25.35 O
% O
and O
30.49 O
% O
at O
14 O
and O
20 O
weeks O
in O
the O
pan O
group O
. O

there O
was O
a O
significant O
correlation O
between O
urinary O
protein O
excretion O
and O
gsi O
(r O
= O
0.808 O
, O
p O
< O
0.0001) O
. O

the O
ratio O
of O
glomerular O
tuft O
area O
to O
the O
area O
of O
bowman's O
capsules O
( O
gt/bc O
) O
in O
the O
pan O
group O
was O
significantly O
increased O
, O
but O
it O
was O
significantly O
lower O
in O
the O
pan/temocapril O
group O
. O

it O
appears O
that O
temocapril O
was O
effective O
in O
retarding O
renal O
progression O
and O
protected O
renal O
function O
in O
pan O
neprotic B-NEG
rats O
. O

-DOCSTART- O

pulmonary B-NEG
hypertension I-NEG
after O
ibuprofen O
prophylaxis O
in O
very O
preterm O
infants O
. O

we O
report O
three O
cases O
of O
severe O
hypoxaemia B-NEG
after O
ibuprofen O
administration O
during O
a O
randomised O
controlled O
trial O
of O
prophylactic O
treatment O
of O
patent B-NEG
ductus I-NEG
arteriosus I-NEG
with O
ibuprofen O
in O
premature O
infants O
born O
at O
less O
than O
28 O
weeks O
of O
gestation O
. O

echocardiography O
showed O
severely O
decreased O
pulmonary O
blood O
flow O
. O
hypoxaemia B-NEG
resolved O
quickly O
on O
inhaled O
nitric O
oxide O
therapy O
. O

we O
suggest O
that O
investigators O
involved O
in O
similar O
trials O
pay O
close O
attention O
to O
pulmonary O
pressure O
if O
hypoxaemia B-NEG
occurs O
after O
prophylactic O
administration O
of O
ibuprofen O
. O

-DOCSTART- O

hyponatremia B-NEG
and O
syndrome B-NEG
of I-NEG
inappropriate I-NEG
anti-diuretic I-NEG
hormone I-NEG
reported O
with O
the O
use O
of O
vincristine O
: O
an O
over-representation O
of O
asians? O

purpose O
: O
this O
retrospective O
study O
used O
a O
pharmaceutical O
company's O
global O
safety O
database O
to O
determine O
the O
reporting O
rate O
of O
hyponatremia B-NEG
and/or O
syndrome B-NEG
of I-NEG
inappropriate I-NEG
secretion I-NEG
of I-NEG
anti-diuretic I-NEG
hormone I-NEG
( O
siadh B-NEG
) O
among O
vincristine-treated O
patients O
and O
to O
explore O
the O
possibility O
of O
at-risk O
population O
subgroups O
. O

method O
: O
we O
searched O
the O
eli O
lilly O
and O
company's O
computerized O
adverse O
event O
database O
for O
all O
reported O
cases O
of O
hyponatremia B-NEG
and/or O
siadh B-NEG
as O
of O
1 O
november O
1999 O
that O
had O
been O
reported O
during O
the O
use O
of O
vincristine O
. O

results O
: O
a O
total O
of O
76 O
cases O
of O
hyponatremia B-NEG
and/or O
siadh B-NEG
associated O
with O
vincristine O
use O
were O
identified O
. O

the O
overall O
reporting O
rate O
was O
estimated O
to O
be O
1.3/100,000 O
treated O
patients O
. O

the O
average O
age O
of O
patients O
was O
35.6 O
+/- O
28.3 O
years O
, O
and O
62% O
were O
males O
. O

approximately O
75% O
of O
the O
patients O
were O
receiving O
treatment O
for O
leukemia B-NEG
or O
lymphoma B-NEG
. O

among O
the O
39 O
reports O
that O
included O
information O
on O
race O
, O
the O
racial O
distribution O
was O
: O
1 O
black O
, O
3 O
caucasian O
, O
and O
35 O
asian O
. O

conclusion O
: O
our O
data O
suggest O
that O
asian O
patients O
may O
be O
at O
increased O
risk O
of O
hyponatremia B-NEG
and/or O
siadh B-NEG
associated O
with O
vincristine O
use O
. O

although O
the O
overall O
reported O
rate O
of O
siadh B-NEG
associated O
with O
vincristine O
is O
very O
low O
, O
physicians O
caring O
for O
asian O
oncology O
patients O
should O
be O
aware O
of O
this O
potential O
serious O
but O
reversible O
adverse O
event O
. O

-DOCSTART- O

delayed O
toxicity B-NEG
of O
cyclophosphamide O
on O
the O
bladder O
of O
dba/2 O
and O
c57bl/6 O
female O
mouse O
. O

the O
present O
study O
describes O
the O
delayed O
development O
of O
a O
severe O
bladder O
pathology O
in O
a O
susceptible O
strain O
of O
mice O
( O
dba/2 O
) O
but O
not O
in O
a O
resistant O
strain O
( O
c57bl/6 O
) O
when O
both O
were O
treated O
with O
a O
single O
300 O
mg/kg O
dose O
of O
cyclophosphamide O
(cy) O
. O

inbred O
dba/2 O
and O
c57bl/6 O
female O
mice O
were O
injected O
with O
cy O
, O
and O
the O
effect O
of O
the O
drug O
on O
the O
bladder O
was O
assessed O
during O
100 O
days O
by O
light O
microscopy O
using O
different O
staining O
procedures O
, O
and O
after O
30 O
days O
by O
conventional O
electron O
microscopy O
. O

early O
cy O
toxicity B-NEG
caused O
a O
typical O
haemorrhagic B-NEG
cystitis B-NEG
in O
both O
strains O
that O
was O
completely O
repaired O
in O
about O
7-10 O
days O
. O

after O
30 O
days O
of O
cy O
injection O
ulcerous O
and O
non-ulcerous O
forms O
of O
chronic O
cystitis B-NEG
appeared O
in O
86% O
of O
dba/2 O
mice O
but O
only O
in O
4% O
of O
c57bl/6 O
mice O
. O

delayed O
cystitis B-NEG
was O
characterized O
by O
infiltration O
and O
transepithelial O
passage O
into O
the O
lumen O
of O
inflammatory O
cells O
and O
by O
frequent O
exfoliation O
of O
the O
urothelium O
. O

mast O
cells O
appeared O
in O
the O
connective O
and O
muscular O
layers O
of O
the O
bladder O
at O
a O
much O
higher O
number O
in O
dba/2 O
mice O
than O
in O
c57bl/6 O
mice O
or O
untreated O
controls O
. O

electron O
microscopy O
disclosed O
the O
absence O
of O
the O
typical O
discoidal O
vesicles O
normally O
present O
in O
the O
cytoplasm O
of O
surface O
cells O
. O

instead O
, O
numerous O
abnormal O
vesicles O
containing O
one O
or O
several O
dark O
granules O
were O
observed O
in O
the O
cytoplasm O
of O
cells O
from O
all O
the O
epithelial O
layers O
. O

delayed O
cystitis B-NEG
still O
persisted O
in O
dba/2 O
mice O
100 O
days O
after O
treatment O
. O

these O
results O
indicate O
that O
delayed O
toxicity B-NEG
of O
cy O
in O
female O
dba/2 O
mice O
causes O
a O
bladder O
pathology O
that O
is O
not O
observed O
in O
c57bl/6 O
mice O
. O

this O
pathology O
resembles O
interstitial B-NEG
cystitis I-NEG
in O
humans O
and O
could O
perhaps O
be O
used O
as O
an O
animal O
model O
for O
studies O
on O
the O
disease O
. O

-DOCSTART- O

high-dose O
5-fluorouracil O
/ O
folinic O
acid O
in O
combination O
with O
three-weekly O
mitomycin O
c O
in O
the O
treatment O
of O
advanced O
gastric B-NEG
cancer I-NEG
. O

a O
phase O
ii O
study O
. O

background O
: O
the O
24-hour O
continuous O
infusion O
of O
5-fluorouracil O
( O
5-fu O
) O
and O
folinic O
acid O
( O
fa O
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric B-NEG
cancer I-NEG
( O
agc B-NEG
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity B-NEG
. O

in O
a O
previous O
phase O
ii O
study O
with O
3-weekly O
bolus O
5-fu O
, O
fa O
and O
mitomycin O
c O
( O
mmc O
) O
we O
found O
a O
low O
toxicity B-NEG
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
elf O
, O
fam O
or O
famtx O
, O
and O
a O
promising O
median O
overall O
survival O
. O

in O
order O
to O
improve O
this O
mmc-dependent O
schedule O
we O
initiated O
a O
phase O
ii O
study O
with O
high-dose O
5-fu/fa O
and O
3-weekly O
bolus O
mmc O
. O

patients O
and O
methods O
: O
from O
february O
, O
1998 O
to O
september O
, O
2000 O
we O
recruited O
33 O
patients O
with O
agc B-NEG
to O
receive O
weekly O
24-hour O
5-fu O
2,600 O
mg/m(2 O
) O
preceded O
by O
2-hour O
fa O
500 O
mg/m(2 O
) O
for O
6 O
weeks O
, O
followed O
by O
a O
2-week O
rest O
period O
. O

bolus O
mmc O
10 O
mg/m(2 O
) O
was O
added O
in O
3-weekly O
intervals O
. O

treatment O
given O
on O
an O
outpatient O
basis O
, O
using O
portable O
pump O
systems O
, O
was O
repeated O
on O
day O
57 O
. O

patients' O
characteristics O
were O
: O
male/female O
ratio O
20/13 O
; O
median O
age O
57 O
( O
27-75 O
) O
years O
; O
median O
who O
status O
1 O
(0-2) O
. O

18 O
patients O
had O
a O
primary O
agc B-NEG
, O
and O
15 O
showed O
a O
relapsed O
agc B-NEG
. O

median O
follow-up O
was O
11.8 O
months O
( O
range O
of O
those O
surviving O
: O
2.7-11.8 O
months) O
. O

results O
: O
32 O
patients O
were O
evaluable O
for O
response O
- O
complete O
remission O
9.1% O
(n O
= O
3) O
, O
partial O
remission O
45.5% O
(n O
= O
15) O
, O
no O
change O
27.3% O
(n O
= O
9) O
, O
progressive O
disease O
15.1% O
(n O
= O
5) O
. O

median O
overall O
survival O
time O
was O
10.2 O
months O
[95% O
confidence O
interval O
(ci) O
: O
8.7-11.6] O
, O
and O
median O
progression-free O
survival O
time O
was O
7.6 O
months O
( O
95% O
ci O
: O
4.4-10.9) O
. O

the O
worst O
toxicities B-NEG
( O
% O
) O
observed O
were O
( O
ctc-nci O
1/2/3) O
: O
leukopenia B-NEG
45.5/18.2/6.1 O
, O
thrombocytopenia B-NEG
33.3/9.1/6.1 O
, O
vomitus B-NEG
24.2/9.1/0 O
, O
diarrhea B-NEG
36.4/6.1/3.0 O
, O
stomatitis B-NEG
18.2/9.1/0 O
, O
hand-foot B-NEG
syndrome I-NEG
12.1/0/0 O
. O

two O
patients O
developed O
hemolytic-uremic B-NEG
syndrome I-NEG
( O
hus B-NEG
). O

conclusions O
: O
high-dose O
5-fu/fa/mmc O
is O
an O
effective O
and O
well-tolerated O
outpatient O
regimen O
for O
agc B-NEG
( O
objective O
response O
rate O
54.6%) O
. O

it O
may O
serve O
as O
an O
alternative O
to O
cisplatin-containing O
regimens O
; O
however O
, O
it O
has O
to O
be O
considered O
that O
possibly O
hus B-NEG
may O
occur O
. O

-DOCSTART- O

persistent O
sterile O
leukocyturia B-NEG
is O
associated O
with O
impaired B-NEG
renal I-NEG
function I-NEG
in O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
type I-NEG
1-infected I-NEG
children O
treated O
with O
indinavir O
. O

background O
: O
prolonged O
administration O
of O
indinavir O
is O
associated O
with O
the O
occurrence O
of O
a O
variety O
of O
renal O
complications O
in O
adults O
. O

these O
well-documented O
side O
effects O
have O
restricted O
the O
use O
of O
this O
potent O
protease O
inhibitor O
in O
children O
. O

design O
: O
a O
prospective O
study O
to O
monitor O
indinavir-related O
nephrotoxicity B-NEG
in O
a O
cohort O
of O
30 O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
type I-NEG
1-infected I-NEG
children O
treated O
with O
indinavir O
. O

methods O
: O
urinary O
ph O
, O
albumin O
, O
creatinine O
, O
the O
presence O
of O
erythrocytes O
, O
leukocytes O
, O
bacteria O
and O
crystals O
, O
and O
culture O
were O
analyzed O
every O
3 O
months O
for O
96 O
weeks O
. O

serum O
creatinine O
levels O
were O
routinely O
determined O
at O
the O
same O
time O
points O
. O

steady-state O
pharmacokinetics O
of O
indinavir O
were O
done O
at O
week O
4 O
after O
the O
initiation O
of O
indinavir O
. O

results O
: O
the O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B-NEG
(> O
or O
=75 O
cells/ O
micro O
l O
in O
at O
least O
2 O
consecutive O
visits O
) O
after O
96 O
weeks O
was O
53% O
. O

persistent O
sterile O
leukocyturia B-NEG
was O
frequently O
associated O
with O
a O
mild O
increase O
in O
the O
urine O
albumin/creatinine O
ratio O
and O
by O
microscopic O
hematuria B-NEG
. O

the O
cumulative O
incidence O
of O
serum O
creatinine O
levels O
>50% O
above O
normal O
was O
33% O
after O
96 O
weeks O
. O

children O
with O
persistent O
sterile O
leukocyturia B-NEG
more O
frequently O
had O
serum O
creatinine O
levels O
of O
50% O
above O
normal O
than O
those O
children O
without O
persistent O
sterile O
leukocyturia B-NEG
. O

in O
children O
younger O
than O
5.6 O
years O
, O
persistent O
sterile O
leukocyturia B-NEG
was O
significantly O
more O
frequent O
than O
in O
older O
children O
. O

a O
higher O
cumulative O
incidence O
of O
persistent O
leukocyturia B-NEG
was O
found O
in O
children O
with O
an O
area O
under O
the O
curve O
>19 O
mg/l O
x O
h O
or O
a O
peak O
serum O
level O
of O
indinavir O
>12 O
mg/l O
. O

in O
4 O
children O
, O
indinavir O
was O
discontinued O
because O
of O
nephrotoxicity B-NEG
. O

subsequently O
, O
the O
serum O
creatinine O
levels O
decreased O
, O
the O
urine O
albumin/creatinine O
ratios O
returned O
to O
zero O
, O
and O
the O
leukocyturia B-NEG
disappeared O
within O
3 O
months O
. O

conclusions O
: O
children O
treated O
with O
indinavir O
have O
a O
high O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B-NEG
. O

children O
with O
persistent O
sterile O
leukocyturia B-NEG
more O
frequently O
had O
an O
increase O
in O
serum O
creatinine O
levels O
of O
>50% O
above O
normal O
. O

younger O
children O
have O
an O
additional O
risk O
for O
renal O
complications O
. O

the O
impairment B-NEG
of I-NEG
the I-NEG
renal I-NEG
function I-NEG
in O
these O
children O
occurred O
in O
the O
absence O
of O
clinical O
symptoms O
of O
nephrolithiasis B-NEG
. O

indinavir-associated O
nephrotoxicity B-NEG
must O
be O
monitored O
closely O
, O
especially O
in O
children O
with O
risk O
factors O
such O
as O
persistent O
sterile O
leukocyturia B-NEG
, O
age O
<5.6 O
years O
, O
an O
area O
under O
the O
curve O
of O
indinavir O
>19 O
mg/l O
x O
h, O
and O
a O
c(max O
) O
>12 O
mg/l O
. O

-DOCSTART- O

utility O
of O
troponin O
i O
in O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
. O

baseline O
electrocardiogram O
abnormalities O
and O
market O
elevations O
not O
associated O
with O
myocardial B-NEG
necrosis I-NEG
make O
accurate O
diagnosis O
of O
myocardial B-NEG
infarction I-NEG
( O
mi B-NEG
) O
difficult O
in O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
. O

troponin O
sampling O
may O
offer O
greater O
diagnostic O
utility O
in O
these O
patients O
. O

objective O
: O
to O
assess O
outcomes O
based O
on O
troponin O
positivity O
in O
patients O
with O
cocaine O
chest B-NEG
pain I-NEG
admitted O
for O
exclusion O
of O
mi B-NEG
. O

methods O
: O
outcomes O
were O
examined O
in O
patients O
admitted O
for O
possible O
mi B-NEG
after O
cocaine O
use O
. O

all O
patients O
underwent O
a O
rapid O
rule-in O
protocol O
that O
included O
serial O
sampling O
of O
creatine O
kinase O
(ck) O
, O
ck-mb O
, O
and O
cardiac O
troponin O
i O
( O
ctni O
) O
over O
eight O
hours O
. O

outcomes O
included O
ck-mb O
mi B-NEG
( O
ck-mb O
>or= O
8 O
ng/ml O
with O
a O
relative O
index O
[(ck-mb O
x O
100)/total O
ck] O
>or= O
4, O
cardiac B-NEG
death I-NEG
, O
and O
significant O
coronary B-NEG
disease I-NEG
(>or=50%) O
. O

results O
: O
of O
the O
246 O
admitted O
patients O
, O
34 O
( O
14% O
) O
met O
ck-mb O
criteria O
for O
mi B-NEG
and O
38 O
( O
16% O
) O
had O
ctni O
elevations O
. O

angiography O
was O
performed O
in O
29 O
of O
38 O
patients O
who O
were O
ctni-positive O
, O
with O
significant O
disease O
present O
in O
25 O
(86%) O
. O

three O
of O
the O
four O
patients O
without O
significant O
disease O
who O
had O
ctni O
elevations O
met O
ck-mb O
criteria O
for O
mi B-NEG
, O
and O
the O
other O
had O
a O
peak O
ck-mb O
level O
of O
13 O
ng/ml O
. O

sensitivities O
, O
specificities O
, O
and O
positive O
and O
negative O
likelihood O
ratios O
for O
predicting O
cardiac B-NEG
death I-NEG
or O
significant O
disease O
were O
high O
for O
both O
ck-mb O
mi B-NEG
and O
ctni O
and O
were O
not O
significantly O
different O
. O

conclusions O
: O
most O
patients O
with O
ctni O
elevations O
meet O
ck-mb O
criteria O
for O
mi B-NEG
, O
as O
well O
as O
have O
a O
high O
incidence O
of O
underlying O
significant O
disease O
. O

troponin O
appears O
to O
have O
an O
equivalent O
diagnostic O
accuracy O
compared O
with O
ck-mb O
for O
diagnosing O
necrosis B-NEG
in O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
and O
suspected O
mi B-NEG
. O

-DOCSTART- O

acute O
interstitial B-NEG
nephritis I-NEG
due O
to O
nicergoline O
(sermion) O
. O

we O
report O
a O
case O
of O
acute O
interstitial B-NEG
nephritis I-NEG
( O
ain B-NEG
) O
due O
to O
nicergoline O
(sermion) O
. O

a O
50-year-old O
patient O
admitted O
to O
our O
hospital O
for O
fever B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
. O

before O
admission O
, O
he O
had O
been O
taking O
nicergoline O
and O
bendazac O
lysine O
due O
to O
retinal B-NEG
vein I-NEG
occlusion I-NEG
at O
ophthalmologic O
department O
. O

thereafter O
, O
he O
experienced O
intermittent O
fever B-NEG
and O
skin B-NEG
rash I-NEG
. O

on O
admission O
, O
clinical O
symptoms O
(i.e O
. O
arthralgia B-NEG
and O
fever B-NEG
) O
and O
laboratory O
findings O
(i.e O
. O
eosinophilia B-NEG
and O
renal B-NEG
failure I-NEG
) O
suggested O
ain B-NEG
, O
and O
which O
was O
confirmed O
by O
pathologic O
findings O
on O
renal O
biopsy O
. O

a O
lymphocyte O
transformation O
test O
demonstrated O
a O
positive O
result O
against O
nicergoline O
. O

treatment O
was O
consisted O
of O
withdrawal O
of O
nicergoline O
and O
intravenous O
methylprednisolone O
, O
and O
his O
renal O
function O
was O
completely O
recovered O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
nicergoline-associated O
ain B-NEG
. O

-DOCSTART- O

neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
complicated O
by O
massive O
intestinal O
bleeding B-NEG
in O
a O
patient O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
. O

a O
patient O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
( O
crf B-NEG
) O
developed O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
( O
nms B-NEG
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

in O
addition O
to O
the O
typical O
symptoms O
of O
nms B-NEG
, O
massive O
intestinal O
bleeding B-NEG
was O
observed O
during O
the O
episode O
. O

this O
report O
suggests O
that O
nms B-NEG
in O
a O
patient O
with O
crf B-NEG
may O
be O
complicated O
by O
intestinal O
bleeding B-NEG
and O
needs O
special O
caution O
for O
this O
complication O
. O

-DOCSTART- O

blood O
brain O
barrier O
in O
right- O
and O
left-pawed O
female O
rats O
assessed O
by O
a O
new O
staining O
method O
. O

the O
asymmetrical O
breakdown O
of O
the O
blood-brain O
barrier O
( O
bbb O
) O
was O
studied O
in O
female O
rats O
. O

paw O
preference O
was O
assessed O
by O
a O
food O
reaching O
test O
. O

adrenaline-induced O
hypertension B-NEG
was O
used O
to O
destroy O
the O
bbb O
, O
which O
was O
evaluated O
using O
triphenyltetrazolium O
( O
ttc O
) O
staining O
of O
the O
brain O
slices O
just O
after O
giving O
adrenaline O
for O
30 O
s. O

in O
normal O
rats O
, O
the O
whole O
brain O
sections O
exhibited O
complete O
staining O
with O
ttc O
. O

after O
adrenaline O
infusion O
for O
30 O
s, O
there O
were O
large O
unstained O
areas O
in O
the O
left O
brain O
in O
right-pawed O
animals O
, O
and O
vice O
versa O
in O
left-pawed O
animals O
. O

similar O
results O
were O
obtained O
in O
seizure B-NEG
-induced O
breakdown O
of O
bbb O
. O

these O
results O
were O
explained O
by O
an O
asymmetric O
cerebral O
blood O
flow O
depending O
upon O
the O
paw O
preference O
in O
rats O
. O

it O
was O
suggested O
that O
this O
new O
method O
and O
the O
results O
are O
consistent O
with O
contralateral O
motor O
control O
that O
may O
be O
important O
in O
determining O
the O
dominant O
cerebral O
hemisphere O
in O
animals O
. O

-DOCSTART- O

carvedilol O
protects O
against O
doxorubicin-induced O
mitochondrial O
cardiomyopathy B-NEG
. O

several O
cytopathic O
mechanisms O
have O
been O
suggested O
to O
mediate O
the O
dose-limiting O
cumulative O
and O
irreversible O
cardiomyopathy B-NEG
caused O
by O
doxorubicin O
. O

recent O
evidence O
indicates O
that O
oxidative O
stress O
and O
mitochondrial B-NEG
dysfunction I-NEG
are O
key O
factors O
in O
the O
pathogenic O
process O
. O

the O
objective O
of O
this O
investigation O
was O
to O
test O
the O
hypothesis O
that O
carvedilol O
, O
a O
nonselective O
beta-adrenergic O
receptor O
antagonist O
with O
potent O
antioxidant O
properties O
, O
protects O
against O
the O
cardiac O
and O
hepatic O
mitochondrial O
bioenergetic O
dysfunction O
associated O
with O
subchronic O
doxorubicin O
toxicity B-NEG
. O

heart O
and O
liver O
mitochondria O
were O
isolated O
from O
rats O
treated O
for O
7 O
weeks O
with O
doxorubicin O
(2 O
mg/kg O
sc/week) O
, O
carvedilol O
(1 O
mg/kg O
ip/week) O
, O
or O
the O
combination O
of O
the O
two O
drugs O
. O

heart O
mitochondria O
isolated O
from O
doxorubicin-treated O
rats O
exhibited O
depressed O
rates O
for O
state O
3 O
respiration O
( O
336 O
+/- O
26 O
versus O
425 O
+/- O
53 O
natom O
o/min/mg O
protein O
) O
and O
a O
lower O
respiratory O
control O
ratio O
( O
rcr O
) O
( O
4.3 O
+/- O
0.6 O
versus O
5.8 O
+/- O
0.4 O
) O
compared O
with O
cardiac O
mitochondria O
isolated O
from O
saline-treated O
rats O
. O

mitochondrial O
calcium-loading O
capacity O
and O
the O
activity O
of O
nadh-dehydrogenase O
were O
also O
suppressed O
in O
cardiac O
mitochondria O
from O
doxorubicin-treated O
rats O
. O

doxorubicin O
treatment O
also O
caused O
a O
decrease O
in O
rcr O
for O
liver O
mitochondria O
( O
3.9 O
+/- O
0.9 O
versus O
5.6 O
+/- O
0.7 O
for O
control O
rats O
) O
and O
inhibition O
of O
hepatic O
cytochrome O
oxidase O
activity O
. O

coadministration O
of O
carvedilol O
decreased O
the O
extent O
of O
cellular O
vacuolization O
in O
cardiac O
myocytes O
and O
prevented O
the O
inhibitory O
effect O
of O
doxorubicin O
on O
mitochondrial O
respiration O
in O
both O
heart O
and O
liver O
. O

carvedilol O
also O
prevented O
the O
decrease O
in O
mitochondrial O
ca(2+ O
) O
loading O
capacity O
and O
the O
inhibition O
of O
the O
respiratory O
complexes O
of O
heart O
mitochondria O
caused O
by O
doxorubicin O
. O

carvedilol O
by O
itself O
did O
not O
affect O
any O
of O
the O
parameters O
measured O
for O
heart O
or O
liver O
mitochondria O
. O

it O
is O
concluded O
that O
this O
protection O
by O
carvedilol O
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose-limiting O
mitochondrial B-NEG
dysfunction I-NEG
and O
cardiomyopathy B-NEG
that O
accompanies O
long-term O
doxorubicin O
therapy O
in O
cancer B-NEG
patients O
. O

-DOCSTART- O

cocaine-induced O
hyperactivity B-NEG
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
than O
amphetamine-induced O
hyperactivity B-NEG
. O

the O
influence O
of O
adenosine O
receptor O
agonists O
and O
antagonists O
on O
cocaine-and O
amphetamine-induced O
hyperactivity B-NEG
was O
examined O
in O
mice O
. O

all O
adenosine O
receptor O
agonists O
significantly O
decreased B-NEG
the I-NEG
locomotor I-NEG
activity I-NEG
in O
mice O
, O
and O
the O
effects O
were O
dose-dependent O
. O

it O
seems O
that O
adenosine O
a1 O
and O
a2 O
receptors O
might O
be O
involved O
in O
this O
reaction O
. O

moreover O
, O
all O
adenosine O
receptor O
agonists O
: O
2-p-(2-carboxyethyl)phenethylamino-5'-n-ethylcarboxamidoadenosine O
( O
cgs O
21680) O
, O
a2a O
receptor O
agonist O
, O
n6-cyclopentyladenosine O
(cpa) O
, O
a1 O
receptor O
agonist O
, O
and O
5'-n-ethylcarboxamidoadenosine O
(neca) O
, O
a2/a1 O
receptor O
agonist O
significantly O
and O
dose-dependently O
decreased O
cocaine-induced O
locomotor O
activity O
. O

cpa O
reduced O
cocaine O
action O
at O
the O
doses O
which O
, O
given O
alone O
, O
did O
not O
influence O
motility O
, O
while O
cgs O
21680 O
and O
neca O
decreased O
the O
action O
of O
cocaine O
at O
the O
doses O
which O
, O
given O
alone O
, O
decreased O
locomotor O
activity O
in O
animals O
. O

these O
results O
suggest O
the O
involvement O
of O
both O
adenosine O
receptors O
in O
the O
action O
of O
cocaine O
although O
agonists O
of O
a1 O
receptors O
seem O
to O
have O
stronger O
influence O
on O
it O
. O

the O
selective O
blockade O
of O
a2 O
adenosine O
receptor O
by O
dmpx O
( O
3,7-dimethyl-1-propargylxanthine O
) O
significantly O
enhanced O
cocaine-induced O
locomotor O
activity O
of O
animals O
. O

caffeine O
had O
similar O
action O
but O
the O
effect O
was O
not O
significant O
. O

cpt O
( O
8-cyclopentyltheophylline)--a1 O
receptor O
antagonist O
, O
did O
not O
show O
any O
influence O
in O
this O
test O
. O

similarly O
, O
all O
adenosine O
receptor O
agonists O
decreased O
amphetamine-induced O
hyperactivity B-NEG
, O
but O
at O
the O
higher O
doses O
than O
those O
which O
were O
active O
in O
cocaine-induced O
hyperactivity B-NEG
. O

the O
selective O
blockade O
of O
a2 O
adenosine O
receptors O
( O
dmpx O
) O
and O
non-selective O
blockade O
of O
adenosine O
receptors O
( O
caffeine O
) O
significantly O
increased O
the O
action O
of O
amphetamine O
in O
the O
locomotor O
activity O
test O
. O

our O
results O
have O
shown O
that O
all O
adenosine O
receptor O
agonists O
( O
a1 O
and O
a2 O
) O
reduce O
cocaine- O
and O
amphetamine-induced O
locomotor O
activity O
and O
indicate O
that O
cocaine-induced O
hyperactivity B-NEG
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
( O
particularly O
a1 O
receptors O
) O
than O
amphetamine-induced O
hyperactivity B-NEG
. O

-DOCSTART- O

amiodarone O
and O
the O
risk O
of O
bradyarrhythmia B-NEG
requiring O
permanent O
pacemaker O
in O
elderly O
patients O
with O
atrial B-NEG
fibrillation I-NEG
and O
prior O
myocardial B-NEG
infarction I-NEG
. O

objectives O
: O
the O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
amiodarone O
in O
patients O
with O
atrial B-NEG
fibrillation I-NEG
( O
af B-NEG
) O
increases O
the O
risk O
of O
bradyarrhythmia B-NEG
requiring O
a O
permanent O
pacemaker O
. O

background O
: O
reports O
of O
severe O
bradyarrhythmia B-NEG
during O
amiodarone O
therapy O
are O
infrequent O
and O
limited O
to O
studies O
assessing O
the O
therapy's O
use O
in O
the O
management O
of O
patients O
with O
ventricular B-NEG
arrhythmias I-NEG
. O

methods O
: O
a O
study O
cohort O
of O
8,770 O
patients O
age O
> O
or O
=65 O
years O
with O
a O
new O
diagnosis O
of O
af B-NEG
was O
identified O
from O
a O
provincewide O
database O
of O
quebec O
residents O
with O
a O
myocardial B-NEG
infarction I-NEG
( O
mi B-NEG
) O
between O
1991 O
and O
1999 O
. O

using O
a O
nested O
case-control O
design O
, O
477 O
cases O
of O
bradyarrhythmia B-NEG
requiring O
a O
permanent O
pacemaker O
were O
matched O
( O
1:4 O
) O
to O
1,908 O
controls O
. O

multivariable O
logistic O
regression O
was O
used O
to O
estimate O
the O
odds O
ratio O
( O
or O
) O
of O
pacemaker O
insertion O
associated O
with O
amiodarone O
use O
, O
controlling O
for O
baseline O
risk O
factors O
and O
exposure O
to O
sotalol O
, O
class O
i O
antiarrhythmic O
agents O
, O
beta-blockers O
, O
calcium O
channel O
blockers O
, O
and O
digoxin O
. O

results O
: O
amiodarone O
use O
was O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
(or O
: O
2.14 O
, O
95% O
confidence O
interval O
[ci] O
: O
1.30 O
to O
3.54) O
. O

this O
effect O
was O
modified O
by O
gender O
, O
with O
a O
greater O
risk O
in O
women O
versus O
men O
(or O
: O
3.86 O
, O
95% O
ci O
: O
1.70 O
to O
8.75 O
vs O
. O
or O
: O
1.52 O
, O
95% O
ci O
: O
0.80 O
to O
2.89) O
. O

digoxin O
was O
the O
only O
other O
medication O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
(or O
: O
1.78 O
, O
95% O
ci O
: O
1.37 O
to O
2.31) O
. O

conclusions O
: O
this O
study O
suggests O
that O
the O
use O
of O
amiodarone O
in O
elderly O
patients O
with O
af B-NEG
and O
a O
previous O
mi B-NEG
increases O
the O
risk O
of O
bradyarrhythmia B-NEG
requiring O
a O
permanent O
pacemaker O
. O

the O
finding O
of O
an O
augmented O
risk O
of O
pacemaker O
insertion O
in O
elderly O
women O
receiving O
amiodarone O
requires O
further O
investigation O
. O

-DOCSTART- O

indomethacin-induced O
morphologic O
changes O
in O
the O
rat O
urinary O
bladder O
epithelium O
. O

objectives O
: O
to O
evaluate O
the O
morphologic O
changes O
in O
rat O
urothelium O
induced O
by O
indomethacin O
. O

nonsteroidal O
anti-inflammatory O
drug-induced O
cystitis B-NEG
is O
a O
poorly O
recognized O
and O
under-reported O
condition O
. O

in O
addition O
to O
tiaprofenic O
acid O
, O
indomethacin O
has O
been O
reported O
to O
be O
associated O
with O
this O
condition O
. O

methods O
: O
three O
groups O
were O
established O
: O
a O
control O
group O
(n O
= O
10) O
, O
a O
high-dose O
group O
(n O
= O
10) O
, O
treated O
with O
one O
intraperitoneal O
injection O
of O
indomethacin O
20 O
mg/kg O
, O
and O
a O
therapeutic O
dose O
group O
(n O
= O
10 O
) O
in O
which O
oral O
indomethacin O
was O
administered O
3.25 O
mg/kg O
body O
weight O
daily O
for O
3 O
weeks O
. O

the O
animals O
were O
then O
killed O
and O
the O
bladders O
removed O
for O
light O
and O
electron O
microscopic O
studies O
. O

results O
: O
the O
light O
microscopic O
findings O
showed O
some O
focal O
epithelial O
degeneration O
that O
was O
more O
prominent O
in O
the O
high-dose O
group O
. O

when O
compared O
with O
the O
control O
group O
, O
both O
indomethacin O
groups O
revealed O
statistically O
increased O
numbers O
of O
mast O
cells O
in O
the O
mucosa O
(p O
<0.0001 O
) O
and O
penetration O
of O
lanthanum O
nitrate O
through O
intercellular O
areas O
of O
the O
epithelium O
. O

furthermore O
, O
the O
difference O
in O
mast O
cell O
counts O
between O
the O
high O
and O
therapeutic O
dose O
groups O
was O
also O
statistically O
significant O
(p O
<0.0001) O
. O

conclusions O
: O
indomethacin O
resulted O
in O
histopathologic O
findings O
typical O
of O
interstitial B-NEG
cystitis I-NEG
, O
such O
as O
leaky O
bladder O
epithelium O
and O
mucosal O
mastocytosis B-NEG
. O

the O
true O
incidence O
of O
nonsteroidal O
anti-inflammatory O
drug-induced O
cystitis B-NEG
in O
humans O
must O
be O
clarified O
by O
prospective O
clinical O
trials O
. O

-DOCSTART- O

an O
open-label O
phase O
ii O
study O
of O
low-dose O
thalidomide O
in O
androgen-independent O
prostate B-NEG
cancer I-NEG
. O

the O
antiangiogenic O
effects O
of O
thalidomide O
have O
been O
assessed O
in O
clinical O
trials O
in O
patients O
with O
various O
solid O
and O
haematological B-NEG
malignancies I-NEG
. O

thalidomide O
blocks O
the O
activity O
of O
angiogenic O
agents O
including O
bfgf O
, O
vegf O
and O
il-6 O
. O

we O
undertook O
an O
open-label O
study O
using O
thalidomide O
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen-independent O
prostate B-NEG
cancer I-NEG
. O

the O
mean O
time O
of O
study O
was O
109 O
days O
( O
median O
107 O
, O
range O
4-184 O
days) O
. O

patients O
underwent O
regular O
measurement O
of O
prostate-specific O
antigen O
(psa) O
, O
urea O
and O
electrolytes O
, O
serum O
bfgf O
and O
vegf O
. O

three O
men O
( O
15% O
) O
showed O
a O
decline O
in O
serum O
psa O
of O
at O
least O
50% O
, O
sustained O
throughout O
treatment O
. O

of O
16 O
men O
treated O
for O
at O
least O
2 O
months O
, O
six O
( O
37.5% O
) O
showed O
a O
fall O
in O
absolute O
psa O
by O
a O
median O
of O
48% O
. O

increasing O
levels O
of O
serum O
bfgf O
and O
vegf O
were O
associated O
with O
progressive O
disease O
; O
five O
of O
six O
men O
who O
demonstrated O
a O
fall O
in O
psa O
also O
showed O
a O
decline O
in O
bfgf O
and O
vegf O
levels O
, O
and O
three O
of O
four O
men O
with O
a O
rising O
psa O
showed O
an O
increase O
in O
both O
growth O
factors O
. O

adverse O
effects O
included O
constipation B-NEG
, O
morning O
drowsiness B-NEG
, O
dizziness B-NEG
and O
rash B-NEG
, O
and O
resulted O
in O
withdrawal O
from O
the O
study O
by O
three O
men O
. O

evidence O
of O
peripheral B-NEG
sensory I-NEG
neuropathy I-NEG
was O
found O
in O
nine O
of O
13 O
men O
before O
treatment O
. O

in O
the O
seven O
men O
who O
completed O
six O
months O
on O
thalidomide O
, O
subclinical O
evidence O
of O
peripheral B-NEG
neuropathy I-NEG
was O
found O
in O
four O
before O
treatment O
, O
but O
in O
all O
seven O
at O
repeat O
testing O
. O

the O
findings O
indicate O
that O
thalidomide O
may O
be O
an O
option O
for O
patients O
who O
have O
failed O
other O
forms O
of O
therapy O
, O
provided O
close O
follow-up O
is O
maintained O
for O
development O
of O
peripheral B-NEG
neuropathy I-NEG
. O

-DOCSTART- O

central B-NEG
nervous I-NEG
system I-NEG
toxicity I-NEG
following O
the O
administration O
of O
levobupivacaine O
for O
lumbar O
plexus O
block O
: O
a O
report O
of O
two O
cases O
. O

background O
and O
objectives O
: O
central B-NEG
nervous I-NEG
system I-NEG
and I-NEG
cardiac I-NEG
toxicity I-NEG
following O
the O
administration O
of O
local O
anesthetics O
is O
a O
recognized O
complication O
of O
regional O
anesthesia O
. O

levobupivacaine O
, O
the O
pure O
s(- O
) O
enantiomer O
of O
bupivacaine O
, O
was O
developed O
to O
improve O
the O
cardiac O
safety O
profile O
of O
bupivacaine O
. O

we O
describe O
2 O
cases O
of O
grand B-NEG
mal I-NEG
seizures I-NEG
following O
accidental O
intravascular O
injection O
of O
levobupivacaine O
. O

case O
report O
: O
two O
patients O
presenting O
for O
elective O
orthopedic O
surgery O
of O
the O
lower O
limb O
underwent O
blockade O
of O
the O
lumbar O
plexus O
via O
the O
posterior O
approach O
. O

immediately O
after O
the O
administration O
of O
levobupivacaine O
0.5% O
with O
epinephrine O
2.5 O
microgram/ml O
, O
the O
patients O
developed O
grand B-NEG
mal I-NEG
seizures I-NEG
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

the O
seizures B-NEG
were O
successfully O
treated O
with O
sodium O
thiopental O
in O
addition O
to O
succinylcholine O
in O
1 O
patient O
. O

neither O
patient O
developed O
signs O
of O
cardiovascular B-NEG
toxicity I-NEG
. O

both O
patients O
were O
treated O
preoperatively O
with O
beta-adrenergic O
antagonist O
medications O
, O
which O
may O
have O
masked O
the O
cardiovascular O
signs O
of O
the O
unintentional O
intravascular O
administration O
of O
levobupivacaine O
with O
epinephrine O
. O

conclusions O
: O
although O
levobupivacaine O
may O
have O
a O
safer O
cardiac B-NEG
toxicity I-NEG
profile O
than O
racemic O
bupivacaine O
, O
if O
adequate O
amounts O
of O
levobupivacaine O
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions B-NEG
. O

plasma O
concentrations O
sufficient O
to O
result O
in O
central B-NEG
nervous I-NEG
system I-NEG
toxicity I-NEG
did O
not O
produce O
manifestations O
of O
cardiac B-NEG
toxicity I-NEG
in O
these O
2 O
patients O
. O

-DOCSTART- O

anaesthetic O
complications O
associated O
with O
myotonia B-NEG
congenita I-NEG
: O
case O
study O
and O
comparison O
with O
other O
myotonic B-NEG
disorders I-NEG
. O
myotonia B-NEG
congenita I-NEG
( O
mc B-NEG
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride O
channel O
function O
, O
which O
may O
cause O
sustained B-NEG
membrane I-NEG
depolarisation I-NEG
. O

we O
describe O
a O
previously O
healthy O
32-year-old O
woman O
who O
developed O
a O
life-threatening O
muscle B-NEG
spasm I-NEG
and O
secondary O
ventilation O
difficulties O
following O
a O
preoperative O
injection O
of O
suxamethonium O
. O

the O
muscle B-NEG
spasms I-NEG
disappeared O
spontaneously O
and O
the O
surgery O
proceeded O
without O
further O
problems O
. O

when O
subsequently O
questioned O
, O
she O
reported O
minor O
symptoms O
suggesting O
a O
myotonic B-NEG
condition I-NEG
. O
myotonia B-NEG
was O
found O
on O
clinical O
examination O
and O
emg O
. O

the O
diagnosis O
mc B-NEG
was O
confirmed O
genetically O
. O

neither O
the O
patient O
nor O
the O
anaesthetist O
were O
aware O
of O
the O
diagnosis O
before O
this O
potentially O
lethal O
complication O
occurred O
. O

we O
give O
a O
brief O
overview O
of O
ion B-NEG
channel I-NEG
disorders I-NEG
including O
malignant B-NEG
hyperthermia I-NEG
and O
their O
anaesthetic O
considerations O
. O

-DOCSTART- O

respiratory O
pattern O
in O
a O
rat O
model O
of O
epilepsy B-NEG
. O

purpose O
: O
apnea B-NEG
is O
known O
to O
occur O
during O
seizures B-NEG
, O
but O
systematic O
studies O
of O
ictal O
respiratory O
changes O
in O
adults O
are O
few O
. O

data O
regarding O
respiratory O
pattern O
defects O
during O
interictal O
periods O
also O
are O
scarce O
. O

here O
we O
sought O
to O
generate O
information O
with O
regard O
to O
the O
interictal O
period O
in O
animals O
with O
pilocarpine-induced O
epilepsy B-NEG
. O

methods O
: O
twelve O
rats O
( O
six O
chronically O
epileptic B-NEG
animals O
and O
six O
controls O
) O
were O
anesthetized O
, O
given O
tracheotomies O
, O
and O
subjected O
to O
hyperventilation B-NEG
or O
hypoventilation O
conditions O
. O

breathing O
movements O
caused O
changes O
in O
thoracic O
volume O
and O
forced O
air O
to O
flow O
tidally O
through O
a O
pneumotachograph O
. O

this O
flow O
was O
measured O
by O
using O
a O
differential O
pressure O
transducer O
, O
passed O
through O
a O
polygraph O
, O
and O
from O
this O
to O
a O
computer O
with O
custom O
software O
that O
derived O
ventilation O
(ve) O
, O
tidal O
volume O
(vt) O
, O
inspiratory O
time O
(ti) O
, O
expiratory O
time O
(te) O
, O
breathing O
frequency O
(f) O
, O
and O
mean O
inspiratory O
flow O
( O
vt/ti O
) O
on O
a O
breath-by-breath O
basis O
. O

results O
: O
the O
hyperventilation B-NEG
maneuver O
caused O
a O
decrease O
in O
spontaneous O
ventilation O
in O
pilocarpine-treated O
and O
control O
rats O
. O

although O
ve O
had O
a O
similar O
decrease O
in O
both O
groups O
, O
in O
the O
epileptic B-NEG
group O
, O
the O
decrease O
in O
ve O
was O
due O
to O
a O
significant O
(p O
< O
0.05 O
) O
increase O
in O
te O
peak O
in O
relation O
to O
that O
of O
the O
control O
animals O
. O

the O
hypoventilation O
maneuver O
led O
to O
an O
increase O
in O
the O
arterial O
paco2 O
, O
followed O
by O
an O
increase O
in O
ve O
. O

in O
the O
epileptic B-NEG
group O
, O
the O
increase O
in O
ve O
was O
mediated O
by O
a O
significant O
(p O
< O
0.05 O
) O
decrease O
in O
te O
peak O
compared O
with O
the O
control O
group O
. O

systemic O
application O
of O
kcn O
, O
to O
evaluate O
the O
effects O
of O
peripheral O
chemoreception O
activation O
on O
ventilation O
, O
led O
to O
a O
similar O
increase O
in O
ve O
for O
both O
groups O
. O

conclusions O
: O
the O
data O
indicate O
that O
pilocarpine-treated O
animals O
have O
an O
altered O
ability O
to O
react O
to O
( O
or O
compensate O
for O
) O
blood O
gas O
changes O
with O
changes O
in O
ventilation O
and O
suggest O
that O
it O
is O
centrally O
determined O
. O

we O
speculate O
on O
the O
possible O
relation O
of O
the O
current O
findings O
on O
treating O
different O
epilepsy B-NEG
-associated O
conditions O
. O

-DOCSTART- O

increased O
serum O
soluble O
fas O
in O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
due O
to O
paracetamol O
overdose B-NEG
. O

background/aims O
: O
experimental O
studies O
have O
suggested O
that O
apoptosis O
via O
the O
fas/fas O
ligand O
signaling O
system O
may O
play O
an O
important O
role O
in O
the O
development O
of O
acute B-NEG
liver I-NEG
failure I-NEG
. O

the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
soluble O
form O
of O
fas O
in O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
. O

methodology O
: O
serum O
levels O
of O
sfas O
( O
soluble O
fas O
) O
were O
measured O
by O
elisa O
in O
24 O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
and O
10 O
normal O
control O
subjects O
. O

serum O
levels O
of O
tumor B-NEG
necrosis B-NEG
factor-alpha O
and O
interferon-gamma O
were O
also O
determined O
by O
elisa O
. O

results O
: O
serum O
sfas O
was O
significantly O
increased O
in O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
(median O
, O
26.8 O
u/ml O
; O
range O
, O
6.9-52.7 O
u/ml O
) O
compared O
to O
the O
normal O
controls O
(median O
, O
8.6 O
u/ml O
; O
range O
, O
6.5-12.0 O
u/ml O
, O
p O
< O
0.0001) O
. O

levels O
were O
significantly O
greater O
in O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
due O
to O
paracetamol O
overdose B-NEG
(median O
, O
28.7 O
u/ml O
; O
range O
, O
12.8-52.7 O
u/ml O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non-a O
to O
e O
hepatitis B-NEG
(median O
, O
12.5 O
u/ml O
; O
range O
, O
6.9-46.0 O
u/ml O
, O
n O
= O
7, O
p O
< O
0.01) O
. O

there O
was O
no O
relationship O
of O
sfas O
to O
eventual O
outcome O
in O
the O
patients O
. O

a O
significant O
correlation O
was O
observed O
between O
serum O
sfas O
levels O
and O
aspartate O
aminotransferase O
(r O
= O
0.613 O
, O
p O
< O
0.01) O
. O

conclusions O
: O
the O
increased O
concentration O
of O
sfas O
in O
serum O
of O
patients O
with O
acute B-NEG
liver I-NEG
failure I-NEG
may O
reflect O
activation O
of O
fas-mediated O
apoptosis O
in O
the O
liver O
and O
this O
together O
with O
increased O
tumor B-NEG
necrosis B-NEG
factor-alpha O
may O
be O
an O
important O
factor O
in O
liver O
cell O
loss O
. O

-DOCSTART- O

bilateral O
subthalamic O
nucleus O
stimulation O
for O
parkinson's B-NEG
disease I-NEG
. O

high O
frequency O
stimulation O
of O
the O
subthalamic O
nucleus O
( O
stn O
) O
is O
known O
to O
ameliorate O
the O
signs O
and O
symptoms O
of O
advanced O
parkinson's B-NEG
disease I-NEG
. O

aim O
: O
we O
studied O
the O
effect O
of O
high O
frequency O
stn O
stimulation O
in O
23 O
patients O
. O

method O
: O
twenty-three O
patients O
suffering O
from O
severe O
parkinson's B-NEG
disease I-NEG
( O
stages O
iii-v O
on O
hoehn O
and O
yahr O
scale O
) O
and O
, O
particularly O
bradykinesia B-NEG
, O
rigidity B-NEG
, O
and O
levodopa-induced O
dyskinesias B-NEG
underwent O
bilateral O
implantation O
of O
electrodes O
in O
the O
stn O
. O

preoperative O
and O
postoperative O
assessments O
of O
these O
patients O
at O
1, O
3, O
6 O
and O
12 O
months O
follow-up O
, O
in O
on O
and O
off O
drug O
conditions O
, O
was O
carried O
out O
using O
unified O
parkinson's B-NEG
disease I-NEG
rating O
scale O
, O
hoehn O
and O
yahr O
staging O
, O
england O
activities O
of O
daily O
living O
score O
and O
video O
recordings O
. O

results O
: O
after O
one O
year O
of O
electrical O
stimulation O
of O
the O
stn O
, O
the O
patients' O
scores O
for O
activities O
of O
daily O
living O
and O
motor O
examination O
scores O
( O
unified O
parkinson's B-NEG
disease I-NEG
rating O
scale O
parts O
ii O
and O
iii O
) O
off O
medication O
improved O
by O
62% O
and O
61% O
respectively O
(p<0.0005) O
. O

the O
subscores O
for O
the O
akinesia B-NEG
, O
rigidity B-NEG
, O
tremor B-NEG
and O
gait O
also O
improved O
. O

(p<0.0005) O
. O

the O
average O
levodopa O
dose O
decreased O
from O
813 O
mg O
to O
359 O
mg O
. O

the O
cognitive O
functions O
remained O
unchanged O
. O

two O
patients O
developed O
device-related O
complications O
and O
two O
patients O
experienced O
abnormal O
weight O
gain O
. O

conclusion O
: O
bilateral O
subthalamic O
nucleus O
stimulation O
is O
an O
effective O
treatment O
for O
advanced O
parkinson's B-NEG
disease I-NEG
. O

it O
reduces O
the O
severity O
of O
off O
phase O
symptoms O
, O
improves O
the O
axial O
symptoms O
and O
reduces O
levodopa O
requirements O
. O

the O
reduction O
in O
the O
levodopa O
dose O
is O
useful O
in O
controlling O
drug-induced B-NEG
dyskinesias I-NEG
. O

-DOCSTART- O

ocular O
motility O
changes O
after O
subtenon O
carboplatin O
chemotherapy O
for O
retinoblastoma B-NEG
. O

background O
: O
focal O
subtenon O
carboplatin O
injections O
have O
recently O
been O
used O
as O
a O
presumably O
toxicity B-NEG
-free O
adjunct O
to O
systemic O
chemotherapy O
for O
intraocular O
retinoblastoma B-NEG
. O

objective O
: O
to O
report O
our O
clinical O
experience O
with O
abnormal B-NEG
ocular I-NEG
motility I-NEG
in O
patients O
treated O
with O
subtenon O
carboplatin O
chemotherapy O
. O

methods O
: O
we O
noted O
abnormal B-NEG
ocular I-NEG
motility I-NEG
in O
10 O
consecutive O
patients O
with O
retinoblastoma B-NEG
who O
had O
received O
subtenon O
carboplatin O
. O

during O
ocular O
manipulation O
under O
general O
anesthesia O
, O
we O
assessed O
their O
eyes O
by O
forced O
duction O
testing O
, O
comparing O
ocular O
motility O
after O
tumor B-NEG
control O
with O
ocular O
motility O
at O
diagnosis O
. O

eyes O
subsequently O
enucleated O
because O
of O
treatment O
failure O
(n O
= O
4) O
were O
examined O
histologically O
. O

results O
: O
limitation O
of O
ocular O
motility O
was O
detected O
in O
all O
12 O
eyes O
of O
10 O
patients O
treated O
for O
intraocular O
retinoblastoma B-NEG
with O
1 O
to O
6 O
injections O
of O
subtenon O
carboplatin O
as O
part O
of O
multimodality O
therapy O
. O

histopathological O
examination O
revealed O
many O
lipophages O
in O
the O
periorbital O
fat O
surrounding O
the O
optic O
nerve O
in O
1 O
eye O
, O
indicative O
of O
phagocytosis O
of O
previously O
existing O
fat O
cells O
and O
suggesting O
prior O
fat O
necrosis B-NEG
. O

the O
enucleations O
were O
technically O
difficult O
and O
hazardous O
for O
globe O
rupture B-NEG
because O
of O
extensive O
orbital O
soft O
tissue O
adhesions O
. O

conclusions O
: O
subtenon O
carboplatin O
chemotherapy O
is O
associated O
with O
significant O
fibrosis B-NEG
of O
orbital O
soft O
tissues O
, O
leading O
to O
mechanical O
restriction O
of O
eye O
movements O
and O
making O
subsequent O
enucleation O
difficult O
. O

subtenon O
carboplatin O
is O
not O
free O
of O
toxicity B-NEG
, O
and O
its O
use O
is O
best O
restricted O
to O
specific O
indications O
. O

-DOCSTART- O

ethambutol O
and O
optic B-NEG
neuropathy I-NEG
. O

purpose O
: O
to O
demonstrate O
the O
association O
between O
ethambutol O
and O
optic B-NEG
neuropathy I-NEG
. O

method O
: O
thirteen O
patients O
who O
developed O
optic B-NEG
neuropathy I-NEG
after O
being O
treated O
with O
ethambutol O
for O
tuberculosis B-NEG
of I-NEG
the I-NEG
lung I-NEG
or I-NEG
lymph I-NEG
node I-NEG
at O
siriraj O
hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

the O
clinical O
characteristics O
and O
initial O
and O
final O
visual O
acuity O
were O
analyzed O
to O
determine O
visual O
outcome O
. O

results O
: O
all O
patients O
had O
optic B-NEG
neuropathy I-NEG
between O
1 O
to O
6 O
months O
( O
mean O
= O
2.9 O
months O
) O
after O
starting O
ethambutol O
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg/kg/day O
( O
mean O
= O
17 O
mg/kg/day) O
. O

seven O
( O
54% O
) O
of O
the O
13 O
patients O
experienced O
visual O
recovery O
after O
stopping O
the O
drug O
. O

of O
6 O
patients O
with O
irreversible O
visual B-NEG
impairment I-NEG
, O
4 O
patients O
had O
diabetes B-NEG
mellitus I-NEG
, O
glaucoma B-NEG
and O
a O
history O
of O
heavy O
smoking O
. O

conclusion O
: O
early O
recognition O
of O
optic B-NEG
neuropathy I-NEG
should O
be O
considered O
in O
patients O
with O
ethambutol O
therapy O
. O

a O
low O
dose O
and O
prompt O
discontinuation O
of O
the O
drug O
is O
recommended O
particularly O
in O
individuals O
with O
diabetes B-NEG
mellitus I-NEG
, O
glaucoma B-NEG
or O
who O
are O
heavy O
smokers O
. O

-DOCSTART- O

treatment O
of O
compensatory O
gustatory B-NEG
hyperhidrosis I-NEG
with O
topical O
glycopyrrolate O
. O
gustatory B-NEG
hyperhidrosis I-NEG
is O
facial O
sweating B-NEG
usually O
associated O
with O
the O
eating O
of O
hot O
spicy O
food O
or O
even O
smelling O
this O
food O
. O

current O
options O
of O
treatment O
include O
oral O
anticholinergic O
drugs O
, O
the O
topical O
application O
of O
anticholinergics O
or O
aluminum O
chloride O
, O
and O
the O
injection O
of O
botulinum O
toxin O
. O

thirteen O
patients O
have O
been O
treated O
to O
date O
with O
1.5% O
or O
2% O
topical O
glycopyrrolate O
. O

all O
patients O
had O
gustatory B-NEG
hyperhidrosis I-NEG
, O
which O
interfered O
with O
their O
social O
activities O
, O
after O
transthroacic O
endoscopic O
sympathectomy O
, O
and O
which O
was O
associated O
with O
compensatory O
focal O
hyperhidrosis B-NEG
. O

after O
applying O
topical O
glycopyrrolate O
, O
the O
subjective O
effect O
was O
excellent O
( O
no O
sweating B-NEG
after O
eating O
hot O
spicy O
food O
) O
in O
10 O
patients O
(77%) O
, O
and O
fair O
( O
clearly O
reduced O
sweating B-NEG
) O
in O
3 O
patients O
(23%) O
. O

all O
had O
reported O
incidents O
of O
being O
very O
embarrassed O
whilst O
eating O
hot O
spicy O
foods O
. O

adverse O
effects O
included O
a O
mildly O
dry B-NEG
mouth I-NEG
and O
a O
sore B-NEG
throat I-NEG
in O
2 O
patients O
( O
2% O
glycopyrrolate) O
, O
a O
light O
headache B-NEG
in O
1 O
patient O
( O
1.5% O
glycopyrrolate) O
. O

the O
topical O
application O
of O
a O
glycopyrrolate O
pad O
appeared O
to O
be O
safe O
, O
efficacious O
, O
well O
tolerated O
, O
and O
a O
convenient O
method O
of O
treatment O
for O
moderate O
to O
severe O
symptoms O
of O
gustatory B-NEG
hyperhidrosis I-NEG
in O
post O
transthoracic O
endoscopic O
sympathectomy O
or O
sympathicotomy O
patients O
, O
with O
few O
side O
effects O
. O

-DOCSTART- O

pharmacological O
characteristics O
and O
side O
effects O
of O
a O
new O
galenic O
formulation O
of O
propofol O
without O
soyabean O
oil O
. O

we O
compared O
the O
pharmacokinetics O
, O
pharmacodynamics O
and O
safety O
profile O
of O
a O
new O
galenic O
formulation O
of O
propofol O
( O
am149 O
1%) O
, O
which O
does O
not O
contain O
soyabean O
oil O
, O
with O
a O
standard O
formulation O
of O
propofol O
( O
disoprivan O
1%) O
. O

in O
a O
randomised O
, O
double-blind O
, O
cross-over O
study O
, O
30 O
healthy O
volunteers O
received O
a O
single O
intravenous O
bolus O
injection O
of O
2.5 O
mg.kg-1 O
propofol O
. O

plasma O
propofol O
levels O
were O
measured O
for O
48 O
h O
following O
drug O
administration O
and O
evaluated O
according O
to O
a O
three-compartment O
model O
. O

the O
pharmacodynamic O
parameters O
assessed O
included O
induction O
and O
emergence O
times O
, O
respiratory O
and O
cardiovascular O
effects O
, O
and O
pain B-NEG
on O
injection O
. O

patients O
were O
monitored O
for O
side O
effects O
over O
48 O
h. O

owing O
to O
a O
high O
incidence O
of O
thrombophlebitis B-NEG
, O
the O
study O
was O
terminated O
prematurely O
and O
only O
the O
data O
of O
the O
two O
parallel O
treatment O
groups O
( O
15 O
patients O
in O
each O
group O
) O
were O
analysed O
. O

plasma O
concentrations O
did O
not O
differ O
significantly O
between O
the O
two O
formulations O
. O

anaesthesia O
induction O
and O
emergence O
times O
, O
respiratory O
and O
cardiovascular O
variables O
showed O
no O
significant O
differences O
between O
the O
two O
treatment O
groups O
. O
pain B-NEG
on O
injection O
( O
80 O
vs O
. O
20% O
, O
p O
< O
0.01 O
) O
and O
thrombophlebitis B-NEG
( O
93.3 O
vs O
. O
6.6% O
, O
p O
< O
0.001 O
) O
occurred O
more O
frequently O
with O
am149 O
than O
with O
disoprivan O
. O

although O
both O
formulations O
had O
similar O
pharmacokinetic O
and O
pharmacodynamic O
profiles O
the O
new O
formulation O
is O
not O
suitable O
for O
clinical O
use O
due O
to O
the O
high O
incidence O
of O
thrombophlebitis B-NEG
produced O
. O

-DOCSTART- O

vinorelbine-related O
cardiac O
events O
: O
a O
meta-analysis O
of O
randomized O
clinical O
trials O
. O

several O
cases O
of O
cardiac O
adverse O
reactions O
related O
to O
vinorelbine O
( O
vnr O
) O
have O
been O
reported O
in O
the O
literature O
. O

in O
order O
to O
quantify O
the O
incidence O
of O
these O
cardiac O
events O
, O
we O
performed O
a O
meta-analysis O
of O
clinical O
trials O
comparing O
vnr O
with O
other O
chemotherapeutic O
agents O
in O
the O
treatment O
of O
various O
malignancies B-NEG
. O

randomized O
clinical O
trials O
comparing O
vnr O
with O
other O
drugs O
in O
the O
treatment O
of O
cancer B-NEG
were O
searched O
in O
medline O
, O
embase O
, O
evidence-based O
medicine O
reviews O
databases O
and O
the O
cochrane O
library O
from O
1987 O
to O
2002 O
. O

outcomes O
of O
interest O
were O
severe O
cardiac O
events O
, O
toxic O
deaths O
and O
cardiac O
event-related O
deaths O
reported O
in O
each O
publication O
. O

we O
found O
19 O
trials O
, O
involving O
2441 O
patients O
treated O
by O
vnr O
and O
2050 O
control O
patients O
. O

the O
incidence O
of O
cardiac O
events O
with O
vnr O
was O
1.19% O
[95% O
confidence O
interval O
( O
ci O
) O
(0.75 O
; O
1.67)] O
. O

there O
was O
no O
difference O
in O
the O
risk O
of O
cardiac O
events O
between O
vnr O
and O
other O
drugs O
[odds O
ratio O
: O
0.92 O
, O
95% O
ci O
(0.54 O
; O
1.55)] O
. O

the O
risk O
of O
vnr O
cardiac O
events O
was O
similar O
to O
vindesine O
( O
vds O
) O
and O
other O
cardiotoxic B-NEG
drugs O
[fluorouracil O
, O
anthracyclines O
, O
gemcitabine O
( O
gem O
) O
em O
leader O
]. O

even O
if O
it O
did O
not O
reach O
statistical O
significance O
because O
of O
a O
few O
number O
of O
cases O
, O
the O
risk O
was O
lower O
in O
trials O
excluding O
patients O
with O
cardiac O
history O
, O
and O
seemed O
to O
be O
higher O
in O
trials O
including O
patients O
with O
pre-existing O
cardiac B-NEG
diseases I-NEG
. O

vinorelbine-related O
cardiac O
events O
concern O
about O
1% O
of O
treated O
patients O
in O
clinical O
trials O
. O

however O
, O
the O
risk O
associated O
with O
vnr O
seems O
to O
be O
similar O
to O
that O
of O
other O
chemotherapeutic O
agents O
in O
the O
same O
indications O
. O

-DOCSTART- O

mri O
findings O
of O
hypoxic O
cortical O
laminar O
necrosis B-NEG
in O
a O
child O
with O
hemolytic B-NEG
anemia I-NEG
crisis O
. O

we O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5-year-old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic B-NEG
anemia I-NEG
crisis O
induced O
by O
trimethoprim-sulfomethoxazole O
, O
resulting O
in O
cerebral B-NEG
anoxia I-NEG
leading O
to O
permanent O
damage O
. O

magnetic O
resonance O
imaging O
revealed O
cortical O
laminar O
necrosis B-NEG
in O
arterial O
border O
zones O
in O
both O
cerebral O
hemispheres O
, O
ischemic O
changes O
in O
subcortical O
white O
matter O
of O
left O
cerebral O
hemisphere O
, O
and O
in O
the O
left O
putamen O
. O

although O
cortical O
laminar O
necrosis B-NEG
is O
a O
classic O
entity O
in O
adulthood O
related O
to O
conditions O
of O
energy O
depletions O
, O
there O
are O
few O
reports O
available O
in O
children O
. O

a O
wide O
review O
of O
the O
literature O
is O
also O
presented O
. O

-DOCSTART- O

the O
natural O
history O
of O
vigabatrin O
associated O
visual B-NEG
field I-NEG
defects I-NEG
in O
patients O
electing O
to O
continue O
their O
medication O
. O

purpose O
: O
to O
determine O
the O
natural O
history O
of O
visual B-NEG
field I-NEG
defects I-NEG
in O
a O
group O
of O
patients O
known O
to O
have O
vigabatrin-associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure B-NEG
control O
. O

methods O
: O
all O
patients O
taking O
vigabatrin O
alone O
or O
in O
combination O
with O
other O
antiepileptic O
drugs O
for O
at O
least O
5 O
years O
( O
range O
5-12 O
years O
) O
were O
entered O
into O
a O
visual O
surveillance O
programme O
. O

patients O
were O
followed O
up O
at O
6-monthly O
intervals O
for O
not O
less O
than O
18 O
months O
( O
range O
18-43 O
months) O
. O

in O
all O
, O
16 O
patients O
with O
unequivocal O
defects O
continued O
the O
medication O
. O

following O
already O
published O
methodology O
( O
eye O
2002 O
; O
16;567-571 O
) O
monocular O
mean O
radial O
degrees O
( O
mrds O
) O
to O
the O
i/4e O
isopter O
on O
goldmann O
perimetry O
was O
calculated O
for O
the O
right O
eye O
at O
the O
time O
of O
discovery O
of O
a O
visual B-NEG
field I-NEG
defect I-NEG
and O
again O
after O
not O
less O
than O
18 O
months O
follow-up O
. O

results O
: O
mean O
right O
eye O
mrd O
at O
presentation O
was O
36.98 O
degrees O
( O
range O
22.25-51.0) O
, O
compared O
to O
38.40 O
degrees O
( O
range O
22.5-49.75 O
) O
after O
follow-up O
; O
p=0.338 O
unpaired O
t-test O
. O

only O
one O
patient O
demonstrated O
a O
deterioration B-NEG
in I-NEG
visual I-NEG
field I-NEG
during O
the O
study O
period O
and O
discontinued O
treatment O
. O

conclusion O
: O
established O
visual B-NEG
field I-NEG
defects I-NEG
presumed O
to O
be O
due O
to O
vigabatrin O
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

these O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
vigabatrin-associated O
visual B-NEG
field I-NEG
defects I-NEG
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose-dependent O
toxicity B-NEG
. O

-DOCSTART- O

induction O
of O
rosaceiform O
dermatitis B-NEG
during O
treatment O
of O
facial B-NEG
inflammatory I-NEG
dermatoses I-NEG
with O
tacrolimus O
ointment O
. O

background O
: O
tacrolimus O
ointment O
is O
increasingly O
used O
for O
anti-inflammatory O
treatment O
of O
sensitive O
areas O
such O
as O
the O
face O
, O
and O
recent O
observations O
indicate O
that O
the O
treatment O
is O
effective O
in O
steroid-aggravated O
rosacea B-NEG
and O
perioral B-NEG
dermatitis I-NEG
. O

we O
report O
on O
rosaceiform O
dermatitis B-NEG
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
. O

observations O
: O
six O
adult O
patients O
with O
inflammatory B-NEG
facial I-NEG
dermatoses I-NEG
were O
treated O
with O
tacrolimus O
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

within O
2 O
to O
3 O
weeks O
of O
initially O
effective O
and O
well-tolerated O
treatment O
, O
3 O
patients O
with O
a O
history O
of O
rosacea B-NEG
and O
1 O
with O
a O
history O
of O
acne B-NEG
experienced O
sudden O
worsening O
with O
pustular O
rosaceiform O
lesions O
. O

biopsy O
revealed O
an O
abundance O
of O
demodex O
mites O
in O
2 O
of O
these O
patients O
. O

in O
1 O
patient O
with O
eyelid O
eczema B-NEG
, O
rosaceiform O
periocular B-NEG
dermatitis I-NEG
gradually O
appeared O
after O
3 O
weeks O
of O
treatment O
. O

in O
1 O
patient O
with O
atopic B-NEG
dermatitis I-NEG
, O
telangiectatic O
and O
papular B-NEG
rosacea I-NEG
insidiously O
appeared O
after O
5 O
months O
of O
treatment O
. O

conclusions O
: O
our O
observations O
suggest O
that O
the O
spectrum O
of O
rosaceiform O
dermatitis B-NEG
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
is O
heterogeneous O
. O

a O
variety O
of O
factors O
, O
such O
as O
vasoactive O
properties O
of O
tacrolimus O
, O
proliferation O
of O
demodex O
due O
to O
local O
immunosuppression O
, O
and O
the O
occlusive O
properties O
of O
the O
ointment O
, O
may O
be O
involved O
in O
the O
observed O
phenomena O
. O

future O
studies O
are O
needed O
to O
identify O
individual O
risk O
factors O
. O

-DOCSTART- O

structural O
abnormalities O
in O
the O
brains O
of O
human O
subjects O
who O
use O
methamphetamine O
. O

we O
visualize O
, O
for O
the O
first O
time O
, O
the O
profile O
of O
structural B-NEG
deficits I-NEG
in I-NEG
the I-NEG
human I-NEG
brain I-NEG
associated O
with O
chronic O
methamphetamine O
( O
ma O
) O
abuse O
. O

studies O
of O
human O
subjects O
who O
have O
used O
ma O
chronically O
have O
revealed O
deficits O
in O
dopaminergic O
and O
serotonergic O
systems O
and O
cerebral O
metabolic B-NEG
abnormalities I-NEG
. O

using O
magnetic O
resonance O
imaging O
( O
mri O
) O
and O
new O
computational O
brain-mapping O
techniques O
, O
we O
determined O
the O
pattern O
of O
structural O
brain O
alterations O
associated O
with O
chronic O
ma O
abuse O
in O
human O
subjects O
and O
related O
these O
deficits O
to O
cognitive B-NEG
impairment I-NEG
. O

we O
used O
high-resolution O
mri O
and O
surface-based O
computational O
image O
analyses O
to O
map O
regional O
abnormalities B-NEG
in I-NEG
the I-NEG
cortex I-NEG
, O
hippocampus I-NEG
, O
white I-NEG
matter I-NEG
, O
and I-NEG
ventricles I-NEG
in O
22 O
human O
subjects O
who O
used O
ma O
and O
21 O
age-matched O
, O
healthy O
controls O
. O

cortical O
maps O
revealed O
severe O
gray-matter O
deficits O
in O
the O
cingulate O
, O
limbic O
, O
and O
paralimbic O
cortices O
of O
ma O
abusers O
( O
averaging O
11.3% O
below O
control O
; O
p O
< O
0.05) O
. O

on O
average O
, O
ma O
abusers O
had O
7.8% O
smaller O
hippocampal O
volumes O
than O
control O
subjects O
(p O
< O
0.01 O
; O
left O
, O
p O
= O
0.01 O
; O
right O
, O
p O
< O
0.05 O
) O
and O
significant O
white-matter O
hypertrophy B-NEG
(7.0% O
; O
p O
< O
0.01) O
. O

hippocampal O
deficits O
were O
mapped O
and O
correlated O
with O
memory O
performance O
on O
a O
word-recall O
test O
(p O
< O
0.05) O
. O

mri-based O
maps O
suggest O
that O
chronic O
methamphetamine O
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired B-NEG
memory I-NEG
performance I-NEG
. O

ma O
may O
selectively O
damage O
the O
medial O
temporal O
lobe O
and O
, O
consistent O
with O
metabolic O
studies O
, O
the O
cingulate-limbic O
cortex O
, O
inducing O
neuroadaptation O
, O
neuropil O
reduction O
, O
or O
cell O
death O
. O

prominent O
white-matter O
hypertrophy B-NEG
may O
result O
from O
altered O
myelination O
and O
adaptive O
glial O
changes O
, O
including O
gliosis B-NEG
secondary O
to O
neuronal B-NEG
damage I-NEG
. O

these O
brain O
substrates O
may O
help O
account O
for O
the O
symptoms O
of O
ma O
abuse O
, O
providing O
therapeutic O
targets O
for O
drug-induced O
brain B-NEG
injury I-NEG
. O

-DOCSTART- O

disruption O
of O
hepatic O
lipid O
homeostasis O
in O
mice O
after O
amiodarone O
treatment O
is O
associated O
with O
peroxisome O
proliferator-activated O
receptor-alpha O
target O
gene O
activation O
. O

amiodarone O
, O
an O
efficacious O
and O
widely O
used O
antiarrhythmic O
agent O
, O
has O
been O
reported O
to O
cause O
hepatotoxicity B-NEG
in O
some O
patients O
. O

to O
gain O
insight O
into O
the O
mechanism O
of O
this O
unwanted O
effect O
, O
mice O
were O
administered O
various O
doses O
of O
amiodarone O
and O
examined O
for O
changes O
in O
hepatic O
histology O
and O
gene O
regulation O
. O

amiodarone O
induced O
hepatomegaly B-NEG
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides O
and O
glucose O
. O

northern O
blot O
analysis O
of O
hepatic O
rna O
revealed O
a O
dose-dependent O
increase O
in O
the O
expression O
of O
a O
number O
of O
genes O
critical O
for O
fatty O
acid O
oxidation O
, O
lipoprotein O
assembly O
, O
and O
lipid O
transport O
. O

many O
of O
these O
genes O
are O
regulated O
by O
the O
peroxisome O
proliferator-activated O
receptor-alpha O
(pparalpha) O
, O
a O
ligand-activated O
nuclear O
hormone O
receptor O
transcription O
factor O
. O

the O
absence O
of O
induction O
of O
these O
genes O
as O
well O
as O
hepatomegaly B-NEG
in O
pparalpha O
knockout O
[pparalpha-/-] O
mice O
indicated O
that O
the O
effects O
of O
amiodarone O
were O
dependent O
upon O
the O
presence O
of O
a O
functional O
pparalpha O
gene O
. O

compared O
to O
wild-type O
mice O
, O
treatment O
of O
pparalpha-/- O
mice O
with O
amiodarone O
resulted O
in O
an O
increased O
rate O
and O
extent O
of O
total O
body O
weight B-NEG
loss I-NEG
. O

the O
inability O
of O
amiodarone O
to O
directly O
activate O
either O
human O
or O
mouse O
pparalpha O
transiently O
expressed O
in O
human O
hepg2 O
hepatoma B-NEG
cells O
indicates O
that O
the O
effects O
of O
amiodarone O
on O
the O
function O
of O
this O
receptor O
were O
indirect O
. O

based O
upon O
these O
results O
, O
we O
conclude O
that O
amiodarone O
disrupts O
hepatic O
lipid O
homeostasis O
and O
that O
the O
increased O
expression O
of O
pparalpha O
target O
genes O
is O
secondary O
to O
this O
toxic O
effect O
. O

these O
results O
provide O
important O
new O
mechanistic O
information O
regarding O
the O
hepatotoxic B-NEG
effects O
of O
amiodarone O
and O
indicate O
that O
pparalpha O
protects O
against O
amiodarone-induced O
hepatotoxicity B-NEG
. O

-DOCSTART- O

safety O
and O
compliance O
with O
once-daily O
niacin O
extended-release/lovastatin O
as O
initial O
therapy O
in O
the O
impact O
of O
medical O
subspecialty O
on O
patient O
compliance O
to O
treatment O
( O
impact O
) O
study O
. O

niacin O
extended-release/lovastatin O
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia B-NEG
and O
mixed O
dyslipidemia B-NEG
. O

this O
open-labeled O
, O
multicenter O
study O
evaluated O
the O
safety O
of O
bedtime O
niacin O
extended-release/lovastatin O
when O
dosed O
as O
initial O
therapy O
and O
patient O
compliance O
to O
treatment O
in O
various O
clinical O
practice O
settings O
. O

a O
total O
of O
4,499 O
patients O
with O
dyslipidemia B-NEG
requiring O
drug O
intervention O
was O
enrolled O
at O
1,081 O
sites O
. O

patients O
were O
treated O
with O
1 O
tablet O
( O
500 O
mg O
of O
niacin O
extended-release/20 O
mg O
of O
lovastatin O
) O
once O
nightly O
for O
4 O
weeks O
and O
then O
2 O
tablets O
for O
8 O
weeks O
. O

patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll-free O
number O
that O
provided O
further O
education O
about O
dyslipidemia B-NEG
and O
niacin O
extended-release/lovastatin O
. O

primary O
end O
points O
were O
study O
compliance O
, O
increases O
in O
liver O
transaminases O
to O
>3 O
times O
the O
upper O
limit O
of O
normal O
, O
and O
clinical O
myopathy B-NEG
. O

final O
study O
status O
was O
available O
for O
4,217 O
patients O
(94%) O
. O

compliance O
to O
niacin O
extended-release/lovastatin O
was O
77% O
, O
with O
3,245 O
patients O
completing O
the O
study O
. O

patients O
in O
the O
southeast O
and O
those O
enrolled O
by O
endocrinologists O
had O
the O
lowest O
compliance O
and O
highest O
adverse O
event O
rates O
. O
flushing B-NEG
was O
the O
most O
common O
adverse O
event O
, O
reported O
by O
18% O
of O
patients O
and O
leading O
to O
discontinuation O
by O
6% O
. O

incidence O
of O
increased O
aspartate O
aminotransferase O
and/or O
alanine O
aminotransferase O
>3 O
times O
the O
upper O
limit O
of O
normal O
was O
<0.3% O
. O

an O
increase O
of O
creatine O
phosphokinase O
to O
>5 O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0.24% O
of O
patients O
, O
and O
no O
cases O
of O
drug-induced O
myopathy B-NEG
were O
observed O
. O

niacin O
extended-release/lovastatin O
1,000/40 O
mg O
, O
dosed O
as O
initial O
therapy O
, O
was O
associated O
with O
good O
compliance O
and O
safety O
and O
had O
very O
low O
incidences O
of O
increased O
liver O
and O
muscle O
enzymes O
. O

-DOCSTART- O

protective O
effect O
of O
terminalia O
chebula O
against O
experimental O
myocardial B-NEG
injury I-NEG
induced O
by O
isoproterenol O
. O

cardioprotective O
effect O
of O
ethanolic O
extract O
of O
terminalia O
chebula O
fruits O
( O
500 O
mg/kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol O
( O
200 O
mg/kg O
body O
wt O
) O
induced O
myocardial B-NEG
damage I-NEG
in O
rats O
. O

in O
isoproterenol O
administered O
rats O
, O
the O
level O
of O
lipid O
peroxides O
increased O
significantly O
in O
the O
serum O
and O
heart O
. O

a O
significant O
decrease O
was O
observed O
in O
the O
activity O
of O
the O
myocardial O
marker O
enzymes O
with O
a O
concomitant O
increase O
in O
their O
activity O
in O
serum O
. O

histopathological O
examination O
was O
carried O
out O
to O
confirm O
the O
myocardial O
necrosis B-NEG
. O

t. O
chebula O
extract O
pretreatment O
was O
found O
to O
ameliorate O
the O
effect O
of O
isoproterenol O
on O
lipid O
peroxide O
formation O
and O
retained O
the O
activities O
of O
the O
diagnostic O
marker O
enzymes O
. O

-DOCSTART- O

a O
case O
of O
postoperative O
anxiety B-NEG
due O
to O
low O
dose O
droperidol O
used O
with O
patient-controlled O
analgesia O
. O

a O
multiparous O
woman O
in O
good O
psychological O
health O
underwent O
urgent O
caesarean O
section O
in O
labour O
. O

postoperatively O
, O
she O
was O
given O
a O
patient-controlled O
analgesia O
device O
delivering O
boluses O
of O
diamorphine O
0.5 O
mg O
and O
droperidol O
0.025 O
mg O
. O

whilst O
using O
the O
device O
she O
gradually O
became O
anxious O
, O
the O
feeling O
worsening O
after O
each O
bolus O
. O

the O
diagnosis O
of O
droperidol-induced O
psychological B-NEG
disturbance I-NEG
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

after O
she O
had O
received O
a O
total O
of O
only O
0.9 O
mg O
droperidol O
, O
a O
syringe O
containing O
diamorphine O
only O
was O
substituted O
and O
her O
unease O
resolved O
completely O
. O

we O
feel O
that O
, O
although O
the O
dramatic O
extrapyramidal O
side O
effects O
of O
dopaminergic O
antiemetics O
are O
well O
known O
, O
more O
subtle O
manifestations O
may O
easily O
be O
overlooked O
. O

-DOCSTART- O

accurate O
patient O
history O
contributes O
to O
differentiating O
diabetes B-NEG
insipidus I-NEG
: O
a O
case O
study O
. O

this O
case O
study O
highlights O
the O
important O
contribution O
of O
nursing O
in O
obtaining O
an O
accurate O
health O
history O
. O

the O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B-NEG
diabetes I-NEG
insipidus I-NEG
( O
di B-NEG
) O
secondary O
to O
a O
traumatic B-NEG
brain I-NEG
injury I-NEG
. O

the O
nursing O
staff O
, O
by O
reviewing O
the O
patient's O
health O
history O
with O
his O
family O
, O
discovered O
a O
history O
of O
polydipsia B-NEG
and O
long-standing O
lithium O
use O
. O

lithium O
is O
implicated O
in O
drug-induced O
nephrogenic B-NEG
di I-NEG
, O
and O
because O
the O
patient O
had O
not O
received O
lithium O
since O
being O
admitted O
to O
the O
hospital O
, O
his O
treatment O
changed O
to O
focus O
on O
nephrogenic B-NEG
di I-NEG
. O

by O
combining O
information O
from O
the O
patient O
history O
, O
the O
physical O
examination O
, O
and O
radiologic O
and O
laboratory O
studies O
, O
the O
critical O
care O
team O
demonstrated O
that O
the O
patient O
had O
been O
self-treating O
his O
lithium-induced O
nephrogenic B-NEG
di I-NEG
and O
developed O
neurogenic B-NEG
di I-NEG
secondary O
to O
brain B-NEG
trauma I-NEG
. O

thus O
successful O
treatment O
required O
that O
nephrogenic O
and O
neurogenic B-NEG
di I-NEG
be O
treated O
concomitantly O
. O

-DOCSTART- O

factors O
contributing O
to O
ribavirin-induced O
anemia B-NEG
. O

background O
and O
aim O
: O
interferon O
and O
ribavirin O
combination O
therapy O
for O
chronic B-NEG
hepatitis I-NEG
c I-NEG
produces O
hemolytic B-NEG
anemia I-NEG
. O

this O
study O
was O
conducted O
to O
identify O
the O
factors O
contributing O
to O
ribavirin-induced O
anemia B-NEG
. O

methods O
: O
eighty-eight O
patients O
with O
chronic B-NEG
hepatitis I-NEG
c I-NEG
who O
received O
interferon-alpha-2b O
at O
a O
dose O
of O
6 O
mu O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

a O
hemoglobin O
concentration O
of O
<10 O
g/dl O
was O
defined O
as O
ribavirin-induced O
anemia B-NEG
. O

results O
: O
ribavirin-induced O
anemia B-NEG
occurred O
in O
18 O
( O
20.5% O
) O
patients O
during O
treatment O
. O

a O
2 O
g/dl O
decrease O
in O
hemoglobin O
concentrations O
in O
patients O
with O
anemia B-NEG
was O
observed O
at O
week O
2 O
after O
the O
start O
of O
treatment O
. O

the O
hemoglobin O
concentration O
in O
patients O
with O
> O
or O
=2 O
g/dl O
decrease O
at O
week O
2 O
was O
observed O
to O
be O
significantly O
lower O
even O
after O
week O
2 O
than O
in O
patients O
with O
<2 O
g/dl O
decrease O
(p O
< O
0.01) O
. O

a O
significant O
relationship O
was O
observed O
between O
the O
rate O
of O
reduction O
of O
hemoglobin O
concentrations O
at O
week O
2 O
and O
the O
severity O
of O
anemia B-NEG
(p O
< O
0.01) O
. O

such O
factors O
as O
sex O
(female) O
, O
age O
(> O
or O
=60 O
years O
old) O
, O
and O
the O
ribavirin O
dose O
by O
body O
weight O
( O
12 O
mg/kg O
or O
more O
) O
were O
significant O
by O
univariate O
analysis O
. O

conclusions O
: O
careful O
administration O
is O
necessary O
in O
patients O
> O
or O
=60 O
years O
old O
, O
in O
female O
patients O
, O
and O
in O
patients O
receiving O
a O
ribavirin O
dose O
of O
12 O
mg/kg O
or O
more O
. O

patients O
who O
experience O
a O
fall O
in O
hemoglobin O
concentrations O
of O
2 O
g/dl O
or O
more O
at O
week O
2 O
after O
the O
start O
of O
treatment O
should O
be O
monitored O
with O
particular O
care O
. O

-DOCSTART- O

oxidative O
damage O
precedes O
nitrative O
damage O
in O
adriamycin-induced O
cardiac O
mitochondrial B-NEG
injury I-NEG
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
elevated O
reactive O
oxygen O
( O
ros)/nitrogen O
species O
( O
rns O
) O
reported O
to O
be O
present O
in O
adriamycin O
( O
adr)-induced O
cardiotoxicity B-NEG
actually O
resulted O
in O
cardiomyocyte O
oxidative/nitrative O
damage O
, O
and O
to O
quantitatively O
determine O
the O
time O
course O
and O
subcellular O
localization O
of O
these O
postulated O
damage O
products O
using O
an O
in O
vivo O
approach O
. O

b6c3 O
mice O
were O
treated O
with O
a O
single O
dose O
of O
20 O
mg/kg O
adr O
. O

ultrastructural O
damage O
and O
levels O
of O
4-hydroxy-2-nonenal O
( O
4hne)-protein O
adducts O
and O
3-nitrotyrosine O
( O
3nt O
) O
were O
analyzed O
. O

quantitative O
ultrastructural O
damage O
using O
computerized O
image O
techniques O
showed O
cardiomyocyte O
injury O
as O
early O
as O
3 O
hours O
, O
with O
mitochondria O
being O
the O
most O
extensively O
and O
progressively O
injured O
subcellular O
organelle O
. O

analysis O
of O
4hne O
protein O
adducts O
by O
immunogold O
electron O
microscopy O
showed O
appearance O
of O
4hne O
protein O
adducts O
in O
mitochondria O
as O
early O
as O
3 O
hours O
, O
with O
a O
peak O
at O
6 O
hours O
and O
subsequent O
decline O
at O
24 O
hours O
. O

3nt O
levels O
were O
significantly O
increased O
in O
all O
subcellular O
compartments O
at O
6 O
hours O
and O
subsequently O
declined O
at O
24 O
hours O
. O

our O
data O
showed O
adr O
induced O
4hne-protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial B-NEG
injury I-NEG
initially O
appeared O
. O

these O
results O
document O
for O
the O
first O
time O
in O
vivo O
that O
mitochondrial B-NEG
oxidative I-NEG
damage I-NEG
precedes O
nitrative O
damage O
. O

the O
progressive O
nature O
of O
mitochondrial B-NEG
injury I-NEG
suggests O
that O
mitochondria O
, O
not O
other O
subcellular O
organelles O
, O
are O
the O
major O
site O
of O
intracellular O
injury O
. O

-DOCSTART- O

sotalol-induced O
coronary B-NEG
spasm I-NEG
in O
a O
patient O
with O
dilated B-NEG
cardiomyopathy I-NEG
associated O
with O
sustained O
ventricular B-NEG
tachycardia I-NEG
. O

a O
54-year-old O
man O
with O
severe O
left O
ventricular B-NEG
dysfunction I-NEG
due O
to O
dilated B-NEG
cardiomyopathy I-NEG
was O
referred O
to O
our O
hospital O
for O
symptomatic O
incessant O
sustained O
ventricular B-NEG
tachycardia I-NEG
( O
vt B-NEG
). O

after O
the O
administration O
of O
nifekalant O
hydrochloride O
, O
sustained O
vt B-NEG
was O
terminated O
. O

an O
alternate O
class O
iii O
agent O
, O
sotalol O
, O
was O
also O
effective O
for O
the O
prevention O
of O
vt B-NEG
. O

however O
, O
one O
month O
after O
switching O
over O
nifekalant O
to O
sotalol O
, O
a O
short O
duration O
of O
st O
elevation O
was O
documented O
in O
ecg O
monitoring O
at O
almost O
the O
same O
time O
for O
three O
consecutive O
days O
. O

st O
elevation O
with O
chest O
discomfort O
disappeared O
since O
he O
began O
taking O
long-acting O
diltiazem O
. O
coronary B-NEG
vasospasm I-NEG
may O
be O
induced O
by O
the O
non-selective O
beta-blocking O
properties O
of O
sotalol O
. O

-DOCSTART- O

effects O
of O
the O
antidepressant O
trazodone O
, O
a O
5-ht O
2a/2c O
receptor O
antagonist O
, O
on O
dopamine-dependent O
behaviors O
in O
rats O
. O

rationale O
: O
5-hydroxytryptamine O
, O
via O
stimulation O
of O
5-ht O
2c O
receptors O
, O
exerts O
a O
tonic O
inhibitory O
influence O
on O
dopaminergic O
neurotransmission O
, O
whereas O
activation O
of O
5-ht O
2a O
receptors O
enhances O
stimulated O
daergic O
neurotransmission O
. O

the O
antidepressant O
trazodone O
is O
a O
5-ht O
2a/2c O
receptor O
antagonist O
. O

objectives O
: O
to O
evaluate O
the O
effect O
of O
trazodone O
treatment O
on O
behaviors O
dependent O
on O
the O
functional O
status O
of O
the O
nigrostriatal O
daergic O
system O
. O

methods O
: O
the O
effect O
of O
pretreatment O
with O
trazodone O
on O
dexamphetamine- O
and O
apomorphine-induced O
oral B-NEG
stereotypies I-NEG
, O
on O
catalepsy B-NEG
induced O
by O
haloperidol O
and O
apomorphine O
( O
0.05 O
mg/kg O
, O
i.p.) O
, O
on O
ergometrine-induced O
wet O
dog O
shake O
( O
wds O
) O
behavior O
and O
fluoxetine-induced O
penile O
erections O
was O
studied O
in O
rats O
. O

we O
also O
investigated O
whether O
trazodone O
induces O
catalepsy B-NEG
in O
rats O
. O

results O
: O
trazodone O
at O
2.5-20 O
mg/kg O
i.p O
. O
did O
not O
induce O
catalepsy B-NEG
, O
and O
did O
not O
antagonize O
apomorphine O
( O
1.5 O
and O
3 O
mg/kg O
) O
stereotypy O
and O
apomorphine O
( O
0.05 O
mg/kg)-induced O
catalepsy B-NEG
. O

however O
, O
pretreatment O
with O
5, O
10 O
and O
20 O
mg/kg O
i.p O
. O
trazodone O
enhanced O
dexamphetamine O
stereotypy O
, O
and O
antagonized O
haloperidol O
catalepsy B-NEG
, O
ergometrine-induced O
wds O
behavior O
and O
fluoxetine-induced O
penile O
erections O
. O

trazodone O
at O
30 O
, O
40 O
and O
50 O
mg/kg O
i.p O
. O
induced O
catalepsy B-NEG
and O
antagonized O
apomorphine O
and O
dexamphetamine O
stereotypies O
. O

conclusions O
: O
our O
results O
indicate O
that O
trazodone O
at O
2.5-20 O
mg/kg O
does O
not O
block O
pre- O
and O
postsynaptic O
striatal O
d2 O
da O
receptors O
, O
while O
at O
30 O
, O
40 O
and O
50 O
mg/kg O
it O
blocks O
postsynaptic O
striatal O
d2 O
da O
receptors O
. O

furthermore O
, O
at O
5, O
10 O
and O
20 O
mg/kg O
, O
trazodone O
blocks O
5-ht O
2a O
and O
5-ht O
2c O
receptors O
. O

we O
suggest O
that O
trazodone O
(5 O
, O
10 O
and O
20 O
mg/kg) O
, O
by O
blocking O
the O
5-ht O
2c O
receptors O
, O
releases O
the O
nigrostriatal O
daergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5-ht O
, O
and O
thereby O
potentiates O
dexamphetamine O
stereotypy O
and O
antagonizes O
haloperidol O
catalepsy B-NEG
. O

-DOCSTART- O

swallowing B-NEG
abnormalities I-NEG
and O
dyskinesia B-NEG
in O
parkinson's B-NEG
disease I-NEG
. O
gastrointestinal B-NEG
abnormalities I-NEG
in O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
have O
been O
known O
for O
almost O
two O
centuries O
, O
but O
many O
aspects O
concerning O
their O
pathophysiology O
have O
not O
been O
completely O
clarified O
. O

the O
aim O
of O
this O
study O
was O
to O
characterize O
the O
oropharyngeal O
dynamics O
in O
pd B-NEG
patients O
with O
and O
without O
levodopa-induced O
dyskinesia B-NEG
. O

fifteen O
dyskinetic B-NEG
, O
12 O
nondyskinetic O
patients O
, O
and O
a O
control O
group O
were O
included O
. O

patients O
were O
asked O
about O
dysphagia B-NEG
and O
evaluated O
with O
the O
unified O
parkinson's B-NEG
disease I-NEG
rating O
scale O
parts O
ii O
and O
iii O
and O
the O
hoehn O
and O
yahr O
scale O
. O

deglutition O
was O
assessed O
using O
modified O
barium O
swallow O
with O
videofluoroscopy O
. O

nondyskinetic O
patients O
, O
but O
not O
the O
dyskinetic B-NEG
ones O
, O
showed O
less O
oropharyngeal O
swallowing O
efficiency O
( O
opse O
) O
for O
liquid O
food O
than O
controls O
(dunnett O
, O
p O
= O
0.02) O
. O
dyskinetic B-NEG
patients O
tended O
to O
have O
a O
greater O
opse O
than O
nondyskinetic O
(dunnett O
, O
p O
= O
0.06) O
. O

patients O
who O
were O
using O
a O
higher O
dose O
of O
levodopa O
had O
a O
greater O
opse O
and O
a O
trend O
toward O
a O
smaller O
oral O
transit O
time O
( O
pearson's O
correlation O
, O
p O
= O
0.01 O
and O
0.08 O
, O
respectively) O
. O

neither O
the O
report O
of O
dysphagia B-NEG
nor O
any O
of O
the O
pd B-NEG
severity O
parameters O
correlated O
to O
the O
videofluoroscopic O
variables O
. O

in O
the O
current O
study O
, O
dyskinetic B-NEG
patients O
performed O
better O
in O
swallowing O
function O
, O
which O
could O
be O
explained O
on O
the O
basis O
of O
a O
greater O
levodopa O
dose O
. O

our O
results O
suggest O
a O
role O
for O
levodopa O
in O
the O
oral O
phase O
of O
deglutition O
and O
confirm O
that O
dysphagia B-NEG
is O
not O
a O
good O
predictor O
of O
deglutition O
alterations O
in O
pd B-NEG
. O

-DOCSTART- O

inhibition O
of O
nuclear O
factor-kappab O
activation O
attenuates O
tubulointerstitial B-NEG
nephritis I-NEG
induced O
by O
gentamicin O
. O

background O
: O
animals O
treated O
with O
gentamicin O
can O
show O
residual O
areas O
of O
interstitial O
fibrosis B-NEG
in O
the O
renal O
cortex O
. O

this O
study O
investigated O
the O
expression O
of O
nuclear O
factor-kappab O
(nf-kappab) O
, O
mitogen-activated O
protein O
( O
map O
) O
kinases O
and O
macrophages O
in O
the O
renal O
cortex O
and O
structural O
and O
functional O
renal O
changes O
of O
rats O
treated O
with O
gentamicin O
or O
gentamicin O
+ O
pyrrolidine O
dithiocarbamate O
(pdtc) O
, O
an O
nf-kappab O
inhibitor O
. O

methods O
: O
38 O
female O
wistar O
rats O
were O
injected O
with O
gentamicin O
, O
40 O
mg/kg O
, O
twice O
a O
day O
for O
9 O
days O
, O
38 O
with O
gentamicin O
+ O
pdtc O
, O
and O
28 O
with O
0.15 O
m O
nacl O
solution O
. O

the O
animals O
were O
killed O
5 O
and O
30 O
days O
after O
these O
injections O
and O
the O
kidneys O
were O
removed O
for O
histological O
and O
immunohistochemical O
studies O
. O

the O
results O
of O
the O
immunohistochemical O
studies O
were O
scored O
according O
to O
the O
extent O
of O
staining O
. O

the O
fractional O
interstitial O
area O
was O
determined O
by O
morphometry O
. O

results O
: O
gentamicin-treated O
rats O
presented O
a O
transitory O
increase O
in O
plasma O
creatinine O
levels O
. O

increased O
ed-1 O
, O
map O
kinases O
and O
nf-kappab O
staining O
were O
also O
observed O
in O
the O
renal O
cortex O
from O
all O
gentamicin-treated O
rats O
compared O
to O
control O
(p O
< O
0.05) O
. O

the O
animals O
killed O
on O
day O
30 O
also O
presented O
fibrosis B-NEG
in O
the O
renal O
cortex O
despite O
the O
recovery O
of O
renal O
function O
. O

treatment O
with O
pdtc O
reduced O
the O
functional O
and O
structural O
changes O
induced O
by O
gentamicin O
. O

conclusions O
: O
these O
data O
show O
that O
inhibition O
of O
nf-kappab O
activation O
attenuates O
tubulointerstitial B-NEG
nephritis I-NEG
induced O
by O
gentamicin O
. O

-DOCSTART- O

glucose O
metabolism O
in O
patients O
with O
schizophrenia B-NEG
treated O
with O
atypical O
antipsychotic O
agents O
: O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
minimal O
model O
analysis O
. O

background O
: O
while O
the O
incidence O
of O
new-onset O
diabetes B-NEG
mellitus I-NEG
may O
be O
increasing O
in O
patients O
with O
schizophrenia B-NEG
treated O
with O
certain O
atypical O
antipsychotic O
agents O
, O
it O
remains O
unclear O
whether O
atypical O
agents O
are O
directly O
affecting O
glucose O
metabolism O
or O
simply O
increasing O
known O
risk O
factors O
for O
diabetes B-NEG
. O

objective O
: O
to O
study O
the O
2 O
drugs O
most O
clearly O
implicated O
( O
clozapine O
and O
olanzapine O
) O
and O
risperidone O
using O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
. O

design O
: O
a O
cross-sectional O
design O
in O
stable O
, O
treated O
patients O
with O
schizophrenia B-NEG
evaluated O
using O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
the O
bergman O
minimal O
model O
analysis O
. O

setting O
: O
subjects O
were O
recruited O
from O
an O
urban O
community O
mental O
health O
clinic O
and O
were O
studied O
at O
a O
general O
clinical O
research O
center O
. O

patients O
fifty O
subjects O
signed O
informed O
consent O
and O
41 O
underwent O
the O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
. O

thirty-six O
nonobese O
subjects O
with O
schizophrenia B-NEG
or O
schizoaffective B-NEG
disorder I-NEG
, O
matched O
by O
body O
mass O
index O
and O
treated O
with O
either O
clozapine O
, O
olanzapine O
, O
or O
risperidone O
, O
were O
included O
in O
the O
analysis O
. O

main O
outcome O
measures O
: O
fasting O
plasma O
glucose O
and O
fasting O
serum O
insulin O
levels O
, O
insulin B-NEG
sensitivity I-NEG
index O
, O
homeostasis O
model O
assessment O
of O
insulin B-NEG
resistance I-NEG
, O
and O
glucose O
effectiveness O
. O

results O
: O
the O
mean O
+/- O
sd O
duration O
of O
treatment O
with O
the O
identified O
atypical O
antipsychotic O
agent O
was O
68.3 O
+/- O
28.9 O
months O
(clozapine) O
, O
29.5 O
+/- O
17.5 O
months O
(olanzapine) O
, O
and O
40.9 O
+/- O
33.7 O
(risperidone) O
. O

fasting O
serum O
insulin O
concentrations O
differed O
among O
groups O
( O
f(33 O
) O
= O
3.35 O
; O
p O
= O
.047 O
) O
( O
clozapine>olanzapine>risperidone O
) O
with O
significant O
differences O
between O
clozapine O
and O
risperidone O
( O
t(33 O
) O
= O
2.32 O
; O
p O
= O
.03 O
) O
and O
olanzapine O
and O
risperidone O
( O
t(33 O
) O
= O
2.15 O
; O
p O
= O
.04) O
. O

there O
was O
a O
significant O
difference O
in O
insulin B-NEG
sensitivity I-NEG
index O
among O
groups O
( O
f(33 O
) O
= O
10.66 O
; O
p<.001 O
) O
(clozapine<olanzapine<risperidone) O
, O
with O
subjects O
who O
received O
clozapine O
and O
olanzapine O
exhibiting O
significant O
insulin B-NEG
resistance I-NEG
compared O
with O
subjects O
who O
were O
treated O
with O
risperidone O
( O
clozapine O
vs O
risperidone O
, O
t(33 O
) O
= O
-4.29 O
; O
p<.001 O
; O
olanzapine O
vs O
risperidone O
, O
t(33 O
) O
= O
-3.62 O
; O
p O
= O
.001 O
[p<.001]) O
. O

the O
homeostasis O
model O
assessment O
of O
insulin B-NEG
resistance I-NEG
also O
differed O
significantly O
among O
groups O
( O
f(33 O
) O
= O
4.92 O
; O
p O
= O
.01 O
) O
( O
clozapine>olanzapine>risperidone O
) O
( O
clozapine O
vs O
risperidone O
, O
t(33 O
) O
= O
2.94 O
; O
p O
= O
.006 O
; O
olanzapine O
vs O
risperidone O
, O
t(33 O
) O
= O
2.42 O
; O
p O
= O
.02) O
. O

there O
was O
a O
significant O
difference O
among O
groups O
in O
glucose O
effectiveness O
( O
f(30 O
) O
= O
4.18 O
; O
p O
= O
.02 O
) O
( O
clozapine<olanzapine<risperidone O
) O
with O
significant O
differences O
between O
clozapine O
and O
risperidone O
( O
t(30 O
) O
= O
-2.59 O
; O
p O
= O
.02 O
) O
and O
olanzapine O
and O
risperidone O
( O
t(30 O
) O
= O
-2.34 O
, O
p O
= O
.03) O
. O

conclusions O
: O
both O
nonobese O
clozapine- O
and O
olanzapine-treated O
groups O
displayed O
significant O
insulin B-NEG
resistance I-NEG
and O
impairment O
of O
glucose O
effectiveness O
compared O
with O
risperidone-treated O
subjects O
. O

patients O
taking O
clozapine O
and O
olanzapine O
must O
be O
examined O
for O
insulin B-NEG
resistance I-NEG
and O
its O
consequences O
. O

-DOCSTART- O

focal O
cerebral B-NEG
ischemia I-NEG
in O
rats O
: O
effect O
of O
phenylephrine-induced O
hypertension B-NEG
during O
reperfusion O
. O

after O
180 O
min O
of O
temporary O
middle B-NEG
cerebral I-NEG
artery I-NEG
occlusion I-NEG
in O
spontaneously O
hypertensive B-NEG
rats O
, O
the O
effect O
of O
phenylephrine-induced O
hypertension B-NEG
on O
ischemic B-NEG
brain I-NEG
injury I-NEG
and O
blood-brain O
barrier O
permeability O
was O
determined O
. O

blood O
pressure O
was O
manipulated O
by O
one O
of O
the O
following O
schedules O
during O
120 O
min O
of O
reperfusion O
: O
control O
, O
normotensive O
reperfusion O
; O
90/ O
hypertension B-NEG
( O
90/ O
htn B-NEG
), O
blood O
pressure O
was O
increased O
by O
35 O
mm O
hg O
during O
the O
initial O
90 O
min O
of O
reperfusion O
only O
; O
15/ O
hypertension B-NEG
( O
15/ O
htn B-NEG
), O
normotensive O
reperfusion O
for O
30 O
min O
followed O
by O
15 O
min O
of O
hypertension B-NEG
and O
75 O
min O
of O
normotension O
. O

part O
a, O
for O
eight O
rats O
in O
each O
group O
brain B-NEG
injury I-NEG
was O
evaluated O
by O
staining O
tissue O
using O
2,3,5-triphenyltetrazolium O
chloride O
and O
edema B-NEG
was O
evaluated O
by O
microgravimetry O
. O

part O
b, O
for O
eight O
different O
rats O
in O
each O
group O
blood-brain O
barrier O
permeability O
was O
evaluated O
by O
measuring O
the O
amount O
and O
extent O
of O
extravasation O
of O
evans O
blue O
dye O
. O
brain B-NEG
injury I-NEG
( O
percentage O
of O
the O
ischemic B-NEG
hemisphere I-NEG
) O
was O
less O
in O
the O
15/ O
htn B-NEG
group O
( O
16 O
+/- O
6, O
mean O
+/- O
sd O
) O
versus O
the O
90/ O
htn B-NEG
group O
( O
30 O
+/- O
6) O
, O
which O
was O
in O
turn O
less O
than O
the O
control O
group O
( O
42 O
+/- O
5) O
. O

specific O
gravity O
was O
greater O
in O
the O
15/ O
htn B-NEG
group O
( O
1.043 O
+/- O
0.002 O
) O
versus O
the O
90/ O
htn B-NEG
( O
1.036 O
+/- O
0.003 O
) O
and O
control O
( O
1.037 O
+/- O
0.003 O
) O
groups O
. O

evans O
blue O
( O
mug O
g-1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90/ O
htn B-NEG
group O
( O
24.4 O
+/- O
6.0 O
) O
versus O
the O
control O
group O
( O
12.3 O
+/- O
4.1) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15/ O
htn B-NEG
group O
( O
7.3 O
+/- O
3.2) O
. O

this O
study O
supports O
a O
hypothesis O
that O
during O
reperfusion O
, O
a O
short O
interval O
of O
hypertension B-NEG
decreases O
brain B-NEG
injury I-NEG
and O
edema B-NEG
; O
and O
that O
sustained O
hypertension B-NEG
increases O
the O
risk O
of O
vasogenic B-NEG
edema I-NEG
. O

-DOCSTART- O

people O
aged O
over O
75 O
in O
atrial B-NEG
fibrillation I-NEG
on O
warfarin O
: O
the O
rate O
of O
major O
hemorrhage B-NEG
and O
stroke B-NEG
in O
more O
than O
500 O
patient-years O
of O
follow-up O
. O

objectives O
: O
to O
determine O
the O
incidence O
of O
major O
hemorrhage B-NEG
and O
stroke B-NEG
in O
people O
aged O
76 O
and O
older O
with O
atrial B-NEG
fibrillation I-NEG
on O
adjusted-dose O
warfarin O
who O
had O
been O
recently O
been O
admitted O
to O
hospital O
. O

design O
: O
a O
retrospective O
observational O
cohort O
study O
. O

setting O
: O
a O
major O
healthcare O
network O
involving O
four O
tertiary O
hospitals O
. O

participants O
: O
two O
hundred O
thirty-five O
patients O
aged O
76 O
and O
older O
admitted O
to O
a O
major O
healthcare O
network O
between O
july O
1, O
2001 O
, O
and O
june O
30 O
, O
2002 O
, O
with O
atrial B-NEG
fibrillation I-NEG
on O
warfarin O
were O
enrolled O
. O

measurements O
: O
information O
regarding O
major O
bleeding B-NEG
episodes O
, O
strokes B-NEG
, O
and O
warfarin O
use O
was O
obtained O
from O
patients O
, O
relatives O
, O
primary O
physicians O
, O
and O
medical O
records O
. O

results O
: O
two O
hundred O
twenty-eight O
patients O
( O
42% O
men O
) O
with O
a O
mean O
age O
of O
81.1 O
( O
range O
76-94 O
) O
were O
included O
in O
the O
analysis O
. O

total O
follow-up O
on O
warfarin O
was O
530 O
years O
( O
mean O
28 O
months) O
. O

there O
were O
53 O
major O
hemorrhages B-NEG
, O
for O
an O
annual O
rate O
of O
10.0% O
, O
including O
24 O
( O
45.3% O
) O
life-threatening O
and O
five O
( O
9.4% O
) O
fatal O
bleeds O
. O

the O
annual O
stroke B-NEG
rate O
after O
initiation O
of O
warfarin O
was O
2.6% O
. O

conclusion O
: O
the O
rate O
of O
major O
hemorrhage B-NEG
was O
high O
in O
this O
old O
, O
frail O
group O
, O
but O
excluding O
fatalities O
, O
resulted O
in O
no O
long-term O
sequelae O
, O
and O
the O
stroke B-NEG
rate O
on O
warfarin O
was O
low O
, O
demonstrating O
how O
effective O
warfarin O
treatment O
is O
. O

-DOCSTART- O

safety O
of O
celecoxib O
in O
patients O
with O
adverse O
skin B-NEG
reactions I-NEG
to O
acetaminophen O
( O
paracetamol O
) O
and O
nimesulide O
associated O
or O
not O
with O
common O
non-steroidal O
anti-inflammatory O
drugs O
. O

background O
: O
acetaminophen O
( O
paracetamol--p O
) O
and O
nimesulide O
( O
n O
) O
are O
widely O
used O
analgesic-antipyretic/anti-inflammatory O
drugs O
. O

the O
rate O
of O
adverse O
hypersensitivity B-NEG
reactions O
to O
these O
agents O
is O
generally O
low O
. O

on O
the O
contrary O
non-steroidal O
anti-inflammatory O
drugs O
( O
nsaids O
) O
are O
commonly O
involved O
in O
such O
reactions O
. O

celecoxib O
( O
ce O
) O
is O
a O
novel O
drug O
, O
with O
high O
selectivity O
and O
affinity O
for O
cox-2 O
enzyme O
. O

objective O
: O
we O
evaluated O
the O
tolerability O
of O
ce O
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous B-NEG
reactions I-NEG
to O
p O
and O
n O
associated O
or O
not O
to O
classic O
nsaids O
. O

methods O
: O
we O
studied O
9 O
patients O
with O
hypersensitivity B-NEG
to O
p O
and O
n O
with O
or O
without O
associated O
reactions O
to O
classic O
nsaids O
. O

the O
diagnosis O
of O
p O
and O
n-induced O
skin B-NEG
reactions I-NEG
was O
based O
in O
vivo O
challenge O
. O

the O
placebo O
was O
blindly O
administered O
at O
the O
beginning O
of O
each O
challenge O
. O

after O
three O
days O
, O
a O
cumulative O
dosage O
of O
200 O
mg O
of O
ce O
in O
refracted O
doses O
were O
given O
. O

after O
2-3 O
days O
, O
a O
single O
dose O
of O
200 O
mg O
was O
administered O
. O

all O
patients O
were O
observed O
for O
6 O
hours O
after O
each O
challenge O
, O
and O
controlled O
again O
after O
24 O
hours O
to O
exclude O
delayed O
reactions O
. O

the O
challenge O
was O
considered O
positive O
if O
one O
or O
more O
of O
the O
following O
appeared O
: O
erythema B-NEG
, O
rush O
or O
urticaria B-NEG
- O
angioedema B-NEG
. O

results O
: O
no O
reaction O
was O
observed O
with O
placebo O
and O
eight O
patients O
( O
88.8% O
) O
tolerated O
ce O
. O

only O
one O
patient O
developed O
a O
moderate O
angioedema B-NEG
of O
the O
lips O
. O

conclusion O
: O
only O
one O
hypersensitivity B-NEG
reaction O
to O
ce O
was O
documented O
among O
9 O
p O
and O
n-highly O
nsaids O
intolerant O
patients O
. O

thus O
, O
we O
conclude O
that O
ce O
is O
a O
reasonably O
safe O
alternative O
to O
be O
used O
in O
subjects O
who O
do O
not O
tolerate O
p O
and O
n. O

-DOCSTART- O

case-control O
study O
of O
regular O
analgesic O
and O
nonsteroidal O
anti-inflammatory O
use O
and O
end-stage B-NEG
renal I-NEG
disease I-NEG
. O

background O
: O
studies O
on O
the O
association O
between O
the O
long-term O
use O
of O
aspirin O
and O
other O
analgesic O
and O
nonsteroidal O
anti-inflammatory O
drugs O
( O
nsaids O
) O
and O
end-stage B-NEG
renal I-NEG
disease I-NEG
( O
esrd B-NEG
) O
have O
given O
conflicting O
results O
. O

in O
order O
to O
examine O
this O
association O
, O
a O
case-control O
study O
with O
incident O
cases O
of O
esrd B-NEG
was O
carried O
out O
. O

methods O
: O
the O
cases O
were O
all O
patients O
entering O
the O
local O
dialysis O
program O
because O
of O
esrd B-NEG
in O
the O
study O
area O
between O
june O
1, O
1995 O
and O
november O
30 O
, O
1997 O
. O

they O
were O
classified O
according O
to O
the O
underlying O
disease O
, O
which O
had O
presumably O
led O
them O
to O
esrd B-NEG
. O

controls O
were O
patients O
admitted O
to O
the O
same O
hospitals O
from O
where O
the O
cases O
arose O
, O
also O
matched O
by O
age O
and O
sex O
. O

odds O
ratios O
were O
calculated O
using O
a O
conditional O
logistic O
model O
, O
including O
potential O
confounding O
factors O
, O
both O
for O
the O
whole O
study O
population O
and O
for O
the O
various O
underlying O
diseases O
. O

results O
: O
five O
hundred O
and O
eighty-three O
cases O
and O
1190 O
controls O
were O
included O
in O
the O
analysis O
. O

long-term O
use O
of O
any O
analgesic O
was O
associated O
with O
an O
overall O
odds O
ratio O
of O
1.22 O
( O
95% O
ci O
, O
0.89-1.66) O
. O

for O
specific O
groups O
of O
drugs O
, O
the O
risks O
were O
1.56 O
( O
1.05-2.30 O
) O
for O
aspirin O
, O
1.03 O
( O
0.60-1.76 O
) O
for O
pyrazolones O
, O
0.80 O
( O
0.39-1.63 O
) O
for O
paracetamol O
, O
and O
0.94 O
( O
0.57-1.56 O
) O
for O
nonaspirin O
nsaids O
. O

the O
risk O
of O
esrd B-NEG
associated O
with O
aspirin O
was O
related O
to O
the O
cumulated O
dose O
and O
duration O
of O
use O
, O
and O
it O
was O
particularly O
high O
among O
the O
subset O
of O
patients O
with O
vascular O
nephropathy B-NEG
as O
underlying O
disease O
[2.35 O
(1.17-4.72)] O
. O

conclusion O
: O
our O
data O
indicate O
that O
long-term O
use O
of O
nonaspirin O
analgesic O
drugs O
and O
nsaids O
is O
not O
associated O
with O
an O
increased O
risk O
of O
esrd B-NEG
. O

however O
, O
the O
chronic O
use O
of O
aspirin O
may O
increase O
the O
risk O
of O
esrd B-NEG
. O

-DOCSTART- O

two O
cases O
of O
amisulpride O
overdose B-NEG
: O
a O
cause O
for O
prolonged B-NEG
qt I-NEG
syndrome I-NEG
. O

two O
cases O
of O
deliberate O
self- O
poisoning B-NEG
with O
5 O
g O
and O
3.6 O
g O
of O
amisulpride O
, O
respectively O
, O
are O
reported O
. O

in O
both O
cases O
, O
qt B-NEG
prolongation I-NEG
and O
hypocalcaemia B-NEG
were O
noted O
. O

the O
qt B-NEG
prolongation I-NEG
appeared O
to O
respond O
to O
administration O
of O
i.v O
. O
calcium O
gluconate O
. O

-DOCSTART- O

growth-associated O
protein O
43 O
expression O
in O
hippocampal O
molecular O
layer O
of O
chronic O
epileptic B-NEG
rats O
treated O
with O
cycloheximide O
. O

purpose O
: O
gap43 O
has O
been O
thought O
to O
be O
linked O
with O
mossy O
fiber O
sprouting O
( O
mfs O
) O
in O
various O
experimental O
models O
of O
epilepsy B-NEG
. O

to O
investigate O
how O
gap43 O
expression O
( O
gap43-ir O
) O
correlates O
with O
mfs O
, O
we O
assessed O
the O
intensity O
( O
densitometry O
) O
and O
extension O
( O
width O
) O
of O
gap43-ir O
in O
the O
inner O
molecular O
layer O
of O
the O
dentate O
gyrus O
( O
iml O
) O
of O
rats O
subject O
to O
status B-NEG
epilepticus I-NEG
induced O
by O
pilocarpine O
(pilo) O
, O
previously O
injected O
or O
not O
with O
cycloheximide O
(chx) O
, O
which O
has O
been O
shown O
to O
inhibit O
mfs O
. O

methods O
: O
chx O
was O
injected O
before O
the O
pilo O
injection O
in O
adult O
wistar O
rats O
. O

the O
pilo O
group O
was O
injected O
with O
the O
same O
drugs O
, O
except O
for O
chx O
. O

animals O
were O
killed O
between O
30 O
and O
60 O
days O
later O
, O
and O
brain O
sections O
were O
processed O
for O
gap43 O
immunohistochemistry O
. O

results O
: O
densitometry O
showed O
no O
significant O
difference O
regarding O
gap43-ir O
in O
the O
iml O
between O
pilo O
, O
chx+pilo O
, O
and O
control O
groups O
. O

however O
, O
the O
results O
of O
the O
width O
of O
the O
gap43-ir O
band O
in O
the O
iml O
showed O
that O
chx+pilo O
and O
control O
animals O
had O
a O
significantly O
larger O
band O
(p O
= O
0.03 O
) O
as O
compared O
with O
that O
in O
the O
pilo O
group O
. O

conclusions O
: O
our O
current O
finding O
that O
animals O
in O
the O
chx+pilo O
group O
have O
a O
gap43-ir O
band O
in O
the O
iml O
, O
similar O
to O
that O
of O
controls O
, O
reinforces O
prior O
data O
on O
the O
blockade O
of O
mfs O
in O
these O
animals O
. O

the O
change O
in O
gap43-ir O
present O
in O
pilo-treated O
animals O
was O
a O
thinning O
of O
the O
band O
to O
a O
very O
narrow O
layer O
just O
above O
the O
granule O
cell O
layer O
that O
is O
likely O
to O
be O
associated O
with O
the O
loss O
of O
hilar O
cell O
projections O
that O
express O
gap-43 O
. O

-DOCSTART- O

nicotine O
antagonizes O
caffeine- O
but O
not O
pentylenetetrazole-induced O
anxiogenic O
effect O
in O
mice O
. O

rationale O
: O
nicotine O
and O
caffeine O
are O
widely O
consumed O
licit O
psychoactive O
drugs O
worldwide O
. O

epidemiological O
studies O
showed O
that O
they O
were O
generally O
used O
concurrently O
. O

although O
some O
studies O
in O
experimental O
animals O
indicate O
clear O
pharmacological O
interactions O
between O
them O
, O
no O
studies O
have O
shown O
a O
specific O
interaction O
on O
anxiety B-NEG
responses O
. O

objectives O
: O
the O
present O
study O
investigates O
the O
effects O
of O
nicotine O
on O
anxiety B-NEG
induced O
by O
caffeine O
and O
another O
anxiogenic O
drug O
, O
pentylenetetrazole O
, O
in O
mice O
. O

the O
elevated O
plus-maze O
( O
epm O
) O
test O
was O
used O
to O
evaluate O
the O
effects O
of O
drugs O
on O
anxiety B-NEG
. O

methods O
: O
adult O
male O
swiss O
webster O
mice O
( O
25-32 O
g) O
were O
given O
nicotine O
( O
0.05-0.25 O
mg/kg O
s.c. O
) O
or O
saline O
10 O
min O
before O
caffeine O
( O
70 O
mg/kg O
i.p. O
) O
or O
pentylenetetrazole O
( O
15 O
and O
30 O
mg/kg O
i.p. O
) O
injections O
. O

after O
15 O
min O
, O
mice O
were O
evaluated O
for O
their O
open- O
and O
closed-arm O
time O
and O
entries O
on O
the O
epm O
for O
a O
10-min O
session O
. O

locomotor O
activity O
was O
recorded O
for O
individual O
groups O
by O
using O
the O
same O
treatment O
protocol O
with O
the O
epm O
test O
. O

results O
: O
nicotine O
( O
0.05-0.25 O
mg/kg O
) O
itself O
did O
not O
produce O
any O
significant O
effect O
in O
the O
epm O
test O
, O
whereas O
caffeine O
( O
70 O
mg/kg O
) O
and O
pentylenetetrazole O
( O
30 O
mg/kg O
) O
produced O
an O
anxiogenic O
effect O
, O
apparent O
with O
decreases O
in O
open-arm O
time O
and O
entry O
. O

nicotine O
( O
0.25 O
mg/kg O
) O
pretreatment O
blocked O
the O
caffeine- O
but O
not O
pentylenetetrazole-induced O
anxiety B-NEG
. O

administration O
of O
each O
drug O
and O
their O
combinations O
did O
not O
produce O
any O
effect O
on O
locomotor O
activity O
. O

conclusions O
: O
our O
results O
suggest O
that O
the O
antagonistic O
effect O
of O
nicotine O
on O
caffeine-induced O
anxiety B-NEG
is O
specific O
to O
caffeine O
, O
instead O
of O
a O
non-specific O
anxiolytic O
effect O
. O

thus O
, O
it O
may O
extend O
the O
current O
findings O
on O
the O
interaction O
between O
nicotine O
and O
caffeine O
. O

-DOCSTART- O

long O
term O
hormone O
therapy O
for O
perimenopausal O
and O
postmenopausal O
women O
. O

background O
: O
hormone O
therapy O
( O
ht O
) O
is O
widely O
used O
for O
controlling O
menopausal B-NEG
symptoms I-NEG
. O

it O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B-NEG
disease I-NEG
, O
osteoporosis B-NEG
and O
dementia B-NEG
in O
older O
women O
but O
the O
evidence O
supporting O
its O
use O
for O
these O
indications O
is O
largely O
observational O
. O

objectives O
: O
to O
assess O
the O
effect O
of O
long-term O
ht O
on O
mortality O
, O
heart B-NEG
disease I-NEG
, O
venous B-NEG
thromboembolism I-NEG
, O
stroke B-NEG
, O
transient B-NEG
ischaemic I-NEG
attacks I-NEG
, O
breast B-NEG
cancer I-NEG
, O
colorectal B-NEG
cancer I-NEG
, O
ovarian B-NEG
cancer I-NEG
, O
endometrial B-NEG
cancer I-NEG
, O
gallbladder B-NEG
disease I-NEG
, O
cognitive O
function O
, O
dementia B-NEG
, O
fractures B-NEG
and O
quality O
of O
life O
. O

search O
strategy O
: O
we O
searched O
the O
following O
databases O
up O
to O
november O
2004 O
: O
the O
cochrane O
menstrual O
disorders O
and O
subfertility O
group O
trials O
register O
, O
cochrane O
central O
register O
of O
controlled O
trials O
(central) O
, O
medline O
, O
embase O
, O
biological O
abstracts O
. O

relevant O
non-indexed O
journals O
and O
conference O
abstracts O
were O
also O
searched O
. O

selection O
criteria O
: O
randomised O
double-blind O
trials O
of O
ht O
( O
oestrogens O
with O
or O
without O
progestogens O
) O
versus O
placebo O
, O
taken O
for O
at O
least O
one O
year O
by O
perimenopausal O
or O
postmenopausal O
women O
. O

data O
collection O
and O
analysis O
: O
fifteen O
rcts O
were O
included O
. O

trials O
were O
assessed O
for O
quality O
and O
two O
review O
authors O
extracted O
data O
independently O
. O

they O
calculated O
risk O
ratios O
for O
dichotomous O
outcomes O
and O
weighted O
mean O
differences O
for O
continuous O
outcomes O
. O

clinical O
heterogeneity O
precluded O
meta-analysis O
for O
most O
outcomes O
. O

main O
results O
: O
all O
the O
statistically O
significant O
results O
were O
derived O
from O
the O
two O
biggest O
trials O
. O

in O
relatively O
healthy O
women O
, O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-NEG
thromboembolism I-NEG
or O
coronary O
event O
( O
after O
one O
year's O
use) O
, O
stroke B-NEG
( O
after O
3 O
years) O
, O
breast B-NEG
cancer I-NEG
( O
after O
5 O
years O
) O
and O
gallbladder B-NEG
disease I-NEG
. O

long-term O
oestrogen-only O
ht O
also O
significantly O
increased O
the O
risk O
of O
stroke B-NEG
and O
gallbladder B-NEG
disease I-NEG
. O

overall O
, O
the O
only O
statistically O
significant O
benefits O
of O
ht O
were O
a O
decreased O
incidence O
of O
fractures B-NEG
and O
colon B-NEG
cancer I-NEG
with O
long-term O
use O
. O

among O
relatively O
healthy O
women O
over O
65 O
years O
taking O
continuous O
combined O
ht O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B-NEG
. O

among O
women O
with O
cardiovascular B-NEG
disease I-NEG
, O
long-term O
use O
of O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-NEG
thromboembolism I-NEG
. O

no O
trials O
focussed O
specifically O
on O
younger O
women O
. O

however O
, O
one O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year-old O
women O
taking O
combined O
continuous O
ht O
and O
1637 O
taking O
oestrogen-only O
ht O
, O
versus O
similar-sized O
placebo O
groups O
. O

the O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B-NEG
thromboembolism I-NEG
in O
women O
taking O
combined O
continuous O
ht O
; O
their O
absolute O
risk O
remained O
very O
low O
. O

authors' O
conclusions O
: O
ht O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic B-NEG
disease I-NEG
. O

we O
need O
more O
evidence O
on O
the O
safety O
of O
ht O
for O
menopausal O
symptom O
control O
, O
though O
short-term O
use O
appears O
to O
be O
relatively O
safe O
for O
healthy O
younger O
women O
. O

-DOCSTART- O

drug-induced B-NEG
liver I-NEG
injury I-NEG
: O
an O
analysis O
of O
461 O
incidences O
submitted O
to O
the O
spanish O
registry O
over O
a O
10-year O
period O
. O

background O
& O
aims O
: O
progress O
in O
the O
understanding O
of O
susceptibility O
factors O
to O
drug-induced B-NEG
liver I-NEG
injury I-NEG
( O
dili B-NEG
) O
and O
outcome O
predictability O
are O
hampered O
by O
the O
lack O
of O
systematic O
programs O
to O
detect O
bona O
fide O
cases O
. O

methods O
: O
a O
cooperative O
network O
was O
created O
in O
1994 O
in O
spain O
to O
identify O
all O
suspicions O
of O
dili B-NEG
following O
a O
prospective O
structured O
report O
form O
. O

the O
liver B-NEG
damage I-NEG
was O
characterized O
according O
to O
hepatocellular O
, O
cholestatic B-NEG
, O
and O
mixed O
laboratory O
criteria O
and O
to O
histologic O
criteria O
when O
available O
. O

further O
evaluation O
of O
causality O
assessment O
was O
centrally O
performed O
. O

results O
: O
since O
april O
1994 O
to O
august O
2004 O
, O
461 O
out O
of O
570 O
submitted O
cases O
, O
involving O
505 O
drugs O
, O
were O
deemed O
to O
be O
related O
to O
dili B-NEG
. O

the O
antiinfective O
group O
of O
drugs O
was O
the O
more O
frequently O
incriminated O
, O
amoxicillin-clavulanate O
accounting O
for O
the O
12.8% O
of O
the O
whole O
series O
. O

the O
hepatocellular O
pattern O
of O
damage O
was O
the O
most O
common O
(58%) O
, O
was O
inversely O
correlated O
with O
age O
(p O
< O
.0001) O
, O
and O
had O
the O
worst O
outcome O
( O
cox O
regression O
, O
p O
< O
.034) O
. O

indeed O
, O
the O
incidence O
of O
liver O
transplantation O
and O
death O
in O
this O
group O
was O
11.7% O
if O
patients O
had O
jaundice B-NEG
at O
presentation O
, O
whereas O
the O
corresponding O
figure O
was O
3.8% O
in O
nonjaundiced O
patients O
(p O
< O
.04) O
. O

factors O
associated O
with O
the O
development O
of O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
were O
female O
sex O
( O
or O
= O
25 O
; O
95% O
ci O
: O
4.1-151 O
; O
p O
< O
.0001) O
, O
hepatocellular O
damage O
( O
or O
= O
7.9 O
; O
95% O
ci O
: O
1.6-37 O
; O
p O
< O
.009) O
, O
and O
higher O
baseline O
plasma O
bilirubin O
value O
( O
or O
= O
1.15 O
; O
95% O
ci O
: O
1.09-1.22 O
; O
p O
< O
.0001) O
. O

conclusions O
: O
patients O
with O
drug-induced O
hepatocellular O
jaundice B-NEG
have O
11.7% O
chance O
of O
progressing O
to O
death O
or O
transplantation O
. O

amoxicillin-clavulanate O
stands O
out O
as O
the O
most O
common O
drug O
related O
to O
dili B-NEG
. O

-DOCSTART- O

morphological O
evaluation O
of O
the O
effect O
of O
d-ribose O
on O
adriamycin-evoked O
cardiotoxicity B-NEG
in O
rats O
. O

the O
influence O
of O
d-ribose O
on O
adriamycin-induced O
myocardiopathy B-NEG
in O
rats O
was O
studied O
. O

adriamycin O
in O
the O
cumulative O
dose O
of O
25 O
mg/kg O
evoked O
fully O
developed O
cardiac B-NEG
toxicity I-NEG
. O

d-ribose O
in O
the O
multiple O
doses O
of O
200 O
mg/kg O
did O
not O
influence O
adr O
cardiotoxicity B-NEG
. O

-DOCSTART- O

in O
vivo O
evidences O
suggesting O
the O
role O
of O
oxidative O
stress O
in O
pathogenesis O
of O
vancomycin-induced O
nephrotoxicity B-NEG
: O
protection O
by O
erdosteine O
. O

the O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin O
( O
vcm)-induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen O
species O
( O
ros O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine O
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
vcm-induced O
renal B-NEG
impairment I-NEG
in O
rats O
. O

rats O
were O
divided O
into O
three O
groups O
: O
sham O
, O
vcm O
and O
vcm O
plus O
erdosteine O
. O

vcm O
was O
administrated O
intraperitoneally O
( O
i.p. O
) O
with O
200mgkg(-1 O
) O
twice O
daily O
for O
7 O
days O
. O

erdosteine O
was O
administered O
orally O
. O

vcm O
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde O
( O
mda O
) O
and O
urinary O
n-acetyl-beta-d-glucosaminidase O
(nag O
, O
a O
marker O
of O
renal B-NEG
tubular I-NEG
injury I-NEG
) O
excretion O
but O
decreased O
superoxide O
dismutase O
( O
sod O
) O
and O
catalase O
( O
cat O
) O
activities O
. O

erdosteine O
administration O
with O
vcm O
injections O
caused O
significantly O
decreased O
renal O
mda O
and O
urinary O
nag O
excretion O
, O
and O
increased O
sod O
activity O
, O
but O
not O
cat O
activity O
in O
renal O
tissue O
when O
compared O
with O
vcm O
alone O
. O

erdosteine O
showed O
histopathological O
protection O
against O
vcm-induced O
nephrotoxicity B-NEG
. O

there O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy B-NEG
, O
desquamation B-NEG
, O
and O
necrosis B-NEG
in O
vcm-treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine O
groups O
. O

erdosteine O
caused O
a O
marked O
reduction O
in O
the O
extent O
of O
tubular O
damage O
. O

it O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
vcm-induced O
nephrotoxicity B-NEG
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine O
reduces O
the O
vcm-induced O
kidney B-NEG
damage I-NEG
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

-DOCSTART- O

does O
domperidone O
potentiate O
mirtazapine-associated O
restless B-NEG
legs I-NEG
syndrome I-NEG
? O

there O
is O
now O
evidence O
to O
suggest O
a O
central O
role O
for O
the O
dopaminergic O
system O
in O
restless B-NEG
legs I-NEG
syndrome I-NEG
( O
rls B-NEG
). O

for O
example O
, O
the O
symptoms O
of O
rls B-NEG
can O
be O
dramatically O
improved O
by O
levodopa O
and O
dopamine O
agonists O
, O
whereas O
central O
dopamine O
d2 O
receptor O
antagonists O
can O
induce O
or O
aggravate O
rls B-NEG
symptoms O
. O

to O
our O
knowledge O
, O
there O
is O
no O
previous O
report O
regarding O
whether O
domperidone O
, O
a O
peripheral O
dopamine O
d2 O
receptor O
antagonist O
, O
can O
also O
induce O
or O
aggravate O
symptoms O
of O
rls B-NEG
. O

mirtazapine O
, O
the O
first O
noradrenergic O
and O
specific O
serotonergic O
antidepressant O
(nassa) O
, O
has O
been O
associated O
with O
rls B-NEG
in O
several O
recent O
publications O
. O

the O
authors O
report O
here O
a O
depressed O
patient O
comorbid O
with O
postprandial B-NEG
dyspepsia I-NEG
who O
developed O
rls B-NEG
after O
mirtazapine O
had O
been O
added O
to O
his O
domperidone O
therapy O
. O

our O
patient O
started O
to O
have O
symptoms O
of O
rls B-NEG
only O
after O
he O
had O
been O
treated O
with O
mirtazapine O
, O
and O
his O
rls B-NEG
symptoms O
resolved O
completely O
upon O
discontinuation O
of O
his O
mirtazapine O
. O

such O
a O
temporal O
relationship O
between O
the O
use O
of O
mirtazapine O
and O
the O
symptoms O
of O
rls B-NEG
in O
our O
patient O
did O
not O
support O
a O
potentiating O
effect O
of O
domperione O
on O
mirtazapine-associated O
rls B-NEG
. O

however O
, O
physicians O
should O
be O
aware O
of O
the O
possibility O
that O
mirtazapine O
can O
be O
associated O
with O
rls B-NEG
in O
some O
individuals O
, O
especially O
those O
receiving O
concomitant O
dopamine O
d2 O
receptor O
antagonists O
. O

-DOCSTART- O

antiandrogenic O
therapy O
can O
cause O
coronary B-NEG
arterial I-NEG
disease I-NEG
. O

aim O
: O
to O
study O
the O
change O
of O
lipid O
metabolism O
by O
antiandrogen O
therapy O
in O
patients O
with O
prostate B-NEG
cancer I-NEG
. O

materials O
and O
methods O
: O
we O
studied O
with O
a O
2.5 O
years O
follow-up O
the O
changes O
in O
plasma O
cholesterols O
(c) O
, O
triglycerides O
(tg) O
, O
lipoproteins O
(lp) O
, O
and O
apolipoproteins O
( O
apo O
) O
b-100 O
, O
a-i O
, O
and O
a-ii O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate B-NEG
cancer I-NEG
(stage O
: O
t1cn0m0 O
, O
gleason O
score O
: O
2-5 O
) O
during O
treatment O
with O
cyproterone O
acetate O
( O
cpa O
) O
without O
surgical O
management O
or O
radiation O
therapy O
. O

results O
: O
significant O
decreases O
of O
hdl-c O
, O
apo O
a-i O
and O
apo O
a-ii O
and O
an O
increase O
of O
triglyceride O
levels O
in O
vldl O
were O
induced O
by O
cpa O
. O

after O
a O
period O
of O
2.5 O
years O
on O
cpa O
treatment O
, O
four O
patients O
out O
of O
twenty-four O
were O
found O
to O
be O
affected O
by O
coronary B-NEG
heart I-NEG
disease I-NEG
. O

conclusions O
: O
ischaemic O
coronary B-NEG
arteriosclerosis I-NEG
with O
an O
incidence O
rate O
of O
16.6% O
as O
caused O
by O
prolonged O
cpa O
therapy O
is O
mediated O
through O
changes O
in O
hdl O
cholesterol O
, O
apo O
a-i O
and O
apo O
a-ii O
pro O
fi O
les O
, O
other O
than O
the O
well-known O
hyperglyceridemic B-NEG
effect I-NEG
caused O
by O
estrogen O
. O

-DOCSTART- O

5-fluorouracil O
cardiotoxicity B-NEG
induced O
by O
alpha-fluoro-beta-alanine O
. O
cardiotoxicity B-NEG
is O
a O
rare O
complication O
occurring O
during O
5-fluorouracil O
( O
5-fu O
) O
treatment O
for O
malignancies B-NEG
. O

we O
herein O
report O
the O
case O
of O
a O
70-year-old O
man O
with O
5-fu-induced O
cardiotoxicity B-NEG
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha-fluoro-beta-alanine O
( O
fbal O
) O
was O
observed O
. O

the O
patient O
, O
who O
had O
unresectable O
colon B-NEG
cancer I-NEG
metastases O
to O
the O
liver O
and O
lung O
, O
was O
referred O
to O
us O
for O
chemotherapy O
from O
an O
affiliated O
hospital O
; O
he O
had O
no O
cardiac O
history O
. O

after O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5-fu O
( O
1000 O
mg/day) O
, O
during O
which O
precordial B-NEG
pain I-NEG
with O
right B-NEG
bundle I-NEG
branch I-NEG
block I-NEG
occurred O
concomitantly O
with O
a O
high O
serum O
fbal O
concentration O
of O
1955 O
ng/ml O
. O

both O
the O
precordial B-NEG
pain I-NEG
and O
the O
electrocardiographic O
changes O
disappeared O
spontaneously O
after O
the O
discontinuation O
of O
5-fu O
. O

as O
the O
precordial B-NEG
pain I-NEG
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5-fu-induced O
cardiotoxicity B-NEG
, O
the O
administration O
of O
5-fu O
was O
abandoned O
. O

instead O
, O
oral O
administration O
of O
s-1 O
(a O
derivative O
of O
5-fu) O
, O
at O
200 O
mg/day O
twice O
a O
week O
, O
was O
instituted O
, O
because O
s-1 O
has O
a O
strong O
inhibitory O
effect O
on O
dihydropyrimidine O
dehydrogenase O
, O
which O
catalyzes O
the O
degradative O
of O
5-fu O
into O
fbal O
. O

the O
serum O
fbal O
concentration O
subsequently O
decreased O
to O
352 O
ng/ml O
, O
the O
same O
as O
the O
value O
measured O
on O
the O
first O
day O
of O
s-1 O
administration O
. O

thereafter O
, O
no O
cardiac B-NEG
symptoms I-NEG
were O
observed O
. O

the O
patient O
achieved O
a O
partial O
response O
6 O
months O
after O
the O
initiation O
of O
the O
s-1 O
treatment O
. O

the O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
fbal O
is O
related O
to O
5-fu-induced O
cardiotoxicity B-NEG
. O

s-1 O
may O
be O
administered O
safely O
to O
patients O
with O
5-fu-induced O
cardiotoxicity B-NEG
. O

-DOCSTART- O

the O
influence O
of O
the O
time O
interval O
between O
monoher O
and O
doxorubicin O
administration O
on O
the O
protection O
against O
doxorubicin-induced O
cardiotoxicity B-NEG
in O
mice O
. O

purpose O
: O
despite O
its O
well-known O
cardiotoxicity B-NEG
, O
the O
anthracyclin O
doxorubicin O
( O
dox O
) O
continues O
to O
be O
an O
effective O
and O
widely O
used O
chemotherapeutic O
agent O
. O

dox-induced O
cardiac B-NEG
damage I-NEG
presumably O
results O
from O
the O
formation O
of O
free O
radicals O
by O
dox O
. O

reactive O
oxygen O
species O
particularly O
affect O
the O
cardiac O
myocytes O
because O
these O
cells O
seem O
to O
have O
a O
relatively O
poor O
antioxidant O
defense O
system O
. O

the O
semisynthetic O
flavonoid O
monohydroxyethylrutoside O
( O
monoher O
) O
showed O
cardioprotection O
against O
dox-induced O
cardiotoxicity B-NEG
through O
its O
radical O
scavenging O
and O
iron O
chelating O
properties O
. O

because O
of O
the O
relatively O
short O
final O
half-life O
of O
monoher O
( O
about O
30 O
min) O
, O
it O
is O
expected O
that O
the O
time O
interval O
between O
monoher O
and O
dox O
might O
be O
of O
influence O
on O
the O
cardioprotective O
effect O
of O
monoher O
. O

therefore O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
this O
possible O
effect O
. O

methods O
: O
six O
groups O
of O
6 O
balb/c O
mice O
were O
treated O
with O
saline O
, O
dox O
alone O
or O
dox O
(4 O
mg/kg O
i.v. O
) O
preceded O
by O
monoher O
( O
500 O
mg/kg O
i.p. O
) O
with O
an O
interval O
of O
10 O
, O
30 O
, O
60 O
or O
120 O
min O
. O

after O
a O
6-week O
treatment O
period O
and O
additional O
observation O
for O
2 O
weeks O
, O
the O
mice O
were O
sacrificed O
. O

their O
cardiac O
tissues O
were O
processed O
for O
light O
microscopy O
, O
after O
which O
cardiomyocyte B-NEG
damage I-NEG
was O
evaluated O
according O
to O
billingham O
( O
in O
cancer B-NEG
treat O
rep O
62(6):865-872 O
, O
1978) O
. O

microscopic O
evaluation O
revealed O
that O
treatment O
with O
dox O
alone O
induced O
significant O
cardiac B-NEG
damage I-NEG
in O
comparison O
to O
the O
saline O
control O
group O
(p<0.001) O
. O

results O
: O
the O
number O
of O
damaged O
cardiomyocytes O
was O
9.6-fold O
( O
95% O
ci O
4.4-21.0 O
) O
higher O
in O
mice O
treated O
with O
dox O
alone O
than O
that O
in O
animals O
of O
the O
control O
group O
. O

the O
ratio O
of O
aberrant O
cardiomyocytes O
in O
mice O
treated O
with O
dox O
preceded O
by O
monoher O
and O
those O
in O
mice O
treated O
with O
saline O
ranged O
from O
1.6 O
to O
2.8 O
( O
mean O
2.2 O
, O
95% O
ci O
1.2-4.1 O
, O
p=0.019) O
. O

the O
mean O
protective O
effect O
by O
adding O
monoher O
before O
dox O
led O
to O
a O
significant O
4.4-fold O
reduction O
(p<0.001 O
, O
95% O
ci O
2.3-8.2 O
) O
of O
abnormal O
cardiomyocytes O
. O

this O
protective O
effect O
did O
not O
depend O
on O
the O
time O
interval O
between O
monoher O
and O
dox O
administration O
(p=0.345) O
. O

conclusion O
: O
the O
results O
indicate O
that O
in O
an O
outpatient O
clinical O
setting O
monoher O
may O
be O
administered O
shortly O
before O
dox O
. O

-DOCSTART- O

clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil O
administration O
for O
atrial B-NEG
fibrillation I-NEG
and I-NEG
flutter I-NEG
. O

background O
: O
bepridil O
hydrochloride O
( O
bpd O
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial B-NEG
fibrillation I-NEG
( O
af B-NEG
) O
and O
atrial B-NEG
flutter I-NEG
( O
afl B-NEG
). O

however O
, O
serious O
adverse O
effects O
, O
including O
torsade B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
), O
have O
been O
reported O
. O

methods O
and O
results O
: O
adverse O
effects O
of O
bpd O
requiring O
discontinuation O
of O
treatment O
were O
evaluated O
. O

bpd O
was O
administered O
to O
459 O
patients O
( O
361 O
males O
, O
63+/-12 O
years O
old O
) O
comprising O
378 O
af B-NEG
and O
81 O
afl B-NEG
cases O
. O

mean O
left O
ventricular O
ejection O
fraction O
and O
atrial O
dimension O
( O
lad O
) O
were O
66+/-11% O
and O
40+/-6 O
mm O
, O
respectively O
. O

adverse O
effects O
were O
observed O
in O
19 O
patients O
( O
4% O
) O
during O
an O
average O
follow-up O
of O
20 O
months O
. O

there O
was O
marked O
qt B-NEG
prolongation I-NEG
greater O
than O
0.55 O
s O
in O
13 O
patients O
, O
bradycardia B-NEG
less O
than O
40 O
beats/min O
in O
6 O
patients O
, O
dizziness B-NEG
and O
general O
fatigue B-NEG
in O
1 O
patient O
each O
. O

in O
4 O
of O
13 O
patients O
with O
qt B-NEG
prolongation I-NEG
, O
tdp B-NEG
occurred O
. O

the O
major O
triggering O
factors O
of O
tdp B-NEG
were O
hypokalemia B-NEG
and O
sudden O
decrease O
in O
heart O
rate O
. O

there O
were O
no O
differences O
in O
the O
clinical O
backgrounds O
of O
the O
patients O
with O
and O
without O
tdp B-NEG
other O
than O
lad O
and O
age O
, O
which O
were O
larger O
and O
older O
in O
the O
patients O
with O
tdp B-NEG
. O

conclusion O
: O
careful O
observation O
of O
serum O
potassium O
concentration O
and O
the O
ecg O
should O
always O
be O
done O
during O
bpd O
administration O
, O
particularly O
in O
elderly O
patients O
. O

-DOCSTART- O

enhanced O
isoproterenol-induced O
cardiac B-NEG
hypertrophy I-NEG
in O
transgenic O
rats O
with O
low O
brain O
angiotensinogen O
. O

we O
have O
previously O
shown O
that O
a O
permanent O
deficiency O
in O
the O
brain O
renin-angiotensin O
system O
( O
ras O
) O
may O
increase O
the O
sensitivity O
of O
the O
baroreflex O
control O
of O
heart O
rate O
. O

in O
this O
study O
we O
aimed O
at O
studying O
the O
involvement O
of O
the O
brain O
ras O
in O
the O
cardiac O
reactivity O
to O
the O
beta-adrenoceptor O
( O
beta-ar O
) O
agonist O
isoproterenol O
(iso) O
. O

transgenic O
rats O
with O
low O
brain O
angiotensinogen O
( O
tgr O
) O
were O
used O
. O

in O
isolated O
hearts O
, O
iso O
induced O
a O
significantly O
greater O
increase O
in O
left O
ventricular O
( O
lv O
) O
pressure O
and O
maximal O
contraction O
( O
+dp/dt(max) O
) O
in O
the O
tgr O
than O
in O
the O
sprague-dawley O
( O
sd O
) O
rats O
. O
lv B-NEG
hypertrophy I-NEG
induced O
by O
iso O
treatment O
was O
significantly O
higher O
in O
tgr O
than O
in O
sd O
rats O
( O
in O
g O
lv O
wt/100 O
g O
body O
wt O
, O
0.28 O
+/- O
0.004 O
vs O
. O
0.24 O
+/- O
0.004 O
, O
respectively) O
. O

the O
greater O
lv B-NEG
hypertrophy I-NEG
in O
tgr O
rats O
was O
associated O
with O
more O
pronounced O
downregulation O
of O
beta-ar O
and O
upregulation O
of O
lv O
beta-ar O
kinase-1 O
mrna O
levels O
compared O
with O
those O
in O
sd O
rats O
. O

the O
decrease O
in O
the O
heart O
rate O
( O
hr O
) O
induced O
by O
the O
beta-ar O
antagonist O
metoprolol O
in O
conscious O
rats O
was O
significantly O
attenuated O
in O
tgr O
compared O
with O
sd O
rats O
( O
-9.9 O
+/- O
1.7% O
vs O
. O
-18.1 O
+/- O
1.5%) O
, O
whereas O
the O
effect O
of O
parasympathetic O
blockade O
by O
atropine O
on O
hr O
was O
similar O
in O
both O
strains O
. O

these O
results O
indicate O
that O
tgr O
are O
more O
sensitive O
to O
beta-ar O
agonist-induced O
cardiac B-NEG
inotropic I-NEG
response O
and O
hypertrophy B-NEG
, O
possibly O
due O
to O
chronically O
low O
sympathetic O
outflow O
directed O
to O
the O
heart O
. O

-DOCSTART- O

drug-induced O
long B-NEG
qt I-NEG
syndrome I-NEG
in O
injection O
drug O
users O
receiving O
methadone O
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

background O
: O
drug-induced O
long B-NEG
qt I-NEG
syndrome I-NEG
is O
a O
serious O
adverse O
drug O
reaction O
. O

methadone O
prolongs O
the O
qt O
interval O
in O
vitro O
in O
a O
dose-dependent O
manner O
. O

in O
the O
inpatient O
setting O
, O
the O
frequency O
of O
qt B-NEG
interval I-NEG
prolongation I-NEG
with O
methadone O
treatment O
, O
its O
dose O
dependence O
, O
and O
the O
importance O
of O
cofactors O
such O
as O
drug-drug O
interactions O
remain O
unknown O
. O

methods O
: O
we O
performed O
a O
systematic O
, O
retrospective O
study O
comparing O
active O
or O
former O
intravenous O
drug O
users O
receiving O
methadone O
and O
those O
not O
receiving O
methadone O
among O
all O
patients O
hospitalized O
over O
a O
5-year O
period O
in O
a O
tertiary O
care O
hospital O
. O

a O
total O
of O
167 O
patients O
receiving O
methadone O
fulfilled O
the O
inclusion O
criteria O
and O
were O
compared O
with O
a O
control O
group O
of O
80 O
injection O
drug O
users O
not O
receiving O
methadone O
. O

in O
addition O
to O
methadone O
dose O
, O
15 O
demographic O
, O
biological O
, O
and O
pharmacological O
variables O
were O
considered O
as O
potential O
risk O
factors O
for O
qt B-NEG
prolongation I-NEG
. O

results O
: O
among O
167 O
methadone O
maintenance O
patients O
, O
the O
prevalence O
of O
qtc O
prolongation O
to O
0.50 O
second((1/2) O
) O
or O
longer O
was O
16.2% O
compared O
with O
0% O
in O
80 O
control O
subjects O
. O

six O
patients O
( O
3.6% O
) O
in O
the O
methadone O
group O
presented O
torsades B-NEG
de I-NEG
pointes I-NEG
. O

qtc O
length O
was O
weakly O
but O
significantly O
associated O
with O
methadone O
daily O
dose O
( O
spearman O
rank O
correlation O
coefficient O
, O
0.20 O
; O
p<.01) O
. O

multivariate O
regression O
analysis O
allowed O
attribution O
of O
31.8% O
of O
qtc O
variability O
to O
methadone O
dose O
, O
cytochrome O
p-450 O
3a4 O
drug-drug O
interactions O
, O
hypokalemia B-NEG
, O
and O
altered O
liver O
function O
. O

conclusions O
: O
qt B-NEG
interval I-NEG
prolongation I-NEG
in O
methadone O
maintenance O
patients O
hospitalized O
in O
a O
tertiary O
care O
center O
is O
a O
frequent O
finding O
. O

methadone O
dose O
, O
presence O
of O
cytochrome O
p-450 O
3a4 O
inhibitors O
, O
potassium O
level O
, O
and O
liver O
function O
contribute O
to O
qt B-NEG
prolongation I-NEG
. O
long B-NEG
qt I-NEG
syndrome I-NEG
can O
occur O
with O
low O
doses O
of O
methadone O
. O

-DOCSTART- O

mechanisms O
of O
hypertension B-NEG
induced O
by O
nitric O
oxide O
( O
no O
) O
deficiency O
: O
focus O
on O
venous O
function O
. O

loss O
of O
endothelial O
cell-derived O
nitric O
oxide O
( O
no O
) O
in O
hypertension B-NEG
is O
a O
hallmark O
of O
arterial B-NEG
dysfunction I-NEG
. O

experimental O
hypertension B-NEG
created O
by O
the O
removal O
of O
no O
, O
however O
, O
involves O
mechanisms O
in O
addition O
to O
decreased O
arterial O
vasodilator O
activity O
. O

these O
include O
augmented O
endothelin-1 O
( O
et-1 O
) O
release O
, O
increased O
sympathetic O
nervous O
system O
activity O
, O
and O
elevated O
tissue O
oxidative O
stress O
. O

we O
hypothesized O
that O
increased O
venous O
smooth O
muscle O
( O
venomotor O
) O
tone O
plays O
a O
role O
in O
nomega-nitro-l-arginine O
( O
lnna O
) O
hypertension B-NEG
through O
these O
mechanisms O
. O

rats O
were O
treated O
with O
the O
no O
synthase O
inhibitor O
lnna O
( O
0.5 O
g/l O
in O
drinking O
water O
) O
for O
2 O
weeks O
. O

mean O
arterial O
pressure O
of O
conscious O
rats O
was O
119 O
+/- O
2 O
mm O
hg O
in O
control O
and O
194 O
+/- O
5 O
mm O
hg O
in O
lnna O
rats O
(p<0.05) O
. O

carotid O
arteries O
and O
vena O
cava O
were O
removed O
for O
measurement O
of O
isometric O
contraction O
. O

maximal O
contraction O
to O
norepinephrine O
was O
modestly O
reduced O
in O
arteries O
from O
lnna O
compared O
with O
control O
rats O
whereas O
the O
maximum O
contraction O
to O
et-1 O
was O
significantly O
reduced O
( O
54% O
control) O
. O

maximum O
contraction O
of O
vena O
cava O
to O
norepinephrine O
( O
37% O
control O
) O
also O
was O
reduced O
but O
no O
change O
in O
response O
to O
et-1 O
was O
observed O
. O

mean O
circulatory O
filling O
pressure O
, O
an O
in O
vivo O
measure O
of O
venomotor O
tone O
, O
was O
not O
elevated O
in O
lnna O
hypertension B-NEG
at O
1 O
or O
2 O
weeks O
after O
lnna O
. O

the O
superoxide O
scavenger O
tempol O
(30 O
, O
100 O
, O
and O
300 O
micromol O
kg(-1) O
, O
iv O
) O
did O
not O
change O
arterial O
pressure O
in O
control O
rats O
but O
caused O
a O
dose-dependent O
decrease O
in O
lnna O
rats O
( O
-18 O
+/- O
8, O
-26 O
+/- O
15 O
, O
and O
-54 O
+/- O
11 O
mm O
hg) O
. O

similarly O
, O
ganglionic O
blockade O
with O
hexamethonium O
caused O
a O
significantly O
greater O
fall O
in O
lnna O
hypertensive B-NEG
rats O
( O
76 O
+/- O
9 O
mm O
hg O
) O
compared O
with O
control O
rats O
( O
35 O
+/- O
10 O
mm O
hg) O
. O

carotid O
arteries O
, O
vena O
cava O
, O
and O
sympathetic O
ganglia O
from O
lnna O
rats O
had O
higher O
basal O
levels O
of O
superoxide O
compared O
with O
those O
from O
control O
rats O
. O

these O
data O
suggest O
that O
while O
no O
deficiency O
increases O
oxidative O
stress O
and O
sympathetic O
activity O
in O
both O
arterial O
and O
venous O
vessels O
, O
the O
impact O
on O
veins O
does O
not O
make O
a O
major O
contribution O
to O
this O
form O
of O
hypertension B-NEG
. O

-DOCSTART- O

association O
of O
drd2 O
polymorphisms O
and O
chlorpromazine-induced O
extrapyramidal B-NEG
syndrome I-NEG
in O
chinese O
schizophrenic B-NEG
patients O
. O

aim O
: O
extrapyramidal B-NEG
syndrome I-NEG
( O
eps B-NEG
) O
is O
most O
commonly O
affected O
by O
typical O
antipsychotic O
drugs O
that O
have O
a O
high O
affinity O
with O
the O
d2 O
receptor O
. O

recently O
, O
many O
research O
groups O
have O
reported O
on O
the O
positive O
relationship O
between O
the O
genetic O
variations O
in O
the O
drd2 O
gene O
and O
the O
therapeutic O
response O
in O
schizophrenia B-NEG
patients O
as O
a O
result O
of O
the O
role O
of O
variations O
in O
the O
receptor O
in O
modulating O
receptor O
expression O
. O

in O
this O
study O
, O
we O
evaluate O
the O
role O
drd2 O
plays O
in O
chlorpromazine-induced O
eps B-NEG
in O
schizophrenic B-NEG
patients O
. O

methods O
: O
we O
identified O
seven O
snp(single O
nucleotide O
polymorphism O
) O
(-141cins>del O
, O
taqib O
, O
taqid O
, O
ser311cys O
, O
rs6275 O
, O
rs6277 O
and O
taqia O
) O
in O
the O
drd2 O
gene O
in O
146 O
schizophrenic B-NEG
inpatients O
( O
59 O
with O
eps B-NEG
and O
87 O
without O
eps B-NEG
according O
to O
the O
simpson-angus O
scale O
) O
treated O
with O
chlorpromazine O
after O
8 O
weeks O
. O

the O
alleles O
of O
all O
loci O
were O
determined O
by O
pcr O
( O
polymerase O
chain O
reaction) O
. O

results O
: O
polymorphisms O
taqid O
, O
ser311cys O
and O
rs6277 O
were O
not O
polymorphic O
in O
the O
population O
recruited O
in O
the O
present O
study O
. O

no O
statistical O
significance O
was O
found O
in O
the O
allele O
distribution O
of O
-141cins>del O
, O
taqib O
, O
rs6275 O
and O
taqia O
or O
in O
the O
estimated O
haplotypes O
( O
constituted O
by O
taqib O
, O
rs6275 O
and O
taqia O
) O
in O
linkage O
disequilibrium O
between O
the O
two O
groups O
. O

conclusion O
: O
our O
results O
did O
not O
lend O
strong O
support O
to O
the O
view O
that O
the O
genetic O
variation O
of O
the O
drd2 O
gene O
plays O
a O
major O
role O
in O
the O
individually O
variable O
adverse O
effect O
induced O
by O
chlorpromazine O
, O
at O
least O
in O
chinese O
patients O
with O
schizophrenia B-NEG
. O

our O
results O
confirmed O
a O
previous O
study O
on O
the O
relationship O
between O
drd2 O
and O
eps B-NEG
in O
caucasians O
. O

-DOCSTART- O

physical O
training O
decreases O
susceptibility O
to O
subsequent O
pilocarpine-induced O
seizures B-NEG
in O
the O
rat O
. O

regular O
motor O
activity O
has O
many O
benefits O
for O
mental O
and O
physical O
condition O
but O
its O
implications O
for O
epilepsy B-NEG
are O
still O
controversial O
. O

in O
order O
to O
elucidate O
this O
problem O
, O
we O
have O
studied O
the O
effect O
of O
long-term O
physical O
activity O
on O
susceptibility O
to O
subsequent O
seizures B-NEG
. O

male O
wistar O
rats O
were O
subjected O
to O
repeated O
training O
sessions O
in O
a O
treadmill O
and O
swimming O
pool O
. O

thereafter O
, O
seizures B-NEG
were O
induced O
by O
pilocarpine O
injections O
in O
trained O
and O
non-trained O
control O
groups O
. O

during O
the O
acute O
period O
of O
status B-NEG
epilepticus I-NEG
, O
we O
measured O
: O
( O
1 O
) O
the O
latency O
of O
the O
first O
motor O
sign O
, O
( O
2 O
) O
the O
intensity O
of O
seizures B-NEG
, O
( O
3 O
) O
the O
time O
when O
it O
occurred O
within O
the O
6-h O
observation O
period O
, O
and O
( O
4 O
) O
the O
time O
when O
the O
acute O
period O
ended O
. O

all O
these O
behavioral O
parameters O
showed O
statistically O
significant O
changes O
suggesting O
that O
regular O
physical O
exercises O
decrease O
susceptibility O
to O
subsequently O
induced O
seizures B-NEG
and O
ameliorate O
the O
course O
of O
experimentally O
induced O
status B-NEG
epilepticus I-NEG
. O

-DOCSTART- O

tonic O
dopaminergic O
stimulation O
impairs B-NEG
associative I-NEG
learning I-NEG
in O
healthy O
subjects O
. O

endogenous O
dopamine O
plays O
a O
central O
role O
in O
salience O
coding O
during O
associative O
learning O
. O

administration O
of O
the O
dopamine O
precursor O
levodopa O
enhances O
learning O
in O
healthy O
subjects O
and O
stroke B-NEG
patients O
. O

because O
levodopa O
increases O
both O
phasic O
and O
tonic O
dopaminergic O
neurotransmission O
, O
the O
critical O
mechanism O
mediating O
the O
enhancement O
of O
learning O
is O
unresolved O
. O

we O
here O
probed O
how O
selective O
tonic O
dopaminergic O
stimulation O
affects O
associative O
learning O
. O

forty O
healthy O
subjects O
were O
trained O
in O
a O
novel O
vocabulary O
of O
45 O
concrete O
nouns O
over O
the O
course O
of O
5 O
consecutive O
training O
days O
in O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
design O
. O

subjects O
received O
the O
tonically O
stimulating O
dopamine-receptor O
agonist O
pergolide O
( O
0.1 O
mg O
) O
vs O
placebo O
120 O
min O
before O
training O
on O
each O
training O
day O
. O

the O
dopamine O
agonist O
significantly O
impaired B-NEG
novel I-NEG
word I-NEG
learning I-NEG
compared O
to O
placebo O
. O

this O
learning O
decrement O
persisted O
up O
to O
the O
last O
follow-up O
4 O
weeks O
post-training O
. O

subjects O
treated O
with O
pergolide O
also O
showed O
restricted O
emotional O
responses O
compared O
to O
the O
placebo O
group O
. O

the O
extent O
of O
'flattened' O
affect O
with O
pergolide O
was O
related O
to O
the O
degree O
of O
learning O
inhibition O
. O

these O
findings O
suggest O
that O
tonic O
occupation O
of O
dopamine O
receptors O
impairs O
learning O
by O
competition O
with O
phasic O
dopamine O
signals O
. O

thus O
, O
phasic O
signaling O
seems O
to O
be O
the O
critical O
mechanism O
by O
which O
dopamine O
enhances O
associative O
learning O
in O
healthy O
subjects O
and O
stroke B-NEG
patients O
. O

-DOCSTART- O

minocycline-induced O
vasculitis B-NEG
fulfilling O
the O
criteria O
of O
polyarteritis B-NEG
nodosa I-NEG
. O

a O
47-year-old O
man O
who O
had O
been O
taking O
minocycline O
for O
palmoplantar B-NEG
pustulosis I-NEG
developed O
fever B-NEG
, O
myalgias B-NEG
, O
polyneuropathy B-NEG
, O
and O
testicular B-NEG
pain I-NEG
, O
with O
elevated O
c-reactive O
protein O
(crp) O
. O

neither O
myeloperoxidase- O
nor O
proteinase-3-antineutrophil O
cytoplasmic O
antibody O
was O
positive O
. O

these O
manifestations O
met O
the O
american O
college O
of O
rheumatology O
1990 O
criteria O
for O
the O
classification O
of O
polyarteritis B-NEG
nodosa I-NEG
. O

stopping O
minocycline O
led O
to O
amelioration O
of O
symptoms O
and O
normalization O
of O
crp O
level O
. O

to O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline-induced O
vasculitis B-NEG
satisfying O
the O
criteria O
. O

differential O
diagnosis O
for O
drug-induced O
disease O
is O
invaluable O
even O
for O
patients O
with O
classical O
polyarteritis B-NEG
nodosa I-NEG
. O

-DOCSTART- O

intramuscular O
hepatitis B-NEG
b I-NEG
immune O
globulin O
combined O
with O
lamivudine O
in O
prevention O
of O
hepatitis B-NEG
b I-NEG
recurrence O
after O
liver O
transplantation O
. O

background O
: O
combined O
hepatitis B-NEG
b I-NEG
immune O
globulin O
( O
hbig O
) O
and O
lamivudine O
in O
prophylaxis O
of O
the O
recurrence O
of O
hepatitis B-NEG
b I-NEG
after O
liver O
transplantation O
has O
significantly O
improved O
the O
survival O
of O
hbsag O
positive O
patients O
. O

this O
study O
was O
undertaken O
to O
evaluate O
the O
outcomes O
of O
liver O
transplantation O
for O
patients O
with O
hepatitis B-NEG
b I-NEG
virus O
(hbv) O
. O

methods O
: O
a O
retrospective O
chart O
analysis O
and O
a O
review O
of O
the O
organ O
transplant O
database O
identified O
51 O
patients O
( O
43 O
men O
and O
8 O
women O
) O
transplanted O
for O
benign O
hbv-related O
cirrhotic B-NEG
diseases I-NEG
between O
june O
2002 O
and O
december O
2004 O
who O
had O
survived O
more O
than O
3 O
months O
. O

hbig O
was O
administered O
intravenously O
during O
the O
first O
week O
and O
intramuscularly O
thereafter O
. O

results O
: O
at O
a O
median O
follow-up O
of O
14.1 O
months O
, O
the O
overall O
recurrence O
rate O
in O
the O
51 O
patients O
was O
3.9% O
(2/51) O
. O

the O
overall O
patient O
survival O
was O
88.3% O
, O
and O
82.4% O
after O
1 O
and O
2 O
years O
, O
respectively O
. O

a O
daily O
oral O
dose O
of O
100 O
mg O
lamivudine O
for O
2 O
weeks O
before O
transplantation O
for O
10 O
patients O
enabled O
57.1% O
( O
4/7 O
) O
and O
62.5% O
( O
5/8 O
) O
of O
hbv-dna O
and O
hbeag O
positive O
patients O
respectively O
to O
convert O
to O
be O
negative O
. O

intramuscular O
hbig O
was O
well O
tolerated O
in O
all O
patients O
. O

conclusion O
: O
lamivudine O
combined O
with O
intramuscular O
hbig O
can O
effectively O
prevent O
allograft O
from O
the O
recurrence O
of O
hbv O
after O
liver O
transplantation O
. O

-DOCSTART- O

anticonvulsant O
effect O
of O
eslicarbazepine O
acetate O
( O
bia O
2-093 O
) O
on O
seizures B-NEG
induced O
by O
microperfusion O
of O
picrotoxin O
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

eslicarbazepine O
acetate O
( O
bia O
2-093 O
, O
s-(-)-10-acetoxy-10,11-dihydro-5h-dibenzo/b,f/azepine-5-carboxamide O
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
phase O
iii O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine O
( O
cbz O
) O
and O
oxcarbazepine O
(oxc) O
. O

we O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine O
acetate O
on O
a O
whole-animal O
model O
in O
which O
partial O
seizures B-NEG
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure B-NEG
patterns O
. O

in O
the O
animals O
treated O
with O
threshold O
doses O
of O
picrotoxin O
, O
the O
average O
number O
of O
seizures B-NEG
was O
2.3+/-1.2 O
, O
and O
average O
seizure B-NEG
duration O
was O
39.5+/-8.4s O
. O

pre-treatment O
with O
a O
dose O
of O
30 O
mg/kg O
2h O
before O
picrotoxin O
microperfusion O
prevented O
seizures B-NEG
in O
the O
75% O
of O
the O
rats O
. O

lower O
doses O
(3 O
and O
10mg/kg O
) O
did O
not O
suppress O
seizures B-NEG
, O
however O
, O
after O
administration O
of O
10mg/kg O
, O
significant O
reductions O
in O
seizures B-NEG
duration O
( O
24.3+/-6.8s O
) O
and O
seizure B-NEG
number O
( O
1.6+/-0.34 O
) O
were O
found O
. O

no O
adverse O
effects O
of O
eslicarbazepine O
acetate O
were O
observed O
in O
the O
behavioral/eeg O
patterns O
studied O
, O
including O
sleep/wakefulness O
cycle O
, O
at O
the O
doses O
studied O
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones O
. O

chinese O
herbal O
medicine O
preparations O
are O
widely O
available O
and O
often O
regarded O
by O
the O
public O
as O
natural O
and O
safe O
remedies O
for O
a O
variety O
of O
medical O
conditions O
. O
nephropathy B-NEG
caused O
by O
chinese O
herbs O
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic O
acids O
. O

we O
report O
a O
23-year-old O
woman O
who O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
following O
prolonged O
use O
of O
a O
proprietary O
chinese O
herbal O
slimming O
pill O
that O
contained O
anthraquinone O
derivatives O
, O
extracted O
from O
rhizoma O
rhei O
(rhubarb) O
. O

the O
renal B-NEG
injury I-NEG
was O
probably O
aggravated O
by O
the O
concomitant O
intake O
of O
a O
non-steroidal O
anti-inflammatory O
drug O
, O
diclofenac O
. O

renal O
pathology O
was O
that O
of O
hypocellular O
interstitial O
fibrosis B-NEG
. O

spontaneous O
renal O
recovery O
occurred O
upon O
cessation O
of O
the O
slimming O
pills O
, O
but O
mild O
interstitial O
fibrosis B-NEG
and O
tubular O
atrophy B-NEG
was O
still O
evident O
histologically O
4 O
months O
later O
. O

although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone-containing O
herbal O
agent O
and O
renal B-NEG
injury I-NEG
remains O
to O
be O
proven O
, O
phytotherapy-associated O
interstitial O
nephropathy B-NEG
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal B-NEG
failure I-NEG
. O

-DOCSTART- O

chloroacetaldehyde O
as O
a O
sulfhydryl O
reagent O
: O
the O
role O
of O
critical O
thiol O
groups O
in O
ifosfamide O
nephropathy B-NEG
. O

chloroacetaldehyde O
( O
caa O
) O
is O
a O
metabolite O
of O
the O
alkylating O
agent O
ifosfamide O
( O
ifo O
) O
and O
putatively O
responsible O
for O
renal B-NEG
damage I-NEG
following O
anti- O
tumor B-NEG
therapy O
with O
ifo O
. O

depletion O
of O
sulfhydryl O
( O
sh O
) O
groups O
has O
been O
reported O
from O
cell O
culture O
, O
animal O
and O
clinical O
studies O
. O

in O
this O
work O
the O
effect O
of O
caa O
on O
human O
proximal O
tubule O
cells O
in O
primary O
culture O
( O
hrptec O
) O
was O
investigated O
. O
toxicity B-NEG
of O
caa O
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
ldh O
release O
, O
trypan O
blue O
exclusion O
assay O
and O
caspase-3 O
activity O
. O

free O
thiols O
were O
measured O
by O
the O
method O
of O
ellman O
. O

caa O
reduced O
hrptec O
cell O
number O
and O
protein O
, O
induced O
a O
loss O
in O
free O
intracellular O
thiols O
and O
an O
increase O
in O
necrosis B-NEG
markers O
. O

caa O
but O
not O
acrolein O
inhibited O
the O
cysteine O
proteases O
caspase-3 O
, O
caspase-8 O
and O
cathepsin O
b. O

caspase O
activation O
by O
cisplatin O
was O
inhibited O
by O
caa O
. O

in O
cells O
stained O
with O
fluorescent O
dyes O
targeting O
lysosomes O
, O
caa O
induced O
an O
increase O
in O
lysosomal O
size O
and O
lysosomal O
leakage O
. O

the O
effects O
of O
caa O
on O
cysteine O
protease O
activities O
and O
thiols O
could O
be O
reproduced O
in O
cell O
lysate O
. O

acidification O
, O
which O
slowed O
the O
reaction O
of O
caa O
with O
thiol O
donors O
, O
could O
also O
attenuate O
effects O
of O
caa O
on O
necrosis B-NEG
markers O
, O
thiol O
depletion O
and O
cysteine O
protease O
inhibition O
in O
living O
cells O
. O

thus O
, O
caa O
directly O
reacts O
with O
cellular O
protein O
and O
non-protein O
thiols O
, O
mediating O
its O
toxicity B-NEG
on O
hrptec O
. O

this O
effect O
can O
be O
reduced O
by O
acidification O
. O

therefore O
, O
urinary O
acidification O
could O
be O
an O
option O
to O
prevent O
ifo O
nephropathy B-NEG
in O
patients O
. O

-DOCSTART- O

stereological O
methods O
reveal O
the O
robust O
size O
and O
stability O
of O
ectopic O
hilar O
granule O
cells O
after O
pilocarpine-induced O
status B-NEG
epilepticus I-NEG
in O
the O
adult O
rat O
. O

following O
status B-NEG
epilepticus I-NEG
in O
the O
rat O
, O
dentate O
granule O
cell O
neurogenesis O
increases O
greatly O
, O
and O
many O
of O
the O
new O
neurons O
appear O
to O
develop O
ectopically O
, O
in O
the O
hilar O
region O
of O
the O
hippocampal O
formation O
. O

it O
has O
been O
suggested O
that O
the O
ectopic O
hilar O
granule O
cells O
could O
contribute O
to O
the O
spontaneous O
seizures B-NEG
that O
ultimately O
develop O
after O
status B-NEG
epilepticus I-NEG
. O

however O
, O
the O
population O
has O
never O
been O
quantified O
, O
so O
it O
is O
unclear O
whether O
it O
is O
substantial O
enough O
to O
have O
a O
strong O
influence O
on O
epileptogenesis O
. O

to O
quantify O
this O
population O
, O
the O
total O
number O
of O
ectopic O
hilar O
granule O
cells O
was O
estimated O
using O
unbiased O
stereology O
at O
different O
times O
after O
pilocarpine-induced O
status B-NEG
epilepticus I-NEG
. O

the O
number O
of O
hilar O
neurons O
immunoreactive O
for O
prox-1 O
, O
a O
granule-cell-specific O
marker O
, O
was O
estimated O
using O
the O
optical O
fractionator O
method O
. O

the O
results O
indicate O
that O
the O
size O
of O
the O
hilar O
ectopic O
granule O
cell O
population O
after O
status B-NEG
epilepticus I-NEG
is O
substantial O
, O
and O
stable O
over O
time O
. O

interestingly O
, O
the O
size O
of O
the O
population O
appears O
to O
be O
correlated O
with O
the O
frequency O
of O
behavioral O
seizures B-NEG
, O
because O
animals O
with O
more O
ectopic O
granule O
cells O
in O
the O
hilus O
have O
more O
frequent O
behavioral O
seizures B-NEG
. O

the O
hilar O
ectopic O
granule O
cell O
population O
does O
not O
appear O
to O
vary O
systematically O
across O
the O
septotemporal O
axis O
, O
although O
it O
is O
associated O
with O
an O
increase O
in O
volume O
of O
the O
hilus O
. O

the O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine O
model O
of O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
. O

-DOCSTART- O

a O
prospective O
, O
open-label O
trial O
of O
galantamine O
in O
autistic B-NEG
disorder I-NEG
. O

objective O
: O
post-mortem O
studies O
have O
reported O
abnormalities O
of O
the O
cholinergic O
system O
in O
autism B-NEG
. O

the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
use O
of O
galantamine O
, O
an O
acetylcholinesterase O
inhibitor O
and O
nicotinic O
receptor O
modulator O
, O
in O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B-NEG
. O

methods O
: O
thirteen O
medication-free O
children O
with O
autism B-NEG
( O
mean O
age O
, O
8.8 O
+/- O
3.5 O
years O
) O
participated O
in O
a O
12-week O
, O
open-label O
trial O
of O
galantamine O
. O

patients O
were O
rated O
monthly O
by O
parents O
on O
the O
aberrant O
behavior O
checklist O
( O
abc O
) O
and O
the O
conners' O
parent O
rating O
scale-revised O
, O
and O
by O
a O
physician O
using O
the O
children's O
psychiatric O
rating O
scale O
and O
the O
clinical O
global O
impressions O
scale O
. O

results O
: O
patients O
showed O
a O
significant O
reduction O
in O
parent-rated O
irritability B-NEG
and O
social O
withdrawal O
on O
the O
abc O
as O
well O
as O
significant O
improvements O
in O
emotional O
lability O
and O
inattention O
on O
the O
conners' O
parent O
rating O
scale--revised O
. O

similarly O
, O
clinician O
ratings O
showed O
reductions O
in O
the O
anger O
subscale O
of O
the O
children's O
psychiatric O
rating O
scale O
. O

eight O
of O
13 O
participants O
were O
rated O
as O
responders O
on O
the O
basis O
of O
their O
improvement O
scores O
on O
the O
clinical O
global O
impressions O
scale O
. O

overall O
, O
galantamine O
was O
well-tolerated O
, O
with O
no O
significant O
adverse O
effects O
apart O
from O
headaches B-NEG
in O
one O
patient O
. O

conclusion O
: O
in O
this O
open O
trial O
, O
galantamine O
was O
well-tolerated O
and O
appeared O
to O
be O
beneficial O
for O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B-NEG
, O
particularly O
aggression B-NEG
, O
behavioral B-NEG
dyscontrol I-NEG
, O
and O
inattention B-NEG
. O

further O
controlled O
trials O
are O
warranted O
. O

-DOCSTART- O

randomized O
comparison O
of O
olanzapine O
versus O
risperidone O
for O
the O
treatment O
of O
first-episode O
schizophrenia B-NEG
: O
4-month O
outcomes O
. O

objective O
: O
the O
authors O
compared O
4-month O
treatment O
outcomes O
for O
olanzapine O
versus O
risperidone O
in O
patients O
with O
first-episode O
schizophrenia B-NEG
spectrum O
disorders O
. O

method O
: O
one O
hundred O
twelve O
subjects O
( O
70% O
male O
; O
mean O
age=23.3 O
years O
[sd O
= O
5.1] O
) O
with O
first-episode O
schizophrenia B-NEG
(75%) O
, O
schizophreniform B-NEG
disorder I-NEG
(17%) O
, O
or O
schizoaffective B-NEG
disorder I-NEG
( O
8% O
) O
were O
randomly O
assigned O
to O
treatment O
with O
olanzapine O
( O
2.5-20 O
mg/day O
) O
or O
risperidone O
( O
1-6 O
mg/day) O
. O

results O
: O
response O
rates O
did O
not O
significantly O
differ O
between O
olanzapine O
(43.7% O
, O
95% O
ci=28.8%-58.6% O
) O
and O
risperidone O
(54.3% O
, O
95% O
ci=39.9%-68.7%) O
. O

among O
those O
responding O
to O
treatment O
, O
more O
subjects O
in O
the O
olanzapine O
group O
(40.9% O
, O
95% O
ci=16.8%-65.0% O
) O
than O
in O
the O
risperidone O
group O
(18.9% O
, O
95% O
ci=0%-39.2% O
) O
had O
subsequent O
ratings O
not O
meeting O
response O
criteria O
. O

negative O
symptom O
outcomes O
and O
measures O
of O
parkinsonism B-NEG
and O
akathisia B-NEG
did O
not O
differ O
between O
medications O
. O
extrapyramidal B-NEG
symptom I-NEG
severity O
scores O
were O
1.4 O
( O
95% O
ci=1.2-1.6 O
) O
with O
risperidone O
and O
1.2 O
( O
95% O
ci=1.0-1.4 O
) O
with O
olanzapine O
. O

significantly O
more O
weight B-NEG
gain I-NEG
occurred O
with O
olanzapine O
than O
with O
risperidone O
: O
the O
increase O
in O
weight O
at O
4 O
months O
relative O
to O
baseline O
weight O
was O
17.3% O
( O
95% O
ci=14.2%-20.5% O
) O
with O
olanzapine O
and O
11.3% O
( O
95% O
ci=8.4%-14.3% O
) O
with O
risperidone O
. O

body O
mass O
index O
at O
baseline O
and O
at O
4 O
months O
was O
24.3 O
( O
95% O
ci=22.8-25.7 O
) O
versus O
28.2 O
( O
95% O
ci=26.7-29.7 O
) O
with O
olanzapine O
and O
23.9 O
( O
95% O
ci=22.5-25.3 O
) O
versus O
26.7 O
( O
95% O
ci=25.2-28.2 O
) O
with O
risperidone O
. O

conclusions O
: O
clinical O
outcomes O
with O
risperidone O
were O
equal O
to O
those O
with O
olanzapine O
, O
and O
response O
may O
be O
more O
stable O
. O

olanzapine O
may O
have O
an O
advantage O
for O
motor O
side O
effects O
. O

both O
medications O
caused O
substantial O
rapid O
weight B-NEG
gain I-NEG
, O
but O
weight B-NEG
gain I-NEG
was O
greater O
with O
olanzapine O
. O

-DOCSTART- O

early O
paracentral O
visual B-NEG
field I-NEG
loss I-NEG
in O
patients O
taking O
hydroxychloroquine O
. O

objective O
: O
to O
review O
the O
natural O
history O
and O
ocular O
and O
systemic O
adverse O
effects O
of O
patients O
taking O
hydroxychloroquine O
sulfate O
who O
attended O
an O
ophthalmic O
screening O
program O
. O

design O
: O
retrospective O
study O
. O

results O
: O
records O
of O
262 O
patients O
who O
were O
taking O
hydroxychloroquine O
and O
screened O
in O
the O
department O
of O
ophthalmology O
were O
reviewed O
. O

of O
the O
262 O
patients O
, O
14 O
( O
18% O
) O
of O
76 O
who O
had O
stopped O
treatment O
at O
the O
time O
of O
the O
study O
experienced O
documented O
adverse O
effects O
. O

systemic O
adverse O
effects O
occurred O
in O
8 O
patients O
( O
10.5% O
) O
and O
ocular O
adverse O
effects O
, O
in O
5 O
(6.5%) O
. O

thirty-five O
patients O
( O
13.4% O
) O
had O
visual B-NEG
field I-NEG
abnormalities I-NEG
, O
which O
were O
attributed O
to O
hydroxychloroquine O
treatment O
in O
4 O
patients O
(1.5%) O
. O

three O
of O
the O
4 O
patients O
were O
taking O
less O
than O
6.5 O
mg/kg O
per O
day O
and O
all O
patients O
had O
normal O
renal O
and O
liver O
function O
test O
results O
. O

conclusions O
: O
the O
current O
study O
used O
a O
protocol O
of O
visual O
acuity O
and O
color O
vision O
assessment O
, O
funduscopy O
, O
and O
humphrey O
10-2 O
visual O
field O
testing O
and O
shows O
that O
visual B-NEG
field I-NEG
defects I-NEG
appeared O
before O
any O
corresponding O
changes O
in O
any O
other O
tested O
clinical O
parameters O
; O
the O
defects O
were O
reproducible O
and O
the O
test O
parameters O
were O
reliable O
. O

patients O
taking O
hydroxychloroquine O
can O
demonstrate O
a O
toxic O
reaction O
in O
the O
retina O
despite O
the O
absence O
of O
known O
risk O
factors O
. O

screening O
, O
including O
humphrey O
10-2 O
visual O
field O
assessment O
, O
is O
recommended O
2 O
years O
after O
the O
initial O
baseline O
and O
yearly O
thereafter O
. O

-DOCSTART- O

peri-operative O
atrioventricular B-NEG
block I-NEG
as O
a O
result O
of O
chemotherapy O
with O
epirubicin O
and O
paclitaxel O
. O

a O
47-year-old O
woman O
presented O
for O
mastectomy O
and O
immediate O
latissimus O
dorsi O
flap O
reconstruction O
having O
been O
diagnosed O
with O
carcinoma B-NEG
of I-NEG
the I-NEG
breast I-NEG
6 O
months O
previously O
. O

in O
the O
preceding O
months O
she O
had O
received O
neo-adjuvant O
chemotherapy O
with O
epirubicin O
, O
paclitaxel O
( O
taxol O
) O
and O
cyclophosphamide O
. O

this O
had O
been O
apparently O
uncomplicated O
and O
she O
had O
maintained O
a O
remarkably O
high O
level O
of O
physical O
activity O
. O

she O
was O
found O
to O
be O
bradycardic B-NEG
at O
pre-operative O
assessment O
but O
had O
no O
cardiac O
symptoms O
. O

second O
degree O
mobitz O
type O
ii O
atrioventricular B-NEG
block I-NEG
was O
diagnosed O
on O
electrocardiogram O
, O
and O
temporary O
transvenous O
ventricular O
pacing O
instituted O
in O
the O
peri-operative O
period O
. O

we O
discuss O
how O
evidence-based O
guidelines O
would O
not O
have O
been O
helpful O
in O
this O
case O
, O
and O
how O
chemotherapy O
can O
exhibit O
substantial O
cardiotoxicity B-NEG
that O
may O
develop O
over O
many O
years O
. O

we O
suggest O
that O
patients O
who O
have O
received O
chemotherapy O
at O
any O
time O
should O
have O
a O
pre-operative O
electrocardiogram O
even O
if O
they O
are O
asymptomatic O
. O

-DOCSTART- O

risks O
and O
benefits O
of O
cox-2 O
inhibitors O
vs O
non-selective O
nsaids O
: O
does O
their O
cardiovascular O
risk O
exceed O
their O
gastrointestinal O
benefit? O

a O
retrospective O
cohort O
study O
. O

objectives O
: O
the O
risk O
of O
acute B-NEG
myocardial I-NEG
infarction I-NEG
( O
ami B-NEG
) O
with O
cox-2 O
inhibitors O
may O
offset O
their O
gastrointestinal O
( O
gi O
) O
benefit O
compared O
with O
non-selective O
( O
ns O
) O
non-steroidal O
anti-inflammatory O
drugs O
(nsaids) O
. O

we O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
ami B-NEG
and O
gi B-NEG
bleeding I-NEG
among O
elderly O
patients O
using O
cox-2 O
inhibitors O
, O
ns-nsaids O
and O
acetaminophen O
. O

methods O
: O
we O
conducted O
a O
retrospective O
cohort O
study O
using O
administrative O
data O
of O
patients O
> O
or O
=65 O
years O
of O
age O
who O
filled O
a O
prescription O
for O
nsaid O
or O
acetaminophen O
during O
1999-2002 O
. O

outcomes O
were O
compared O
using O
cox O
regression O
models O
with O
time-dependent O
exposures O
. O

results O
: O
person-years O
of O
exposure O
among O
non-users O
of O
aspirin O
were O
: O
75,761 O
to O
acetaminophen O
, O
42,671 O
to O
rofecoxib O
65,860 O
to O
celecoxib O
, O
and O
37,495 O
to O
ns-nsaids O
. O

among O
users O
of O
aspirin O
, O
they O
were O
: O
14,671 O
to O
rofecoxib O
, O
22,875 O
to O
celecoxib O
, O
9,832 O
to O
ns-nsaids O
and O
38,048 O
to O
acetaminophen O
. O

among O
non-users O
of O
aspirin O
, O
the O
adjusted O
hazard O
ratios O
( O
95% O
confidence O
interval O
) O
of O
hospitalization O
for O
ami B-NEG
/gi O
vs O
the O
acetaminophen O
( O
with O
no O
aspirin O
) O
group O
were O
: O
rofecoxib O
1.27 O
(1.13 O
, O
1.42) O
, O
celecoxib O
0.93 O
(0.83 O
, O
1.03) O
, O
naproxen O
1.59 O
(1.31 O
, O
1.93) O
, O
diclofenac O
1.17 O
(0.99 O
, O
1.38 O
) O
and O
ibuprofen O
1.05 O
(0.74 O
, O
1.51) O
. O

among O
users O
of O
aspirin O
, O
they O
were O
: O
rofecoxib O
1.73 O
(1.52 O
, O
1.98) O
, O
celecoxib O
1.34 O
(1.19 O
, O
1.52) O
, O
ibuprofen O
1.51 O
(0.95 O
, O
2.41) O
, O
diclofenac O
1.69 O
(1.35 O
, O
2.10) O
, O
naproxen O
1.35 O
(0.97 O
, O
1.88 O
) O
and O
acetaminophen O
1.29 O
(1.17 O
, O
1.42) O
. O

conclusion O
: O
among O
non-users O
of O
aspirin O
, O
naproxen O
seemed O
to O
carry O
the O
highest O
risk O
for O
ami B-NEG
/ O
gi B-NEG
bleeding I-NEG
. O

the O
ami B-NEG
/gi O
toxicity B-NEG
of O
celecoxib O
was O
similar O
to O
that O
of O
acetaminophen O
and O
seemed O
to O
be O
better O
than O
those O
of O
rofecoxib O
and O
ns-nsaids O
. O

among O
users O
of O
aspirin O
, O
both O
celecoxib O
and O
naproxen O
seemed O
to O
be O
the O
least O
toxic O
. O

-DOCSTART- O

quinine-induced O
arrhythmia B-NEG
in O
a O
patient O
with O
severe B-NEG
malaria I-NEG
. O

it O
was O
reported O
that O
there O
was O
a O
case O
of O
severe B-NEG
malaria I-NEG
patient O
with O
jaundice B-NEG
who O
presented O
with O
arrhythmia B-NEG
( O
premature B-NEG
ventricular I-NEG
contraction I-NEG
) O
while O
getting O
quinine O
infusion O
was O
reported O
. O

a O
man O
, O
25 O
years O
old O
, O
was O
admitted O
to O
hospital O
with O
high O
fever B-NEG
, O
chill B-NEG
, O
vomiting B-NEG
, O
jaundice B-NEG
. O

the O
patient O
was O
fully O
conscious O
, O
blood O
pressure O
120/80 O
mmhg O
, O
pulse O
rate O
100 O
x/minute O
, O
regular O
. O

on O
admission O
, O
laboratory O
examination O
showed O
plasmodium O
falciparum O
(++++) O
, O
total O
bilirubin O
8.25 O
mg/dl O
, O
conjugated O
bilirubin O
4.36 O
mg/dl O
, O
unconjugated O
bilirubin O
3.89 O
mg/dl O
, O
potassium O
3.52 O
meq/l O
patient O
was O
diagnosed O
as O
severe B-NEG
malaria I-NEG
with O
jaundice B-NEG
and O
got O
quinine O
infusion O
in O
dextrose O
5% O
500 O
mg/8 O
hour O
. O

on O
the O
second O
day O
the O
patient O
had O
vomitus B-NEG
, O
diarrhea B-NEG
, O
tinnitus B-NEG
, O
loss B-NEG
of I-NEG
hearing I-NEG
. O

after O
30 O
hours O
of O
quinine O
infusion O
the O
patient O
felt O
palpitation B-NEG
and O
electrocardiography O
( O
ecg O
) O
recording O
showed O
premature B-NEG
ventricular I-NEG
contraction I-NEG
( O
pvc B-NEG
) O
> O
5 O
x/minute O
, O
trigemini O
, O
constant O
type-- O
sinoatrial B-NEG
block I-NEG
, O
positive O
u O
wave O
. O

he O
was O
treated O
with O
lidocaine O
50 O
mg O
intravenously O
followed O
by O
infusion O
1500 O
mg O
in O
dextrose O
5%/24 O
hour O
and O
potassium O
aspartate O
tablet O
. O

quinine O
infusion O
was O
discontinued O
and O
changed O
with O
sulfate O
quinine O
tablets O
. O

three O
hours O
later O
the O
patient O
felt O
better O
, O
the O
frequency O
of O
pvc B-NEG
reduced O
to O
4 O
- O
5 O
x/minute O
and O
on O
the O
third O
day O
ecg O
was O
normal O
, O
potassium O
level O
was O
3.34 O
meq/l O
. O

he O
was O
discharged O
on O
7th O
day O
in O
good O
condition O
. O

quinine O
, O
like O
quinidine O
, O
is O
a O
chincona O
alkaloid O
that O
has O
anti- O
arrhythmic B-NEG
property O
, O
although O
it O
also O
pro- O
arrhythmic B-NEG
that O
can O
cause O
various O
arrhythmias B-NEG
, O
including O
severe O
arrhythmia B-NEG
such O
as O
multiple O
pvc B-NEG
. O

administration O
of O
parenteral O
quinine O
must O
be O
done O
carefully O
and O
with O
good O
observation O
because O
of O
its O
pro- O
arrhythmic B-NEG
effect O
, O
especially O
in O
older O
patients O
who O
have O
heart B-NEG
diseases I-NEG
or O
patients O
with O
electrolyte B-NEG
disorder I-NEG
( O
hypokalemia B-NEG
) O
which O
frequently O
occurs O
due O
to O
vomiting B-NEG
and O
or O
diarrhea B-NEG
in O
malaria B-NEG
cases O
. O

-DOCSTART- O

penicillamine-related O
lichenoid B-NEG
dermatitis I-NEG
and O
utility O
of O
zinc O
acetate O
in O
a O
wilson B-NEG
disease I-NEG
patient O
with O
hepatic O
presentation O
, O
anxiety B-NEG
and O
spect O
abnormalities O
. O
wilson's B-NEG
disease I-NEG
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper O
metabolism O
with O
consequent O
copper O
accumulation O
and O
toxicity B-NEG
in O
many O
tissues O
and O
consequent O
hepatic B-NEG
, O
neurologic I-NEG
and I-NEG
psychiatric I-NEG
disorders I-NEG
. O

we O
report O
a O
case O
of O
wilson's B-NEG
disease I-NEG
with O
chronic B-NEG
liver I-NEG
disease I-NEG
; O
moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B-NEG
without O
depression B-NEG
, O
99mtc-ecd-spect O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

during O
the O
follow-up O
of O
our O
patient O
, O
penicillamine O
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid B-NEG
dermatitis I-NEG
, O
and O
zinc O
acetate O
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side-effects O
. O

in O
our O
case O
the O
therapy O
with O
zinc O
acetate O
represented O
an O
effective O
treatment O
for O
a O
wilson's B-NEG
disease I-NEG
patient O
in O
which O
penicillamine-related O
side O
effects O
appeared O
. O

the O
safety O
of O
the O
zinc O
acetate O
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
wilson's B-NEG
disease I-NEG
. O

since O
most O
of O
wilson's B-NEG
disease I-NEG
penicillamine-treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin B-NEG
lesion I-NEG
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
wilson's B-NEG
disease I-NEG
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
wilson's B-NEG
disease I-NEG
phenotypes O
. O

-DOCSTART- O

a O
dramatic O
drop B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
following O
prehospital O
gtn O
administration O
. O

a O
male O
in O
his O
sixties O
with O
no O
history O
of O
cardiac O
chest B-NEG
pain I-NEG
awoke O
with O
chest B-NEG
pain I-NEG
following O
an O
afternoon O
sleep O
. O

the O
patient O
did O
not O
self O
medicate O
. O

the O
patient's O
observations O
were O
within O
normal O
limits O
, O
he O
was O
administered O
oxygen O
via O
a O
face O
mask O
and O
glyceryl O
trinitrate O
(gtn) O
. O

several O
minutes O
after O
the O
gtn O
the O
patient O
experienced O
a O
sudden O
drop B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine O
sulphate O
and O
a O
fluid O
challenge O
. O

there O
was O
no O
further O
deterioration O
in O
the O
patient's O
condition O
during O
transport O
to O
hospital O
. O

there O
are O
very O
few O
documented O
case O
like O
this O
in O
the O
prehospital O
scientific O
literature O
. O

the O
cause O
appears O
to O
be O
the O
bezold-jarish O
reflex O
, O
stimulation O
of O
the O
ventricular O
walls O
which O
in O
turn O
decreases O
sympathetic O
outflow O
from O
the O
vasomotor O
centre O
. O

prehospital O
care O
providers O
who O
are O
managing O
any O
patient O
with O
a O
syncopal B-NEG
episode I-NEG
that O
fails O
to O
recover O
within O
a O
reasonable O
time O
frame O
should O
consider O
the O
bezold-jarisch O
reflex O
as O
the O
cause O
and O
manage O
the O
patient O
accordingly O
. O

-DOCSTART- O

acute B-NEG
encephalopathy I-NEG
and O
cerebral B-NEG
vasospasm I-NEG
after O
multiagent O
chemotherapy O
including O
peg-asparaginase O
and O
intrathecal O
cytarabine O
for O
the O
treatment O
of O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
. O

a O
7-year-old O
girl O
with O
an O
unusual O
reaction O
to O
induction O
chemotherapy O
for O
precursor O
b-cell O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
( O
all B-NEG
) O
is O
described O
. O

the O
patient O
developed O
acute B-NEG
encephalopathy I-NEG
evidenced O
by O
behavioral O
changes O
, O
aphasia B-NEG
, O
incontinence B-NEG
, O
visual B-NEG
hallucinations I-NEG
, O
and O
right-sided O
weakness B-NEG
with O
diffuse O
cerebral B-NEG
vasospasm I-NEG
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine O
. O

vincristine O
, O
dexamethasone O
, O
and O
polyethylene O
glycol-asparaginase O
were O
also O
administered O
before O
the O
episode O
as O
part O
of O
induction O
therapy O
. O

neurologic O
status O
returned O
to O
baseline O
within O
10 O
days O
of O
the O
acute O
event O
, O
and O
magnetic O
resonance O
angiography O
findings O
returned O
to O
normal O
4 O
months O
later O
. O

-DOCSTART- O

comparison O
of O
valsartan/hydrochlorothiazide O
combination O
therapy O
at O
doses O
up O
to O
320/25 O
mg O
versus O
monotherapy O
: O
a O
double-blind O
, O
placebo-controlled O
study O
followed O
by O
long-term O
combination O
therapy O
in O
hypertensive B-NEG
adults O
. O

background O
: O
one O
third O
of O
patients O
treated O
for O
hypertension B-NEG
attain O
adequate O
blood O
pressure O
( O
bp O
) O
control O
, O
and O
multidrug O
regimens O
are O
often O
required O
. O

given O
the O
lifelong O
nature O
of O
hypertension B-NEG
, O
there O
is O
a O
need O
to O
evaluate O
the O
long-term O
efficacy O
and O
tolerability O
of O
higher O
doses O
of O
combination O
anti- O
hypertensive B-NEG
therapies O
. O

objective O
: O
this O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan O
( O
val O
) O
or O
hydrochlorothiazide O
( O
hctz)-monotherapy O
and O
higher-dose O
combinations O
in O
patients O
with O
essential B-NEG
hypertension I-NEG
. O

methods O
: O
the O
first O
part O
of O
this O
study O
was O
an O
8-week O
, O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo O
controlled O
, O
parallel-group O
trial O
. O

patients O
with O
essential B-NEG
hypertension I-NEG
( O
mean O
sitting O
diastolic O
bp O
[msdbp] O
, O
> O
or O
=95 O
mm O
hg O
and O
<110 O
mm O
hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
val O
160 O
or O
320 O
mg O
; O
hctz O
12.5 O
or O
25 O
mg O
; O
val/hctz O
160/12.5 O
, O
320/12.5 O
, O
or O
320/25 O
mg O
; O
or O
placebo O
. O

mean O
changes O
in O
msdbp O
and O
mean O
sitting O
systolic O
bp O
( O
mssbp O
) O
were O
analyzed O
at O
the O
8-week O
core O
study O
end O
point O
. O

val/hctz O
320/12.5 O
and O
320/25 O
mg O
were O
further O
investigated O
in O
a O
54-week O
, O
open-label O
extension O
. O

response O
was O
defined O
as O
msdbp O
<90 O
mm O
hg O
or O
a O
> O
or O
=10 O
mm O
hg O
decrease O
compared O
to O
baseline O
. O

control O
was O
defined O
as O
msdbp O
<90 O
mm O
hg O
compared O
with O
baseline O
. O

tolerability O
was O
assessed O
by O
monitoring O
adverse O
events O
at O
randomization O
and O
all O
subsequent O
study O
visits O
and O
regular O
evaluation O
of O
hematology O
and O
blood O
chemistry O
. O

results O
: O
a O
total O
of O
1346 O
patients O
were O
randomized O
into O
the O
8-week O
core O
study O
( O
734 O
men O
, O
612 O
women O
; O
924 O
white O
, O
291 O
black O
, O
23 O
asian O
, O
108 O
other O
; O
mean O
age O
, O
52.7 O
years O
; O
mean O
weight O
, O
92.6 O
kg) O
. O

all O
active O
treatments O
were O
associated O
with O
significantly O
reduced O
mssbp O
and O
msdbp O
during O
the O
core O
8-week O
study O
, O
with O
each O
monotherapy O
significantly O
contributing O
to O
the O
overall O
effect O
of O
combination O
therapy O
( O
val O
and O
hctz O
, O
p O
< O
0.001) O
. O

each O
combination O
was O
associated O
with O
significantly O
greater O
reductions O
in O
mssbp O
and O
msdbp O
compared O
with O
the O
monotherapies O
and O
placebo O
(all O
, O
p O
< O
0.001) O
. O

the O
mean O
reduction O
in O
mssbp/msdbp O
with O
val/hctz O
320/25 O
mg O
was O
24.7/16.6 O
mm O
hg O
, O
compared O
with O
5.9/7.0 O
mm O
hg O
with O
placebo O
. O

the O
reduction O
in O
mssbp O
was O
significantly O
greater O
with O
val/hctz O
320/25 O
mg O
compared O
with O
val/hctz O
160/12.5 O
mg O
(p O
< O
0.002) O
. O

rates O
of O
response O
and O
bp O
control O
were O
significantly O
higher O
in O
the O
groups O
that O
received O
combination O
treatment O
compared O
with O
those O
that O
received O
monotherapy O
. O

the O
incidence O
of O
hypokalemia B-NEG
was O
lower O
with O
val/hctz O
combinations O
( O
1.8%-6.1% O
) O
than O
with O
hctz O
monotherapies O
(7.1%-13.3%) O
. O

the O
majority O
of O
adverse O
events O
in O
the O
core O
study O
were O
of O
mild O
to O
moderate O
severity O
. O

the O
efficacy O
and O
tolerability O
of O
val/hctz O
combinations O
were O
maintained O
during O
the O
extension O
( O
797 O
patients) O
. O

conclusions O
: O
in O
this O
study O
population O
, O
combination O
therapies O
with O
val/hctz O
were O
associated O
with O
significantly O
greater O
bp O
reductions O
compared O
with O
either O
monotherapy O
, O
were O
well O
tolerated O
, O
and O
were O
associated O
with O
less O
hypokalemia B-NEG
than O
hctz O
alone O
. O

-DOCSTART- O

succimer O
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead-exposed O
rats O
but O
produces O
lasting O
cognitive B-NEG
impairment I-NEG
in O
the O
absence O
of O
lead O
exposure O
. O

background O
: O
there O
is O
growing O
pressure O
for O
clinicians O
to O
prescribe O
chelation O
therapy O
at O
only O
slightly O
elevated O
blood O
lead O
levels O
. O

however O
, O
very O
few O
studies O
have O
evaluated O
whether O
chelation O
improves O
cognitive O
outcomes O
in O
pb-exposed O
children O
, O
or O
whether O
these O
agents O
have O
adverse O
effects O
that O
may O
affect O
brain O
development O
in O
the O
absence O
of O
pb O
exposure O
. O

objectives O
: O
the O
present O
study O
was O
designed O
to O
answer O
these O
questions O
, O
using O
a O
rodent O
model O
of O
early O
childhood O
pb O
exposure O
and O
treatment O
with O
succimer O
, O
a O
widely O
used O
chelating O
agent O
for O
the O
treatment O
of O
pb B-NEG
poisoning I-NEG
. O

results O
: O
pb O
exposure O
produced O
lasting O
impairments B-NEG
in I-NEG
learning I-NEG
, O
attention I-NEG
, O
inhibitory I-NEG
control I-NEG
, O
and I-NEG
arousal I-NEG
regulation I-NEG
, O
paralleling O
the O
areas O
of O
dysfunction O
seen O
in O
pb-exposed O
children O
. O

succimer O
treatment O
of O
the O
pb-exposed O
rats O
significantly O
improved O
learning O
, O
attention O
, O
and O
arousal O
regulation O
, O
although O
the O
efficacy O
of O
the O
treatment O
varied O
as O
a O
function O
of O
the O
pb O
exposure O
level O
and O
the O
specific O
functional O
deficit O
. O

in O
contrast O
, O
succimer O
treatment O
of O
rats O
not O
previously O
exposed O
to O
pb O
produced O
lasting O
and O
pervasive O
cognitive B-NEG
and I-NEG
affective I-NEG
dysfunction I-NEG
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
pb O
exposure O
regimen O
. O

conclusions O
: O
these O
are O
the O
first O
data O
, O
to O
our O
knowledge O
, O
to O
show O
that O
treatment O
with O
any O
chelating O
agent O
can O
alleviate O
cognitive B-NEG
deficits I-NEG
due O
to O
pb O
exposure O
. O

these O
findings O
suggest O
that O
it O
may O
be O
possible O
to O
identify O
a O
succimer O
treatment O
protocol O
that O
improves O
cognitive O
outcomes O
in O
pb-exposed O
children O
. O

however O
, O
they O
also O
suggest O
that O
succimer O
treatment O
should O
be O
strongly O
discouraged O
for O
children O
who O
do O
not O
have O
elevated O
tissue O
levels O
of O
pb O
or O
other O
heavy O
metals O
. O

-DOCSTART- O

caffeine O
challenge O
test O
in O
panic B-NEG
disorder I-NEG
and O
depression B-NEG
with O
panic B-NEG
attacks I-NEG
. O

our O
aim O
was O
to O
observe O
if O
patients O
with O
panic B-NEG
disorder I-NEG
( O
pd B-NEG
) O
and O
patients O
with O
major B-NEG
depression I-NEG
with O
panic B-NEG
attacks I-NEG
( O
mdp B-NEG
) O
( O
diagnostic O
and O
statistical O
manual O
of O
mental B-NEG
disorders I-NEG
, O
fourth O
edition O
criteria O
) O
respond O
in O
a O
similar O
way O
to O
the O
induction O
of O
panic B-NEG
attacks I-NEG
by O
an O
oral O
caffeine O
challenge O
test O
. O

we O
randomly O
selected O
29 O
patients O
with O
pd B-NEG
, O
27 O
with O
mdp B-NEG
, O
25 O
with O
major B-NEG
depression I-NEG
without O
panic B-NEG
attacks I-NEG
( O
md B-NEG
), O
and O
28 O
healthy O
volunteers O
. O

the O
patients O
had O
no O
psychotropic O
drug O
for O
at O
least O
a O
4-week O
period O
. O

in O
a O
randomized O
double-blind O
experiment O
performed O
in O
2 O
occasions O
7 O
days O
apart O
, O
480 O
mg O
caffeine O
and O
a O
caffeine-free O
( O
placebo O
) O
solution O
were O
administered O
in O
a O
coffee O
form O
and O
anxiety B-NEG
scales O
were O
applied O
before O
and O
after O
each O
test O
. O

a O
total O
of O
58.6% O
(n O
= O
17 O
) O
of O
patients O
with O
pd B-NEG
, O
44.4% O
(n O
= O
12 O
) O
of O
patients O
with O
mdp B-NEG
, O
12.0% O
(n O
= O
3) O
of O
patients O
with O
md B-NEG
, O
and O
7.1% O
( O
n= O
2) O
of O
control O
subjects O
had O
a O
panic B-NEG
attack I-NEG
after O
the O
480-mg O
caffeine O
challenge O
test O
( O
chi(2)(3 O
) O
= O
16.22 O
, O
p O
= O
.001) O
. O

the O
patients O
with O
pd B-NEG
and O
mdp B-NEG
were O
more O
sensitive O
to O
caffeine O
than O
were O
patients O
with O
md B-NEG
and O
healthy O
volunteers O
. O

no O
panic B-NEG
attack I-NEG
was O
observed O
after O
the O
caffeine-free O
solution O
intake O
. O

the O
patients O
with O
md B-NEG
had O
a O
lower O
heart O
rate O
response O
to O
the O
test O
than O
all O
the O
other O
groups O
( O
2-way O
analysis O
of O
variance O
, O
group O
by O
time O
interaction O
with O
greenhouse-geisser O
correction O
: O
f(3,762 O
) O
= O
2.85 O
, O
p O
= O
.026) O
. O

our O
data O
suggest O
that O
there O
is O
an O
association O
between O
panic B-NEG
attacks I-NEG
, O
no O
matter O
if O
associated O
with O
pd B-NEG
or O
mdp B-NEG
, O
and O
hyperreactivity O
to O
an O
oral O
caffeine O
challenge O
test O
. O

-DOCSTART- O

mitral O
annuloplasty O
as O
a O
ventricular O
restoration O
method O
for O
the O
failing B-NEG
left I-NEG
ventricle I-NEG
: O
a O
pilot O
study O
. O

background O
and O
aim O
of O
the O
study O
: O
undersized O
mitral O
annuloplasty O
( O
map O
) O
is O
effective O
in O
patients O
with O
dilated B-NEG
cardiomyopathy I-NEG
and O
functional O
mitral B-NEG
regurgitation I-NEG
( O
mr B-NEG
) O
since O
, O
as O
well O
as O
addressing O
the O
mr B-NEG
, O
the O
map O
may O
also O
reshape O
the O
dilated O
left O
ventricular O
( O
lv O
) O
base O
. O

however O
, O
the O
direct O
benefits O
of O
this O
possible O
reshaping O
on O
lv O
function O
in O
the O
absence O
of O
underlying O
mr B-NEG
remain O
incompletely O
understood O
. O

the O
study O
aim O
was O
to O
identify O
these O
benefits O
in O
a O
canine O
model O
of O
acute O
heart B-NEG
failure I-NEG
. O

methods O
: O
six O
dogs O
underwent O
map O
with O
a O
prosthetic O
band O
on O
the O
posterior O
mitral O
annulus O
, O
using O
four O
mattress O
sutures O
. O

the O
sutures O
were O
passed O
individually O
through O
four O
tourniquets O
and O
exteriorized O
untied O
via O
the O
left O
atriotomy O
. O

sonomicrometry O
crystals O
were O
implanted O
around O
the O
mitral O
annulus O
and O
left O
ventricle O
to O
measure O
geometry O
and O
regional O
function O
. O

acute O
heart B-NEG
failure I-NEG
was O
induced O
by O
propranolol O
and O
volume O
loading O
after O
weaning O
from O
cardiopulmonary O
bypass O
; O
an O
absence O
of O
mr B-NEG
was O
confirmed O
by O
echocardiography O
. O

map O
was O
accomplished O
by O
cinching O
the O
tourniquets O
. O

data O
were O
acquired O
at O
baseline O
, O
after O
induction O
of O
acute O
heart B-NEG
failure I-NEG
, O
and O
after O
map O
. O

results O
: O
map O
decreased O
mitral O
annular O
dimensions O
in O
both O
commissure-commissure O
and O
septal-lateral O
directions O
. O

concomitantly O
, O
the O
diastolic O
diameter O
of O
the O
lv O
base O
and O
lv O
sphericity O
decreased O
(i.e. O
, O
improved O
) O
from O
37.4 O
+/- O
9.3 O
to O
35.9 O
+/- O
10 O
mm O
(p O
= O
0.063) O
, O
and O
from O
67.9 O
+/- O
18.6% O
to O
65.3 O
+/- O
18.9% O
(p O
= O
0.016) O
, O
respectively O
. O

decreases O
were O
evident O
in O
both O
lv O
end-diastolic O
pressure O
( O
from O
17 O
+/- O
7 O
to O
15 O
+/- O
6 O
mmhg O
, O
p O
= O
0.0480 O
and O
tau O
( O
from O
48 O
+/- O
8 O
to O
45 O
+/- O
8 O
ms O
, O
p O
<0.01) O
, O
while O
fractional O
shortening O
at O
the O
lv O
base O
increased O
from O
7.7 O
+/- O
4.5% O
to O
9.4 O
+/- O
4.5% O
(p O
= O
0.045) O
. O

after O
map O
, O
increases O
were O
identified O
in O
both O
cardiac O
output O
( O
from O
1.54 O
+/- O
0.57 O
to O
1.65 O
+/- O
0.57 O
1/min O
) O
and O
emax O
( O
from O
1.86 O
+/- O
0.9 O
to O
2.41 O
+/- O
1.31 O
mmhg/ml) O
. O

conclusion O
: O
the O
data O
acquired O
suggest O
that O
isolated O
map O
may O
have O
certain O
benefits O
on O
lv O
dimension/function O
in O
acute O
heart B-NEG
failure I-NEG
, O
even O
in O
the O
absence O
of O
mr B-NEG
. O

however O
, O
further O
investigations O
are O
warranted O
in O
a O
model O
of O
chronic O
heart B-NEG
failure I-NEG
. O

-DOCSTART- O

piperacillin/tazobactam-induced O
seizure B-NEG
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

despite O
popular O
use O
of O
piperacillin O
, O
the O
dire O
neurotoxicity B-NEG
associated O
with O
piperacillin O
still O
goes O
unrecognized O
, O
leading O
to O
a O
delay O
in O
appropriate O
management O
. O

we O
report O
a O
57-year-old O
woman O
with O
end-stage B-NEG
renal I-NEG
disease I-NEG
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
(capd) O
, O
who O
developed O
slurred O
speech O
, O
tremor B-NEG
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion B-NEG
, O
and O
2 O
episodes O
of O
generalized O
tonic-clonic B-NEG
seizure I-NEG
( O
gtcs B-NEG
) O
after O
5 O
doses O
of O
piperacillin/tazobactam O
(2 O
g/250 O
mg O
) O
were O
given O
for O
bronchiectasis B-NEG
with O
secondary B-NEG
infection I-NEG
. O

the O
laboratory O
data O
revealed O
normal O
plasma O
electrolyte O
and O
ammonia O
levels O
but O
leukocytosis B-NEG
. O

neurologic O
examinations O
showed O
dysarthria B-NEG
and O
bilateral O
babinski O
sign O
. O

computed O
tomography O
of O
brain O
and O
electroencephalogram O
were O
unremarkable O
. O

despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
gtcs B-NEG
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin/tazobactam O
. O

brain O
magnetic O
resonance O
imaging O
did O
not O
demonstrate O
acute O
infarction B-NEG
and O
organic B-NEG
brain I-NEG
lesions I-NEG
. O

initiation O
of O
high-flux O
hemodialysis O
rapidly O
reversed O
the O
neurologic O
symptoms O
within O
4 O
hours O
. O

piperacillin-induced O
encephalopathy B-NEG
should O
be O
considered O
in O
any O
uremic B-NEG
patients O
with O
unexplained O
neurological O
manifestations O
. O

capd O
is O
inefficient O
in O
removing O
piperacillin O
, O
whereas O
hemodialysis O
can O
rapidly O
terminate O
the O
piperacillin-induced O
encephalopathy B-NEG
. O

-DOCSTART- O

frequency O
of O
transient O
ipsilateral O
vocal B-NEG
cord I-NEG
paralysis I-NEG
in O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

background O
: O
especially O
because O
of O
improvements O
in O
clinical O
neurologic O
monitoring O
, O
carotid O
endarterectomy O
done O
under O
local O
anesthesia O
has O
become O
the O
technique O
of O
choice O
in O
several O
centers O
. O

temporary O
ipsilateral O
vocal B-NEG
nerve I-NEG
palsies I-NEG
due O
to O
local O
anesthetics O
have O
been O
described O
, O
however O
. O

such O
complications O
are O
most O
important O
in O
situations O
where O
there O
is O
a O
pre-existing O
contralateral O
paralysis B-NEG
. O

we O
therefore O
examined O
the O
effect O
of O
local O
anesthesia O
on O
vocal O
cord O
function O
to O
better O
understand O
its O
possible O
consequences O
. O

methods O
: O
this O
prospective O
study O
included O
28 O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

vocal O
cord O
function O
was O
evaluated O
before O
, O
during O
, O
and O
after O
surgery O
( O
postoperative O
day O
1) O
using O
flexible O
laryngoscopy O
. O

anesthesia O
was O
performed O
by O
injecting O
20 O
to O
40 O
ml O
of O
a O
mixture O
of O
long-acting O
( O
ropivacaine O
) O
and O
short-acting O
( O
prilocaine O
) O
anesthetic O
. O

results O
: O
all O
patients O
had O
normal O
vocal O
cord O
function O
preoperatively O
. O

twelve O
patients O
( O
43% O
) O
were O
found O
to O
have O
intraoperative O
ipsilateral O
vocal B-NEG
cord I-NEG
paralysis I-NEG
. O

it O
resolved O
in O
all O
cases O
< O
or O
=24 O
hours O
. O

there O
were O
no O
significant O
differences O
in O
operating O
time O
or O
volume O
or O
frequency O
of O
anesthetic O
administration O
in O
patients O
with O
temporary O
vocal B-NEG
cord I-NEG
paralysis I-NEG
compared O
with O
those O
without O
. O

conclusion O
: O
local O
anesthesia O
led O
to O
temporary O
ipsilateral O
vocal B-NEG
cord I-NEG
paralysis I-NEG
in O
almost O
half O
of O
these O
patients O
. O

because O
pre-existing O
paralysis B-NEG
is O
of O
a O
relevant O
frequency O
( O
up O
to O
3%) O
, O
a O
preoperative O
evaluation O
of O
vocal O
cord O
function O
before O
carotid O
endarterectomy O
under O
local O
anesthesia O
is O
recommended O
to O
avoid O
intraoperative O
bilateral O
paralysis B-NEG
. O

in O
patients O
with O
preoperative O
contralateral O
vocal B-NEG
cord I-NEG
paralysis I-NEG
, O
surgery O
under O
general O
anesthesia O
should O
be O
considered O
. O

-DOCSTART- O

neuroprotective O
effects O
of O
melatonin O
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
bcnu-induced O
cortical B-NEG
dysplasia I-NEG
. O
cortical B-NEG
dysplasia I-NEG
is O
a O
malformation O
characterized O
by O
defects O
in O
proliferation O
, O
migration O
and O
maturation O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine-[1,3-bis O
( O
2-chloroethyl)-1-nitrosoure] O
( O
bcnu O
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin O
upon O
cerebellar O
bcnu-induced O
cortical B-NEG
dysplasia I-NEG
, O
using O
histological O
and O
biochemical O
analyses O
. O

pregnant O
wistar O
rats O
were O
assigned O
to O
five O
groups O
: O
intact-control O
, O
saline-control O
, O
melatonin-treated O
, O
bcnu-exposed O
and O
bcnu-exposed O
plus O
melatonin O
. O

rats O
were O
exposed O
to O
bcnu O
on O
embryonic O
day O
15 O
and O
melatonin O
was O
given O
until O
delivery O
. O

immuno/histochemistry O
and O
electron O
microscopy O
were O
carried O
out O
on O
the O
offspring O
cerebellum O
, O
and O
levels O
of O
malondialdehyde O
and O
superoxide O
dismutase O
were O
determined O
. O

histopathologically O
, O
typical O
findings O
were O
observed O
in O
the O
cerebella O
from O
the O
control O
groups O
, O
but O
the O
findings O
consistent O
with O
early O
embryonic O
development O
were O
noted O
in O
bcnu-exposed O
cortical B-NEG
dysplasia I-NEG
group O
. O

there O
was O
a O
marked O
increase O
in O
the O
number O
of O
tunel O
positive O
cells O
and O
nestin O
positive O
cells O
in O
bcnu-exposed O
group O
, O
but O
a O
decreased O
immunoreactivity O
to O
glial O
fibrillary O
acidic O
protein O
, O
synaptophysin O
and O
transforming O
growth O
factor O
beta1 O
was O
observed O
, O
indicating O
a O
delayed O
maturation O
, O
and O
melatonin O
significantly O
reversed O
these O
changes O
. O

malondialdehyde O
level O
in O
bcnu-exposed O
group O
was O
higher O
than O
those O
in O
control O
groups O
and O
melatonin O
decreased O
malondialdehyde O
levels O
in O
bcnu O
group O
(p<0.01) O
, O
while O
there O
were O
no O
significant O
differences O
in O
the O
superoxide O
dismutase O
levels O
between O
these O
groups O
. O

these O
data O
suggest O
that O
exposure O
of O
animals O
to O
bcnu O
during O
pregnancy O
leads O
to O
delayed O
maturation O
of O
offspring O
cerebellum O
and O
melatonin O
protects O
the O
cerebellum O
against O
the O
effects O
of O
bcnu O
. O

-DOCSTART- O

myo-inositol-1-phosphate O
( O
mip O
) O
synthase O
inhibition O
: O
in-vivo O
study O
in O
rats O
. O

lithium O
and O
valproate O
are O
the O
prototypic O
mood O
stabilizers O
and O
have O
diverse O
structures O
and O
targets O
. O

both O
drugs O
influence O
inositol O
metabolism O
. O

lithium O
inhibits O
impase O
and O
valproate O
inhibits O
mip O
synthase O
. O

this O
study O
shows O
that O
mip O
synthase O
inhibition O
does O
not O
replicate O
or O
augment O
the O
effects O
of O
lithium O
in O
the O
inositol O
sensitive O
pilocarpine-induced O
seizures B-NEG
model O
. O

this O
lack O
of O
effects O
may O
stem O
from O
the O
low O
contribution O
of O
de-novo O
synthesis O
to O
cellular O
inositol O
supply O
or O
to O
the O
inhibition O
of O
the O
de-novo O
synthesis O
by O
lithium O
itself O
. O

-DOCSTART- O

non-steroidal O
anti-inflammatory O
drugs-associated O
acute O
interstitial B-NEG
nephritis I-NEG
with O
granular O
tubular O
basement O
membrane O
deposits O
. O
acute B-NEG
tubulo-interstitial I-NEG
nephritis I-NEG
( O
atin B-NEG
) O
is O
an O
important O
cause O
of O
acute B-NEG
renal I-NEG
failure I-NEG
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex-mediated O
tubulo-interstitial B-NEG
injury I-NEG
, O
but O
drugs O
such O
as O
non-steroidal O
anti-inflammatory O
drugs O
( O
nsaids O
) O
are O
a O
far O
more O
frequent O
cause O
. O

overall O
, O
as O
an O
entity O
, O
atin B-NEG
remains O
under-diagnosed O
, O
as O
symptoms O
resolve O
spontaneously O
if O
the O
medication O
is O
stopped O
. O

we O
report O
on O
a O
14-year-old O
boy O
who O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
2 O
weeks O
after O
aortic O
valve O
surgery O
. O

he O
was O
put O
on O
aspirin O
following O
surgery O
and O
took O
ibuprofen O
for O
fever B-NEG
for O
nearly O
a O
week O
prior O
to O
presentation O
. O

he O
then O
presented O
to O
the O
emergency O
department O
feeling O
quite O
ill O
and O
was O
found O
to O
have O
a O
blood O
urea O
nitrogen O
( O
bun O
) O
concentration O
of O
of O
147 O
mg/dl O
, O
creatinine O
of O
15.3 O
mg/dl O
and O
serum O
potassium O
of O
8.7 O
meq/l O
. O

dialysis O
was O
immediately O
initiated O
. O

a O
kidney O
biopsy O
showed O
inflammatory O
infiltrate O
consistent O
with O
atin B-NEG
. O

however O
, O
in O
the O
tubular O
basement O
membrane O
(tbm) O
, O
very O
intense O
granular O
deposits O
of O
polyclonal O
igg O
and O
c3 O
were O
noted O
. O

he O
needed O
dialysis O
for O
2 O
weeks O
and O
was O
treated O
successfully O
with O
steroids O
for O
6 O
months O
. O

his O
renal O
recovery O
and O
disappearance O
of O
proteinuria B-NEG
took O
a O
year O
. O

in O
conclusion O
, O
this O
is O
a O
first O
report O
of O
nsaids-associated O
atin B-NEG
, O
showing O
deposits O
of O
granular O
immune O
complex O
present O
only O
in O
the O
tbm O
and O
not O
in O
the O
glomeruli O
. O

-DOCSTART- O

rifampicin-associated O
segmental O
necrotizing O
glomerulonephritis B-NEG
in O
staphylococcal B-NEG
endocarditis I-NEG
. O

segmental O
necrotising O
glomerulonephritis B-NEG
has O
been O
reported O
as O
complication O
of O
rifampicin O
therapy O
in O
patients O
receiving O
treatment O
for O
tuberculosis B-NEG
. O

changing O
epidemiology O
of O
infections B-NEG
such O
as O
infective B-NEG
endocarditis I-NEG
( O
ie B-NEG
) O
has O
led O
to O
an O
increase O
in O
the O
use O
of O
rifampicin O
for O
staphylococcal B-NEG
infections I-NEG
. O

we O
describe O
a O
case O
of O
a O
patient O
with O
staphylococcal B-NEG
ie I-NEG
who O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis B-NEG
while O
being O
treated O
with O
rifampicin O
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin O
therapy O
. O

-DOCSTART- O

rate O
of O
ymdd O
motif O
mutants O
in O
lamivudine-untreated O
iranian O
patients O
with O
chronic B-NEG
hepatitis I-NEG
b I-NEG
virus I-NEG
infection I-NEG
. O

background O
: O
lamivudine O
is O
used O
for O
the O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
b I-NEG
patients O
. O

recent O
studies O
show O
that O
the O
ymdd O
motif O
mutants O
( O
resistant O
hepatitis B-NEG
b I-NEG
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine-untreated O
chronic B-NEG
hepatitis I-NEG
b I-NEG
patients O
. O

in O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
ymdd O
motif O
mutants O
in O
lamivudine-untreated O
chronic B-NEG
hepatitis I-NEG
b I-NEG
patients O
in O
iran O
. O

patients O
and O
methods O
: O
a O
total O
of O
77 O
chronic B-NEG
hepatitis I-NEG
b I-NEG
patients O
who O
had O
not O
been O
treated O
with O
lamivudine O
were O
included O
in O
the O
study O
. O

serum O
samples O
from O
patients O
were O
tested O
by O
polymerase O
chain O
reaction-restriction O
fragment O
length O
polymorphism O
( O
pcr-rflp O
) O
for O
detection O
of O
ymdd O
motif O
mutants O
. O

all O
patients O
were O
also O
tested O
for O
liver O
enzymes O
, O
anti-hcv O
, O
hbeag O
, O
and O
anti-hbe O
. O

results O
: O
of O
the O
77 O
patients O
enrolled O
in O
the O
study O
, O
73% O
were O
male O
and O
27% O
were O
female O
. O

mean O
alt O
and O
ast O
levels O
were O
124.4+/-73.4 O
and O
103.1+/-81 O
iu/l O
, O
respectively O
. O

hbeag O
was O
positive O
in O
40% O
and O
anti-hbe O
in O
60% O
of O
the O
patients O
. O

anti-hcv O
was O
negative O
in O
all O
of O
them O
. O

ymdd O
motif O
mutants O
were O
not O
detected O
in O
any O
of O
the O
patients O
despite O
the O
liver O
enzyme O
levels O
and O
the O
presence O
of O
hbeag O
or O
anti-hbe O
. O

conclusion O
: O
although O
the O
natural O
occurrence O
of O
ymdd O
motif O
mutants O
in O
lamivudine-untreated O
patients O
with O
chronic B-NEG
hepatitis I-NEG
b I-NEG
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
iranian O
lamivudine-untreated O
chronic B-NEG
hepatitis I-NEG
b I-NEG
patients O
. O

-DOCSTART- O

branch O
retinal B-NEG
vein I-NEG
occlusion I-NEG
and O
fluoxetine O
. O

a O
case O
of O
branch O
retinal B-NEG
vein I-NEG
occlusion I-NEG
associated O
with O
fluoxetine-induced O
secondary O
hypertension B-NEG
is O
described O
. O

although O
an O
infrequent O
complication O
of O
selective O
serotonin O
reuptake O
inhibitor O
therapy O
, O
it O
is O
important O
that O
ophthalmologists O
are O
aware O
that O
these O
agents O
can O
cause O
hypertension B-NEG
because O
this O
class O
of O
drugs O
is O
widely O
prescribed O
. O

-DOCSTART- O

the O
differential O
effects O
of O
bupivacaine O
and O
lidocaine O
on O
prostaglandin O
e2 O
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain B-NEG
in O
a O
clinical O
pain B-NEG
model O
. O

background O
: O
in O
addition O
to O
blocking O
nociceptive O
input O
from O
surgical O
sites O
, O
long-acting O
local O
anesthetics O
might O
directly O
modulate O
inflammation B-NEG
. O

in O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine O
on O
local O
prostaglandin O
e2 O
( O
pge2 O
) O
production O
and O
cyclooxygenase O
( O
cox O
) O
gene O
expression O
that O
increases O
postoperative B-NEG
pain I-NEG
in O
human O
subjects O
. O

methods O
: O
subjects O
(n O
= O
114 O
) O
undergoing O
extraction O
of O
impacted O
third O
molars O
received O
either O
2% O
lidocaine O
or O
0.5% O
bupivacaine O
before O
surgery O
and O
either O
rofecoxib O
50 O
mg O
or O
placebo O
orally O
90 O
min O
before O
surgery O
and O
for O
the O
following O
48 O
h. O

oral O
mucosal O
biopsies O
were O
taken O
before O
surgery O
and O
48 O
h O
after O
surgery O
. O

after O
extraction O
, O
a O
microdialysis O
probe O
was O
placed O
at O
the O
surgical O
site O
for O
pge2 O
and O
thromboxane O
b2 O
( O
txb2 O
) O
measurements O
. O

results O
: O
the O
bupivacaine/rofecoxib O
group O
reported O
significantly O
less O
pain B-NEG
, O
as O
assessed O
by O
a O
visual O
analog O
scale O
, O
compared O
with O
the O
other O
three O
treatment O
groups O
over O
the O
first O
4 O
h. O

however O
, O
the O
bupivacaine/placebo O
group O
reported O
significantly O
more O
pain B-NEG
at O
24 O
h O
and O
pge2 O
levels O
during O
the O
first O
4 O
h O
were O
significantly O
higher O
than O
the O
other O
three O
treatment O
groups O
. O

moreover O
, O
bupivacaine O
significantly O
increased O
cox-2 O
gene O
expression O
at O
48 O
h O
as O
compared O
with O
the O
lidocaine/placebo O
group O
. O

thromboxane O
levels O
were O
not O
significantly O
affected O
by O
any O
of O
the O
treatments O
, O
indicating O
that O
the O
effects O
seen O
were O
attributable O
to O
inhibition O
of O
cox-2 O
, O
but O
not O
cox-1 O
. O

conclusions O
: O
these O
results O
suggest O
that O
bupivacaine O
stimulates O
cox-2 O
gene O
expression O
after O
tissue B-NEG
injury I-NEG
, O
which O
is O
associated O
with O
higher O
pge2 O
production O
and O
pain B-NEG
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

-DOCSTART- O

p75ntr O
expression O
in O
rat O
urinary O
bladder O
sensory O
neurons O
and O
spinal O
cord O
with O
cyclophosphamide-induced O
cystitis B-NEG
. O

a O
role O
for O
nerve O
growth O
factor O
( O
ngf O
) O
in O
contributing O
to O
increased O
voiding O
frequency O
and O
altered O
sensation O
from O
the O
urinary O
bladder O
has O
been O
suggested O
. O

previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine O
kinase O
receptors O
( O
trks O
) O
in O
micturition O
reflexes O
with O
urinary B-NEG
bladder I-NEG
inflammation I-NEG
. O

the O
present O
studies O
examine O
the O
expression O
and O
regulation O
of O
another O
receptor O
known O
to O
bind O
ngf O
, O
p75(ntr) O
, O
after O
various O
durations O
of O
bladder B-NEG
inflammation I-NEG
induced O
by O
cyclophosphamide O
(cyp) O
. O

cyp-induced O
cystitis B-NEG
increased O
(p O
< O
or O
= O
0.001 O
) O
p75(ntr O
) O
expression O
in O
the O
superficial O
lateral O
and O
medial O
dorsal O
horn O
in O
l1-l2 O
and O
l6-s1 O
spinal O
segments O
. O

the O
number O
of O
p75(ntr)-immunoreactive O
( O
-ir O
) O
cells O
in O
the O
lumbosacral O
dorsal O
root O
ganglia O
( O
drg O
) O
also O
increased O
(p O
< O
or O
= O
0.05 O
) O
with O
cyp-induced O
cystitis B-NEG
(acute O
, O
intermediate O
, O
and O
chronic) O
. O

quantitative O
, O
real-time O
polymerase O
chain O
reaction O
also O
demonstrated O
significant O
increases O
(p O
< O
or O
= O
0.01 O
) O
in O
p75(ntr O
) O
mrna O
in O
drg O
with O
intermediate O
and O
chronic O
cyp-induced O
cystitis B-NEG
. O

retrograde O
dye-tracing O
techniques O
with O
fastblue O
were O
used O
to O
identify O
presumptive O
bladder O
afferent O
cells O
in O
the O
lumbosacral O
drg O
. O

in O
bladder O
afferent O
cells O
in O
drg O
, O
p75(ntr)-ir O
was O
also O
increased O
(p O
< O
or O
= O
0.01 O
) O
with O
cystitis B-NEG
. O

in O
addition O
to O
increases O
in O
p75(ntr)-ir O
in O
drg O
cell O
bodies O
, O
increases O
(p O
< O
or O
= O
0.001 O
) O
in O
pericellular O
( O
encircling O
drg O
cells O
) O
p75(ntr)-ir O
in O
drg O
also O
increased O
. O

confocal O
analyses O
demonstrated O
that O
pericellular O
p75(ntr)-ir O
was O
not O
colocalized O
with O
the O
glial O
marker O
, O
glial O
fibrillary O
acidic O
protein O
(gfap) O
. O

these O
studies O
demonstrate O
that O
p75(ntr O
) O
expression O
in O
micturition O
reflexes O
is O
present O
constitutively O
and O
modified O
by O
bladder B-NEG
inflammation I-NEG
. O

the O
functional O
significance O
of O
p75(ntr O
) O
expression O
in O
micturition O
reflexes O
remains O
to O
be O
determined O
. O

-DOCSTART- O

azathioprine-induced O
suicidal O
erythrocyte O
death O
. O

background O
: O
azathioprine O
is O
widely O
used O
as O
an O
immunosuppressive O
drug O
. O

the O
side O
effects O
of O
azathioprine O
include O
anemia B-NEG
, O
which O
has O
been O
attributed O
to O
bone O
marrow O
suppression O
. O

alternatively O
, O
anemia B-NEG
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine O
( O
ps O
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

methods O
: O
the O
present O
experiments O
explored O
whether O
azathioprine O
influences O
eryptosis O
. O

according O
to O
annexin O
v O
binding O
, O
erythrocytes O
from O
patients O
indeed O
showed O
a O
significant O
increase O
of O
ps O
exposure O
within O
1 O
week O
of O
treatment O
with O
azathioprine O
. O

in O
a O
second O
series O
, O
cytosolic O
ca2+ O
activity O
( O
fluo3 O
fluorescence) O
, O
cell O
volume O
( O
forward O
scatter) O
, O
and O
ps-exposure O
( O
annexin O
v O
binding O
) O
were O
determined O
by O
facs O
analysis O
in O
erythrocytes O
from O
healthy O
volunteers O
. O

results O
: O
exposure O
to O
azathioprine O
(> O
or O
=2 O
microg/ml O
) O
for O
48 O
hours O
increased O
cytosolic O
ca2+ O
activity O
and O
annexin O
v O
binding O
and O
decreased O
forward O
scatter O
. O

the O
effect O
of O
azathioprine O
on O
both O
annexin O
v O
binding O
and O
forward O
scatter O
was O
significantly O
blunted O
in O
the O
nominal O
absence O
of O
extracellular O
ca2+ O
. O

conclusions O
: O
azathioprine O
triggers O
suicidal O
erythrocyte O
death O
, O
an O
effect O
presumably O
contributing O
to O
azathioprine-induced O
anemia B-NEG
. O

-DOCSTART- O

clinical O
comparison O
of O
cardiorespiratory O
effects O
during O
unilateral O
and O
conventional O
spinal O
anaesthesia O
. O

background O
: O
spinal O
anaesthesia O
is O
widely O
employed O
in O
clinical O
practice O
but O
has O
the O
main O
drawback O
of O
post-spinal O
block O
hypotension B-NEG
. O

efforts O
must O
therefore O
continue O
to O
be O
made O
to O
obviate O
this O
setback O
objective O
: O
to O
evaluate O
the O
cardiovascular O
and O
respiratory O
changes O
during O
unilateral O
and O
conventional O
spinal O
anaesthesia O
. O

methods O
: O
with O
ethical O
approval O
, O
we O
studied O
74 O
american O
society O
of O
anesthesiologists O
(asa) O
, O
physical O
status O
class O
1 O
and O
2 O
patients O
scheduled O
for O
elective O
unilateral O
lower O
limb O
surgery O
. O

patients O
were O
randomly O
allocated O
into O
one O
of O
two O
groups O
: O
lateral O
and O
conventional O
spinal O
anaesthesia O
groups O
. O

in O
the O
lateral O
position O
with O
operative O
side O
down O
, O
patients O
recived O
10 O
mg O
( O
2mls O
) O
of O
0.5% O
hyperbaric O
bupivacaine O
through O
a O
25-gauge O
spinal O
needle O
. O

patients O
in O
the O
unilateral O
group O
were O
maintained O
in O
the O
lateral O
position O
for O
15 O
minutes O
following O
spinal O
injection O
while O
those O
in O
the O
conventional O
group O
were O
turned O
supine O
immediately O
after O
injection O
. O

blood O
pressure O
, O
heart O
rate O
, O
respiratory O
rate O
and O
oxygen O
saturation O
were O
monitored O
over O
1 O
hour O
. O

results O
: O
three O
patients O
( O
8.1% O
) O
in O
the O
unilateral O
group O
and O
5 O
( O
13.5% O
) O
in O
the O
conventional O
group O
developed O
hypotension B-NEG
, O
p= O
0.71 O
. O

four O
( O
10.8% O
) O
patients O
in O
the O
conventional O
group O
and O
1 O
( O
2.7% O
) O
in O
the O
unilateral O
group O
, O
p= O
0.17 O
required O
epinephrine O
infusion O
to O
treat O
hypotension B-NEG
. O

patients O
in O
the O
conventional O
group O
had O
statistically O
significant O
greater O
fall O
in O
the O
systolic O
blood O
pressures O
at O
15 O
, O
30 O
and O
45 O
minutes O
when O
compared O
to O
the O
baseline O
( O
p= O
0.003 O
, O
0.001 O
and O
0.004) O
. O

the O
mean O
respiratory O
rate O
and O
oxygen O
saturations O
in O
the O
two O
groups O
were O
similar O
. O

conclusion O
: O
compared O
to O
conventional O
spinal O
anaesthesia O
, O
unilateral O
spinal O
anaesthesia O
was O
associated O
with O
fewer O
cardiovascular O
perturbations O
. O

also O
, O
the O
type O
of O
spinal O
block O
instituted O
affected O
neither O
the O
respiratory O
rate O
nor O
the O
arterial O
oxygen O
saturation O
. O

-DOCSTART- O

spectrum O
of O
adverse O
events O
after O
generic O
haart O
in O
southern O
indian O
hiv-infected B-NEG
patients O
. O

to O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long-term O
, O
fixed-dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
use O
among O
hiv-infected B-NEG
individuals O
in O
south O
india O
, O
we O
examined O
the O
experiences O
of O
3154 O
hiv-infected B-NEG
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
haart O
between O
february O
1996 O
and O
december O
2006 O
at O
a O
tertiary O
hiv O
care O
referral O
center O
in O
south O
india O
. O

the O
most O
common O
regimens O
were O
3tc O
+ O
d4t O
+ O
nevirapine O
( O
nvp O
) O
(54.8%) O
, O
zidovudine O
( O
azt O
) O
+ O
3tc O
+ O
nvp O
(14.5%) O
, O
3tc O
+ O
d4t O
+ O
efavirenz O
( O
efv O
) O
(20.1%) O
, O
and O
azt O
+ O
3tc O
+ O
efv O
(5.4%) O
. O

the O
most O
common O
adverse O
events O
and O
median O
cd4 O
at O
time O
of O
event O
were O
rash B-NEG
(15.2% O
; O
cd4 O
, O
285 O
cells/microl O
) O
and O
peripheral B-NEG
neuropathy I-NEG
( O
9.0% O
and O
348 O
cells/microl) O
. O

clinically O
significant O
anemia B-NEG
( O
hemoglobin O
<7 O
g/dl O
) O
was O
observed O
in O
5.4% O
of O
patients O
(cd4 O
, O
165 O
cells/microl O
) O
and O
hepatitis B-NEG
( O
clinical O
jaundice B-NEG
with O
alanine O
aminotransferase O
> O
5 O
times O
upper O
limits O
of O
normal O
) O
in O
3.5% O
of O
patients O
(cd4 O
, O
260 O
cells/microl) O
. O

women O
were O
significantly O
more O
likely O
to O
experience O
lactic B-NEG
acidosis I-NEG
, O
while O
men O
were O
significantly O
more O
likely O
to O
experience O
immune B-NEG
reconstitution I-NEG
syndrome I-NEG
(p O
< O
0.05) O
. O

among O
the O
patients O
with O
1 O
year O
of O
follow-up O
, O
nvp O
therapy O
was O
significantly O
associated O
with O
developing O
rash B-NEG
and O
d4t O
therapy O
with O
developing O
peripheral B-NEG
neuropathy I-NEG
(p O
< O
0.05) O
. O
anemia B-NEG
and O
hepatitis B-NEG
often O
occur O
within O
12 O
weeks O
of O
initiating O
generic O
haart O
. O

frequent O
and O
early O
monitoring O
for O
these O
toxicities B-NEG
is O
warranted O
in O
developing O
countries O
where O
generic O
haart O
is O
increasingly O
available O
. O

-DOCSTART- O

thalidomide O
and O
sensory B-NEG
neurotoxicity I-NEG
: O
a O
neurophysiological O
study O
. O

background O
: O
recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory B-NEG
axonal I-NEG
neuropathy I-NEG
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide O
. O

the O
study's O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
sap O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous B-NEG
lupus I-NEG
erythematosus I-NEG
( O
cle B-NEG
) O
treated O
with O
thalidomide O
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic B-NEG
potential O
of O
thalidomide O
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

patients O
and O
methods O
: O
clinical O
and O
electrophysiological O
data O
in O
12 O
female O
patients O
with O
cle B-NEG
during O
treatment O
with O
thalidomide O
and O
up O
to O
47 O
months O
after O
discontinuation O
of O
treatment O
were O
analysed O
. O

sural O
nerve O
sap O
amplitude O
reduction O
> O
or O
=40% O
was O
the O
criteria O
for O
discontinuing O
therapy O
. O

results O
: O
during O
treatment O
, O
11 O
patients O
showed O
a O
reduction O
in O
sural O
nerve O
sap O
amplitude O
compared O
to O
baseline O
values O
(9 O
with O
a O
reduction O
> O
or O
=50% O
and O
2 O
<50%) O
. O

one O
patient O
showed O
no O
changes O
in O
sap O
amplitude O
. O

five O
patients O
complained O
of O
paresthesias B-NEG
and O
leg O
cramps B-NEG
. O

after O
thalidomide O
treatment O
, O
sural O
sap O
amplitude O
recovered O
in O
3 O
patients O
. O

at O
detection O
of O
reduction O
in O
sural O
nerve O
sap O
amplitude O
, O
the O
median O
thalidomide O
cumulative O
dose O
was O
21.4 O
g. O

the O
threshold O
neurotoxic B-NEG
dosage O
is O
lower O
than O
previously O
reported O
. O

conclusions O
: O
sural O
nerve O
sap O
amplitude O
reduction O
is O
a O
reliable O
and O
sensitive O
marker O
of O
degeneration O
and O
recovery O
of O
sensory O
fibres O
. O

this O
electrophysiological O
parameter O
provides O
information O
about O
subclinical O
neurotoxic B-NEG
potential O
of O
thalidomide O
but O
is O
not O
helpful O
in O
predicting O
the O
appearance O
of O
sensory O
symptoms O
. O

-DOCSTART- O

amiodarone-related O
pulmonary B-NEG
mass I-NEG
and O
unique O
membranous B-NEG
glomerulonephritis I-NEG
in O
a O
patient O
with O
valvular B-NEG
heart I-NEG
disease I-NEG
: O
diagnostic O
pitfall O
and O
new O
findings O
. O

amiodarone O
is O
an O
anti- O
arrhythmic B-NEG
drug O
for O
life-threatening O
tachycardia B-NEG
, O
but O
various O
adverse O
effects O
have O
been O
reported O
. O

reported O
herein O
is O
an O
autopsy O
case O
of O
valvular B-NEG
heart I-NEG
disease I-NEG
, O
in O
a O
patient O
who O
developed O
a O
lung B-NEG
mass I-NEG
( O
1.5 O
cm O
in O
diameter O
) O
and O
proteinuria B-NEG
( O
2.76 O
g/day O
) O
after O
treatment O
with O
amiodarone O
for O
a O
long O
time O
. O

the O
lung B-NEG
mass I-NEG
was O
highly O
suspected O
to O
be O
lung B-NEG
cancer I-NEG
on O
ct O
and O
positron O
emission O
tomography O
, O
but O
histologically O
the O
lesion O
was O
composed O
of O
lymphoplasmacytic O
infiltrates O
in O
alveolar O
walls O
and O
intra-alveolar O
accumulation O
of O
foamy O
macrophages O
containing O
characteristic O
myelinoid O
bodies O
, O
indicating O
that O
it O
was O
an O
amiodarone-related O
lesion O
. O

in O
addition O
, O
the O
lung O
tissue O
had O
unevenly O
distributed O
hemosiderin B-NEG
deposition O
, O
and O
abnormally O
tortuous O
capillaries O
were O
seen O
in O
the O
mass O
and O
in O
heavily O
hemosiderotic B-NEG
lung O
portions O
outside O
the O
mass O
. O

in O
the O
kidneys O
, O
glomeruli O
had O
membrane O
spikes O
, O
prominent O
swelling O
of O
podocytes O
and O
subepithelial O
deposits O
, O
which O
were O
sometimes O
large O
and O
hump-like O
. O
autoimmune B-NEG
diseases I-NEG
, O
viral B-NEG
hepatitis I-NEG
, O
malignant O
neoplasms B-NEG
or O
other O
diseases O
with O
a O
known O
relationship O
to O
membranous B-NEG
glomerulonephritis I-NEG
were O
not O
found O
. O

the O
present O
case O
highlights O
the O
possibility O
that O
differential O
diagnosis O
between O
an O
amiodarone-related O
pulmonary B-NEG
lesion I-NEG
and O
a O
neoplasm B-NEG
can O
be O
very O
difficult O
radiologically O
, O
and O
suggests O
that O
membranous B-NEG
glomerulonephritis I-NEG
might O
be O
another O
possible O
complication O
of O
amiodarone O
treatment O
. O

-DOCSTART- O

risk O
of O
coronary B-NEG
artery I-NEG
disease I-NEG
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B-NEG
2 I-NEG
diabetes I-NEG
: O
a O
matched O
case-control O
study O
. O

aims O
: O
this O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B-NEG
artery I-NEG
disease I-NEG
( O
cad B-NEG
) O
associated O
with O
initial O
treatment O
of O
type B-NEG
2 I-NEG
diabetes I-NEG
with O
different O
sulphonylureas O
. O

methods O
: O
in O
type B-NEG
2 I-NEG
diabetic I-NEG
patients O
, O
cases O
who O
developed O
cad B-NEG
were O
compared O
retrospectively O
with O
controls O
that O
did O
not O
. O

the O
20-year O
risk O
of O
cad B-NEG
at O
diagnosis O
of O
diabetes B-NEG
, O
using O
the O
ukpds O
risk O
engine O
, O
was O
used O
to O
match O
cases O
with O
controls O
. O

results O
: O
the O
76 O
cases O
of O
cad B-NEG
were O
compared O
with O
152 O
controls O
. O

the O
hazard O
of O
developing O
cad B-NEG
( O
95% O
ci O
) O
associated O
with O
initial O
treatment O
increased O
by O
2.4-fold O
(1.3-4.3 O
, O
p=0.004 O
) O
with O
glibenclamide O
; O
2-fold O
(0.9-4.6 O
, O
p=0.099 O
) O
with O
glipizide O
; O
2.9-fold O
(1.6-5.1 O
, O
p=0.000 O
) O
with O
either O
, O
and O
was O
unchanged O
with O
metformin O
. O

the O
hazard O
decreased O
0.3-fold O
(0.7-1.7 O
, O
p=0.385 O
) O
with O
glimepiride O
, O
0.4-fold O
(0.7-1.3 O
, O
p=0.192 O
) O
with O
gliclazide O
, O
and O
0.4-fold O
(0.7-1.1 O
, O
p=0.09 O
) O
with O
either O
. O

conclusions O
: O
initiating O
treatment O
of O
type B-NEG
2 I-NEG
diabetes I-NEG
with O
glibenclamide O
or O
glipizide O
is O
associated O
with O
increased O
risk O
of O
cad B-NEG
in O
comparison O
to O
gliclazide O
or O
glimepiride O
. O

if O
confirmed O
, O
this O
may O
be O
important O
because O
most O
indian O
patients O
receive O
the O
cheaper O
older O
sulphonylureas O
, O
and O
present O
guidelines O
do O
not O
distinguish O
between O
individual O
agents O
. O

-DOCSTART- O

reduced O
progression O
of O
adriamycin O
nephropathy B-NEG
in O
spontaneously O
hypertensive B-NEG
rats O
treated O
by O
losartan O
. O

background O
: O
the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin O
ii O
type-1 O
receptor O
blocker O
, O
losartan O
, O
and O
its O
potential O
in O
slowing O
down O
renal B-NEG
disease I-NEG
progression O
in O
spontaneously O
hypertensive B-NEG
rats O
( O
shr O
) O
with O
adriamycin O
( O
adr O
) O
nephropathy B-NEG
. O

methods O
: O
six-month-old O
female O
shr O
were O
randomly O
selected O
in O
six O
groups O
. O

two O
control O
groups O
(sh(6) O
, O
sh(12) O
) O
received O
vehicle O
. O

groups O
adr(6) O
, O
adr+los(6 O
) O
and O
adr(12) O
, O
and O
adr+los(12 O
) O
received O
adr O
(2 O
mg/kg/b.w O
. O
i.v. O
) O
twice O
in O
a O
3-week O
interval O
. O

group O
adr+los(6 O
) O
received O
losartan O
( O
10 O
mg/kg/b.w./day O
by O
gavages O
) O
for O
6 O
weeks O
and O
group O
adr+los(12 O
) O
for O
12 O
weeks O
after O
second O
injection O
of O
adr O
. O

animals O
were O
killed O
after O
6 O
or O
12 O
weeks O
, O
respectively O
. O

haemodynamic O
measurements O
were O
performed O
on O
anaesthetized O
animals O
, O
blood O
and O
urine O
samples O
were O
taken O
for O
biochemical O
analysis O
and O
the O
left O
kidney O
was O
processed O
for O
morphological O
studies O
. O

results O
: O
short-term O
losartan O
treatment O
, O
besides O
antihypertensive O
effect O
, O
improved O
glomerular O
filtration O
rate O
and O
ameliorated O
glomerulosclerosis B-NEG
resulting O
in O
decreased O
proteinuria B-NEG
. O

prolonged O
treatment O
with O
losartan O
showed O
further O
reduction O
of O
glomerulosclerosis B-NEG
associated O
with O
reduced O
progression O
of O
tubular O
atrophy B-NEG
and O
interstitial B-NEG
fibrosis I-NEG
, O
thus O
preventing O
heavy O
proteinuria B-NEG
and O
chronic B-NEG
renal I-NEG
failure I-NEG
. O

losartan O
reduced O
uraemia B-NEG
and O
increased O
urea O
clearance O
in O
advanced O
adr O
nephropathy B-NEG
in O
shr O
. O

histological O
examination O
showed O
that O
losartan O
could O
prevent O
tubular O
atrophy B-NEG
, O
interstitial O
infiltration O
and O
fibrosis B-NEG
in O
adr O
nephropathy B-NEG
. O

conclusion O
: O
losartan O
reduces O
the O
rate O
of O
progression O
of O
adr-induced O
focal B-NEG
segmental I-NEG
glomerulosclerosis I-NEG
to O
end-stage B-NEG
renal I-NEG
disease I-NEG
in O
shr O
. O

-DOCSTART- O

the O
risks O
of O
aprotinin O
and O
tranexamic O
acid O
in O
cardiac O
surgery O
: O
a O
one-year O
follow-up O
of O
1188 O
consecutive O
patients O
. O

background O
: O
our O
aim O
was O
to O
investigate O
postoperative O
complications O
and O
mortality O
after O
administration O
of O
aprotinin O
compared O
to O
tranexamic O
acid O
in O
an O
unselected O
, O
consecutive O
cohort O
. O

methods O
: O
perioperative O
data O
from O
consecutive O
cardiac O
surgery O
patients O
were O
prospectively O
collected O
between O
september O
2005 O
and O
june O
2006 O
in O
a O
university-affiliated O
clinic O
(n O
= O
1188) O
. O

during O
the O
first O
5 O
mo O
, O
596 O
patients O
received O
aprotinin O
( O
group O
a) O
; O
in O
the O
next O
5 O
mo O
, O
592 O
patients O
were O
treated O
with O
tranexamic O
acid O
( O
group O
t) O
. O

except O
for O
antifibrinolytic O
therapy O
, O
the O
anesthetic O
and O
surgical O
protocols O
remained O
unchanged O
. O

results O
: O
the O
pre- O
and O
intraoperative O
variables O
were O
comparable O
between O
the O
treatment O
groups O
. O

postoperatively O
, O
a O
significantly O
higher O
incidence O
of O
seizures B-NEG
was O
found O
in O
group O
t O
( O
4.6% O
vs O
1.2% O
, O
p O
< O
0.001) O
. O

this O
difference O
was O
also O
significant O
in O
the O
primary O
valve O
surgery O
and O
the O
high O
risk O
surgery O
subgroups O
( O
7.9% O
vs O
1.2% O
, O
p O
= O
0.003 O
; O
7.3% O
vs O
2.4% O
, O
p O
= O
0.035 O
, O
respectively) O
. O

persistent O
atrial O
fibrillation O
( O
7.9% O
vs O
2.3% O
, O
p O
= O
0.020 O
) O
and O
renal B-NEG
failure I-NEG
( O
9.7% O
vs O
1.7% O
, O
p O
= O
0.002 O
) O
were O
also O
more O
common O
in O
group O
t, O
in O
the O
primary O
valve O
surgery O
subgroup O
. O

on O
the O
contrary O
, O
among O
primary O
coronary O
artery O
bypass O
surgery O
patients O
, O
there O
were O
more O
acute O
myocardial B-NEG
infarctions I-NEG
and O
renal B-NEG
dysfunction I-NEG
in O
group O
a O
( O
5.8% O
vs O
2.0% O
, O
p O
= O
0.027 O
; O
22.5% O
vs O
15.2% O
, O
p O
= O
0.036 O
, O
respectively) O
. O

the O
1-yr O
mortality O
was O
significantly O
higher O
after O
aprotinin O
treatment O
in O
the O
high O
risk O
surgery O
group O
( O
17.7% O
vs O
9.8% O
, O
p O
= O
0.034) O
. O

conclusion O
: O
both O
antifibrinolytic O
drugs O
bear O
the O
risk O
of O
adverse O
outcome O
depending O
on O
the O
type O
of O
cardiac O
surgery O
. O

administration O
of O
aprotinin O
should O
be O
avoided O
in O
coronary O
artery O
bypass O
graft O
and O
high O
risk O
patients O
, O
whereas O
administration O
of O
tranexamic O
acid O
is O
not O
recommended O
in O
valve O
surgery O
. O

-DOCSTART- O

the O
biological O
properties O
of O
the O
optical O
isomers O
of O
propranolol O
and O
their O
effects O
on O
cardiac B-NEG
arrhythmias I-NEG
. O

1. O

the O
optical O
isomers O
of O
propranolol O
have O
been O
compared O
for O
their O
beta-blocking O
and O
antiarrhythmic O
activities.2 O
. O

in O
blocking O
the O
positive O
inotropic O
and O
chronotropic O
responses O
to O
isoprenaline O
, O
( O
+)-propranolol O
had O
less O
than O
one O
hundredth O
the O
potency O
of O
(-)-propranolol O
. O

at O
dose O
levels O
of O
( O
+)-propranolol O
which O
attenuated O
the O
responses O
to O
isoprenaline O
, O
there O
was O
a O
significant O
prolongation O
of O
the O
pr O
interval O
of O
the O
electrocardiogram.3 O
. O

the O
metabolic O
responses O
to O
isoprenaline O
in O
dogs O
( O
an O
increase O
in O
circulating O
glucose O
, O
lactate O
and O
free O
fatty O
acids O
) O
were O
all O
blocked O
by O
(-)-propranolol O
. O

( O
+)-propranolol O
had O
no O
effect O
on O
fatty O
acid O
mobilization O
but O
significantly O
reduced O
the O
increments O
in O
both O
lactate O
and O
glucose.4 O
. O

both O
isomers O
of O
propranolol O
possessed O
similar O
depressant O
potency O
on O
isolated O
atrial O
muscle O
taken O
from O
guinea-pigs.5 O
. O

the O
isomers O
of O
propranolol O
exhibited O
similar O
local O
anaesthetic O
potencies O
on O
an O
isolated O
frog O
nerve O
preparation O
at O
a O
level O
approximately O
three O
times O
that O
of O
procaine O
. O

the O
racemic O
compound O
was O
significantly O
less O
potent O
than O
either O
isomer.6 O
. O

both O
isomers O
of O
propranolol O
were O
capable O
of O
preventing O
adrenaline-induced O
cardiac B-NEG
arrhythmias I-NEG
in O
cats O
anaesthetized O
with O
halothane O
, O
but O
the O
mean O
dose O
of O
( O
-)-propranolol O
was O
0.09+/-0.02 O
mg/kg O
whereas O
that O
of O
( O
+)-propranolol O
was O
4.2+/-1.2 O
mg/kg O
. O

at O
the O
effective O
dose O
level O
of O
( O
+)-propranolol O
there O
was O
a O
significant O
prolongation O
of O
the O
pr O
interval O
of O
the O
electrocardiogram O
. O

blockade O
of O
arrhythmias B-NEG
with O
both O
isomers O
was O
surmountable O
by O
increasing O
the O
dose O
of O
adrenaline.7 O
. O

both O
isomers O
of O
propranolol O
were O
also O
capable O
of O
reversing O
ventricular B-NEG
tachycardia I-NEG
caused O
by O
ouabain O
in O
anaesthetized O
cats O
and O
dogs O
. O

the O
dose O
of O
( O
-)-propranolol O
was O
significantly O
smaller O
than O
that O
of O
( O
+)-propranolol O
in O
both O
species O
but O
much O
higher O
than O
that O
required O
to O
produce O
evidence O
of O
beta-blockade.8 O
. O

the O
implications O
of O
these O
results O
are O
discussed O
. O

-DOCSTART- O

topotecan O
in O
combination O
with O
radiotherapy O
in O
unresectable O
glioblastoma B-NEG
: O
a O
phase O
2 O
study O
. O

improving O
glioblastoma B-NEG
multiforme I-NEG
( O
gbm B-NEG
) O
treatment O
with O
radio-chemotherapy O
remains O
a O
challenge O
. O

topotecan O
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma B-NEG
as O
well O
as O
brain O
penetration O
. O

the O
present O
study O
assessed O
the O
combination O
of O
radiotherapy O
( O
60 O
gy/30 O
fractions/40 O
days O
) O
and O
topotecan O
( O
0.9 O
mg/m(2)/day O
on O
days O
1-5 O
on O
weeks O
1, O
3 O
and O
5) O
in O
50 O
adults O
with O
histologically O
proven O
and O
untreated O
gbm B-NEG
. O

the O
incidence O
of O
non-hematological O
toxicities B-NEG
was O
low O
and O
grade O
3-4 O
hematological O
toxicities B-NEG
were O
reported O
in O
20 O
patients O
( O
mainly O
lymphopenia B-NEG
and O
neutropenia B-NEG
). O

partial O
response O
and O
stabilization O
rates O
were O
2% O
and O
32% O
, O
respectively O
, O
with O
an O
overall O
time O
to O
progression O
of O
12 O
weeks O
. O

one-year O
overall O
survival O
( O
os O
) O
rate O
was O
42% O
, O
with O
a O
median O
os O
of O
40 O
weeks O
. O

topotecan O
in O
combination O
with O
radiotherapy O
was O
well O
tolerated O
. O

however O
, O
while O
response O
and O
stabilization O
concerned O
one-third O
of O
the O
patients O
, O
the O
study O
did O
not O
show O
increased O
benefits O
in O
terms O
of O
survival O
in O
patients O
with O
unresectable O
gbm B-NEG
. O

-DOCSTART- O

long-term O
lithium O
therapy O
leading O
to O
hyperparathyroidism B-NEG
: O
a O
case O
report O
. O

purpose O
: O
this O
paper O
reviews O
the O
effect O
of O
chronic O
lithium O
therapy O
on O
serum O
calcium O
level O
and O
parathyroid O
glands O
, O
its O
pathogenesis O
, O
and O
treatment O
options O
. O

we O
examined O
the O
case O
of O
a O
lithium-treated O
patient O
who O
had O
recurrent O
hypercalcemia B-NEG
to O
better O
understand O
the O
disease O
process O
. O

conclusion O
: O
primary B-NEG
hyperparathyroidism I-NEG
is O
a O
rare O
but O
potentially O
life-threatening O
side O
effect O
of O
long-term O
lithium O
therapy O
. O

careful O
patient O
selection O
and O
long-term O
follow-up O
can O
reduce O
morbidity O
. O

practical O
implications O
: O
as O
much O
as O
15% O
of O
lithium-treated O
patients O
become O
hypercalcemic B-NEG
. O

by O
routinely O
monitoring O
serum O
calcium O
levels O
, O
healthcare O
providers O
can O
improve O
the O
quality O
of O
life O
of O
this O
patient O
group O
. O

-DOCSTART- O

comparison O
of O
laryngeal O
mask O
with O
endotracheal O
tube O
for O
anesthesia O
in O
endoscopic O
sinus O
surgery O
. O

background O
: O
the O
purpose O
of O
this O
study O
was O
to O
compare O
surgical O
conditions O
, O
including O
the O
amount O
of O
intraoperative O
bleeding B-NEG
as O
well O
as O
intraoperative O
blood O
pressure O
, O
during O
functional O
endoscopic O
sinus O
surgery O
( O
fess O
) O
using O
flexible O
reinforced O
laryngeal O
mask O
airway O
( O
frlma O
) O
versus O
endotracheal O
tube O
( O
ett O
) O
in O
maintaining O
controlled O
hypotension B-NEG
anesthesia O
induced O
by O
propofol-remifentanil O
total O
i.v O
. O
anesthesia O
(tiva) O
. O

methods O
: O
sixty O
normotensive O
american O
society O
of O
anesthesiologists O
i-ii O
adult O
patients O
undergoing O
fess O
under O
controlled O
hypotension B-NEG
anesthesia O
caused O
by O
propofol-remifentanil-tiva O
were O
randomly O
assigned O
into O
two O
groups O
: O
group O
i, O
frlma O
; O
group O
ii O
, O
ett O
. O
hemorrhage B-NEG
was O
measured O
and O
the O
visibility O
of O
the O
operative O
field O
was O
evaluated O
according O
to O
a O
six-point O
scale O
. O

results O
: O
controlled O
hypotension B-NEG
was O
achieved O
within O
a O
shorter O
period O
using O
laryngeal O
mask O
using O
lower O
rates O
of O
remifentanil O
infusion O
and O
lower O
total O
dose O
of O
remifentanil O
. O

conclusion O
: O
in O
summary O
, O
our O
results O
indicate O
that O
airway O
management O
using O
frlma O
during O
controlled O
hypotension B-NEG
anesthesia O
provided O
better O
surgical O
conditions O
in O
terms O
of O
quality O
of O
operative O
field O
and O
blood O
loss O
and O
allowed O
for O
convenient O
induced O
hypotension B-NEG
with O
low O
doses O
of O
remifentanil O
during O
tiva O
in O
patients O
undergoing O
fess O
. O

-DOCSTART- O

nonalcoholic B-NEG
fatty I-NEG
liver I-NEG
disease I-NEG
during O
valproate O
therapy O
. O

valproic O
acid O
( O
vpa O
) O
is O
effective O
for O
the O
treatment O
of O
many O
types O
of O
epilepsy B-NEG
, O
but O
its O
use O
can O
be O
associated O
with O
an O
increase O
in O
body O
weight O
. O

we O
report O
a O
case O
of O
nonalcoholic B-NEG
fatty I-NEG
liver I-NEG
disease I-NEG
( O
nafld B-NEG
) O
arising O
in O
a O
child O
who O
developed O
obesity B-NEG
during O
vpa O
treatment O
. O

laboratory O
data O
revealed O
hyperinsulinemia B-NEG
with O
insulin B-NEG
resistance I-NEG
. O

after O
the O
withdrawal O
of O
vpa O
therapy O
, O
our O
patient O
showed O
a O
significant O
weight B-NEG
loss I-NEG
, O
a O
decrease O
of O
body O
mass O
index O
, O
and O
normalization O
of O
metabolic O
and O
endocrine O
parameters O
; O
moreover O
, O
ultrasound O
measurements O
showed O
a O
complete O
normalization O
. O

the O
present O
case O
suggests O
that O
obesity B-NEG
, O
hyperinsulinemia B-NEG
, O
insulin B-NEG
resistance I-NEG
, O
and O
long-term O
treatment O
with O
vpa O
may O
be O
all O
associated O
with O
the O
development O
of O
nafld B-NEG
; O
this O
side O
effect O
is O
reversible O
after O
vpa O
withdrawal O
. O

-DOCSTART- O

carbimazole O
induced O
anca B-NEG
positive I-NEG
vasculitis I-NEG
. O

anti-thyroid O
drugs O
, O
like O
carbimazole O
and O
propylthiouracil O
( O
ptu O
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism B-NEG
. O

one O
should O
be O
aware O
of O
the O
side O
effects O
of O
antithyroid O
medications O
. O
antineutrophil B-NEG
cytoplasmic I-NEG
antibody I-NEG
( O
anca)--associated I-NEG
vasculitis I-NEG
is O
a O
potentially O
life-threatening O
adverse O
effect O
of O
antithyroidmedications O
. O

we O
report O
a O
patient O
with O
graves' B-NEG
disease I-NEG
who O
developed O
anca O
positive O
carbimazole O
induced O
vasculitis B-NEG
. O

the O
episode O
was O
characterized O
by O
a O
vasculitic B-NEG
skin B-NEG
rash I-NEG
associated O
with O
large O
joint O
arthritis B-NEG
, O
pyrexia B-NEG
and O
parotiditis B-NEG
but O
no O
renal O
or O
pulmonary O
involvement O
. O

he O
was O
referred O
to O
us O
for O
neurological O
evaluation O
because O
he O
had O
difficulty O
in O
getting O
up O
from O
squatting O
position O
and O
was O
suspected O
to O
have O
myositis B-NEG
. O

carbimazole O
and O
methimazole O
have O
a O
lower O
incidence O
of O
reported O
anca O
positive O
side O
effects O
than O
put O
. O

to O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
anca O
positive O
carbimazole O
induced O
vasculitis B-NEG
case O
reported O
from O
india O
. O

-DOCSTART- O

aspirin O
for O
the O
primary O
prevention O
of O
cardiovascular O
events O
: O
an O
update O
of O
the O
evidence O
for O
the O
u.s O
. O

preventive O
services O
task O
force O
. O

background O
: O
coronary B-NEG
heart I-NEG
disease I-NEG
and O
cerebrovascular B-NEG
disease I-NEG
are O
leading O
causes O
of O
death O
in O
the O
united O
states O
. O

in O
2002 O
, O
the O
u.s O
. O

preventive O
services O
task O
force O
( O
uspstf O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin O
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary B-NEG
heart I-NEG
disease I-NEG
. O

purpose O
: O
to O
determine O
the O
benefits O
and O
harms O
of O
taking O
aspirin O
for O
the O
primary O
prevention O
of O
myocardial B-NEG
infarctions I-NEG
, O
strokes B-NEG
, O
and O
death O
. O

data O
sources O
: O
medline O
and O
cochrane O
library O
( O
search O
dates O
, O
1 O
january O
2001 O
to O
28 O
august O
2008) O
, O
recent O
systematic O
reviews O
, O
reference O
lists O
of O
retrieved O
articles O
, O
and O
suggestions O
from O
experts O
. O

study O
selection O
: O
english-language O
randomized O
, O
controlled O
trials O
(rcts) O
; O
case-control O
studies O
; O
meta-analyses O
; O
and O
systematic O
reviews O
of O
aspirin O
versus O
control O
for O
the O
primary O
prevention O
of O
cardiovascular B-NEG
disease I-NEG
( O
cvd B-NEG
) O
were O
selected O
to O
answer O
the O
following O
questions O
: O
does O
aspirin O
decrease O
coronary O
heart O
events O
, O
strokes B-NEG
, O
death O
from O
coronary O
heart O
events O
or O
stroke B-NEG
, O
or O
all-cause O
mortality O
in O
adults O
without O
known O
cvd B-NEG
? O

does O
aspirin O
increase O
gastrointestinal B-NEG
bleeding I-NEG
or O
hemorrhagic B-NEG
strokes I-NEG
? O

data O
extraction O
: O
all O
studies O
were O
reviewed O
, O
abstracted O
, O
and O
rated O
for O
quality O
by O
using O
predefined O
uspstf O
criteria O
. O

data O
synthesis O
: O
new O
evidence O
from O
1 O
good-quality O
rct O
, O
1 O
good-quality O
meta-analysis O
, O
and O
2 O
fair-quality O
subanalyses O
of O
rcts O
demonstrates O
that O
aspirin O
use O
reduces O
the O
number O
of O
cvd B-NEG
events O
in O
patients O
without O
known O
cvd B-NEG
. O

men O
in O
these O
studies O
experienced O
fewer O
myocardial B-NEG
infarctions I-NEG
and O
women O
experienced O
fewer O
ischemic O
strokes B-NEG
. O

aspirin O
does O
not O
seem O
to O
affect O
cvd B-NEG
mortality O
or O
all-cause O
mortality O
in O
either O
men O
or O
women O
. O

the O
use O
of O
aspirin O
for O
primary O
prevention O
increases O
the O
risk O
for O
major O
bleeding B-NEG
events O
, O
primarily O
gastrointestinal B-NEG
bleeding I-NEG
events O
, O
in O
both O
men O
and O
women O
. O

men O
have O
an O
increased O
risk O
for O
hemorrhagic B-NEG
strokes I-NEG
with O
aspirin O
use O
. O

a O
new O
rct O
and O
meta-analysis O
suggest O
that O
the O
risk O
for O
hemorrhagic B-NEG
strokes I-NEG
in O
women O
is O
not O
statistically O
significantly O
increased O
. O

limitations O
: O
new O
evidence O
on O
aspirin O
for O
the O
primary O
prevention O
of O
cvd B-NEG
is O
limited O
. O

the O
dose O
of O
aspirin O
used O
in O
the O
rcts O
varied O
, O
which O
prevented O
the O
estimation O
of O
the O
most O
appropriate O
dose O
for O
primary O
prevention O
. O

several O
of O
the O
rcts O
were O
conducted O
within O
populations O
of O
health O
professionals O
, O
which O
potentially O
limits O
generalizability O
. O

conclusion O
: O
aspirin O
reduces O
the O
risk O
for O
myocardial B-NEG
infarction I-NEG
in O
men O
and O
strokes B-NEG
in O
women O
. O

aspirin O
use O
increases O
the O
risk O
for O
serious O
bleeding B-NEG
events O
. O

-DOCSTART- O

reducing O
harm O
associated O
with O
anticoagulation O
: O
practical O
considerations O
of O
argatroban O
therapy O
in O
heparin-induced O
thrombocytopenia B-NEG
. O

argatroban O
is O
a O
hepatically O
metabolized O
, O
direct O
thrombin O
inhibitor O
used O
for O
prophylaxis O
or O
treatment O
of O
thrombosis B-NEG
in O
heparin-induced O
thrombocytopenia B-NEG
( O
hit B-NEG
) O
and O
for O
patients O
with O
or O
at O
risk O
of O
hit B-NEG
undergoing O
percutaneous O
coronary O
intervention O
(pci) O
. O

the O
objective O
of O
this O
review O
is O
to O
summarize O
practical O
considerations O
of O
argatroban O
therapy O
in O
hit B-NEG
. O

the O
us O
fda-recommended O
argatroban O
dose O
in O
hit B-NEG
is O
2 O
microg/kg/min O
( O
reduced O
in O
patients O
with O
hepatic B-NEG
impairment I-NEG
and O
in O
paediatric O
patients) O
, O
adjusted O
to O
achieve O
activated O
partial O
thromboplastin O
times O
( O
aptts O
) O
1.5-3 O
times O
baseline O
( O
not O
>100 O
seconds) O
. O

contemporary O
experiences O
indicate O
that O
reduced O
doses O
are O
also O
needed O
in O
patients O
with O
conditions O
associated O
with O
hepatic O
hypoperfusion O
, O
e.g O
. O
heart B-NEG
failure I-NEG
, O
yet O
are O
unnecessary O
for O
renal B-NEG
dysfunction I-NEG
, O
adult O
age O
, O
sex O
, O
race/ethnicity O
or O
obesity B-NEG
. O

argatroban O
0.5-1.2 O
microg/kg/min O
typically O
supports O
therapeutic O
aptts O
. O

the O
fda-recommended O
dose O
during O
pci O
is O
25 O
microg/kg/min O
( O
350 O
microg/kg O
initial O
bolus) O
, O
adjusted O
to O
achieve O
activated O
clotting O
times O
( O
acts O
) O
of O
300-450 O
sec O
. O

for O
pci O
, O
argatroban O
has O
not O
been O
investigated O
in O
hepatically O
impaired O
patients O
; O
dose O
adjustment O
is O
unnecessary O
for O
adult O
age O
, O
sex O
, O
race/ethnicity O
or O
obesity B-NEG
, O
and O
lesser O
doses O
may O
be O
adequate O
with O
concurrent O
glycoprotein O
iib/iiia O
inhibition O
. O

argatroban O
prolongs O
the O
international O
normalized O
ratio O
, O
and O
published O
approaches O
for O
monitoring O
the O
argatroban-to-warfarin O
transition O
should O
be O
followed O
. O

major O
bleeding B-NEG
with O
argatroban O
is O
0-10% O
in O
the O
non-interventional O
setting O
and O
0-5.8% O
periprocedurally O
. O

argatroban O
has O
no O
specific O
antidote O
, O
and O
if O
excessive O
anticoagulation O
occurs O
, O
argatroban O
infusion O
should O
be O
stopped O
or O
reduced O
. O

improved O
familiarity O
of O
healthcare O
professionals O
with O
argatroban O
therapy O
in O
hit B-NEG
, O
including O
in O
special O
populations O
and O
during O
pci O
, O
may O
facilitate O
reduction O
of O
harm O
associated O
with O
hit B-NEG
(e.g O
. O
fewer O
thromboses O
) O
or O
its O
treatment O
(e.g O
. O
fewer O
argatroban O
medication O
errors) O
. O

-DOCSTART- O

rhabdomyolysis B-NEG
and O
brain O
ischemic B-NEG
stroke I-NEG
in O
a O
heroin-dependent O
male O
under O
methadone O
maintenance O
therapy O
. O

objective O
: O
there O
are O
several O
complications O
associated O
with O
heroin B-NEG
abuse I-NEG
, O
some O
of O
which O
are O
life-threatening O
. O

methadone O
may O
aggravate O
this O
problem O
. O

method O
: O
a O
clinical O
case O
description O
. O

results O
: O
a O
33-year-old O
man O
presented O
with O
rhabdomyolysis B-NEG
and O
cerebral O
ischemic B-NEG
stroke I-NEG
after O
intravenous O
heroin O
. O

he O
had O
used O
heroin O
since O
age O
20 O
, O
and O
had O
used O
150 O
mg O
methadone O
daily O
for O
6 O
months O
. O

he O
was O
found O
unconsciousness B-NEG
at O
home O
and O
was O
sent O
to O
our O
hospital O
. O

in O
the O
er O
, O
his O
opiate O
level O
was O
4497 O
ng/ml O
. O

in O
the O
icu O
, O
we O
found O
rhabdomyolysis B-NEG
, O
acute B-NEG
renal I-NEG
failure I-NEG
and O
acute O
respiratory B-NEG
failure I-NEG
. O

after O
transfer O
to O
an O
internal O
ward O
, O
we O
noted O
aphasia B-NEG
and O
weakness B-NEG
of O
his O
left O
limbs O
. O

after O
mri O
, O
we O
found O
cerebral B-NEG
ischemic I-NEG
infarction I-NEG
. O

conclusion O
: O
those O
using O
methadone O
and O
heroin O
simultaneously O
may O
increase O
risk O
of O
rhabdomyolysis B-NEG
and O
ischemic B-NEG
stroke I-NEG
. O

patients O
under O
methadone O
maintenance O
therapy O
should O
be O
warned O
regarding O
these O
serious O
adverse O
events O
. O

hypotheses O
of O
heroin-related O
rhabdomyolysis B-NEG
and O
stroke B-NEG
in O
heroin O
abusers O
are O
discussed O
. O

-DOCSTART- O

increased O
vulnerability O
to O
6-hydroxydopamine O
lesion O
and O
reduced O
development O
of O
dyskinesias B-NEG
in O
mice O
lacking O
cb1 O
cannabinoid O
receptors O
. O

motor O
impairment O
, O
dopamine O
( O
da O
) O
neuronal O
activity O
and O
proenkephalin O
( O
penk O
) O
gene O
expression O
in O
the O
caudate-putamen O
( O
cpu O
) O
were O
measured O
in O
6-ohda-lesioned O
and O
treated O
( O
l-dopa+benserazide O
) O
cb1 O
ko O
and O
wt O
mice O
. O

a O
lesion O
induced O
by O
6-ohda O
produced O
more O
severe O
motor O
deterioration O
in O
cb1 O
ko O
mice O
accompanied O
by O
more O
loss O
of O
da O
neurons O
and O
increased O
penk O
gene O
expression O
in O
the O
cpu O
. O

oxidative/nitrosative O
and O
neuroinflammatory O
parameters O
were O
estimated O
in O
the O
cpu O
and O
cingulate O
cortex O
(cg) O
. O

cb1 O
ko O
mice O
exhibited O
higher O
mda O
levels O
and O
inos O
protein O
expression O
in O
the O
cpu O
and O
cg O
compared O
to O
wt O
mice O
. O

treatment O
with O
l-dopa+benserazide O
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias B-NEG
in O
cb1 O
ko O
than O
in O
wt O
mice O
. O

the O
results O
revealed O
that O
the O
lack O
of O
cannabinoid O
cb1 O
receptors O
increased O
the O
severity O
of O
motor O
impairment O
and O
da O
lesion O
, O
and O
reduced O
l-dopa-induced O
dyskinesias B-NEG
. O

these O
results O
suggest O
that O
activation O
of O
cb1 O
receptors O
offers O
neuroprotection O
against O
dopaminergic O
lesion O
and O
the O
development O
of O
l-dopa-induced O
dyskinesias B-NEG
. O

-DOCSTART- O

animal O
model O
of O
mania B-NEG
induced O
by O
ouabain O
: O
evidence O
of O
oxidative O
stress O
in O
submitochondrial O
particles O
of O
the O
rat O
brain O
. O

the O
intracerebroventricular O
( O
icv O
) O
administration O
of O
ouabain O
(a O
na(+)/k(+)-atpase O
inhibitor O
) O
in O
rats O
has O
been O
suggested O
to O
mimic O
some O
symptoms O
of O
human O
bipolar B-NEG
mania I-NEG
. O

clinical O
studies O
have O
shown O
that O
bipolar B-NEG
disorder I-NEG
may O
be O
related O
to O
mitochondrial B-NEG
dysfunction I-NEG
. O

herein O
, O
we O
investigated O
the O
behavioral O
and O
biochemical O
effects O
induced O
by O
the O
icv O
administration O
of O
ouabain O
in O
rats O
. O

to O
achieve O
this O
aim O
, O
the O
effects O
of O
ouabain O
injection O
immediately O
after O
and O
7 O
days O
following O
a O
single O
icv O
administration O
( O
at O
concentrations O
of O
10(-2 O
) O
and O
10(-3)m O
) O
on O
locomotion O
was O
measured O
using O
the O
open-field O
test O
. O

additionally O
, O
thiobarbituric O
acid O
reactive O
substances O
( O
tbarss O
) O
and O
superoxide O
production O
were O
measured O
in O
submitochondrial O
particles O
of O
the O
prefrontal O
cortex O
, O
hippocampus O
, O
striatum O
and O
amygdala O
. O

our O
findings O
demonstrated O
that O
ouabain O
at O
10(-2 O
) O
and O
10(-3)m O
induced O
hyperlocomotion B-NEG
in O
rats O
, O
and O
this O
response O
remained O
up O
to O
7 O
days O
following O
a O
single O
icv O
injection O
. O

in O
addition O
, O
we O
observed O
that O
the O
persistent O
increase O
in O
the O
rat O
spontaneous O
locomotion O
is O
associated O
with O
increased O
tbars O
levels O
and O
superoxide O
generation O
in O
submitochondrial O
particles O
in O
the O
prefrontal O
cortex O
, O
striatum O
and O
amygdala O
. O

in O
conclusion O
, O
ouabain-induced O
mania B-NEG
-like O
behavior O
may O
provide O
a O
useful O
animal O
model O
to O
test O
the O
hypothesis O
of O
the O
involvement O
of O
oxidative O
stress O
in O
bipolar B-NEG
disorder I-NEG
. O

-DOCSTART- O

intraoperative O
dialysis O
during O
liver O
transplantation O
with O
citrate O
dialysate O
. O

liver O
transplantation O
for O
acutely O
ill O
patients O
with O
fulminant B-NEG
liver I-NEG
failure I-NEG
carries O
high O
intraoperative O
and O
immediate O
postoperative O
risks O
. O

these O
are O
increased O
with O
the O
presence O
of O
concomitant O
acute B-NEG
kidney I-NEG
injury I-NEG
( O
aki B-NEG
) O
and O
intraoperative O
dialysis O
is O
sometimes O
required O
to O
allow O
the O
transplant O
to O
proceed O
. O

the O
derangements O
in O
the O
procoagulant O
and O
anticoagulant O
pathways O
during O
fulminant B-NEG
liver I-NEG
failure I-NEG
can O
lead O
to O
difficulties O
with O
anticoagulation O
during O
dialysis O
, O
especially O
when O
continued O
in O
the O
operating O
room O
. O

systemic O
anticoagulation O
is O
unsafe O
and O
regional O
citrate O
anticoagulation O
in O
the O
absence O
of O
a O
functional O
liver O
carries O
the O
risk O
of O
citrate O
toxicity B-NEG
. O

citrate O
dialysate O
, O
a O
new O
dialysate O
with O
citric O
acid O
can O
be O
used O
for O
anticoagulation O
in O
patients O
who O
cannot O
tolerate O
heparin O
or O
regional O
citrate O
. O

we O
report O
a O
case O
of O
a O
40-year-old O
female O
with O
acetaminophen-induced O
fulminant B-NEG
liver I-NEG
failure I-NEG
with O
associated O
aki B-NEG
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transplantation O
anticoagulated O
with O
citrate O
dialysate O
during O
the O
entire O
procedure O
. O

the O
patient O
tolerated O
the O
procedure O
well O
without O
any O
signs O
of O
citrate O
toxicity B-NEG
and O
maintained O
adequate O
anticoagulation O
for O
patency O
of O
the O
dialysis O
circuit O
. O

citrate O
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transplantation O
in O
fulminant B-NEG
liver I-NEG
failure I-NEG
. O

-DOCSTART- O

delirium B-NEG
in O
a O
patient O
with O
toxic O
flecainide O
plasma O
concentrations O
: O
the O
role O
of O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

objective O
: O
to O
describe O
a O
case O
of O
flecainide-induced O
delirium B-NEG
associated O
with O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

case O
summary O
: O
a O
69-year-old O
white O
female O
presented O
to O
the O
emergency O
department O
with O
a O
history O
of O
confusion B-NEG
and O
paranoia B-NEG
over O
the O
past O
several O
days O
. O

on O
admission O
the O
patient O
was O
taking O
carvedilol O
12 O
mg O
twice O
daily O
, O
warfarin O
2 O
mg/day O
, O
folic O
acid O
1 O
mg/day O
, O
levothyroxine O
100 O
microg/day O
, O
pantoprazole O
40 O
mg/day O
, O
paroxetine O
40 O
mg/day O
, O
and O
flecainide O
100 O
mg O
twice O
daily O
. O

flecainide O
had O
been O
started O
2 O
weeks O
prior O
for O
atrial B-NEG
fibrillation I-NEG
. O

laboratory O
test O
findings O
on O
admission O
were O
notable O
only O
for O
a O
flecainide O
plasma O
concentration O
of O
1360 O
microg/l O
( O
reference O
range O
200-1000) O
. O

a O
metabolic O
drug O
interaction O
between O
flecainide O
and O
paroxetine O
, O
which O
the O
patient O
had O
been O
taking O
for O
more O
than O
5 O
years O
, O
was O
considered O
. O

paroxetine O
was O
discontinued O
and O
the O
dose O
of O
flecainide O
was O
reduced O
to O
50 O
mg O
twice O
daily O
. O

her O
delirium B-NEG
resolved O
3 O
days O
later O
. O

discussion O
: O
flecainide O
and O
pharmacologically O
similar O
agents O
that O
interact O
with O
sodium O
channels O
may O
cause O
delirium B-NEG
in O
susceptible O
patients O
. O

a O
medline O
search O
( O
1966-january O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide O
, O
a O
cyp2d6 O
substrate O
, O
and O
paroxetine O
, O
a O
cyp2d6 O
inhibitor O
, O
as O
well O
as O
3 O
case O
reports O
of O
flecainide-induced O
delirium B-NEG
. O

according O
to O
the O
naranjo O
probability O
scale O
, O
flecainide O
was O
the O
probable O
cause O
of O
the O
patient's O
delirium B-NEG
; O
the O
horn O
drug O
interaction O
probability O
scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide O
and O
paroxetine O
. O

conclusions O
: O
supratherapeutic O
flecainide O
plasma O
concentrations O
may O
cause O
delirium B-NEG
. O

because O
toxicity B-NEG
may O
occur O
when O
flecainide O
is O
prescribed O
with O
paroxetine O
and O
other O
potent O
cyp2d6 O
inhibitors O
, O
flecainide O
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
cyp2d6 O
inhibitors O
. O

-DOCSTART- O

efficacy O
of O
everolimus O
( O
rad001 O
) O
in O
patients O
with O
advanced O
nsclc B-NEG
previously O
treated O
with O
chemotherapy O
alone O
or O
with O
chemotherapy O
and O
egfr O
inhibitors O
. O

background O
: O
treatment O
options O
are O
scarce O
in O
pretreated O
advanced O
non-small-cell B-NEG
lung I-NEG
cancer I-NEG
( O
nsclc B-NEG
) O
patients O
. O

rad001 O
, O
an O
oral O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin O
(mtor) O
, O
has O
shown O
phase O
i O
efficacy O
in O
nsclc B-NEG
. O

methods O
: O
stage O
iiib O
or O
iv O
nsclc B-NEG
patients O
, O
with O
two O
or O
fewer O
prior O
chemotherapy O
regimens O
, O
one O
platinum O
based O
( O
stratum O
1) O
or O
both O
chemotherapy O
and O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitors O
( O
stratum O
2) O
, O
received O
rad001 O
10 O
mg/day O
until O
progression O
or O
unacceptable O
toxicity B-NEG
. O

primary O
objective O
was O
overall O
response O
rate O
(orr) O
. O

analyses O
of O
markers O
associated O
with O
the O
mtor O
pathway O
were O
carried O
out O
on O
archival O
tumor B-NEG
from O
a O
subgroup O
using O
immunohistochemistry O
( O
ihc O
) O
and O
direct O
mutation O
sequencing O
. O

results O
: O
eighty-five O
patients O
were O
enrolled O
, O
42 O
in O
stratum O
1 O
and O
43 O
in O
stratum O
. O

orr O
was O
4.7% O
( O
7.1% O
stratum O
1; O
2.3% O
stratum O
2) O
. O

overall O
disease O
control O
rate O
was O
47.1% O
. O

median O
progression-free O
survivals O
( O
pfss O
) O
were O
2.6 O
( O
stratum O
1) O
and O
2.7 O
months O
( O
stratum O
2) O
. O

common O
> O
or O
=grade O
3 O
events O
were O
fatigue B-NEG
, O
dyspnea B-NEG
, O
stomatitis B-NEG
, O
anemia B-NEG
, O
and O
thrombocytopenia B-NEG
. O
pneumonitis B-NEG
, O
probably O
or O
possibly O
related O
, O
mainly O
grade O
1/2 O
, O
occurred O
in O
25% O
. O

cox O
regression O
analysis O
of O
ihc O
scores O
found O
that O
only O
phospho O
akt O
( O
pakt O
) O
was O
a O
significant O
independent O
predictor O
of O
worse O
pfs O
. O

conclusions O
: O
rad001 O
10 O
mg/day O
was O
well O
tolerated O
, O
showing O
modest O
clinical O
activity O
in O
pretreated O
nsclc B-NEG
. O

evaluation O
of O
rad001 O
plus O
standard O
therapy O
for O
metastatic O
nsclc B-NEG
continues O
. O

-DOCSTART- O

posttransplant O
anemia B-NEG
: O
the O
role O
of O
sirolimus O
. O

posttransplant O
anemia B-NEG
is O
a O
common O
problem O
that O
may O
hinder O
patients' O
quality O
of O
life O
. O

it O
occurs O
in O
12 O
to O
76% O
of O
patients O
, O
and O
is O
most O
common O
in O
the O
immediate O
posttransplant O
period O
. O

a O
variety O
of O
factors O
have O
been O
identified O
that O
increase O
the O
risk O
of O
posttransplant O
anemia B-NEG
, O
of O
which O
the O
level O
of O
renal O
function O
is O
most O
important O
. O

sirolimus O
, O
a O
mammalian O
target O
of O
rapamycin O
inhibitor O
, O
has O
been O
implicated O
as O
playing O
a O
special O
role O
in O
posttransplant O
anemia B-NEG
. O

this O
review O
considers O
anemia B-NEG
associated O
with O
sirolimus O
, O
including O
its O
presentation O
, O
mechanisms O
, O
and O
management O
. O

-DOCSTART- O

coronary O
computerized O
tomography O
angiography O
for O
rapid O
discharge O
of O
low-risk O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
. O

background O
: O
most O
patients O
presenting O
to O
emergency O
departments O
( O
eds O
) O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
rule O
out O
acute B-NEG
coronary I-NEG
syndrome I-NEG
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

in O
patients O
without O
cocaine O
use O
, O
coronary O
computerized O
tomography O
angiography O
( O
cta O
) O
has O
been O
shown O
to O
be O
useful O
for O
identifying O
a O
group O
of O
patients O
at O
low O
risk O
for O
cardiac O
events O
who O
can O
be O
safely O
discharged O
. O

it O
is O
unclear O
whether O
a O
coronary O
cta O
strategy O
would O
be O
efficacious O
in O
cocaine-associated O
chest B-NEG
pain I-NEG
, O
as O
coronary B-NEG
vasospasm I-NEG
may O
account O
for O
some O
of O
the O
ischemia B-NEG
. O

we O
studied O
whether O
a O
negative O
coronary O
cta O
in O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
could O
identify O
a O
subset O
safe O
for O
discharge O
. O

methods O
: O
we O
prospectively O
evaluated O
the O
safety O
of O
coronary O
cta O
for O
low-risk O
patients O
who O
presented O
to O
the O
ed O
with O
cocaineassociated O
chest B-NEG
pain I-NEG
( O
self-reported O
or O
positive O
urine O
test) O
. O

consecutive O
patients O
received O
either O
immediate O
coronary O
cta O
in O
the O
ed O
( O
without O
serial O
markers O
) O
or O
underwent O
coronary O
cta O
after O
a O
brief O
observation O
period O
with O
serial O
cardiac O
marker O
measurements O
. O

patients O
with O
negative O
coronary O
cta O
( O
maximal O
stenosis B-NEG
less O
than O
50% O
) O
were O
discharged O
. O

the O
main O
outcome O
was O
30-day O
cardiovascular O
death O
or O
myocardial B-NEG
infarction I-NEG
. O

results O
: O
a O
total O
of O
59 O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
were O
evaluated O
. O

patients O
had O
a O
mean O
age O
of O
45.6 O
+/- O
6.6 O
yrs O
and O
were O
86% O
black O
, O
66% O
male O
. O

seventy-nine O
percent O
had O
a O
normal O
or O
nonspecific O
ecg O
and O
85% O
had O
a O
timi O
score O
<2 O
. O

twenty O
patients O
received O
coronary O
cta O
immediately O
in O
the O
ed O
, O
18 O
of O
whom O
were O
discharged O
following O
cta O
(90%) O
. O

thirty-nine O
received O
coronary O
cta O
after O
a O
brief O
observation O
period O
, O
with O
37 O
discharged O
home O
following O
cta O
(95%) O
. O

six O
patients O
had O
coronary B-NEG
stenosis I-NEG
>or=50% O
. O

during O
the O
30-day O
follow-up O
period O
, O
no O
patients O
died O
of O
a O
cardiovascular O
event O
(0% O
; O
95% O
ci O
, O
0-6.1% O
) O
and O
no O
patient O
sustained O
a O
nonfatal O
myocardial B-NEG
infarction I-NEG
(0% O
; O
95% O
ci O
, O
0-6.1%) O
. O

conclusions O
: O
although O
cocaine-associated O
myocardial B-NEG
ischemia I-NEG
can O
result O
from O
coronary O
vasoconstriction O
, O
patients O
with O
cocaine O
associated O
chest B-NEG
pain I-NEG
, O
a O
non- O
ischemic B-NEG
ecg O
, O
and O
a O
timi O
risk O
score O
<2 O
may O
be O
safely O
discharged O
from O
the O
ed O
after O
a O
negative O
coronary O
cta O
with O
a O
low O
risk O
of O
30-day O
adverse O
events O
. O

-DOCSTART- O

late O
fulminant O
posterior B-NEG
reversible I-NEG
encephalopathy I-NEG
syndrome I-NEG
after O
liver O
transplant O
. O

objectives O
: O
posterior B-NEG
leukoencephalopathy I-NEG
due O
to O
calcineurin-inhibitor-related O
neurotoxicity B-NEG
is O
a O
rare O
but O
severe O
complication O
that O
results O
from O
treatment O
with O
immunosuppressive O
agents O
( O
primarily O
those O
administered O
after O
a O
liver O
or O
kidney O
transplant) O
. O

the O
pathophysiologic O
mechanisms O
of O
that O
disorder O
remain O
unknown O
. O

case O
: O
we O
report O
the O
case O
of O
a O
46-year-old O
woman O
who O
received O
a O
liver O
transplant O
in O
our O
center O
as O
treatment O
for O
alcoholic B-NEG
cirrhosis I-NEG
and O
in O
whom O
either O
a O
fulminant O
course O
of O
posterior B-NEG
leukoencephalopathy I-NEG
or O
posterior B-NEG
reversible I-NEG
encephalopathy I-NEG
syndrome I-NEG
developed O
110 O
days O
after O
transplant O
. O

after O
an O
initially O
uneventful O
course O
after O
the O
transplant O
, O
the O
patient O
rapidly O
fell O
into O
deep O
coma O
. O

results O
: O
cerebral O
mri O
scan O
showed O
typical O
signs O
of O
enhancement O
in O
the O
pontine O
and O
posterior O
regions O
. O

switching O
the O
immunosuppressive O
regimen O
from O
tacrolimus O
to O
cyclosporine O
did O
not O
improve O
the O
clinical O
situation O
. O

the O
termination O
of O
treatment O
with O
any O
calcineurin O
inhibitor O
resulted O
in O
a O
complete O
resolution O
of O
that O
complication O
. O

conclusions O
: O
posterior B-NEG
reversible I-NEG
encephalopathy I-NEG
syndrome I-NEG
after O
liver O
transplant O
is O
rare O
. O

we O
recommend O
a O
complete O
cessation O
of O
any O
calcineurin O
inhibitor O
rather O
than O
a O
dose O
reduction O
. O

-DOCSTART- O

prolonged O
hypothermia B-NEG
as O
a O
bridge O
to O
recovery O
for O
cerebral B-NEG
edema I-NEG
and O
intracranial B-NEG
hypertension I-NEG
associated O
with O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
. O

background O
: O
to O
review O
evidence-based O
treatment O
options O
in O
patients O
with O
cerebral B-NEG
edema I-NEG
complicating O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
( O
fhf B-NEG
) O
and O
discuss O
the O
potential O
applications O
of O
hypothermia B-NEG
. O

method O
: O
case-based O
observations O
from O
a O
medical O
intensive O
care O
unit O
( O
micu O
) O
in O
a O
tertiary O
care O
facility O
in O
a O
27-year-old O
female O
with O
fhf B-NEG
from O
acetaminophen O
and O
resultant O
cerebral B-NEG
edema I-NEG
. O

results O
: O
our O
patient O
was O
admitted O
to O
the O
micu O
after O
being O
found O
unresponsive O
with O
presumed O
toxicity B-NEG
from O
acetaminophen O
which O
was O
ingested O
over O
a O
2-day O
period O
. O

the O
patient O
had O
depressed O
of O
mental O
status O
lasting O
at O
least O
24 O
h O
prior O
to O
admission O
. O

initial O
evaluation O
confirmed O
fhf B-NEG
from O
acetaminophen O
and O
cerebral B-NEG
edema I-NEG
. O

the O
patient O
was O
treated O
with O
hyperosmolar O
therapy O
, O
hyperventilation B-NEG
, O
sedation O
, O
and O
chemical O
paralysis B-NEG
. O

her O
intracranial O
pressure O
remained O
elevated O
despite O
maximal O
medical O
therapy O
. O

we O
then O
initiated O
therapeutic O
hypothermia B-NEG
which O
was O
continued O
for O
5 O
days O
. O

at O
re-warming O
, O
patient O
had O
resolution O
of O
her O
cerebral B-NEG
edema I-NEG
and O
intracranial B-NEG
hypertension I-NEG
. O

at O
discharge O
, O
she O
had O
complete O
recovery O
of O
neurological O
and O
hepatic O
functions O
. O

conclusion O
: O
in O
patients O
with O
fhf B-NEG
and O
cerebral B-NEG
edema I-NEG
from O
acetaminophen O
overdose B-NEG
, O
prolonged O
therapeutic O
hypothermia B-NEG
could O
potentially O
be O
used O
as O
a O
life O
saving O
therapy O
and O
a O
bridge O
to O
hepatic O
and O
neurological O
recovery O
. O

a O
clinical O
trial O
of O
hypothermia B-NEG
in O
patients O
with O
this O
condition O
is O
warranted O
. O

-DOCSTART- O

binasal B-NEG
visual I-NEG
field I-NEG
defects I-NEG
are O
not O
specific O
to O
vigabatrin O
. O

this O
study O
investigated O
the O
visual B-NEG
defects I-NEG
associated O
with O
the O
antiepileptic O
drug O
vigabatrin O
(vgb) O
. O

two O
hundred O
four O
people O
with O
epilepsy B-NEG
were O
grouped O
on O
the O
basis O
of O
antiepileptic O
drug O
therapy O
(current O
, O
previous O
, O
or O
no O
exposure O
to O
vgb) O
. O

groups O
were O
matched O
with O
respect O
to O
age O
, O
gender O
, O
and O
seizure B-NEG
frequency O
. O

all O
patients O
underwent O
objective O
assessment O
of O
electrophysiological O
function O
( O
wide-field O
multifocal O
electroretinography O
) O
and O
conventional O
visual O
field O
testing O
( O
static O
perimetry) O
. O

bilateral O
visual O
field O
constriction O
was O
observed O
in O
59% O
of O
patients O
currently O
taking O
vgb O
, O
43% O
of O
patients O
who O
previously O
took O
vgb O
, O
and O
24% O
of O
patients O
with O
no O
exposure O
to O
vgb O
. O

assessment O
of O
retinal O
function O
revealed O
abnormal O
responses O
in O
48% O
of O
current O
vgb O
users O
and O
22% O
of O
prior O
vgb O
users O
, O
but O
in O
none O
of O
the O
patients O
without O
previous O
exposure O
to O
vgb O
. O
bilateral B-NEG
visual I-NEG
field I-NEG
abnormalities I-NEG
are O
common O
in O
the O
treated O
epilepsy B-NEG
population O
, O
irrespective O
of O
drug O
history O
. O

assessment O
by O
conventional O
static O
perimetry O
may O
neither O
be O
sufficiently O
sensitive O
nor O
specific O
to O
reliably O
identify O
retinal B-NEG
toxicity I-NEG
associated O
with O
vgb O
. O

-DOCSTART- O

smoking O
of O
crack O
cocaine O
as O
a O
risk O
factor O
for O
hiv B-NEG
infection I-NEG
among O
people O
who O
use O
injection O
drugs O
. O

background O
: O
little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack O
cocaine O
has O
on O
the O
incidence O
of O
hiv B-NEG
infection I-NEG
. O

given O
the O
increasing O
use O
of O
crack O
cocaine O
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
hiv B-NEG
infection I-NEG
. O

methods O
: O
we O
included O
data O
from O
people O
participating O
in O
the O
vancouver O
injection O
drug O
users O
study O
who O
reported O
injecting O
illicit O
drugs O
at O
least O
once O
in O
the O
month O
before O
enrolment O
, O
lived O
in O
the O
greater O
vancouver O
area O
, O
were O
hiv-negative O
at O
enrolment O
and O
completed O
at O
least O
1 O
follow-up O
study O
visit O
. O

to O
determine O
whether O
the O
risk O
of O
hiv B-NEG
seroconversion I-NEG
among O
daily O
smokers O
of O
crack O
cocaine O
changed O
over O
time O
, O
we O
used O
cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
may O
1, O
1996-nov O
. O
30 O
, O
1999 O
( O
period O
1) O
, O
dec O
. O
1, O
1999-nov O
. O
30 O
, O
2002 O
( O
period O
2) O
, O
and O
dec O
. O
1, O
2002-dec O
. O
30 O
, O
2005 O
( O
period O
3) O
. O

results O
: O
overall O
, O
1048 O
eligible O
injection O
drug O
users O
were O
included O
in O
our O
study O
. O

of O
these O
, O
137 O
acquired O
hiv B-NEG
infection I-NEG
during O
follow-up O
. O

the O
mean O
proportion O
of O
participants O
who O
reported O
daily O
smoking O
of O
crack O
cocaine O
increased O
from O
11.6% O
in O
period O
1 O
to O
39.7% O
in O
period O
3. O

after O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
hiv B-NEG
seroconversion I-NEG
among O
participants O
who O
were O
daily O
smokers O
of O
crack O
cocaine O
increased O
over O
time O
( O
period O
1: O
hazard O
ratio O
[hr] O
1.03 O
, O
95% O
confidence O
interval O
[ci] O
0.57-1.85 O
; O
period O
2: O
hr O
1.68 O
, O
95% O
ci O
1.01-2.80 O
; O
and O
period O
3: O
hr O
2.74 O
, O
95% O
ci O
1.06-7.11) O
. O

interpretation O
: O
smoking O
of O
crack O
cocaine O
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
hiv B-NEG
seroconversion I-NEG
among O
people O
who O
were O
injection O
drug O
users O
. O

this O
finding O
points O
to O
the O
urgent O
need O
for O
evidence-based O
public O
health O
initiatives O
targeted O
at O
people O
who O
smoke O
crack O
cocaine O
. O

-DOCSTART- O

fluoxetine O
improves O
the O
memory B-NEG
deficits I-NEG
caused O
by O
the O
chemotherapy O
agent O
5-fluorouracil O
. O
cancer B-NEG
patients O
who O
have O
been O
treated O
with O
systemic O
adjuvant O
chemotherapy O
have O
described O
experiencing O
deteriorations O
in O
cognition O
. O

a O
widely O
used O
chemotherapeutic O
agent O
, O
5-fluorouracil O
(5-fu) O
, O
readily O
crosses O
the O
blood-brain O
barrier O
and O
so O
could O
have O
a O
direct O
effect O
on O
brain O
function O
. O

in O
particular O
this O
anti O
mitotic O
drug O
could O
reduce O
cell O
proliferation O
in O
the O
neurogenic O
regions O
of O
the O
adult O
brain O
. O

in O
contrast O
reports O
indicate O
that O
hippocampal O
dependent O
neurogenesis O
and O
cognition O
are O
enhanced O
by O
the O
ssri O
antidepressant O
fluoxetine O
. O

in O
this O
investigation O
the O
behavioural O
effects O
of O
chronic O
( O
two O
week O
) O
treatment O
with O
5-fu O
and O
( O
three O
weeks O
) O
with O
fluoxetine O
either O
separately O
or O
in O
combination O
with O
5-fu O
were O
tested O
on O
adult O
lister O
hooded O
rats O
. O

behavioural O
effects O
were O
tested O
using O
a O
context O
dependent O
conditioned O
emotional O
response O
test O
( O
cer O
) O
which O
showed O
that O
animals O
treated O
with O
5-fu O
had O
a O
significant O
reduction O
in O
freezing O
time O
compared O
to O
controls O
. O

a O
separate O
group O
of O
animals O
was O
tested O
using O
a O
hippocampal O
dependent O
spatial O
working O
memory O
test O
, O
the O
object O
location O
recognition O
test O
(olr) O
. O

animals O
treated O
only O
with O
5-fu O
showed O
significant O
deficits O
in O
their O
ability O
to O
carry O
out O
the O
olr O
task O
but O
co O
administration O
of O
fluoxetine O
improved O
their O
performance O
. O

5-fu O
chemotherapy O
caused O
a O
significant O
reduction O
in O
the O
number O
of O
proliferating O
cells O
in O
the O
sub O
granular O
zone O
of O
the O
dentate O
gyrus O
compared O
to O
controls O
. O

this O
reduction O
was O
eliminated O
when O
fluoxetine O
was O
co O
administered O
with O
5-fu O
. O

fluoxetine O
on O
its O
own O
had O
no O
effect O
on O
proliferating O
cell O
number O
or O
behaviour O
. O

these O
findings O
suggest O
that O
5-fu O
can O
negatively O
affect O
both O
cell O
proliferation O
and O
hippocampal O
dependent O
working O
memory O
and O
that O
these O
deficits O
can O
be O
reversed O
by O
the O
simultaneous O
administration O
of O
the O
antidepressant O
fluoxetine O
. O

-DOCSTART- O

liver-specific O
ablation O
of O
integrin-linked O
kinase O
in O
mice O
results O
in O
enhanced O
and O
prolonged O
cell O
proliferation O
and O
hepatomegaly B-NEG
after O
phenobarbital O
administration O
. O

we O
have O
recently O
demonstrated O
that O
disruption O
of O
extracellular O
matrix O
( O
ecm)/integrin O
signaling O
via O
elimination O
of O
integrin-linked O
kinase O
( O
ilk O
) O
in O
hepatocytes O
interferes O
with O
signals O
leading O
to O
termination O
of O
liver O
regeneration O
. O

this O
study O
investigates O
the O
role O
of O
ilk O
in O
liver O
enlargement O
induced O
by O
phenobarbital O
(pb) O
. O

wild-type O
( O
wt O
) O
and O
ilk:liver-/- O
mice O
were O
given O
pb O
( O
0.1% O
in O
drinking O
water O
) O
for O
10 O
days O
. O

livers O
were O
harvested O
on O
2, O
5, O
and O
10 O
days O
during O
pb O
administration O
. O

in O
the O
hepatocyte-specific O
ilk/liver-/- O
mice O
, O
the O
liver:body O
weight O
ratio O
was O
more O
than O
double O
as O
compared O
to O
0 O
h O
at O
day O
2 O
( O
2.5 O
times) O
, O
while O
at O
days O
5 O
and O
10 O
, O
it O
was O
enlarged O
three O
times O
. O

in O
the O
wt O
mice O
, O
the O
increase O
was O
as O
expected O
from O
previous O
literature O
( O
1.8 O
times O
) O
and O
seems O
to O
have O
leveled O
off O
after O
day O
2. O

there O
were O
slightly O
increased O
proliferating O
cell O
nuclear O
antigen-positive O
cells O
in O
the O
ilk/liver-/- O
animals O
at O
day O
2 O
as O
compared O
to O
wt O
after O
pb O
administration O
. O

in O
the O
wt O
animals O
, O
the O
proliferative O
response O
had O
come O
back O
to O
normal O
by O
days O
5 O
and O
10 O
. O

hepatocytes O
of O
the O
ilk/liver-/- O
mice O
continued O
to O
proliferate O
up O
until O
day O
10 O
. O

ilk/liver-/- O
mice O
also O
showed O
increased O
expression O
of O
key O
genes O
involved O
in O
hepatocyte O
proliferation O
at O
different O
time O
points O
during O
pb O
administration O
. O

in O
summary O
, O
ecm O
proteins O
communicate O
with O
the O
signaling O
machinery O
of O
dividing O
cells O
via O
ilk O
to O
regulate O
hepatocyte O
proliferation O
and O
termination O
of O
the O
proliferative O
response O
. O

lack O
of O
ilk O
in O
the O
hepatocytes O
imparts O
prolonged O
proliferative O
response O
not O
only O
to O
stimuli O
related O
to O
liver O
regeneration O
but O
also O
to O
xenobiotic O
chemical O
mitogens O
, O
such O
as O
pb O
. O

-DOCSTART- O

decreased O
expression O
of O
na/k-atpase O
, O
nhe3 O
, O
nbc1 O
, O
aqp1 O
and O
oat O
in O
gentamicin-induced O
nephropathy B-NEG
. O

the O
present O
study O
was O
aimed O
to O
determine O
whether O
there O
is O
an O
altered O
regulation O
of O
tubular O
transporters O
in O
gentamicin-induced O
nephropathy B-NEG
. O

sprague-dawley O
male O
rats O
( O
200~250 O
g) O
were O
subcutaneously O
injected O
with O
gentamicin O
( O
100 O
mg/kg O
per O
day O
) O
for O
7 O
days O
, O
and O
the O
expression O
of O
tubular O
transporters O
was O
determined O
by O
immunoblotting O
and O
immunohistochemistry O
. O

the O
mrna O
and O
protein O
expression O
of O
oat O
was O
also O
determined O
. O

gentamicin-treated O
rats O
exhibited O
significantly O
decreased O
creatinine O
clearance O
along O
with O
increased O
plasma O
creatinine O
levels O
. O

accordingly O
, O
the O
fractional O
excretion O
of O
sodium O
increased O
. O

urine O
volume O
was O
increased O
, O
while O
urine O
osmolality O
and O
free O
water O
reabsorption O
were O
decreased O
. O

immunoblotting O
and O
immunohistochemistry O
revealed O
decreased O
expression O
of O
na(+)/k(+)-atpase O
, O
nhe3 O
, O
nbc1 O
, O
and O
aqp1 O
in O
the O
kidney O
of O
gentamicin-treated O
rats O
. O

the O
expression O
of O
oat1 O
and O
oat3 O
was O
also O
decreased O
. O

gentamicin-induced O
nephropathy B-NEG
may O
at O
least O
in O
part O
be O
causally O
related O
with O
a O
decreased O
expression O
of O
na(+)/k(+)-atpase O
, O
nhe3 O
, O
nbc1 O
, O
aqp1 O
and O
oat O
. O

-DOCSTART- O

longitudinal O
association O
of O
alcohol O
use O
with O
hiv B-NEG
disease I-NEG
progression O
and O
psychological O
health O
of O
women O
with O
hiv O
. O

we O
evaluated O
the O
association O
of O
alcohol O
consumption O
and O
depression B-NEG
, O
and O
their O
effects O
on O
hiv B-NEG
disease I-NEG
progression O
among O
women O
with O
hiv O
. O

the O
study O
included O
871 O
women O
with O
hiv O
who O
were O
recruited O
from O
1993-1995 O
in O
four O
us O
cities O
. O

the O
participants O
had O
physical O
examination O
, O
medical O
record O
extraction O
, O
and O
venipuncture O
, O
cd4+t-cell O
counts O
determination O
, O
measurement O
of O
depression B-NEG
symptoms O
( O
using O
the O
self-report O
center O
for O
epidemiological O
studies- O
depression B-NEG
scale) O
, O
and O
alcohol O
use O
assessment O
at O
enrollment O
, O
and O
semiannually O
until O
march O
2000 O
. O

multilevel O
random O
coefficient O
ordinal O
models O
as O
well O
as O
multilevel O
models O
with O
joint O
responses O
were O
used O
in O
the O
analysis O
. O

there O
was O
no O
significant O
association O
between O
level O
of O
alcohol O
use O
and O
cd4+ O
t-cell O
counts O
. O

when O
participants O
were O
stratified O
by O
antiretroviral O
therapy O
( O
art O
) O
use O
, O
the O
association O
between O
alcohol O
and O
cd4+ O
t-cell O
did O
not O
reach O
statistical O
significance O
. O

the O
association O
between O
alcohol O
consumption O
and O
depression B-NEG
was O
significant O
(p<0.001) O
. O
depression B-NEG
had O
a O
significant O
negative O
effect O
on O
cd4+ O
t-cell O
counts O
over O
time O
regardless O
of O
art O
use O
. O

our O
findings O
suggest O
that O
alcohol O
consumption O
has O
a O
direct O
association O
with O
depression B-NEG
. O

moreover O
, O
depression B-NEG
is O
associated O
with O
hiv B-NEG
disease I-NEG
progression O
. O

our O
findings O
have O
implications O
for O
the O
provision O
of O
alcohol O
use O
interventions O
and O
psychological O
resources O
to O
improve O
the O
health O
of O
women O
with O
hiv O
. O

-DOCSTART- O

chemokine O
ccl2 O
and O
its O
receptor O
ccr2 O
are O
increased O
in O
the O
hippocampus O
following O
pilocarpine-induced O
status B-NEG
epilepticus I-NEG
. O

background O
: O
neuroinflammation B-NEG
occurs O
after O
seizures B-NEG
and O
is O
implicated O
in O
epileptogenesis O
. O

ccr2 O
is O
a O
chemokine O
receptor O
for O
ccl2 O
and O
their O
interaction O
mediates O
monocyte O
infiltration O
in O
the O
neuroinflammatory B-NEG
cascade O
triggered O
in O
different O
brain O
pathologies O
. O

in O
this O
work O
ccr2 O
and O
ccl2 O
expression O
were O
examined O
following O
status B-NEG
epilepticus I-NEG
( O
se B-NEG
) O
induced O
by O
pilocarpine O
injection O
. O

methods O
: O
se B-NEG
was O
induced O
by O
pilocarpine O
injection O
. O

control O
rats O
were O
injected O
with O
saline O
instead O
of O
pilocarpine O
. O

five O
days O
after O
se B-NEG
, O
ccr2 O
staining O
in O
neurons O
and O
glial O
cells O
was O
examined O
using O
imunohistochemical O
analyses O
. O

the O
number O
of O
ccr2 O
positive O
cells O
was O
determined O
using O
stereology O
probes O
in O
the O
hippocampus O
. O

ccl2 O
expression O
in O
the O
hippocampus O
was O
examined O
by O
molecular O
assay O
. O

results O
: O
increased O
ccr2 O
was O
observed O
in O
the O
hippocampus O
after O
se B-NEG
. O
seizures B-NEG
also O
resulted O
in O
alterations O
to O
the O
cell O
types O
expressing O
ccr2 O
. O

increased O
numbers O
of O
neurons O
that O
expressed O
ccr2 O
was O
observed O
following O
se B-NEG
. O

microglial O
cells O
were O
more O
closely O
apposed O
to O
the O
ccr2-labeled O
cells O
in O
se B-NEG
rats O
. O

in O
addition O
, O
rats O
that O
experienced O
se B-NEG
exhibited O
ccr2-labeling O
in O
populations O
of O
hypertrophied B-NEG
astrocytes O
, O
especially O
in O
ca1 O
and O
dentate O
gyrus O
. O

these O
ccr2+ O
astroctytes O
were O
not O
observed O
in O
control O
rats O
. O

examination O
of O
ccl2 O
expression O
showed O
that O
it O
was O
elevated O
in O
the O
hippocampus O
following O
se B-NEG
. O

conclusion O
: O
the O
data O
show O
that O
ccr2 O
and O
ccl2 O
are O
up-regulated O
in O
the O
hippocampus O
after O
pilocarpine-induced O
se B-NEG
. O
seizures B-NEG
also O
result O
in O
changes O
to O
ccr2 O
receptor O
expression O
in O
neurons O
and O
astrocytes O
. O

these O
changes O
might O
be O
involved O
in O
detrimental O
neuroplasticity O
and O
neuroinflammatory B-NEG
changes O
that O
occur O
following O
seizures B-NEG
. O

-DOCSTART- O

metallothionein O
induction O
reduces O
caspase-3 O
activity O
and O
tnfalpha O
levels O
with O
preservation O
of O
cognitive O
function O
and O
intact O
hippocampal O
neurons O
in O
carmustine-treated O
rats O
. O

hippocampal O
integrity O
is O
essential O
for O
cognitive O
functions O
. O

on O
the O
other O
hand O
, O
induction O
of O
metallothionein O
( O
mt O
) O
by O
znso(4 O
) O
and O
its O
role O
in O
neuroprotection O
has O
been O
documented O
. O

the O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
mt O
induction O
on O
carmustine O
( O
bcnu)-induced O
hippocampal O
cognitive B-NEG
dysfunction I-NEG
in O
rats O
. O

a O
total O
of O
60 O
male O
wistar O
albino O
rats O
were O
randomly O
divided O
into O
four O
groups O
(15/group) O
: O
the O
control O
group O
injected O
with O
single O
doses O
of O
normal O
saline O
( O
i.c.v O
) O
followed O
24 O
h O
later O
by O
bcnu O
solvent O
(i.v) O
. O

the O
second O
group O
administered O
znso(4 O
) O
( O
0.1 O
micromol/10 O
microl O
normal O
saline O
, O
i.c.v O
, O
once O
) O
then O
bcnu O
solvent O
( O
i.v O
) O
after O
24 O
h. O

third O
group O
received O
bcnu O
( O
20 O
mg/kg O
, O
i.v O
, O
once O
) O
24 O
h O
after O
injection O
with O
normal O
saline O
(i.c.v) O
. O

fourth O
group O
received O
a O
single O
dose O
of O
znso(4 O
) O
( O
0.1 O
micromol/10 O
microl O
normal O
saline O
, O
i.c.v O
) O
then O
bcnu O
( O
20 O
mg/kg O
, O
i.v O
, O
once O
) O
after O
24 O
h. O

the O
obtained O
data O
revealed O
that O
bcnu O
administration O
resulted O
in O
deterioration B-NEG
of I-NEG
learning I-NEG
and I-NEG
short-term I-NEG
memory I-NEG
(stm) O
, O
as O
measured O
by O
using O
radial O
arm O
water O
maze O
, O
accompanied O
with O
decreased O
hippocampal O
glutathione O
reductase O
( O
gr O
) O
activity O
and O
reduced O
glutathione O
( O
gsh O
) O
content O
. O

also O
, O
bcnu O
administration O
increased O
serum O
tumor B-NEG
necrosis B-NEG
factor-alpha O
(tnfalpha) O
, O
hippocampal O
mt O
and O
malondialdehyde O
( O
mda O
) O
contents O
as O
well O
as O
caspase-3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

znso(4 O
) O
pretreatment O
counteracted O
bcnu-induced O
inhibition O
of O
gr O
and O
depletion O
of O
gsh O
and O
resulted O
in O
significant O
reduction O
in O
the O
levels O
of O
mda O
and O
tnfalpha O
as O
well O
as O
the O
activity O
of O
caspase-3 O
. O

the O
histological O
features O
were O
improved O
in O
hippocampus O
of O
rats O
treated O
with O
znso(4 O
) O
+ O
bcnu O
compared O
to O
only O
bcnu-treated O
animals O
. O

in O
conclusion O
, O
mt O
induction O
halts O
bcnu-induced O
hippocampal O
toxicity B-NEG
as O
it O
prevented O
gr O
inhibition O
and O
gsh O
depletion O
and O
counteracted O
the O
increased O
levels O
of O
tnfalpha O
, O
mda O
and O
caspase-3 O
activity O
with O
subsequent O
preservation O
of O
cognition O
. O

-DOCSTART- O

fatal O
carbamazepine O
induced O
fulminant B-NEG
eosinophilic I-NEG
( O
hypersensitivity B-NEG
) O
myocarditis B-NEG
: O
emphasis O
on O
anatomical O
and O
histological O
characteristics O
, O
mechanisms O
and O
genetics O
of O
drug B-NEG
hypersensitivity I-NEG
and O
differential O
diagnosis O
. O

the O
most O
severe O
adverse O
reactions O
to O
carbamazepine O
have O
been O
observed O
in O
the O
haemopoietic O
system O
, O
the O
liver O
and O
the O
cardiovascular O
system O
. O

a O
frequently O
fatal O
, O
although O
exceptionally O
rare O
side O
effect O
of O
carbamazepine O
is O
necrotizing O
eosinophilic O
( O
hypersensitivity B-NEG
) O
myocarditis B-NEG
. O

we O
report O
a O
case O
of O
hypersensitivity B-NEG
myocarditis B-NEG
secondary O
to O
administration O
of O
carbamazepine O
. O

acute O
hypersensitivity B-NEG
myocarditis B-NEG
was O
not O
suspected O
clinically O
, O
and O
the O
diagnosis O
was O
made O
post-mortem O
. O

histology O
revealed O
diffuse O
infiltration O
of O
the O
myocardium O
by O
eosinophils O
and O
lymphocytes O
with O
myocyte O
damage O
. O

clinically O
, O
death O
was O
due O
to O
cardiogenic B-NEG
shock I-NEG
. O

to O
best O
of O
our O
knowledge O
this O
is O
the O
second O
case O
of O
fatal O
carbamazepine O
induced O
myocarditis B-NEG
reported O
in O
english O
literature O
. O

-DOCSTART- O

neuropsychiatric O
behaviors O
in O
the O
mptp O
marmoset O
model O
of O
parkinson's B-NEG
disease I-NEG
. O

objectives O
: O
neuropsychiatric O
symptoms O
are O
increasingly O
recognised O
as O
a O
significant O
problem O
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
). O

these O
symptoms O
may O
be O
due O
to O
'sensitisation' O
following O
repeated O
levodopa O
treatment O
or O
a O
direct O
effect O
of O
dopamine O
on O
the O
disease O
state O
. O

the O
levodopa-treated O
mptp-lesioned O
marmoset O
was O
used O
as O
a O
model O
of O
neuropsychiatric B-NEG
symptoms I-NEG
in O
pd B-NEG
patients O
. O

here O
we O
compare O
the O
time O
course O
of O
levodopa-induced O
motor O
fluctuations O
and O
neuropsychiatric-like B-NEG
behaviors I-NEG
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

methods O
: O
marmosets O
were O
administered O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine O
( O
2.0 O
mg/kg O
s.c. O
) O
for O
five O
days O
, O
resulting O
in O
stable O
parkinsonism B-NEG
. O

levodopa O
( O
15 O
mg/kg O
and O
benserazide O
, O
3.75 O
mg/kg O
) O
p.o O
. O

b.i.d O
, O
was O
administered O
for O
30 O
days O
. O

animals O
were O
evaluated O
for O
parkinsonian B-NEG
disability I-NEG
, O
dyskinesia B-NEG
and O
on-time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric-like B-NEG
behaviors I-NEG
on O
day O
0 O
( O
prior O
to O
levodopa O
) O
and O
on O
days O
1, O
7, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
dvd O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

results O
: O
the O
neuropsychiatric-like B-NEG
behavior I-NEG
rating O
scale O
demonstrated O
high O
interrater O
reliability O
between O
three O
trained O
raters O
of O
differing O
professional O
backgrounds O
. O

as O
anticipated O
, O
animals O
exhibited O
a O
progressive O
increase O
in O
levodopa-induced O
motor O
fluctuations O
, O
dyskinesia B-NEG
and O
wearing-off O
, O
that O
correlated O
with O
the O
duration O
of O
levodopa O
therapy O
. O

in O
contrast O
, O
levodopa-induced O
neuropsychiatric-like B-NEG
behaviors I-NEG
were O
present O
on O
day O
1 O
of O
levodopa O
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

conclusions O
: O
the O
data O
suggest O
that O
neuropsychiatric B-NEG
disorders I-NEG
in O
pd B-NEG
are O
more O
likely O
an O
interaction O
between O
levodopa O
and O
the O
disease O
state O
than O
a O
consequence O
of O
sensitisation O
to O
repeated O
dopaminergic O
therapy O
. O

-DOCSTART- O

contrast O
medium O
nephrotoxicity B-NEG
after O
renal O
artery O
and O
coronary O
angioplasty O
. O

background O
: O
renal B-NEG
dysfunction I-NEG
induced O
by O
iodinated O
contrast O
medium O
( O
cm O
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
(ptra) O
. O

purpose O
: O
to O
compare O
the O
susceptibility O
to O
nephrotoxic B-NEG
effect O
of O
cm O
in O
patients O
undergoing O
ptra O
with O
that O
of O
patients O
submitted O
to O
percutaneous O
coronary O
intervention O
(pci) O
. O

material O
and O
methods O
: O
a O
total O
of O
33 O
patients O
successfully O
treated O
with O
ptra O
( O
ptra O
group O
, O
mean O
age O
70+/-12 O
years O
, O
23 O
female O
, O
basal O
creatinine O
1.46+/-0.79 O
, O
range O
0.7-4.9 O
mg/dl O
) O
were O
compared O
with O
33 O
patients O
undergoing O
successful O
pci O
( O
pci O
group) O
, O
matched O
for O
basal O
creatinine O
(1.44+/-0.6 O
, O
range O
0.7-3.4 O
mg/dl) O
, O
gender O
, O
and O
age O
. O

in O
both O
groups O
postprocedural O
( O
48 O
h) O
serum O
creatinine O
was O
measured O
. O

results O
: O
postprocedural O
creatinine O
level O
decreased O
nonsignificantly O
in O
the O
ptra O
group O
( O
1.46+/-0.8 O
vs O
. O
1.34+/-0.5 O
mg/dl O
, O
p=ns O
) O
and O
increased O
significantly O
in O
the O
pci O
group O
( O
1.44+/-0.6 O
vs O
. O
1.57+/-0.7 O
mg/dl O
, O
p<0.02) O
. O

changes O
in O
serum O
creatinine O
after O
intervention O
( O
after-before O
) O
were O
significantly O
different O
between O
the O
ptra O
and O
pci O
groups O
( O
-0.12+/-0.5 O
vs O
. O
0.13+/-0.3 O
, O
p=0.014) O
. O

this O
difference O
was O
not O
related O
to O
either O
a O
different O
clinical O
risk O
profile O
or O
to O
the O
volume O
of O
cm O
administered O
. O

conclusion O
: O
in O
this O
preliminary O
study O
patients O
submitted O
to O
ptra O
showed O
a O
lower O
susceptibility O
to O
renal B-NEG
damage I-NEG
induced O
by O
cm O
administration O
than O
pci O
patients O
. O

the O
effectiveness O
of O
ptra O
on O
renal O
function O
seems O
to O
be O
barely O
influenced O
by O
cm O
toxicity B-NEG
. O

-DOCSTART- O

medical O
and O
psychiatric O
outcomes O
for O
patients O
transplanted O
for O
acetaminophen-induced O
acute B-NEG
liver I-NEG
failure I-NEG
: O
a O
case-control O
study O
. O

background O
: O
acetaminophen-induced O
hepatotoxicity B-NEG
is O
the O
most O
common O
cause O
of O
acute B-NEG
liver I-NEG
failure I-NEG
( O
alf B-NEG
) O
in O
the O
uk O
. O

patients O
often O
consume O
the O
drug O
with O
suicidal O
intent O
or O
with O
a O
background O
of O
substance O
dependence O
. O

aims O
and O
methods O
: O
we O
compared O
the O
severity O
of O
pretransplant O
illness O
, O
psychiatric O
co-morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transplantation O
( O
lt O
) O
emergently O
between O
1999-2004 O
for O
acetaminophen-induced O
alf B-NEG
( O
n=36 O
) O
with O
age- O
and O
sex-matched O
patients O
undergoing O
emergent O
lt O
for O
non-acetaminophen-induced O
alf B-NEG
( O
n=35 O
) O
and O
elective O
lt O
for O
chronic B-NEG
liver I-NEG
disease I-NEG
( O
cld B-NEG
, O
n=34) O
. O

results O
: O
acetaminophen-induced O
alf B-NEG
patients O
undergoing O
lt O
had O
a O
greater O
severity O
of O
pre-lt O
illness O
reflected O
by O
higher O
acute O
physiology O
and O
chronic O
health O
evaluation O
ii O
scores O
and O
requirement O
for O
organ O
support O
compared O
with O
the O
other O
two O
groups O
. O

twenty O
( O
56% O
) O
acetaminophen-induced O
alf B-NEG
patients O
had O
a O
formal O
psychiatric O
diagnosis O
before O
lt O
( O
non-acetaminophen-induced O
alf B-NEG
=0/35 O
, O
cld B-NEG
=2/34 O
; O
p<0.01 O
for O
all O
) O
and O
nine O
( O
25% O
) O
had O
a O
previous O
suicide O
attempt O
. O

during O
follow-up O
( O
median O
5 O
years) O
, O
there O
were O
no O
significant O
differences O
in O
rejection O
( O
acute O
and O
chronic) O
, O
graft O
failure O
or O
survival O
between O
the O
groups O
( O
acetaminophen-induced O
alf B-NEG
1 O
year O
87% O
, O
5 O
years O
75% O
; O
non-acetaminophen-induced O
alf B-NEG
88% O
, O
78% O
; O
cld B-NEG
93% O
, O
82% O
: O
p>0.6 O
log O
rank) O
. O

two O
acetaminophen-induced O
alf B-NEG
patients O
reattempted O
suicide O
post-lt O
( O
one O
died O
8 O
years O
post-lt) O
. O

conclusions O
: O
despite O
a O
high O
prevalence O
of O
psychiatric O
disturbance O
, O
outcomes O
for O
patients O
transplanted O
emergently O
for O
acetaminophen-induced O
alf B-NEG
were O
comparable O
to O
those O
transplanted O
for O
non-acetaminophen-induced O
alf B-NEG
and O
electively O
for O
cld B-NEG
. O

multidisciplinary O
approaches O
with O
long-term O
psychiatric O
follow-up O
may O
contribute O
to O
low O
post-transplant O
suicide O
rates O
seen O
and O
low O
rates O
of O
graft O
loss O
because O
of O
non-compliance O
. O

-DOCSTART- O

studies O
of O
synergy O
between O
morphine O
and O
a O
novel O
sodium O
channel O
blocker O
, O
cnsb002 O
, O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B-NEG
pain I-NEG
. O

objective O
: O
this O
study O
determined O
the O
antihyperalgesic O
effect O
of O
cnsb002 O
, O
a O
sodium O
channel O
blocker O
with O
antioxidant O
properties O
given O
alone O
and O
in O
combinations O
with O
morphine O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B-NEG
pain I-NEG
. O

design O
: O
dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine O
and O
cnsb002 O
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain B-NEG
models O
: O
carrageenan-induced O
paw O
inflammation B-NEG
and O
streptozotocin O
( O
stz)-induced O
diabetic B-NEG
neuropathy I-NEG
. O

results O
: O
the O
maximum O
nonsedating O
doses O
were O
: O
morphine O
, O
3.2 O
mg/kg O
; O
cnsb002 O
10.0 O
mg/kg O
; O
5.0 O
mg/kg O
cnsb002 O
with O
morphine O
3.2 O
mg/kg O
in O
combination O
. O

the O
doses O
calculated O
to O
cause O
50% O
reversal O
of O
hyperalgesia B-NEG
( O
ed50 O
) O
were O
7.54 O
( O
1.81 O
) O
and O
4.83 O
( O
1.54 O
) O
in O
the O
carrageenan O
model O
and O
44.18 O
( O
1.37 O
) O
and O
9.14 O
( O
1.24 O
) O
in O
the O
stz-induced O
neuropathy B-NEG
model O
for O
cnsb002 O
and O
morphine O
, O
respectively O
(mg/kg O
; O
mean O
, O
sem) O
. O

these O
values O
were O
greater O
than O
the O
maximum O
nonsedating O
doses O
. O

the O
ed50 O
values O
for O
morphine O
when O
given O
in O
combination O
with O
cnsb002 O
(5 O
mg/kg O
) O
were O
less O
than O
the O
maximum O
nonsedating O
dose O
: O
0.56 O
( O
1.55 O
) O
in O
the O
carrageenan O
model O
and O
1.37 O
( O
1.23 O
) O
in O
the O
neuropathy B-NEG
model O
(mg/kg O
; O
mean O
, O
sem) O
. O

the O
antinociception O
after O
morphine O
( O
3.2 O
mg/kg O
) O
was O
increased O
by O
co-administration O
with O
cnsb002 O
from O
28.0 O
and O
31.7% O
to O
114.6 O
and O
56.9% O
reversal O
of O
hyperalgesia B-NEG
in O
the O
inflammatory O
and O
neuropathic B-NEG
models O
, O
respectively O
(p O
< O
0.01 O
; O
one-way O
analysis O
of O
variance-significantly O
greater O
than O
either O
drug O
given O
alone) O
. O

conclusions O
: O
the O
maximum O
antihyperalgesic O
effect O
achievable O
with O
nonsedating O
doses O
of O
morphine O
may O
be O
increased O
significantly O
when O
the O
drug O
is O
used O
in O
combination O
with O
cnsb002 O
. O

-DOCSTART- O

heparin-induced O
thrombocytopenia B-NEG
: O
a O
practical O
review O
. O

heparin-induced O
thrombocytopenia B-NEG
( O
hit B-NEG
) O
remains O
under-recognized O
despite O
its O
potentially O
devastating O
outcomes O
. O

it O
begins O
when O
heparin O
exposure O
stimulates O
the O
formation O
of O
heparin-platelet O
factor O
4 O
antibodies O
, O
which O
in O
turn O
triggers O
the O
release O
of O
procoagulant O
platelet O
particles O
. O
thrombosis B-NEG
and O
thrombocytopenia B-NEG
that O
follow O
comprise O
the O
2 O
hallmark O
traits O
of O
hit B-NEG
, O
with O
the O
former O
largely O
responsible O
for O
significant O
vascular O
complications O
. O

the O
prevalence O
of O
hit B-NEG
varies O
among O
several O
subgroups O
, O
with O
greater O
incidence O
in O
surgical O
as O
compared O
with O
medical O
populations O
. O
hit B-NEG
must O
be O
acknowledged O
for O
its O
intense O
predilection O
for O
thrombosis B-NEG
and O
suspected O
whenever O
thrombosis B-NEG
occurs O
after O
heparin O
exposure O
. O

early O
recognition O
that O
incorporates O
the O
clinical O
and O
serologic O
clues O
is O
paramount O
to O
timely O
institution O
of O
treatment O
, O
as O
its O
delay O
may O
result O
in O
catastrophic O
outcomes O
. O

the O
treatment O
of O
hit B-NEG
mandates O
an O
immediate O
cessation O
of O
all O
heparin O
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct O
thrombin O
inhibitor O
. O

current O
diagnostic O
tests O
, O
which O
primarily O
include O
functional O
and O
antigenic O
assays O
, O
have O
more O
of O
a O
confirmatory O
than O
diagnostic O
role O
in O
the O
management O
of O
hit B-NEG
. O

special O
attention O
must O
be O
paid O
to O
cardiac O
patients O
who O
are O
often O
exposed O
to O
heparin O
multiple O
times O
during O
their O
course O
of O
treatment O
. O

direct O
thrombin O
inhibitors O
are O
appropriate O
, O
evidence-based O
alternatives O
to O
heparin O
in O
patients O
with O
a O
history O
of O
hit B-NEG
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

as O
heparin O
remains O
one O
of O
the O
most O
frequently O
used O
medications O
today O
with O
potential O
for O
hit B-NEG
with O
every O
heparin O
exposure O
, O
a O
close O
vigilance O
of O
platelet O
counts O
must O
be O
practiced O
whenever O
heparin O
is O
initiated O
. O

-DOCSTART- O

abductor O
paralysis B-NEG
after O
botox O
injection O
for O
adductor B-NEG
spasmodic I-NEG
dysphonia I-NEG
. O

objectives/hypothesis O
: O
botulinum O
toxin O
( O
botox O
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor B-NEG
spasmodic I-NEG
dysphonia I-NEG
( O
adsd B-NEG
). O

reported O
adverse O
effects O
include O
a O
period O
of O
breathiness O
, O
throat B-NEG
pain I-NEG
, O
and O
difficulty O
with O
swallowing O
liquids O
. O

here O
we O
report O
multiple O
cases O
of O
bilateral O
abductor O
paralysis B-NEG
following O
botox O
injections O
for O
adsd B-NEG
, O
a O
complication O
previously O
unreported O
. O

study O
design O
: O
retrospective O
case O
series O
. O

methods O
: O
patients O
that O
received O
botox O
injections O
for O
spasmodic B-NEG
dysphonia I-NEG
between O
january O
2000 O
and O
october O
2009 O
were O
evaluated O
. O

patients O
with O
adsd B-NEG
were O
identified O
. O

the O
number O
of O
treatments O
received O
and O
adverse O
effects O
were O
noted O
. O

for O
patients O
with O
bilateral O
abductor O
paralysis B-NEG
, O
age O
, O
sex O
, O
paralytic O
botox O
dose O
, O
prior O
botox O
dose O
, O
and O
course O
following O
paralysis B-NEG
were O
noted O
. O

results O
: O
from O
a O
database O
of O
452 O
patients O
receiving O
botox O
, O
352 O
patients O
had O
been O
diagnosed O
with O
adsd B-NEG
. O

of O
these O
352 O
patients O
, O
eight O
patients O
suffered O
bilateral O
abductor O
paralysis B-NEG
, O
and O
two O
suffered O
this O
complication O
twice O
. O

all O
affected O
patients O
were O
females O
over O
the O
age O
of O
50 O
years O
. O

most O
patients O
had O
received O
treatments O
prior O
to O
abductor O
paralysis B-NEG
and O
continued O
receiving O
after O
paralysis B-NEG
. O

seven O
patients O
recovered O
after O
a O
brief O
period O
of O
activity O
restrictions O
, O
and O
one O
underwent O
a O
tracheotomy O
. O

the O
incidence O
of O
abductor O
paralysis B-NEG
after O
botox O
injection O
for O
adsd B-NEG
was O
0.34% O
. O

conclusions O
: O
bilateral O
abductor O
paralysis B-NEG
is O
a O
rare O
complication O
of O
botox O
injections O
for O
adsd B-NEG
, O
causing O
difficulty O
with O
breathing O
upon O
exertion O
. O

the O
likely O
mechanism O
of O
paralysis B-NEG
is O
diffusion O
of O
botox O
around O
the O
muscular O
process O
of O
the O
arytenoid O
to O
the O
posterior O
cricoarytenoid O
muscles O
. O

the O
paralysis B-NEG
is O
temporary O
, O
and O
watchful O
waiting O
with O
restriction O
of O
activity O
is O
the O
recommended O
management O
. O

-DOCSTART- O

mitochondrial B-NEG
impairment I-NEG
contributes O
to O
cocaine-induced O
cardiac B-NEG
dysfunction I-NEG
: O
prevention O
by O
the O
targeted O
antioxidant O
mitoq O
. O

the O
goal O
of O
this O
study O
was O
to O
assess O
mitochondrial O
function O
and O
ros O
production O
in O
an O
experimental O
model O
of O
cocaine-induced O
cardiac B-NEG
dysfunction I-NEG
. O

we O
hypothesized O
that O
cocaine B-NEG
abuse I-NEG
may O
lead O
to O
altered O
mitochondrial O
function O
that O
in O
turn O
may O
cause O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
. O

seven O
days O
of O
cocaine O
administration O
to O
rats O
led O
to O
an O
increased O
oxygen O
consumption O
detected O
in O
cardiac O
fibers O
, O
specifically O
through O
complex O
i O
and O
complex O
iii O
. O

ros O
levels O
were O
increased O
, O
specifically O
in O
interfibrillar O
mitochondria O
. O

in O
parallel O
there O
was O
a O
decrease O
in O
atp O
synthesis O
, O
whereas O
no O
difference O
was O
observed O
in O
subsarcolemmal O
mitochondria O
. O

this O
uncoupling O
effect O
on O
oxidative O
phosphorylation O
was O
not O
detectable O
after O
short-term O
exposure O
to O
cocaine O
, O
suggesting O
that O
these O
mitochondrial B-NEG
abnormalities I-NEG
were O
a O
late O
rather O
than O
a O
primary O
event O
in O
the O
pathological O
response O
to O
cocaine O
. O

mitoq O
, O
a O
mitochondrial-targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial B-NEG
abnormalities I-NEG
as O
well O
as O
cardiac B-NEG
dysfunction I-NEG
characterized O
here O
by O
a O
diastolic B-NEG
dysfunction I-NEG
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure-volume O
data O
. O

taken O
together O
, O
these O
results O
extend O
previous O
studies O
and O
demonstrate O
that O
cocaine-induced O
cardiac B-NEG
dysfunction I-NEG
may O
be O
due O
to O
a O
mitochondrial B-NEG
defect I-NEG
. O

-DOCSTART- O

trimethoprim-induced O
immune O
hemolytic B-NEG
anemia I-NEG
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

a O
10-year-old O
male O
with O
acute B-NEG
leukemia I-NEG
presented O
with O
post-chemotherapy O
anemia B-NEG
. O

during O
red O
cell O
transfusion O
, O
he O
developed O
hemoglobinuria B-NEG
. O

transfusion O
reaction O
workup O
was O
negative O
. O

drug-induced O
immune O
hemolytic B-NEG
anemia I-NEG
was O
suspected O
because O
of O
positive O
direct O
antiglobulin O
test O
, O
negative O
eluate O
, O
and O
microspherocytes O
on O
smear O
pre- O
and O
post-transfusion O
. O

drug O
studies O
using O
the O
indirect O
antiglobulin O
test O
were O
strongly O
positive O
with O
trimethoprim O
and O
trimethoprim-sulfamethoxazole O
but O
negative O
with O
sulfamethoxazole O
. O

the O
patient O
recovered O
after O
discontinuing O
the O
drug O
, O
with O
no O
recurrence O
in O
2 O
years O
. O

other O
causes O
of O
anemia B-NEG
should O
be O
considered O
in O
patients O
with O
worse-than-expected O
anemia B-NEG
after O
chemotherapy O
. O

furthermore O
, O
hemolysis B-NEG
during O
transfusion O
is O
not O
always O
a O
transfusion O
reaction O
. O

-DOCSTART- O

blockade O
of O
endothelial-mesenchymal O
transition O
by O
a O
smad3 O
inhibitor O
delays O
the O
early O
development O
of O
streptozotocin-induced O
diabetic B-NEG
nephropathy I-NEG
. O

objective O
: O
a O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin-angiotensin O
system O
in O
patients O
with O
type B-NEG
1 I-NEG
diabetes I-NEG
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy B-NEG
, O
suggesting O
that O
other O
mechanism(s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic B-NEG
nephropathy I-NEG
( O
diabetic B-NEG
nephropathy I-NEG
). O

we O
have O
previously O
demonstrated O
that O
endothelial-mesenchymal-transition O
( O
endomt O
) O
contributes O
to O
the O
early O
development O
of O
renal O
interstitial O
fibrosis B-NEG
independently O
of O
microalbuminuria O
in O
mice O
with O
streptozotocin O
( O
stz)-induced O
diabetes B-NEG
. O

in O
the O
present O
study O
, O
we O
hypothesized O
that O
blocking O
endomt O
reduces O
the O
early O
development O
of O
diabetic B-NEG
nephropathy I-NEG
. O

research O
design O
and O
methods O
: O
endomt O
was O
induced O
in O
a O
mouse O
pancreatic O
microvascular O
endothelial O
cell O
line O
( O
mmec O
) O
in O
the O
presence O
of O
advanced O
glycation O
end O
products O
( O
ages O
) O
and O
in O
the O
endothelial O
lineage-traceble O
mouse O
line O
tie2-cre;loxp-egfp O
by O
administration O
of O
ages O
, O
with O
nonglycated O
mouse O
albumin O
serving O
as O
a O
control O
. O

phosphorylated O
smad3 O
was O
detected O
by O
immunoprecipitation/western O
blotting O
and O
confocal O
microscopy O
. O

blocking O
studies O
using O
receptor O
for O
age O
sirna O
and O
a O
specific O
inhibitor O
of O
smad3 O
( O
sis3 O
) O
were O
performed O
in O
mmecs O
and O
in O
stz-induced O
diabetic B-NEG
nephropathy I-NEG
in O
tie2-cre;loxp-egfp O
mice O
. O

results O
: O
confocal O
microscopy O
and O
real-time O
pcr O
demonstrated O
that O
ages O
induced O
endomt O
in O
mmecs O
and O
in O
tie2-cre;loxp-egfp O
mice O
. O

immunoprecipitation/western O
blotting O
showed O
that O
smad3 O
was O
activated O
by O
ages O
but O
was O
inhibited O
by O
sis3 O
in O
mmecs O
and O
in O
stz-induced O
diabetic B-NEG
nephropathy I-NEG
. O

confocal O
microscopy O
and O
real-time O
pcr O
further O
demonstrated O
that O
sis3 O
abrogated O
endomt O
, O
reduced O
renal O
fibrosis B-NEG
, O
and O
retarded O
progression O
of O
nephropathy B-NEG
. O

conclusions O
: O
endomt O
is O
a O
novel O
pathway O
leading O
to O
early O
development O
of O
diabetic B-NEG
nephropathy I-NEG
. O

blockade O
of O
endomt O
by O
sis3 O
may O
provide O
a O
new O
strategy O
to O
retard O
the O
progression O
of O
diabetic B-NEG
nephropathy I-NEG
and O
other O
diabetes B-NEG
complications I-NEG
. O

-DOCSTART- O

cytostatic O
and O
anti-angiogenic O
effects O
of O
temsirolimus O
in O
refractory O
mantle B-NEG
cell I-NEG
lymphoma I-NEG
. O
mantle B-NEG
cell I-NEG
lymphoma I-NEG
( O
mcl B-NEG
) O
is O
a O
rare O
and O
aggressive O
type O
of O
b-cell B-NEG
non-hodgkin's I-NEG
lymphoma I-NEG
. O

patients O
become O
progressively O
refractory O
to O
conventional O
chemotherapy O
, O
and O
their O
prognosis O
is O
poor O
. O

however O
, O
a O
38% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
mcl B-NEG
treated O
with O
temsirolimus O
, O
a O
mtor O
inhibitor.here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
mcl B-NEG
who O
had O
tumor B-NEG
regression O
two O
months O
after O
temsirolimus O
treatment O
, O
and O
a O
progression-free O
survival O
of O
10 O
months O
. O

in O
this O
case O
, O
lymph O
node O
biopsies O
were O
performed O
before O
and O
six O
months O
after O
temsirolimus O
therapy O
. O

comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus O
inhibited O
tumor B-NEG
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor B-NEG
cells O
. O

apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus O
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor B-NEG
microvessel O
density O
and O
of O
vegf O
expression O
. O

moreover O
, O
numerous O
patchy O
, O
well-limited O
fibrotic O
areas O
, O
compatible O
with O
post- O
necrotic B-NEG
tissue O
repair O
, O
were O
found O
after O
6-month O
temsirolimus O
therapy O
. O

thus O
, O
temsirolimus O
reduced O
tumor B-NEG
burden O
through O
associated O
cytostatic O
and O
anti-angiogenic O
effects.this O
dual O
effect O
of O
temsirolimus O
on O
tumor B-NEG
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
mcl B-NEG
resistant O
to O
conventional O
chemotherapy O
. O

-DOCSTART- O

syncope B-NEG
caused O
by O
hyperkalemia B-NEG
during O
use O
of O
a O
combined O
therapy O
with O
the O
angiotensin-converting O
enzyme O
inhibitor O
and O
spironolactone O
. O

a O
76 O
year-old O
woman O
with O
a O
history O
of O
coronary O
artery O
bypass O
grafting O
and O
prior O
myocardial B-NEG
infarction I-NEG
was O
transferred O
to O
the O
emergency O
room O
with O
loss B-NEG
of I-NEG
consciousness I-NEG
due O
to O
marked O
bradycardia B-NEG
caused O
by O
hyperkalemia B-NEG
. O

the O
concentration O
of O
serum O
potassium O
was O
high O
, O
and O
normal O
sinus O
rhythm O
was O
restored O
after O
correction O
of O
the O
serum O
potassium O
level O
. O

the O
cause O
of O
hyperkalemia B-NEG
was O
considered O
to O
be O
several O
doses O
of O
spiranolactone O
, O
an O
aldosterone O
antagonist O
, O
in O
addition O
to O
the O
long-term O
intake O
of O
ramipril O
, O
an O
ace O
inhibitor O
. O

this O
case O
is O
a O
good O
example O
of O
electrolyte O
imbalance O
causing O
acute O
life-threatening O
cardiac O
events O
. O

clinicians O
should O
be O
alert O
to O
the O
possibility O
of O
hyperkalemia B-NEG
, O
especially O
in O
elderly O
patients O
using O
ace/arb O
in O
combination O
with O
potassium O
sparing O
agents O
and O
who O
have O
mild O
renal B-NEG
disturbance I-NEG
. O

-DOCSTART- O

diffuse O
skeletal O
pain B-NEG
after O
administration O
of O
alendronate O
. O

background O
: O
osteoporosis B-NEG
is O
caused O
by O
bone O
resorption O
in O
excess O
of O
bone O
formation O
, O
and O
bisphosphonates O
, O
are O
used O
to O
inhibit O
bone O
resorption O
. O

alendronate O
, O
a O
biphosphonate O
, O
is O
effective O
for O
both O
the O
treatment O
and O
prevention O
of O
osteoporosis B-NEG
in O
postmenopausal O
women O
. O

side O
effects O
are O
relatively O
few O
and O
prominently O
gastrointestinal O
. O
musculoskeletal B-NEG
pain I-NEG
may O
be O
an O
important O
side O
effect O
in O
these O
patients O
. O

we O
presented O
a O
patient O
admitted O
to O
our O
out-patient O
clinic O
with O
diffuse O
skeletal O
pain B-NEG
after O
three O
consecutive O
administration O
of O
alendronate O
. O

conclusion O
: O
we O
conclude O
that O
patients O
with O
osteoporosis B-NEG
can O
report O
pain B-NEG
, O
and O
bisphosphonate-related O
pain B-NEG
should O
also O
be O
considered O
before O
ascribing O
this O
complaint O
to O
osteoporosis B-NEG
. O

-DOCSTART- O

cerebrospinal O
fluid O
penetration O
of O
high-dose O
daptomycin O
in O
suspected O
staphylococcus O
aureus O
meningitis B-NEG
. O

objective O
: O
to O
report O
a O
case O
of O
methicillin-sensitive O
staphylococcus O
aureus O
( O
mssa O
) O
bacteremia B-NEG
with O
suspected O
mssa O
meningitis B-NEG
treated O
with O
high-dose O
daptomycin O
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
csf O
) O
concentrations O
. O

case O
summary O
: O
a O
54-year-old O
male O
presented O
to O
the O
emergency O
department O
with O
generalized O
weakness B-NEG
and O
presumed O
health-care-associated O
pneumonia B-NEG
shown O
on O
chest O
radiograph O
. O

treatment O
was O
empirically O
initiated O
with O
vancomycin O
, O
levofloxacin O
, O
and O
piperacillin/tazobactam O
. O

blood O
cultures O
revealed O
s. O
aureus O
susceptible O
to O
oxacillin O
. O

empiric O
antibiotic O
treatment O
was O
narrowed O
to O
nafcillin O
on O
day O
4. O

on O
day O
8, O
the O
patient O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
( O
serum O
creatinine O
1.9 O
mg/dl O
, O
increased O
from O
1.2 O
mg/dl O
the O
previous O
day O
and O
0.8 O
mg/dl O
on O
admission) O
. O

the O
patient's O
glasgow O
coma O
score O
was O
3, O
with O
normal O
findings O
shown O
on O
computed O
tomography O
scan O
of O
the O
head O
72 O
hours O
following O
an O
episode O
of O
cardiac B-NEG
arrest I-NEG
on O
day O
10 O
. O

the O
patient O
experienced O
relapsing O
mssa O
bacteremia B-NEG
on O
day O
9, O
increasing O
the O
suspicion O
for O
a O
central O
nervous O
system O
( O
cns O
) O
infection B-NEG
. O

nafcillin O
was O
discontinued O
and O
daptomycin O
9 O
mg/kg O
daily O
was O
initiated O
for O
suspected O
meningitis B-NEG
and O
was O
continued O
until O
the O
patient's O
death O
on O
day O
16 O
. O

daptomycin O
serum O
and O
csf O
trough O
concentrations O
were O
11.21 O
ug/ml O
and O
0.52 O
ug/ml O
, O
respectively O
, O
prior O
to O
the O
third O
dose O
. O

lumbar O
puncture O
results O
were O
inconclusive O
and O
no O
further O
blood O
cultures O
were O
positive O
for O
mssa O
. O

creatine O
kinase O
levels O
were O
normal O
prior O
to O
daptomycin O
therapy O
and O
were O
not O
reassessed O
. O

discussion O
: O
daptomycin O
was O
initiated O
in O
our O
patient O
secondary O
to O
possible O
nafcillin-induced O
acute O
interstitial B-NEG
nephritis I-NEG
and O
relapsing O
bacteremia B-NEG
. O

at O
a O
dose O
of O
9 O
mg/kg O
, O
resultant O
penetration O
of O
5% O
was O
higher O
than O
in O
previous O
reports O
, O
more O
consistent O
with O
inflamed O
meninges O
. O

conclusions O
: O
high-dose O
daptomycin O
may O
be O
an O
alternative O
option O
for O
mssa O
bacteremia B-NEG
with O
or O
without O
a O
cns O
source O
in O
patients O
who O
have O
failed O
or O
cannot O
tolerate O
standard O
therapy O
. O

further O
clinical O
evaluation O
in O
patients O
with O
confirmed O
meningitis B-NEG
is O
warranted O
. O

-DOCSTART- O

the O
role O
of O
nitric O
oxide O
in O
convulsions B-NEG
induced O
by O
lindane O
in O
rats O
. O

lindane O
is O
an O
organochloride O
pesticide O
and O
scabicide O
. O

it O
evokes O
convulsions B-NEG
mainly O
trough O
the O
blockage O
of O
gaba(a O
) O
receptors O
. O

nitric O
oxide O
(no) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
l-arginine O
, O
precursor O
of O
no O
syntheses O
(nos) O
, O
and O
l-name O
( O
nos O
inhibitor O
) O
observed O
in O
different O
epilepsy B-NEG
models O
. O

the O
aim O
of O
the O
current O
study O
was O
to O
determine O
the O
effects O
of O
no O
on O
the O
behavioral O
and O
eeg O
characteristics O
of O
lindane-induced O
epilepsy B-NEG
in O
male O
wistar O
albino O
rats O
. O

the O
administration O
of O
l-arginine O
(600 O
, O
800 O
and O
1000 O
mg/kg O
, O
i.p. O
) O
in O
dose-dependent O
manner O
significantly O
increased O
convulsion B-NEG
incidence O
and O
severity O
and O
shortened O
latency O
time O
to O
first O
convulsion B-NEG
elicited O
by O
lower O
lindane O
dose O
(4 O
mg/kg O
, O
i.p.) O
. O

on O
the O
contrary O
, O
pretreatment O
with O
l-name O
(500 O
, O
700 O
and O
900 O
mg/kg O
, O
i.p. O
) O
decreased O
convulsion B-NEG
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion B-NEG
following O
injection O
with O
a O
convulsive B-NEG
dose O
of O
lindane O
(8 O
mg/kg O
, O
i.p.) O
. O

eeg O
analyses O
showed O
increase O
of O
number O
and O
duration O
of O
ictal O
periods O
in O
eeg O
of O
rats O
receiving O
l-arginine O
prior O
to O
lindane O
and O
decrease O
of O
this O
number O
in O
rats O
pretreated O
with O
l-name O
. O

these O
results O
support O
the O
conclusion O
that O
no O
plays O
a O
role O
of O
endogenous O
convulsant O
in O
rat O
model O
of O
lindane O
seizures B-NEG
. O

-DOCSTART- O

long-term O
oral O
galactose O
treatment O
prevents O
cognitive B-NEG
deficits I-NEG
in O
male O
wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin O
. O

basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia B-NEG
of O
sporadic O
alzheimer's B-NEG
disease I-NEG
( O
sad O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin-receptor O
( O
ir O
) O
system O
followed O
by O
decreased O
glucose O
transport O
via O
glucose O
transporter O
glut4 O
and O
decreased O
glucose O
metabolism O
in O
brain O
cells O
. O

an O
alternative O
source O
of O
energy O
is O
d-galactose O
( O
the O
c-4-epimer O
of O
d-glucose O
) O
which O
is O
transported O
into O
the O
brain O
by O
insulin-independent O
glut3 O
transporter O
where O
it O
might O
be O
metabolized O
to O
glucose O
via O
the O
leloir O
pathway O
. O

exclusively O
parenteral O
daily O
injections O
of O
galactose O
induce O
memory B-NEG
deterioration I-NEG
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose O
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

we O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose O
( O
200 O
mg/kg/day O
) O
treatment O
on O
cognitive B-NEG
deficits I-NEG
in O
streptozotocin-induced O
( O
stz-icv O
) O
rat O
model O
of O
sad O
, O
tested O
by O
morris O
water O
maze O
and O
passive O
avoidance O
test O
, O
respectively O
. O

one O
month O
of O
oral O
galactose O
treatment O
initiated O
immediately O
after O
the O
stz-icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
stz-icv-induced O
cognitive B-NEG
deficits I-NEG
. O

beneficial O
effect O
of O
oral O
galactose O
was O
independent O
of O
the O
rat O
age O
and O
of O
the O
galactose O
dose O
ranging O
from O
100 O
to O
300 O
mg/kg/day O
. O

additionally O
, O
oral O
galactose O
administration O
led O
to O
the O
appearance O
of O
galactose O
in O
the O
blood O
. O

the O
increase O
of O
galactose O
concentration O
in O
the O
cerebrospinal O
fluid O
was O
several O
times O
lower O
after O
oral O
than O
after O
parenteral O
administration O
of O
the O
same O
galactose O
dose O
. O

oral O
galactose O
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive B-NEG
deficits I-NEG
associated O
with O
glucose B-NEG
hypometabolism I-NEG
in O
ad B-NEG
. O

-DOCSTART- O

adult B-NEG
acute I-NEG
lymphocytic I-NEG
leukemia I-NEG

-DOCSTART- O

cough B-NEG
due O
to O
pulmonary B-NEG
flaccidity I-NEG

-DOCSTART- O

quality O
of O
life O
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
others O
, O
protective B-NEU
immunity I-NEU
, O
inflammation B-NEG

-DOCSTART- O

dysentery B-NEG

-DOCSTART- O

to O
dissipate O
binds O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

cisplatin O
complexes O
react O
in O
vivo O
, O
binding O
to O
and O
causing O
crosslinking O
of O
dna B-DNP
which O
ultimately O
triggers O
apoptosis B-NEU
( O
programmed O
cell B-NEU
death I-NEU
) O
. O

gemcitabine O
is O
converted O
intracellularly O
to O
the O
active O
metabolites O
difluorodeoxycytidine O
di- O
and O
triphosphate O
( O
dfdcdp O
, O
dfdctp O
) O
. O

dfdcdp O
inhibits O
ribonucleotide B-DNP
reductase I-DNP
, O
thereby O
decreasing O
the O
deoxynucleotide O
pool O
available O
for O
dna B-NEU
synthesis I-NEU
; O
dfdctp O
is O
incorporated O
into O
dna B-DNP
, O
resulting O
in O
dna B-NEU
strand I-NEU
termination I-NEU
and O
apoptosis B-NEU
. O

-DOCSTART- O

childhood B-NEG
b I-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG
with O
t(9;22)(q34;q11.2 O
) O
; O
bcr-abl1 O

-DOCSTART- O

moisten B-NEU
face I-NEU

-DOCSTART- O

epigastric O
twisting O
pain B-NEG
. O

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
inv(16)(p13.1q22 O
) O
; O
cbfb-myh11 O

-DOCSTART- O

this O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-NEG
febrile I-NEG
disease I-NEG
from O
taeyanggyeong O
to O
yangmyeonggyeong O
. O

-DOCSTART- O

adult B-NEG
acute I-NEG
monocytic I-NEG
leukemia I-NEG

-DOCSTART- O

food B-NEG
damage I-NEG
; O

injury B-NEG
due O
to O
improper O
diet O
; O

eating O
food O
much O
injury B-NEG
of O
spleen O
and O
stomach O

-DOCSTART- O

fever B-NEG
; O
feverishness B-NEG

-DOCSTART- O

to O
reduce O
masses B-NEG
by O
dissipating O
blood B-NEG
stasis I-NEG
, O
and O
to O
relieve O
pain B-NEG
by O
removing O
stagnancy B-NEG
of O
food O
. O

-DOCSTART- O

stop O
dysentery B-NEG

-DOCSTART- O

to O
clear O
heat B-NEU
and O
eliminate O
pus B-NEG
. O

-DOCSTART- O

lidocaine O
alters O
signal O
conduction O
in O
neurons B-DNP
by O
blocking O
the O
fast O
voltage B-DNP
gated I-DNP
sodium I-DNP
( I-DNP
na+ I-DNP
) I-DNP
channels I-DNP
in O
the O
neuronal B-DNP
cell I-DNP
membrane I-DNP
that O
are O
responsible O
for O
signal O
propagation O
. O

ceftriaxone O
works O
by O
inhibiting O
the O
mucopeptide B-NEU
synthesis I-NEU
and O
results O
in O
the O
formation O
of O
defective B-NEG
cell I-NEG
walls I-NEG
and O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

for O
appendicitis B-NEG
, O
used O
together O
with O
same O
dose O
of O
pills O
of O
radix O
et O
rhizoma O
rhei O
and O
rhizoma O
coptidis O
, O
or O
mixed O
with O
same O
dose O
of O
cinnabaris O
, O
applying O
on O
point O
lanwei O
( O
extra33 O
) O
. O

-DOCSTART- O

treatment O
of O
stagnancy B-NEG
of I-NEG
undigested I-NEG
food I-NEG
with O
abdominal B-NEG
distension I-NEG
and O
constipation B-NEG
, O
weakness B-NEG
and O
edema B-NEG
of O
the O
legs O
with O
oliguria B-NEG
. O

-DOCSTART- O

this O
is O
a O
syndrome O
with O
ooze O
from O
a O
sore B-NEG
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP
and O
disperse O
food O

-DOCSTART- O

wind B-NEG
rash I-NEG
; O
german B-NEG
measles I-NEG
; O
rubella B-NEG
; O
urticaria B-NEG

-DOCSTART- O

tuberculosis B-NEG
, O
weak O
yin O
and O
agitated O
fire O
, O
thin B-NEU
and I-NEU
hot I-NEU
body I-NEU
, O
cough B-NEG
, O
phlegm B-NEG
, O
spitting B-NEG
blood I-NEG
, O
chest B-NEG
pain I-NEG
, O
dry B-NEG
mouth I-NEG
, O
frequent B-NEG
pulse I-NEG

-DOCSTART- O

( O
1 O
) O
pain B-NEG
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O
( O
2 O
) O
upper B-NEG
abdominal I-NEG
pain I-NEG

-DOCSTART- O

stagnation O
of O
milk O
without O
secretion O
after O
delivery O
. O

-DOCSTART- O

for O
bacterial B-NEG
infections I-NEG
of O
eyes O

-DOCSTART- O

excessive B-NEG
thought I-NEG
; O
anxiety O

-DOCSTART- O

repel O
all O
malign O
sore B-NEG

-DOCSTART- O

effect O
of O
hachimijiogan O
( O
hj O
) O
on O
dopamine B-DNP
( O
da B-DNP
) O
, O
serotonin B-DNP
( O
5-ht B-DNP
) O
and O
vasoactive B-DNP
intestinal I-DNP
peptide I-DNP
( O
vip B-DNP
) O
was O
examined O
in O
plasma O
and O
hypothalamic O
tissue O
of O
sulpiride-induced O
hyperprolactinemic O
rats O
( O
shr O
) O
. O

similar O
to O
bromocriptine B-DNP
( O
br B-DNP
) O
, O
hj O
, O
in O
combination O
with O
sulpiride O
, O
suppressed O
plasma B-NEU
prolactin I-NEU
levels I-NEU
raised O
by O
sulpiride O
alone O
. O

furthermore O
, O
hj O
, O
together O
with O
sulpiride O
, O
increased O
plasma B-NEU
da I-NEU
levels I-NEU
decreased O
by O
sulpiride O
alone O
, O
while O
5-ht B-DNP
in O
plasma O
was O
increased O
by O
sulpiride O
and O
hj O
, O
individually O
or O
in O
combination O
. O

however O
, O
plasma B-NEU
vip I-NEU
levels I-NEU
were O
under O
detection O
limits O
on O
some O
occasions O
after O
hj O
treatment O
. O

successively O
, O
da B-NEU
, I-NEU
5-ht I-NEU
and I-NEU
vip I-NEU
levels I-NEU
in O
the O
hypothalamus O
were O
determined O
. O

similar O
to O
the O
effect O
caused O
by O
br B-NEU
, I-NEU
da I-NEU
and I-NEU
5-ht I-NEU
levels I-NEU
in O
hypothalamic O
tissue O
reduced O
by O
sulpiride O
alone O
were O
also O
significantly O
increased O
by O
hj O
together O
with O
sulpiride O
, O
while O
vip B-NEU
levels I-NEU
were O
sometimes O
under O
detection O
levels O
with O
or O
without O
hj O
. O

these O
results O
suggest O
that O
hj O
stimulates O
the O
hypothalamus B-DNP
to O
increase O
da B-DNP
and O
5-ht B-DNP
in O
shr O
, O
providing O
evidence O
for O
the O
clinical O
efficiency O
of O
hj O
in O
combating O
hyperprolactinemia B-NEG
. O

the O
effect O
of O
hj O
on O
vip B-DNP
in O
plasma O
or O
hypothalamic O
tissue O
is O
, O
however O
, O
questionable O
. O

-DOCSTART- O

pain B-NEG
in O
lumbus O
and O
legs O
. O

-DOCSTART- O

fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

gsk2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-NEU
of I-NEU
leukotrienes I-NEU
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ete O
) O
. O

-DOCSTART- O

the O
role O
of O
crude O
polysaccharide O
fractions O
on O
the O
mitogenic B-NEU
activity I-NEU
by O
shosaikoto O
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
respiratory B-DNP
systems I-DNP
, O
respiratory B-DNP
systems I-DNP
health I-DNP
, O
motility B-NEU
, O
absorption B-NEU
, O
others O
, O
protective B-NEU
immunity I-NEU

-DOCSTART- O

nourish O
eum O
( O
yin O
) O
and O
nourish O
blood B-DNP

-DOCSTART- O

reinforce O
blood B-DNP

-DOCSTART- O

intravenous O
anesthetic O
interaction O
unrecognized B-NEG
condition I-NEG

-DOCSTART- O

efficacy O
of O
keishibukuryogan O
, O
a O
traditional O
japanese O
herbal O
medicine O
, O
in O
treating O
cold B-NEG
sensation I-NEG
and O
numbness B-NEG
after O
stroke B-NEG
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke B-NEG
patients O
. O

-DOCSTART- O

neoplasms B-NEG
, I-NEG
hormone-dependent I-NEG

-DOCSTART- O

there O
are O
two O
isoforms O
of O
ace O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular O
isoform O
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm B-NEU
maturation I-NEU
and O
binding O
of O
sperm O
to O
the O
oviduct O
epithelium O
. O

somatic O
ace O
has O
two O
functionally O
active O
domains O
, O
n O
and O
c, O
which O
arise O
from O
tandem O
gene O
duplication O
. O

although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

the O
c-domain O
is O
predominantly O
involved O
in O
blood B-NEU
pressure I-NEU
regulation O
while O
the O
n-domain O
plays O
a O
role O
in O
hematopoietic O
stem O
cell O
differentiation O
and O
proliferation O
. O

ace O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
c-domain O
. O

quinaprilat O
, O
the O
principle O
active O
metabolite O
of O
quinapril O
, O
competes O
with O
ati O
for O
binding O
to O
ace O
and O
inhibits O
and O
enzymatic O
proteolysis O
of O
ati O
to O
atii O
. O

decreasing O
atii O
levels O
in O
the O
body O
decreases O
blood B-NEU
pressure I-NEU
by O
inhibiting O
the O
pressor O
effects O
of O
atii O
as O
described O
in O
the O
pharmacology O
section O
above O
. O

quinaprilat O
also O
causes O
an O
increase O
in O
plasma O
renin O
activity O
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
atii O
on O
the O
release O
of O
renin O
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

-DOCSTART- O

yokukansan O
( O
yks O
) O
is O
a O
traditional O
japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-NEG
, O
insomnia B-NEG
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-NEG
. O

this O
study O
examined O
the O
effects O
of O
yks O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

daily O
oral O
administration O
of O
yks O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

the O
inhibitory O
effect O
of O
yks O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor O
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor O
antagonist O
, O
prazosin O
. O

a O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

the O
membrane O
expression O
of O
a(2a)-adrenoceptors O
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
yks O
or O
yohimbine O
. O

competitive O
radioligand O
and O
[(35)s]guanosine-5'-o-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
yks O
and O
its O
constituent O
herbs O
, O
glycyrrhiza O
( O
gr O
) O
and O
uncaria O
hook O
( O
uh O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2a)-adrenoceptor O
. O

certain O
chemical O
constituents O
, O
including O
gr O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
uh-derived O
geissoschizine O
methyl O
ether O
( O
gme O
) O
, O
shared O
such O
activities O
. O

repeated O
administration O
of O
gr O
, O
uh O
, O
glycyrrhizin O
or O
gme O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

these O
results O
suggest O
that O
yks O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2a)-adrenoceptor O
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O

despite O
the O
development O
of O
radiotherapy O
machines O
and O
technologies O
, O
a O
proportion O
of O
patients O
suffer O
from O
radiation-induced B-NEG
lymphedema I-NEG
. O

saireito O
( O
srt O
) O
is O
a O
traditional O
japanese O
herbal O
medicine O
that O
has O
been O
used O
for O
treating O
edema B-NEG
and O
inflammation B-NEG
in O
conditions O
such O
as O
nephritic B-NEG
disease I-NEG
. O

this O
study O
investigated O
the O
effect O
of O
srt O
on O
lymphedema B-NEG
caused O
by O
radiotherapy O
. O

four O
patients O
were O
treated O
with O
srt O
at O
a O
dose O
of O
9 O
g/day O
. O

the O
severity O
of O
lymphedema B-NEG
was O
evaluated O
using O
the O
common O
terminology O
criteria O
for O
adverse O
events O
version O
4 O
and O
numerical O
rating O
scale O
before O
and O
after O
srt O
treatment O
. O

after O
the O
treatment O
with O
srt O
, O
2 O
of O
4 O
patients O
( O
0.5 O
) O
showed O
apparent O
improvement O
in O
lymphedema B-NEG
. O

one O
of O
the O
cases O
had O
difficulty O
in O
wearing O
the O
custom-made O
thermoplastic O
cast O
, O
but O
after O
srt O
administration O
, O
he O
could O
wear O
the O
mask O
easily O
. O

one O
case O
decided O
to O
stop O
taking O
srt O
3 O
days O
after O
initiation O
because O
cough B-NEG
and O
fever B-NEG
appeared O
. O

in O
conclusion O
, O
it O
is O
important O
to O
control O
the O
side O
effects O
of O
radiotherapy O
, O
which O
leads O
to O
improved O
tumor B-POS
control I-POS
rates I-POS
. O

prospective O
randomized O
studies O
are O
necessary O
to O
confirm O
the O
findings O
of O
this O
case O
series O
study O
. O

-DOCSTART- O

seven O
injuries B-NEG
; O
seven O
kinds O
of O
impairments B-NEG

-DOCSTART- O

restrain O
acid B-NEU

-DOCSTART- O

promote O
the O
stomach B-DNP
and O
increase O
food B-NEU
intake I-NEU

-DOCSTART- O

tbc3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin O
, O
a O
potent O
mediator O
of O
blood O
vessel O
constriction O
and O
growth O
of O
smooth O
muscle O
in O
vascular B-DNP
walls I-DNP
. O
it O
is O
a O
next-generation O
endothelin O
a O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
thelin(tm O
) O
( O
sitaxsentan O
sodium O
) O
encysive's O
oral O
treatment O
for O
pulmonary B-NEG
arterial I-NEG
hypertension I-NEG
. O
tbc3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
a O
receptor O
versus O
the O
endothelin O
b O
receptor O
. O

-DOCSTART- O

enteritis B-NEG
, O
dysentery B-NEG
, O
prolapse B-NEG
of O
rectum O
, O
emission O
, O
knocks O
and O
falls O
. O

-DOCSTART- O

erlotinib O
inhibits O
the O
intracellular B-NEU
phosphorylation I-NEU
of I-NEU
tyrosine I-NEU
kinase I-NEU
associated O
with O
the O
epidermal O
growth O
factor O
receptor O
( O
egfr O
) O
which O
is O
expressed O
on O
the O
cell O
surface O
of O
normal O
cells B-DNP
and O
cancer B-NEG
cells I-NEG
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
parkinson's B-NEG
disease I-NEG
. O

-DOCSTART- O

diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
hemostatic B-DNP
function I-DNP
, O
others O

-DOCSTART- O

this O
is O
a O
syndrome B-NEG
with I-NEG
numbness I-NEG
and O
a O
pain B-NEG
due O
to O
wind-dampness B-NEG
. O

-DOCSTART- O

heat B-NEG
in O
the O
stomach O
; O

stomach B-NEG
heat I-NEG
; O

stomach B-DNP
affected O
by O
heat B-NEG
impairment I-NEG
of O
the O
stomach O
by O
pathogenic B-NEG
heat I-NEG
or O
taking O
excessive O
heat-producing O
food O
, O
marked O
by O
thirst B-NEU
, O
halitosis B-NEG
, O
hyperorexia B-NEG
, O
oliguria B-NEG
with O
dark B-NEG
urine I-NEG
, O
constipation B-NEG
or O
even O
ulceration B-NEG
of O
the O
mouth O
, O
gingivitis B-NEG
. O

-DOCSTART- O

its O
chief O
component O
is O
berberine O
. O

-DOCSTART- O

1 O
for O
cases O
of O
menorrhagia B-NEG
accompanied O
with O
listlessness B-NEG
and O
pale B-NEG
complexion I-NEG
due O
to O
deficiency B-NEG
of I-NEG
vital I-NEG
energy I-NEG
radix O
ginseng O
jilin O
to O
invigorate O
vital B-POS
energy I-POS
and O
control O
blood B-DNP
of O
profuse O
uterine B-NEG
bleeding I-NEG
leading O
to O
deadly O
coldness B-NEG
of I-NEG
limbs I-NEG
and O

-DOCSTART- O

constipation B-NEG
; O
suffer B-NEG
from I-NEG
constipation I-NEG

-DOCSTART- O

dysenteric B-NEG
disorder I-NEG
; O
dysentery B-NEG

-DOCSTART- O

10-gingerol O
, O
a O
component O
of O
rikkunshito O
, O
improves O
cisplatin-induced B-NEG
anorexia I-NEG
by O
inhibiting O
acylated B-DNP
ghrelin I-DNP
degradation I-DNP
. O

-DOCSTART- O

rikkunshito O
improves O
globus B-NEG
sensation I-NEG
in O
patients O
with O
proton-pump O
inhibitor-refractory O
laryngopharyngeal B-NEG
reflux I-NEG
. O

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
bladder B-NEG
cancer I-NEG
. O

-DOCSTART- O

inhibited O
urination B-NEU
, O
dribbling O
pain B-NEG
of O
urination O
, O
edema B-NEG
, O
bloody B-NEG
urine I-NEG
, O
damp-heat B-NEG
dysentery I-NEG
, O
asthma B-NEG
, O
sore B-NEG
swollen I-NEG
throat I-NEG
, O
toxin B-NEG
swelling I-NEG
of O
sores O
, O
wind-damp B-NEG
pain I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
bleeding B-NEG
knife O
wound O
. O

-DOCSTART- O

pseudoephedrine O
relaxes O
bronchial B-DNP
smooth I-DNP
muscle I-DNP
by O
stimulating O
beta2-adrenergic O
receptors O
. O

-DOCSTART- O

nocturnal B-NEG
enuresis I-NEG
and O
frequency B-NEG
of I-NEG
micturition I-NEG

-DOCSTART- O

weakness B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG

-DOCSTART- O

treatment O
of O
carbuncle B-NEG
and O
boil B-NEG
at O
the O
early O
stage O
or O
formation B-NEG
of I-NEG
abscess I-NEG
difficult O
to O
burst B-NEU
, O
external O
use O
for O
scabies B-NEG
and O
leprosy B-NEG
. O

-DOCSTART- O

heart B-NEG
failure I-NEG
. O

-DOCSTART- O

affection O
by O
cold B-NEG
1 O
common O
cold B-NEG
2 O
influenza B-NEG

-DOCSTART- O

stop O
itching B-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
body B-NEU
weight I-NEU

-DOCSTART- O

flatulence B-NEG
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O

-DOCSTART- O
damage O
of O
kidney I-NEG

-DOCSTART- O

hemiplegia B-NEG
; O

paralysis B-NEG

-DOCSTART- O

lumbago B-NEG
due O
to O
strain B-NEG
and O
contusion B-NEG

-DOCSTART- O

reinforce O
the O
spleen B-DNP

-DOCSTART- O

adult B-NEG
acute I-NEG
monoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

rikkunshito O
, O
an O
herbal O
medicine O
, O
suppresses O
cisplatin-induced B-NEG
anorexia I-NEG
in O
rats O
via O
5-ht2 O
receptor O
antagonism O
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
cataracts B-NEG
, O
eye B-NEG
disorders I-NEG
/ I-NEG
infections I-NEG
, O
glaucoma B-NEG
, O
and O
macular B-NEG
degeneration I-NEG
. O

-DOCSTART- O

for O
the O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
b O
in O
adult O
and O
adolescent O
patients O
??6 O
years O
of O
age O
with O
evidence O
of O
viral O
replication O
and O
either O
evidence O
of O
persistent O
elevations O
in O
serum O
aminotransferases O
( O
alt O
or O
ast O
) O
or O
histologically O
active O
disease O
. O

-DOCSTART- O

for O
acute O
and O
long-term O
management O
of O
signs O
and O
symptoms O
of O
osteoarthritis B-NEG
and O
rheumatoid B-NEG
arthritis I-NEG
, O
as O
well O
as O
for O
the O
management O
of O
pain B-NEG
. O

-DOCSTART- O

diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
blood B-NEU
pressure I-NEU

-DOCSTART- O

( O
1 O
) O
hernia B-NEG
( O
2 O
) O
diseases B-NEG
of I-NEG
genitalia I-NEG
( O
3 O
) O
severe O
pain B-NEG
in O
the O
lower O
abdomen O

-DOCSTART- O

diabetes B-NEG

-DOCSTART- O

( O
1 O
) O
diarrhea B-NEG
( O
2 O
) O
diarrhea B-NEG
and O
urination B-NEG
( O
3 O
) O
diarrhea B-NEG
and O
dysentery B-NEG

-DOCSTART- O

liver B-NEG
cancer I-NEG

-DOCSTART- O

malaria B-NEG
with O
mass O
under O
left O
hypochondrium O

-DOCSTART- O

hemophilia B-NEG
a I-NEG

-DOCSTART- O

detection O
of O
primary O
and O
metastatic B-NEG
pheochromocytoma I-NEG
or O
neuroblastoma B-NEG

-DOCSTART- O

enzalutamide O
is O
indicated O
for O
the O
treatment O
of O
patients O
with O
metastatic B-NEG
castration-resistant I-NEG
prostate I-NEG
cancer I-NEG
who O
have O
previously O
received O
docetaxel O
. O

-DOCSTART- O

cool O
blood B-DNP
and O
stop O
dysentery B-NEG

-DOCSTART- O

to O
regulate O
menstruation B-NEU
, O
replenish O
blood B-DNP
and O
regulate O
qi O
to O
relieve O
pain B-NEG
. O

-DOCSTART- O

to O
quicken O
blood B-DNP
and O
dispel O
stasis B-NEG
, O
regulate O
menstruation B-NEU
and O
relieve O
pain B-NEG
, O
nourish O
blood B-DNP
and O
quiet O
spirit O
, O
cool O
blood B-DNP
and O
disperse O
welling O
abscess B-NEG
. O

-DOCSTART- O

hypercholesterolemia B-NEG

-DOCSTART- O

purging B-NEG
by O
moisterizing O

-DOCSTART- O

gingivitis B-NEG
; O
epulis B-NEG

-DOCSTART- O

the O
symptom O
caused O
by O
stagnation O
of O
phlegm-heat B-NEG

-DOCSTART- O

zidovudine O
inhibits O
the O
activity B-NEU
of I-NEU
hiv-1 I-NEU
reverse I-NEU
transcriptase I-NEU
( O
rt O
) O
via O
dna B-NEU
chain I-NEU
termination I-NEU
after O
incorporation O
of O
the O
nucleotide B-DNP
analogue I-DNP
. O

-DOCSTART- O

used O
to O
prolong O
the O
time O
to O
recurrence O
of O
paroxysmal B-NEG
atrial I-NEG
fibrillation/flutter I-NEG
( O
paf B-NEG
) O
associated O
with O
disabling O
symptoms O
in O
patients O
without O
structural B-NEG
heart I-NEG
disease I-NEG
. O

also O
used O
for O
the O
treatment O
of O
life-threatening O
documented O
ventricular B-NEG
arrhythmias I-NEG
, O
such O
as O
sustained B-NEG
ventricular I-NEG
tachycardia I-NEG
. O

-DOCSTART- O

abdominal B-NEG
mass I-NEG
; O
accumulation O

-DOCSTART- O

( O
1 O
) O
pea-like O
skin B-NEG
sores I-NEG
; O
pox B-NEG
pea-shaped O
eruption B-NEG
filled O
with O
setrotic O
fluid O
such O
as O
smallpox B-NEG
and O
chickenpox B-NEG
. O

( O
2 O
) O
blister B-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
kids O
, O
others O
, O
fetus O

-DOCSTART- O

colorectal B-NEG
cancer I-NEG

-DOCSTART- O

profuse B-NEG
bleeding I-NEG
after O
delivery B-NEU

-DOCSTART- O

essential B-NEG
hypertension I-NEG

-DOCSTART- O

damp-warm B-NEG
disease I-NEG
febrile B-NEG
disease I-NEG
often O
occurring O
around O
mid-summer O
, O
july O
, O
caused O
by O
damp-heat B-NEG
pathogene I-NEG
, O
which O
mainly O
involves O
the O
gastro-intestinal B-DNP
tract I-DNP
often O
in O
a O
protracted O
course O
. O

it O
may O
sometimes O
be O
seen O
in O
diseases O
such O
as O
typhoid B-NEG
fever I-NEG
. O

-DOCSTART- O

nrp409 O
is O
presumed O
to O
work O
like O
the O
endogenous O
thyroid O
hormone O
thyroxine B-DNP
( O
t O
4 O
, O
a O
tetra-iodinated O
tyrosine O
derivative O
) O
. O

in O
the O
liver B-DNP
and O
kidney B-DNP
, O
t O
4 O
is O
converted O
to O
t O
3, O
the O
active O
metabolite B-NEU
. O

in O
order O
to O
increase O
solubility O
, O
the O
thyroid B-DNP
hormones I-DNP
attach O
to O
thyroid O
hormone O
binding O
proteins O
, O
thyroxin-binding B-DNP
globulin I-DNP
, O
and O
thyroxin-binding B-DNP
prealbumin I-DNP
( O
transthyretin B-DNP
) O
. O

transport O
and O
binding O
to O
thyroid O
hormone O
receptors O
in O
the O
cytoplasm O
and O
nucleus O
then O
takes O
place O
. O

thus O
by O
acting O
as O
a O
replacement O
for O
natural O
thyroxine B-DNP
, O
symptoms O
of O
thyroxine B-NEG
deficiency I-NEG
are O
relieved O
. O

-DOCSTART- O

calm O
the O
fetus O

-DOCSTART- O

aortic B-NEG
valve I-NEG
stenosis I-NEG

-DOCSTART- O

treatment O
of O
wind-heat B-NEG
type O
common O
cold B-NEG
, O
headache B-NEG
and O
dizziness B-NEG
, O
inflammation B-NEG
of O
the O
eye O
, O
blurred B-NEG
vision I-NEG
. O

-DOCSTART- O

ticarcillin's O
antibiotic O
properties O
arise O
from O
its O
ability O
to O
prevent O
cross-linking O
of O
peptidoglycan O
during O
cell B-DNP
wall I-DNP
synthesis I-DNP
when O
the O
bacteria O
tries O
to O
divide O
, O
causing O
death B-NEG
. O

-DOCSTART- O

hasten O
delivery O

-DOCSTART- O

( O
1 O
) O
pestilent B-NEG
lesions I-NEG
; O
leprosy B-NEG
( O
2 O
) O
malignant B-NEG
furuncle I-NEG

-DOCSTART- O

join O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

rk-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-NEG
, O
is O
based O
on O
the O
company's O
progelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
n-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O

decompensated B-NEG
cirrhosis I-NEG

-DOCSTART- O

based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
mr O
) O
instruments O
. O

paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

when O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

mr O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

mr O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
t1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
t2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

in O
magnetic O
resonance O
imaging O
( O
mri O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
t1 O
, O
and O
variation O
in O
the O
t2 O
. O

when O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
t1 O
and O
the O
t2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

at O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
t1 O
relaxation O
time O
, O
thus O
producing O
an O
increase O
in O
signal O
intensity O
. O

gadodiamide O
does O
not O
cross O
the O
intact O
blood-brain B-DNP
barrier I-DNP
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-DNP
nervous I-DNP
system I-DNP
( O
cns B-DNP
) O
lesions O
that O
have O
not O
caused O
an O
abnormal O
blood-brain B-DNP
barrier I-DNP
( O
e.g O
. O
, O
cysts O
, O
mature O
post-operative O
scars O
) O
. O

abnormal B-NEG
vascularity I-NEG
or O
disruption B-NEG
of I-NEG
the I-NEG
blood-brain I-NEG
barrier I-NEG
allows O
accumulation O
of O
gadodiamide B-DNP
in I-DNP
lesions I-DNP
such O
as O
neoplasms B-DNP
, O
abscesses B-NEG
, O
and O
subacute B-NEG
infarcts I-NEG
. O

-DOCSTART- O

to O
clear O
heat B-NEG
and O
engender O
liquid O
, O
moisten O
dryness B-NEG
and O
harmonize O
center O
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

chronic B-NEG
renal I-NEG
failure I-NEG

-DOCSTART- O

the O
bactericidal O
action O
of O
dalbavancin O
results O
primarily O
from O
inhibition O
of O
cell-wall B-NEU
biosynthesis I-NEU
. O

-DOCSTART- O

stagnation O
of O
qi O
and O
blood B-DNP
marked O
by O
chest B-NEG
pain I-NEG
; O
dry B-NEG
cough I-NEG
with O
shortness B-NEG
of I-NEG
breath I-NEG
; O
insomnia B-NEG
. O

-DOCSTART- O

oxamniquine O
may O
associate O
with O
an O
irreversible O
inhibition O
of O
the O
nucleic B-NEU
acid I-NEU
metabolism I-NEU
of I-NEU
the I-NEU
parasites I-NEU
. O

a O
hypothesis O
has O
been O
put O
forth O
that O
the O
drug O
is O
activated O
by O
a O
single O
step O
, O
in O
which O
a O
schistosome O
sulfotransferase O
enzyme O
converts O
oxamniquine O
into O
an O
ester O
( O
probably O
acetate O
, O
phosphate O
, O
or O
sulfate O
) O
. O

subsequently O
, O
the O
ester O
spontaneously O
dissociates O
, O
the O
resulting O
electrophilic O
reactant O
is O
capable O
of O
alkylation O
of O
schistosome O
dna O
. O

-DOCSTART- O

besifloxacin O
is O
a O
bactericidal O
fluroquinolone-type O
antibiotic O
that O
inhibits O
bacterial B-DNP
enzymes I-DNP
, O
dna B-DNP
gyrase I-DNP
and O
topoisomerase B-DNP
iv I-DNP
. O

by O
inhibiting O
dna B-DNP
gyrase I-DNP
, O
dna B-NEU
replication O
, O
transcription O
, O
and O
repair O
is O
impaired O
. O

by O
inhibiting O
topoisomerase B-DNP
iv I-DNP
, O
decatenation O
during O
cell O
devision O
is O
impaired O
. O

inhibiting O
these O
two O
targets O
also O
slows O
down O
development O
of O
resistance O
. O

-DOCSTART- O

chronic B-NEG
hepatitis I-NEG
b I-NEG
virus I-NEG

-DOCSTART- O

dizziness B-NEG
; O
vertigo B-NEG

-DOCSTART- O

ascites B-NEG
. O

croton O
seed O
( O
badou O
) O
is O
used O
with O
apricot O
seed O
( O
xingren O
) O
. O

-DOCSTART- O

hypoglycemia B-NEG

-DOCSTART- O

eye B-DNP
health I-DNP
, O
hemostatic B-NEU
function I-NEU
, O
eye B-DNP
, O
diet B-NEG
cardiovascular I-NEG
disease I-NEG

-DOCSTART- O

diarrhea B-NEG
due O
to O
damp-heat B-NEG

-DOCSTART- O

to O
provide O
some O
insights O
how O
herbal O
medicines O
affect O
deoxyribonucleic B-NEU
acid I-NEU
( I-NEU
dna I-NEU
) I-NEU
synthesis I-NEU
in O
the O
uterus O
, O
the O
dna B-NEU
polymerase I-NEU
activities I-NEU
( O
alpha O
and O
beta O
) O
in O
uterine O
samples O
taken O
from O
rats O
were O
measured O
. O

dna B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
with O
respect O
to O
dna O
content O
revealed O
alpha O
cyclic O
change O
with O
the O
highest O
level O
on O
proestrus O
, O
while O
dna B-NEU
polymerase I-NEU
beta I-NEU
activity I-NEU
showed O
no O
significant O
changes O
during O
the O
estrous O
cycle O
. O

the O
increased O
period O
of O
the O
activity O
coincided O
with O
that O
of O
17 B-DNP
beta-estradiol I-DNP
( O
e2 B-DNP
) O
but O
not O
progesterone B-DNP
( O
p4 B-DNP
) O
in O
the O
blood O
. O

injection O
of O
10 O
iu O
pregnant B-DNP
mare I-DNP
serum I-DNP
gonadotropin I-DNP
( O
pms B-DNP
) O
on O
day O
27 O
of O
age O
gradually O
increased O
dna B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
in O
uteri O
, O
while O
concomitant O
treatment O
with O
pms B-DNP
and O
200 O
micrograms O
tokishakuyakusan O
( O
ts O
) O
, O
keishibukuryogan O
( O
kb O
) O
or O
unkeito O
( O
ut O
) O
suppressed O
the O
enzyme B-NEU
activity I-NEU
, O
with O
a O
most O
remarkable O
effect O
of O
kb O
. O

these O
results O
suggest O
that O
ts O
, O
kb O
or O
ut O
suppresses O
in O
vivo O
dna B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
induced O
by O
pms B-DNP
in O
the O
rat O
uterus O
. O

-DOCSTART- O

1 O
treatment O
of O
skin B-NEG
infection I-NEG
, O
sorethroat B-NEG
, O
erysipelas B-NEG
, O
appendicitis B-NEG
, O
etc O
. O
recently O
also O
used O
for O
leptospirosis B-NEG
. O
2 O
treatment O
of O
conjunctivitis B-NEG
. O
recently O
used O
for O
acute O
and O
chronic B-NEG
conjunctivitis I-NEG
, O
trachoma B-NEG
, O
keratitis B-NEG
, O
corneal B-NEG
ulcer I-NEG
, O
etc O
. O
, O
orally O
or O
toptically O
. O
diarrhea B-NEG
and O
dysentery B-NEG
of O
dampness-heat B-NEG
type O
, O
skin B-NEG
lesions I-NEG
of O
dampness B-NEU
type O
, O
etc O
. O

-DOCSTART- O

treatment O
of O
: O
1 O
hemorrhages B-NEG
due O
to O
external B-NEG
injuries I-NEG
. O
dragon's O
blood O
( O
xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
cattail O
pollen O
( O
puhuang O
) O
. O

-DOCSTART- O

sores B-NEG
of O
the O
mouth O
or O
tongue O
; O
aphthae B-NEG
and O
boil B-NEG
of O
mouth O
and O
tongue O

-DOCSTART- O

lung B-NEG
cancer I-NEG

-DOCSTART- O

binding O
of O
dalbavancin O
to O
the O
d-ala-d-ala O
prevents O
the O
incorporation O
of O
the O
nam/nag-peptide O
subunits O
into O
the O
peptidoglycan O
matrix O
. O

-DOCSTART- O

vaginal B-DNP
discharge I-DNP
, O
strangury B-NEG
syndrome I-NEG
, O
swelling B-NEG
toxin I-NEG
of O
clove O
sore B-NEG
, O
parotitis B-NEG
, O
mastitis B-NEG
, O
lymphrnoditis B-NEG
. O

-DOCSTART- O

polycystic B-NEG
ovary I-NEG
syndrome I-NEG

-DOCSTART- O

to O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
, O
disinhibit O
water O
and O
disperse O
edema B-NEG
. O

-DOCSTART- O

excessive O
drinking O
of O
water O
due O
to O
thirst B-NEU

-DOCSTART- O

ulcer B-NEG

-DOCSTART- O

pull O
up O
toxicity B-NEG
and O
regenerate O
flesh B-DNP

-DOCSTART- O

sore B-NEG

-DOCSTART- O

pain B-NEG

-DOCSTART- O

the O
previous O
experimental O
studies O
have O
demonstrated O
that O
addition O
of O
huang O
qi O
( O
[symbol O
: O
see O
text] O
radix O
astragali O
) O
to O
the O
formulated O
recipe O
sheng O
mai O
yin O
( O
[symbol O
: O
see O
text] O
decoction O
for O
pulse-activation O
) O
exerts O
the O
effects O
of O
strengthening O
the O
myodynamia B-DNP
, O
increasing O
the O
coronary B-DNP
flow I-DNP
, O
improving O
myocardial B-DNP
metabolism I-DNP
, O
and O
resisting O
the O
arrhythmia B-NEG
. O

the O
active O
component O
of O
huang O
lian O
( O
[symbol O
: O
see O
text] O
rhizoma O
coptidis O
) O
can O
prolong O
the O
myocardial B-DNP
action I-DNP
potential O
and O
antagonize O
the O
chloroform- O
, O
aconitine- O
, O
barium O
chloride- O
, O
epinephrine- O
or O
coronary B-NEG
ligation-induced I-NEG
arrhythmia I-NEG
by O
blocking O
the O
calcium O
channel O
. O

ku O
shen O
( O
[symbol O
: O
see O
text] O
radix O
sophorae O
flavescentis O
) O
contains O
matrine O
and O
flavones O
, O
which O
act O
as O
quinidine O
to O
decrease O
the O
excitability B-NEU
of I-NEU
the I-NEU
myocardium I-NEU
, O
prolong O
the O
refractory O
period O
, O
and O
inhibit O
the O
ectopic B-NEG
cardiac I-NEG
rhythm I-NEG
. O

and O
dan O
shen O
( O
[symbol O
: O
see O
text] O
radix O
salviae O
miltiorrhizae O
) O
has O
the O
action O
of O
improving O
the O
ischemic B-NEG
state I-NEG
of O
the O
myocardium B-DNP
by O
dilating O
the O
coronary B-DNP
vessels I-DNP
. O

in O
conclusion O
, O
the O
definite O
therapeutic O
effects O
of O
huang O
lian O
sheng O
mai O
yin O
in O
treating O
ventricular B-NEG
, I-NEG
atrial I-NEG
and I-NEG
nodal I-NEG
arrhythmia I-NEG
suggests O
that O
the O
prescription O
is O
rational O
and O
accords O
with O
the O
therapeutic O
principle O
of O
tcm O
. O

except O
discomfort B-NEG
in O
the O
gastric B-NEG
cavity I-NEG
and O
poor O
appetite B-NEU
experienced O
by O
some O
patients O
, O
there O
is O
no B-NEG
toxic I-NEG
or O
adverse O
reaction O
. O

-DOCSTART- O

refers O
to O
the O
pain B-NEG
and O
damage B-NEG
due O
to O
the O
physical O
injury B-NEG

-DOCSTART- O

deficiency O
of O
gi O
( O
vital O
energy O
) O
of O
the O
stomach O

-DOCSTART- O

diabetes B-NEG
, O
annoyment O
, O
thirst B-NEG
, O
easy O
to O
get O
hungry B-NEG
, O
tiredness B-NEG
and O
underweight B-NEG
, O
dry B-NEG
mouth I-NEG
and I-NEG
throat I-NEG
, O
short B-NEG
breath I-NEG
and O
nervousness B-NEG
, O
sweating B-NEU
, O
dry B-NEG
stool I-NEG
, O
red B-NEG
tong I-NEG
and O
lack B-NEG
of I-NEG
saliva I-NEG
, O
weak O
and O
frequent B-NEG
pulse I-NEG

-DOCSTART- O

fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
class O
, O
and O
blocks O
the O
reuptake B-NEU
of I-NEU
serotonin I-NEU
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-NEU
of I-NEU
serotonin I-NEU
on O
5ht<sub>1a</sub> O
autoreceptors O
. O

venlafaxine O
and O
its O
active O
metabolite O
, O
o-desmethylvenlafaxine O
( O
odv O
) O
, O
inhibit O
the O
reuptake B-NEU
of I-NEU
both I-NEU
serotonin I-NEU
and I-NEU
norepinephrine I-NEU
with O
a O
potency O
greater O
for O
the O
5-ht O
than O
for O
the O
ne O
reuptake O
process O
. O

quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism B-NEU
at O
d2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5ht2a O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O

quality O
of O
life O

-DOCSTART- O

cool O
the O
blood B-DNP

-DOCSTART- O

tropicamide O
acts O
by O
blocking O
the O
responses O
of O
the O
iris B-DNP
sphincter I-DNP
muscle I-DNP
to O
the O
iris B-DNP
and I-DNP
ciliary I-DNP
muscles I-DNP
to O
cholinergic B-NEU
stimulation I-NEU
, O
producing O
dilation B-NEU
of O
the O
pupil O
and O
paralysis B-NEG
of O
the O
ciliary O
muscle O
. O

hydroxyamphetamine O
is O
a O
sympathomimetic O
drug O
, O
that O
is O
, O
a O
drug O
that O
stimulates O
the O
sympathetic B-DNP
nervous I-DNP
system I-DNP
as O
an O
agonist O
of O
human O
taar1 O
. O

-DOCSTART- O

pectoral B-NEG
pain I-NEG
with O
stuffiness B-NEG
; O
chest B-NEG
impediment I-NEG
; O
chest B-NEG
blockage I-NEG
; O
obstruction O
of O
gi O
in O
the O
chest O
( O
1 O
) O
a O
morbid B-NEG
condition I-NEG
due O
to O
stagnation B-NEG
of B-NEG
dampness B-NEG
and O
phlegm B-NEG
, O
marked O
by O
choking B-NEG
pain I-NEG
in O
the O
chest O
, O
sometimes O
referring O
to O
the O
back B-DNP
, O
usually O
accompanied O
by O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cough B-NEG
. O
( O

2 O
) O
obstruction O
of O
gi O
in O
the O
stomach O
, O
chest B-NEG
pain I-NEG
that O
occurs O
immediately O
after O
eating O
, O
accompanied O
by O
difficulty B-NEG
in I-NEG
swallowing I-NEG
and O
frequent O
vomiting B-NEG
. O

-DOCSTART- O

uncomplicated B-NEG
falciparum I-NEG
malaria I-NEG

-DOCSTART- O

bradycardia B-NEG
, O
sick B-NEG
sinus I-NEG
syndrome I-NEG
, O
angina B-NEG
and O
cardiac B-NEG
insufficiency I-NEG
, O
arrhythmia B-NEG
. O

-DOCSTART- O

blood-heat B-NEU

-DOCSTART- O

mania-withdrawal B-NEG
; O

mania B-NEG
; O

manic-depressive B-NEG
psychosis I-NEG

-DOCSTART- O

to O
replenish O
the O
liver B-DNP
and O
kidney B-DNP
, O
improve O
eyesight B-POS
and O
promote O
the O
growth B-POS
of I-POS
black I-POS
hair I-POS
. O

-DOCSTART- O

conservative O
treatment O
of O
benign B-NEG
prostatic I-NEG
hypertrophy I-NEG
- O
clinical O
effects O
of O
increased O
administration O
of O
hachimijiogan O
and O
the O
relation O
between O
these O
effects O
and O
the O
sho O
of O
chinese O
medicine O
. O

-DOCSTART- O

a O
stomachache B-NEG
due O
to O
exhaustion O
of O
vital O
energy O

-DOCSTART- O

settle O
fright O

-DOCSTART- O

mucosal B-NEG
melanoma I-NEG

-DOCSTART- O

expel O
malign B-DNP
blood I-DNP

-DOCSTART- O

the O
herbal O
medicine O
tokishakuyakusan O
increases O
fetal O
blood B-NEU
glucose I-NEU
concentrations I-NEU
and O
growth B-NEU
hormone I-NEU
levels I-NEU
and O
improves O
intrauterine B-NEG
growth I-NEG
retardation I-NEG
induced O
by O
n(omega)-nitro-l-arginine O
methyl O
ester O
. O

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
move O
water O
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

festering O
sore B-NEG
or O
abscess B-NEG
with O
inadequate O
drainage O
or O
initial O
granulation O
. O

-DOCSTART- O

to O
dispel O
wind-heat B-NEG
, O
to O
subdue O
hyperactivity B-NEG
of I-NEG
the I-NEG
liver I-NEG
, O
and O
improve O
eyesight B-POS
. O

-DOCSTART- O

to O
relieve O
rheumatic B-NEG
conditions I-NEG
, O
and O
to O
remove O
damp-heat B-NEG
. O

-DOCSTART- O

this O
is O
a O
symptom O
with O
yellow B-NEG
body I-NEG
due O
to O
blood B-NEG
deficiency I-NEG
. O

-DOCSTART- O

epidemic B-NEG
smallpox I-NEG

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
woman O
, O
endocrine B-DNP
system I-DNP
, O
lipid B-NEU
profile I-NEU
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
general O
woman O

-DOCSTART- O

diabetes B-NEG
; O
wasting B-NEG
( O
emaciation B-NEG
) O
and O
thirsting B-NEG
syndrome I-NEG

-DOCSTART- O

this O
is O
a O
symptom O
with O
fullness B-NEG
and I-NEG
pain I-NEG
in I-NEG
the I-NEG
chest I-NEG
and I-NEG
abdomen I-NEG
. O

-DOCSTART- O

stage O
ii O
non-contiguous O
adult B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

adult B-NEG
b I-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

nephrolithiasis B-NEG

-DOCSTART- O

doxorubicin O
forms O
complexes O
with O
dna O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase B-NEU
ii I-NEU
activity I-NEU
by O
stabilizing O
the O
dna-topoisomerase B-DNP
ii I-DNP
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase B-NEU
ii I-NEU
catalyzes I-NEU
. O

-DOCSTART- O

warm O
the O
kidney B-DNP
and O
support O
yang O

-DOCSTART- O

vomiting B-NEG
and O
regurgitation B-NEG

-DOCSTART- O

treatment O
of O
consumptive B-NEG
diseases I-NEG
, O
impotence B-NEG
, O
cold B-NEG
sperm I-NEG
, O
lassitude B-NEG
in O
the O
loins O
and O
legs O
due O
to O
deficiency O
of O
the O
kidney-yang O
, O
etc O
. O

-DOCSTART- O

blood B-NEG
stagnation I-NEG
caused O
by O
falling B-NEG
or O
strike B-NEG

-DOCSTART- O

to O
clear O
heat B-NEU
and O
transform O
damp B-NEU
, O
disperse O
accumulation O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

insomnia B-NEG

-DOCSTART- O

post-operative B-NEG
pain I-NEG

-DOCSTART- O

move O
gi(qi O
) O
and O
blood B-DNP

-DOCSTART- O

1 O
to O
moisurize O
the O
lung B-DNP
and O
relieve O
cough B-NEG
( O
lung-dryness B-NEG
with O
cough B-NEG
and O
hemoptysis B-NEG
) O
. O
2 O
to O
relieve O
cardiac B-NEG
heat I-NEG
and O
tranquilize O
the O
mind O
( O
convalescence O
of O
febrile B-NEG
diseases I-NEG
or O
yin-deficiency O
with O
heat B-NEU
manifested O
as O
irritability B-NEG
, O
insomnia B-NEG
, O
dreaminess B-NEU
, O
palpitation B-NEG
and O
absent-mindedness B-NEG
) O
. O

-DOCSTART- O

coronary B-NEG
heart I-NEG
disease I-NEG
, O
angina B-NEG
pectoris I-NEG
, O
hypercholesterolemia B-NEG
, O
parkinson B-NEG
disease I-NEG
, O
peripheral B-NEG
arterial I-NEG
diseases I-NEG
, O
chest B-NEG
impediment I-NEG
and O
heart B-NEG
pain I-NEG
, O
cough B-NEG
of O
phlegm B-DNP
asthma B-NEG
, O
diarrhea B-NEG
and O
dysentery B-NEG
, O
vaginal B-DNP
discharge I-DNP
, O
emission O
, O
retinal B-NEG
insufficiency I-NEG
syndrome I-NEG
. O

-DOCSTART- O

vomiting B-NEG
due O
to O
dysphagia B-NEG

-DOCSTART- O

ureterostomy O
; O
functional B-NEG
disturbance I-NEG

-DOCSTART- O

treatment O
of O
pains B-NEG
caused O
by O
blood B-NEG
stagnation I-NEG
. O

-DOCSTART- O

1 O
containing O
potassium O
acetate O
and O
chloride O
which O
exert O
diuretic B-NEU
effect I-NEU
. O
2 O
. O
orall O
adminstration O
of O
its O
decoction O
or O
infusion O
( O
2g/kg O
) O
can O
reduce O
vaccine-induced O
fever B-NEG
in O
rabbits O
. O
3 O
. O
cardiotonic O
on O
the O
heart O
of O
frog O
weakened O
by O
quinine O
. O
also O
causing O
constriction B-NEU
of I-NEU
blood I-NEU
vessels I-NEU
and O
rising O
of O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

lubricate O
the O
intestines B-DNP

-DOCSTART- O

interferon O
alpha O
binds O
to O
type O
i O
interferon O
receptors O
which O
activate O
two O
jak1 O
and O
tyk2 O
and O
activate O
multiple O
dowmstream O
immunomodulatory B-NEU
and O
antiviral O
proteins O
. O

ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine B-DNP
monophosphate I-DNP
dehydrogenase I-DNP
, O
viral B-DNP
rna I-DNP
polymerase I-DNP
and O
mrna B-DNP
guanylyltransferase I-DNP
( O
viral O
) O
and O
can O
be O
incorporated O
into O
rna O
in O
rna O
viral O
species O
. O

telaprevir O
is O
an O
inhibitor O
of O
the O
hcv B-DNP
ns3/4a I-DNP
serine I-DNP
protease I-DNP
, O
necessary O
for O
the O
proteolytic O
cleavage O
of O
the O
hcv O
encoded O
polyprotein O
into O
mature O
forms O
of O
the O
ns4a O
, O
ns4b O
, O
ns5a O
and O
ns5b O
proteins O
and O
essential O
for O
viral O
replication O
. O

-DOCSTART- O

hepatoma B-NEG

-DOCSTART- O

crohn's B-NEG
disease I-NEG

-DOCSTART- O

warfarin O
inhibits O
vitamin B-DNP
k I-DNP
reductase I-DNP
, O
resulting O
in O
depletion O
of O
the O
reduced O
form O
of O
vitamin B-DNP
k I-DNP
which O
reduces O
the O
thrombogenicity B-NEG
of I-NEG
clots I-NEG
. O

heparin O
binds O
to O
antithrombin O
iii O
to O
form O
a O
heparin-antithrombin O
iii O
complex O
. O

the O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin B-DNP
and O
other O
activated O
clotting B-DNP
factors I-DNP
, O
such O
as O
factors O
ix O
, O
x, O
xi O
, O
and O
xii O
, O
thereby O
preventing O
the O
polymerization B-NEU
of I-NEU
fibrinogen I-NEU
to O
fibrin O
and O
the O
subsequent O
formation B-NEU
of I-NEU
clots I-NEU
. O

-DOCSTART- O

frequent B-NEG
vomiting I-NEG

-DOCSTART- O

cyclosporine O
binds O
to O
cyclophilin O
which O
inhibits O
lymphokine B-NEU
production I-NEU
and O
interleukin B-NEU
release I-NEU
, O
shows O
potent O
immunosuppressant O
medication O
. O

-DOCSTART- O

one O
of O
cough B-NEG
that O
gets O
worst O
at O
night O
. O

that O
occurs O
by O
insubstantial O
fire O
in O
the O
lung O
due O
to O
insufficiency O
of O
the O
kidney O
eum O

-DOCSTART- O

in O
addition O
, O
dalbavancin O
alters O
bacterial O
- O
cell O
- O
membrane O
permeability O
and O
rna B-NEU
synthesis I-NEU
. O

-DOCSTART- O

reproductive B-DNP
systems I-DNP
, O
mood O
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
menopausal B-NEG
woman I-NEG
, O
endocrine B-DNP
system I-DNP
, O
endurance B-NEU
, O
energy O
supply O
and O
recovery O
, O
mimmuietabolic O
rate/energy O
expenditure O
, O
metabolism B-NEU
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
woman O
, O
quality O
of O
life O
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
neurological B-DNP
systems I-DNP
, O
liver B-DNP
, O
others O
, O
kids O
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
liver B-DNP
health I-DNP
, O
strength B-POS
and O
power B-POS
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
intelligence B-POS
, O
overall O
cvd B-NEG
, O
general O
woman O
, O
body B-NEU
weight I-NEU
, O
protective B-NEU
immunity I-NEU

-DOCSTART- O

distention B-NEG
and I-NEG
pain I-NEG
in I-NEG
chest I-NEG
and I-NEG
abdomen I-NEG
with O
driving O
up O
qi O

-DOCSTART- O

allogeneic O
haplo-stem O
cell O
transplatation O
( O
sct O
) O

-DOCSTART- O

alleviate O
edema B-NEG
and O
toxin B-NEG

-DOCSTART- O

yin O
chen O
hao O
tang O
, O
a O
chinese O
prescription O
, O
inhibits O
both O
herpes B-NEG
simplex I-NEG
virus I-NEG
type-1 I-NEG
and I-NEG
type-2 I-NEG
infections I-NEG
in O
vitro O
. O

-DOCSTART- O

abdominal B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
parasitosis I-NEG
; O
abdominal B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
ascariasis I-NEG

-DOCSTART- O

a O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-NEG
pain I-NEG
and O
general O
fatigue B-NEG
. O

he O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-NEG
pain I-NEG
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain B-NEG
more O
intense O
than O
usual O
. O

chest O
x-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

a O
drug O
lymphocyte O
stimulation O
test O
( O
dlst O
) O
was O
also O
performed O
at O
that O
time O
. O

steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-NEG
and O
chest O
x-ray O
findings O
. O

dlst O
performed O
again O
with O
yokukansan O
and O
hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
yokukansan O
was O
positive O
. O

this O
result O
showed O
yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced B-NEG
pneumonitis I-NEG
. O

any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic B-NEG
pneumonitis I-NEG
. O

-DOCSTART- O

clear O
( O
pathogenic O
) O
fire B-NEU
and O
invigorate O
blood B-DNP

-DOCSTART- O

sleep B-NEG
disturbance I-NEG

-DOCSTART- O

a O
lumbago B-NEG
pain I-NEG
. O

occur O
by O
invasion B-NEG
of I-NEG
wind-heat I-NEG
in O
kidney O
meridian O
. O

-DOCSTART- O

to O
benefit O
qi O
and O
revitalize O
blood B-DNP
; O
to O
nourish O
yin O
and O
tonify O
yang O

-DOCSTART- O

neurological O
systems O
health O
, O
dietnarelated O
cardiovascular O
disease O
, O
memory O
, O
neurological O
systems O
, O
hemostatic O
function O
, O
mental B-NEG
state I-NEG
and O
performance O

-DOCSTART- O

release O
muscles B-DNP

-DOCSTART- O

halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
a2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

it O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis B-NEU
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins B-DNP
and O
leukotrienes B-DNP
by O
inhibiting O
the O
release O
of O
their O
common O
precursor O
arachidonic B-DNP
acid I-DNP
. O

arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
a2 O
. O

the O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

after O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
gre O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

the O
dna O
bound O
receptor O
then O
interacts O
with O
basic O
transcription B-DNP
factors I-DNP
, O
causing O
the O
increase O
in O
expression B-NEU
of I-NEU
specific I-NEU
target I-NEU
genes I-NEU
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
depression B-NEG
. O

-DOCSTART- O

to O
warm O
the O
kidney B-DNP
and O
cause O
diuresis B-NEG
. O

-DOCSTART- O

breast B-NEG
pain I-NEG

-DOCSTART- O

treament O
of O
arthritis B-NEG
with O
ankylosis B-NEG
, O
aching B-NEG
and I-NEG
heaviness I-NEG
sensation I-NEG
of O
the O
loins O
and O
knees O
, O
systremma B-NEG
due O
to O
vomiting B-NEG
and O
diarrhea B-NEG
, O
edema B-NEG
and O
weakness B-NEG
of I-NEG
the I-NEG
legs I-NEG
. O

-DOCSTART- O

heat B-NEG
vexation I-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
vomiting B-NEG
nausea I-NEG
, O
vacuity B-NEG
heat I-NEG
cough I-NEG
, O
dry B-NEG
stool I-NEG
, O
swelling B-NEG
of I-NEG
welling I-NEG
abscess I-NEG
, O
welling B-NEG
abscess I-NEG
and O
flat B-NEG
abscess I-NEG
with O
swelling B-NEG
sore I-NEG
. O

-DOCSTART- O

for O
the O
treatment O
of O
rheumatoid B-NEG
arthritis I-NEG
( O
ra B-NEG
) O
. O

-DOCSTART- O

clear O
heat B-NEU
and O
moisten O
the O
lung B-DNP

-DOCSTART- O

malaria B-NEG
; O
malarial B-NEG
disorder I-NEG
malaria B-NEG
and O
other O
disease O
characterized O
by O
intermittent O
rigor B-NEG
, O
high O
fever B-NEG
and O
sweating B-NEU
. O

-DOCSTART- O

applicable O
to O
cases O
of O
watery B-NEG
diarrhea I-NEG
with O
increased O
gurgling O
sounds O
, O
abdominal B-NEG
pain I-NEG
, O
nausea B-NEG
, O
vomiting B-NEG
, O
vexation B-NEG
, O
thirst B-NEU
, O
yellow B-NEU
and I-NEU
greasy I-NEU
fur I-NEU
, O
soft O
and O
floating O
, O
smooth B-NEU
pulse I-NEU
, O
which O
are O
attributive O
to O
dampness-heat B-NEG
of I-NEG
intestines I-NEG
and I-NEG
stomach I-NEG
( O
predominantly O
da O

-DOCSTART- O

juvenile B-NEG
idiopathic I-NEG
arthritis I-NEG

-DOCSTART- O

dyspepsia B-NEG
; O
indigestion B-NEG

-DOCSTART- O

harmonize O
blood B-DNP

-DOCSTART- O

to O
invigorate O
blood B-DNP
and O
remove O
stagnation B-NEG
. O

-DOCSTART- O

old O
ulceration B-NEG

-DOCSTART- O

for O
desolving O
stasis O
and O
stopping O
bleeding O

-DOCSTART- O

constrain O
the O
lung B-DNP

-DOCSTART- O

postpartum B-NEG
depressive I-NEG
mood I-NEG

-DOCSTART- O

atopic B-NEG
dermatitis I-NEG

-DOCSTART- O

both O
tolterodine O
and O
its O
active O
metabolite O
, O
5-hydroxymethyltolterodine O
, O
act O
as O
competitive O
antagonists O
at O
muscarinic O
receptors O
. O
this O
antagonism O
results O
in O
inhibition O
of O
bladder B-NEG
contraction I-NEG
, O
decrease O
in O
detrusor B-NEG
pressure I-NEG
, O
and O
an O
incomplete O
emptying O
of O
the O
bladder B-DNP
. O

-DOCSTART- O

a O
symptom O
that O
gi O
gets O
together O
and O
blood B-DNP
does O
not O
circulate O
well O
. O

an O
affected O
part O
has O
abdominal B-NEG
distension I-NEG
or O
a O
sore B-NEG
. O

if O
it O
keeps O
long O
, O
it O
becomes O
blood B-NEG
stagnation I-NEG
, O
and O
causes O
a O
hard B-NEG
swelling I-NEG
and O
a O
serious B-NEG
pain I-NEG
on O
the O
part O
. O

-DOCSTART- O

postreperfusion B-NEG
syndrome I-NEG

-DOCSTART- O

to O
disperse O
the O
stagnated O
liver-qi O
, O
to O
remove O
heat B-NEU
, O
invigorate O
the O
spleen B-DNP
and O
nourishing O
blood B-DNP
. O

-DOCSTART- O

iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O

bofutsushosan O
, O
a O
traditional O
chinese O
formulation O
, O
prevents O
intimal B-NEG
thickening I-NEG
and O
vascular B-NEU
smooth I-NEU
muscle I-NEU
cell I-NEU
proliferation I-NEU
induced O
by O
balloon O
endothelial B-NEG
denudation I-NEG
in O
rats O
. O

-DOCSTART- O

unspecified O
childhood O
solid B-NEG
tumor I-NEG
, O
protocol O
specific O

-DOCSTART- O

purging B-POS
by O
aggression O

-DOCSTART- O

relieve O
throat B-DNP

-DOCSTART- O

cough B-NEG
due O
to O
lung B-NEG
exhaustion I-NEG
syndrome I-NEG

-DOCSTART- O

for O
the O
treatment O
of O
cancer B-NEG
patients O
with O
severe O
pain B-NEG
that O
breaks O
through O
their O
regular O
narcotic O
therapy O
. O

-DOCSTART- O

consumption B-NEG
; O

deficiency B-NEG
syndrome I-NEG
; O

disease O
due O
to O
asthenia B-NEG
of O
the O
viscera O

-DOCSTART- O

disperse O
glomus B-NEG

-DOCSTART- O

bladder B-NEG
, I-NEG
neurogenic I-NEG

-DOCSTART- O

ceruminal B-NEG
impaction I-NEG

-DOCSTART- O

acute B-NEG
viral I-NEG
bronchiolitis I-NEG

-DOCSTART- O

1 O
l-tetrahydropalmatine O
20-40mg/kg O
intraperitoneally O
in O
mice O
and O
15mg/kg O
intravenously O
in O
rabbits O
exert O
analgesic O
and O
sedative O
effects O
. O

2 O
reducing O
the O
body O
temperature O
in O
healthy O
or O
thyroidectomized O
rats O
. O

-DOCSTART- O

to O
benefit O
vital O
qi O
, O
invigorate O
the O
spleen B-DNP
and O
nourish O
the O
stomach B-DNP
. O

for O
hypofunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
, O
peptic B-NEG
ulcer I-NEG
and O
chronic B-NEG
gastritis I-NEG
. O

recently O
, O
also O
used O
for O
the O
cancers B-NEG
of I-NEG
erophagus I-NEG
, I-NEG
stomach I-NEG
and I-NEG
intestines I-NEG
. O

-DOCSTART- O

to O
remove O
toxic B-NEG
heat I-NEG
, O
to O
soothe O
the O
sore B-NEG
throat I-NEG
, O
to O
resolve O
phlegm B-NEG
, O
and O
to O
relieve O
dysuria B-NEG
. O

-DOCSTART- O

1 O
its O
decoction O
can O
lower O
blood B-NEU
pressure I-NEU

2 O
. O
inhibiting O
the O
growth B-NEU
of I-NEU
(a)-streptococcus I-NEU

3 O
. O
shortening O
the O
bleeding B-NEG
time O
. O

4 O
. O
anti-inflammatory B-POS

5 O
. O
diuretic O
. O

-DOCSTART- O

treament O
of O
heat B-NEU
in O
the O
lung O
with O
cough B-NEG
, O
sticky B-NEG
and I-NEG
bloody I-NEG
sputum I-NEG
, O
and O
distress B-NEG
in O
the O
chest O
. O

-DOCSTART- O

thiotepa O
is O
used O
a O
as O
conditioning O
treatment O
prior O
to O
allogeneic O
or O
autologous O
haematopoietic O
progenitor O
cell O
transplantation O
( O
hpct O
) O
in O
haematological B-NEG
diseases I-NEG
in O
adult O
and O
paediatric O
patients O
. O

also O
, O
when O
high O
dose O
chemotherapy O
with O
hpct O
support O
it O
is O
appropriate O
for O
the O
treatment O
of O
solid B-NEG
tumours I-NEG
in O
adult O
and O
paediatric O
patients O
. O

-DOCSTART- O

vaginitis B-NEG

-DOCSTART- O

this O
is O
a O
syndrome O
with O
throat B-NEG
pain I-NEG
due O
to O
wind-heat B-NEG
. O

it O
has O
red B-NEG
spots I-NEG
on O
all O
of O
the O
body O
, O
burning B-NEG
heat I-NEG
, O
difficulty B-NEG
in I-NEG
swallowing I-NEG
foods I-NEG
, O
headache B-NEG
, O
and O
aversion B-NEG
to O
cold O
. O

-DOCSTART- O

promote O
the O
stomach B-DNP
and O
increased O
food B-NEU
intake I-NEU

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
reproductive B-DNP
systems I-DNP
, O
physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
quality O
of O
life O
, O
endocrine B-DNP
system I-DNP
, O
motivation O
, O
endurance B-NEU
, O
memory B-POS
, O
hemostatic B-DNP
function I-DNP
, O
energy O
supply O
and O
recovery B-POS
, O
liver B-DNP
health I-DNP
, O
protective B-NEU
immunity I-NEU
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
liver B-DNP
, O
others O
, O
respiratory B-DNP
systems I-DNP
, O
effort O
, O
respiratory B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

dizziness B-NEG
and O
palpitation B-NEG
due O
to O
congested B-NEG
fluids I-NEG

-DOCSTART- O

all O
kinds O
of O
malignant B-NEG
furuncle I-NEG

-DOCSTART- O

once O
bound O
, O
the O
receptor O
/ O
ligand O
complex O
localizes O
to O
the O
nucleus O
and O
acts O
as O
a O
dna B-DNP
binding I-DNP
transcription I-DNP
factor I-DNP
, O
regulating O
gene B-NEU
expression I-NEU
. O

-DOCSTART- O

for O
the O
treatment O
of O
adult O
patients O
diagnosed O
with O
anaplastic B-NEG
astrocytoma I-NEG
whose O
disease O
has O
progressed O
after O
therapy O
with O
nitrosourea O
and O
procarbazine O
, O
as O
well O
as O
concomitantly O
with O
radiation O
therapy O
for O
treatment O
of O
newly O
diagnosed O
glioblastoma B-NEG
multiforme I-NEG
. O
also O
used O
as O
maintenance O
therapy O
for O
glioblastoma B-NEG
multiforme I-NEG
. O

-DOCSTART- O

strengthen O
the O
heart B-DNP
and O
replenish O
qi O
, O
activating O
yang O
and O
blood B-DNP
circulation I-DNP
, O
promoting O
the O
restoration B-POS
of I-POS
consciousness I-POS
with O
drugs O
of O
fragnant O
flavour O
, O
relieving O
pain B-NEG
. O

-DOCSTART- O

acute O
infantile B-NEG
convulsion I-NEG

-DOCSTART- O

heroin O
is O
a O
mu-opioid O
agonist O
. O

it O
acts O
on O
endogenous O
mu-opioid O
receptors O
that O
are O
spread O
in O
discrete O
packets O
throughout O
the O
brain O
, O
spinal O
cord O
and O
gut O
in O
almost O
all O
mammals O
. O

heroin O
, O
along O
with O
other O
opioids B-NEG
, O
are O
agonists O
to O
four O
endogenous B-DNP
neurotransmitters I-DNP
. O

they O
are O
beta-endorphin B-DNP
, O
dynorphin B-DNP
, O
leu-enkephalin B-DNP
, O
and O
met-enkephalin B-DNP
. O

the O
body O
responds O
to O
heroin O
in O
the O
brain O
by O
reducing O
( O
and O
sometimes O
stopping O
) O
production B-NEU
of I-NEU
the I-NEU
endogenous I-NEU
opioids I-NEU
when O
heroin O
is O
present O
. O

endorphins B-DNP
are O
regularly O
released O
in O
the O
brain B-DNP
and O
nerves B-DNP
, O
attenuating O
pain B-NEG
. O

their O
other O
functions O
are O
still O
obscure O
, O
but O
are O
probably O
related O
to O
the O
effects O
produced O
by O
heroin O
besides O
analgesia B-NEU
( O
antitussin O
, O
anti-diarrheal O
) O
. O

-DOCSTART- O

uncaria O
hook O
( O
uh O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
yokukansan O
. O

however O
, O
the O
pharmacokinetics O
of O
uh O
alkaloids O
after O
oral O
administration O
of O
yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
lc/ms/ms O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
uh O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

after O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
ascentis O
express O
rp-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
ml/min O
. O

all O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

the O
validated O
lc/ms/ms O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
uh O
alkaloids O
after O
oral O
administration O
of O
yokukansan O
to O
rats O
. O

in O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

these O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
yokukansan O
. O

-DOCSTART- O

wind-damp B-NEG
bone I-NEG
pain I-NEG
, O
knocks O
and O
falls O
, O
bleeding B-NEG
due O
to O
external O
injury B-NEG
, O
child O
gan O
accumulation O
. O

-DOCSTART- O

dalfopristin O
inhibits O
the O
early O
phase O
of O
protein B-NEU
synthesis I-NEU
by O
acting O
on O
bacterial O
ribosome O
. O
quinupristin O
binds O
to O
a O
nearby O
site O
on O
the O
50s O
ribosomal O
subunit O
and O
prevents O
elongation O
of O
the O
polypeptide O
as O
well O
as O
causing O
incomplete O
chains O
to O
be O
released O
. O

-DOCSTART- O

to O
eliminate O
phlegm B-NEG
( O
powder O
insufflation O
for O
pharyngitis B-NEG
and O
diphtheria B-NEG
) O
. O

-DOCSTART- O

liver B-NEG
cirrhosis I-NEG

-DOCSTART- O

nourish O
bone B-DNP
marrow I-DNP

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
quicken O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

diarrhea B-NEG

dysentery B-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
woman O
, O
quality O
of O
life O
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
general O
woman O
, O
inflammation B-NEG
, O
others O
, O
hemostatic B-POS
function I-POS

-DOCSTART- O

to O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
. O

-DOCSTART- O

1 O
oral O
administration O
increases O
the O
level O
of O
camp B-DNP
and O
decrease O
the O
level B-NEU
of I-NEU
cgmp I-NEU
in O
plasma O
and O
in O
leukocytes O
. O
protect O
the O
liver B-DNP
from O
damage O
. O
hypotensive B-NEG
. O

-DOCSTART- O

overactive B-NEG
bladder I-NEG
( O
oab B-NEG
) O

-DOCSTART- O

it O
contains O
polysaccharide O
and O
polypeptide O
mainly O
. O

1 O
inhibiting O
synthesis B-NEU
of I-NEU
dna I-NEU
and I-NEU
rna I-NEU
in O
cancer O
cells O
. O

2 O
inhibiting O
sarcoma180 B-NEG
and O
ehrlich-ascites B-NEG
tumor I-NEG
in O
vitro O
. O

-DOCSTART- O

infant B-NEG
, I-NEG
newborn I-NEG
, I-NEG
diseases I-NEG

-DOCSTART- O

vomiting B-NEG
and O
diarrhea B-NEG

-DOCSTART- O

childhood B-NEG
t I-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

liver B-DNP
health I-DNP
, O
liver B-DNP
. O

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
with O
chest B-NEG
congested I-NEG

-DOCSTART- O

used O
in O
the O
treatment O
of O
rheumatoid B-NEG
arthritis I-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
mimmuietabolic B-NEU
rate I-NEU
/ I-NEU
energy I-NEU
expenditure I-NEU

-DOCSTART- O

to O
kill O
worms B-NEG
. O

-DOCSTART- O

wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
pain B-NEG
from O
arthritis O
, O
painful O
swelling B-NEG
from O
knocks O
and O
falls O
, O
amenorrhea B-NEG
, O
dysmenorrhea B-NEG
, O
swollen B-NEG
welling I-NEG
abscess I-NEG
, O
erysipelas B-NEG
, O
goose-foot B-NEG
wind I-NEG
, O
snake B-NEG
or I-NEG
insect I-NEG
bites I-NEG
. O

-DOCSTART- O

for O
desolving O
phlegm B-NEG
, O
stopping O
cougth B-NEG
, O
and O
soothing O
breathing B-NEU

-DOCSTART- O

to O
dissipate O
cold B-NEG
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
and O
disinhibit O
damp B-NEU
. O

-DOCSTART- O

cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-NEG
, O
cold O
mounting O
with O
abdominal B-NEG
pain I-NEG
, O
menstrual O
disorder O
. O

-DOCSTART- O

1 O
for O
cases O
of O
metrorrhagia B-NEG
attributive O
to O
failure O
of O
the O
spleen B-DNP
to O
control O
blood B-DNP
, O
subtract O
aucklandiae O
and O
polygalae O
and O
add O
fructus O
corni O
to O
nourish O
liver B-DNP
and O
stop O
metrorrhagia B-NEG
. O
2 O
for O
cases O
with O
bloody B-NEG
stools I-NEG
attributive O
to O
hypofunction B-NEG
of I-NEG
spleen I-NEG
with O

-DOCSTART- O

schizophrenia B-NEG

-DOCSTART- O

pyogenic B-NEG
infections I-NEG
due O
to O
furuncle B-NEG

-DOCSTART- O

venous B-NEG
insufficiency I-NEG

-DOCSTART- O

treatment O
of O
measles B-NEG
without O
adequate O
eruption B-NEG
, O
urticaria B-NEG
with O
itching B-NEG
, O
edema B-NEG
with O
oliguria B-NEG
. O

-DOCSTART- O

to O
replenish O
the O
kidney B-DNP
, O
to O
strengthen O
the O
bones B-DNP
, O
to O
promote O
the O
healing B-POS
of I-POS
fracture I-POS
, O
and O
to O
relieve O
pain B-NEG
. O

-DOCSTART- O

methotrexate B-NEU
anti-tumor I-NEU
activity I-NEU
is O
a O
result O
of O
the O
inhibition O
of O
folic B-DNP
acid I-DNP
reductase I-DNP
, O
leading O
to O
inhibition O
of O
dna B-NEU
synthesis I-NEU
and O
inhibition O
of O
cellular B-NEU
replication I-NEU
. O

tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
rars O
) O
, O
thereby O
inducing O
changes B-NEU
in I-NEU
gene I-NEU
expression I-NEU
that O
lead O
to O
cell B-NEU
differentiation I-NEU
, O
decreased O
cell B-NEU
proliferation I-NEU
, O
and O
inhibition O
of O
tumorigenesis B-NEG
. O

mercaptopurine O
inhibits O
nucleotide B-NEU
interconversions I-NEU
and O
de O
novo O
purine B-NEU
synthesis I-NEU
, O
thereby O
blocking O
the O
formation B-NEU
of I-NEU
purine I-NEU
nucleotides I-NEU
and O
inhibiting O
dna B-NEU
synthesis I-NEU
. O

idarubicin O
intercalates O
into O
dna B-NEU
and O
interferes O
with O
the O
activity B-NEU
of I-NEU
topoisomerase I-NEU
ii I-NEU
, O
thereby O
inhibiting O
dna B-NEU
replication I-NEU
, O
rna B-NEU
transcription I-NEU
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

flaccidity B-NEG
and O
limping B-NEG

-DOCSTART- O

to O
soothe O
liver B-DNP
and O
clear O
heat B-NEU
; O
to O
constrain O
qi O
and O
strengthen O
spleen B-DNP
; O
to O
calm O
spirit B-DNP

-DOCSTART- O

vertigo B-NEG
due O
to O
wind-phlegm B-NEG

-DOCSTART- O

promote O
water O
and O
purge O
/ O
relieve O
toxicity B-NEG
and O
alleviate O
edema B-NEG

-DOCSTART- O

kidney O
transplantation O

-DOCSTART- O

this O
is O
carbuncle B-NEG
and O
cellulites B-NEU
occurred I-NEU
on I-NEU
the I-NEU
back I-NEU
. O

-DOCSTART- O

this O
is O
a O
syndrome O
with O
poor B-NEG
appetite I-NEG
, O
vomiting B-NEG
, O
and O
diarrhea B-NEG
due O
to O
various O
reasons O
. O

-DOCSTART- O

fever B-NEG

-DOCSTART- O

the O
body O
is O
fatigued O
and O
cannot O
walk O
because O
of O
a O
flaccidity B-NEG
of I-NEG
lower I-NEG
limbs I-NEG

-DOCSTART- O

1 O
its O
decoction O
enhances O
th O
intestinal B-NEU
contraction I-NEU
and O
tensity O
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O
2 O
. O
inhibiting O
the O
growth O
of O
sarcoma B-NEG
180 I-NEG
in O
mice O
. O

-DOCSTART- O

infection B-NEG
of O
upper O
respiratory O
tract O
, O
pneumonia B-NEG
, O
acute B-NEG
gastroenteritis I-NEG
, O
dysentery B-NEG
, O
sore B-NEG
and O
boil B-NEG
, O
scab B-NEG
and O
lichen B-NEG
, O
eczema B-NEG
, O
burns B-NEG
and O
scalds B-NEG
, O
infection B-NEG
of O
biliary O
tract O
, O
poisonous B-NEG
insect I-NEG
stings I-NEG
. O

-DOCSTART- O

vomiting B-NEG
of O
milk O

-DOCSTART- O

papule B-NEG

-DOCSTART- O

gastric B-NEG
varices I-NEG

-DOCSTART- O

docetaxel O
binds O
to O
microtubules O
reversibly O
with O
high O
affinity O
, O
which O
stabilises O
microtubules O
and O
prevents O
depolymerisation O
from O
calcium O
ions O
, O
decreased B-NEG
temperature I-NEG
and O
dilution B-NEG
, O
preferentially O
at O
the O
plus O
end O
of O
the O
microtubule O
. O

irinotecan O
, O
a O
prodrug O
, O
is O
converted O
to O
a O
biologically O
active O
metabolite O
7-ethyl-10-hydroxy-camptothecin O
( O
sn-38 O
) O
by O
a O
carboxylesterase-converting O
enzyme O
. O

sn-38 O
inhibits O
topoisomerase B-NEU
i I-NEU
activity I-NEU
by O
stabilizing O
the O
cleavable O
complex O
between O
topoisomerase B-DNP
i I-DNP
and O
dna B-DNP
, O
resulting O
in O
dna B-NEU
breaks I-NEU
that O
inhibit O
dna B-NEU
replication I-NEU
and O
trigger O
apoptotic B-NEU
cell I-NEU
death I-NEU
. O

-DOCSTART- O

pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-DNP
synthase I-DNP
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
dna B-NEU
synthesis I-NEU
. O

abt-751 O
binds O
to O
the O
colchicine-binding O
site O
on O
beta-tubulin O
and O
inhibits O
the O
polymerization O
of O
microtubules O
, O
thereby O
preventing O
tumor B-NEG
cell I-NEG
replication I-NEG
. O

-DOCSTART- O

exhaustion B-NEG
syndrome I-NEG
; O

consumption B-NEG
; O

exhaustion B-NEG
of I-NEG
strength I-NEG
; O

overstrain B-NEG
; O

asthenic B-NEG
disease I-NEG
; O

weakness B-NEG
and O
fatigue B-NEG

-DOCSTART- O

1 O
aloperine O
inhibits O
exudative B-NEG
inflammation I-NEG
and O
hemolysis B-NEG
of O
red O
blood B-DNP
cells O
2 O
. O
its O
decoction O
or O
sophocarpine O
relieves O
asthma B-NEG
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O
3 O
. O
sophocarpine O
or O
matrine O
inhibits O
sarcoma180 B-NEG
in O
vitro O
. O

-DOCSTART- O

fluid B-NEG
retention I-NEG
; O

phlegm B-NEG
and O
retained B-NEG
fluid I-NEG
; O

congested B-NEG
fluids I-NEG

-DOCSTART- O

[case O
of O
pneumonitis B-NEG
caused O
by O
yokukansan] O
. O

-DOCSTART- O

numbness B-NEG
of O
the O
limbs O

-DOCSTART- O

major B-NEG
depressive I-NEG
disorder I-NEG

-DOCSTART- O

warm O
large B-DNP
intestine I-DNP

-DOCSTART- O

coronary O
artery O
bypass O
graft O
redo O

-DOCSTART- O

dispel O
wind B-NEG
and O
drain O
dampness B-NEG

-DOCSTART- O

to O
invigorate O
blood B-DNP
and O
stop O
pain B-NEG
. O

-DOCSTART- O

1 O
to O
reduce O
heat B-NEU
caused O
by O
deficient O
yin O
; O
2 O
to O
clear O
heat B-NEU
in O
infants O
caused O
by O
malnutrition B-NEG

-DOCSTART- O

digestant O
. O

-DOCSTART- O

move O
stasis B-NEG

-DOCSTART- O

restore O
depression B-NEG
and O
dissipate O
bind O

-DOCSTART- O

profuse B-NEG
metrorrhagia I-NEG

-DOCSTART- O

chronic B-NEG
hepatitis I-NEG

-DOCSTART- O

lymphoma B-NEG
, I-NEG
lymphoblastic I-NEG

-DOCSTART- O

a O
symptom O
of O
not O
vomiting B-NEG
despite O
nausea B-NEG

-DOCSTART- O

swelling B-NEG
of O
the O
foot O
; O
edema B-NEG
of O
foot O

-DOCSTART- O

kampo O
medicines O
are O
currently O
manufactured O
under O
strict O
quality O
controls O
. O

the O
ministry O
of O
health O
, O
labour O
and O
welfare O
of O
japan O
has O
approved O
148 O
kampo O
formulas O
. O

there O
is O
increasing O
evidence O
for O
the O
efficacy O
of O
kampo O
medicines O
, O
and O
some O
are O
used O
clinically O
for O
palliative O
care O
in O
japan O
. O

the O
specific O
aim O
of O
this O
review O
is O
to O
evaluate O
the O
clinical O
use O
of O
kampo O
medicines O
in O
palliative O
care O
in O
the O
treatment O
of O
cancer O
. O

the O
conclusions O
are O
as O
follows O
: O
juzentaihoto O
inhibits O
the O
progression O
of O
liver B-NEG
tumors I-NEG
in O
a O
dose-dependent O
manner O
and O
contributes O
to O
long-term O
survival O
. O

hochuekkito O
has O
clinical O
effects O
on O
cachexia B-NEG
for O
genitourinary B-NEG
cancer I-NEG
and O
improves O
the O
qol O
and O
immunological B-NEU
status I-NEU
of O
weak O
patients O
, O
such O
as O
postoperative O
patients O
. O

daikenchuto O
increases O
intestinal B-NEU
motility I-NEU
and O
decreases O
the O
postoperative B-NEG
symptoms I-NEG
of O
patients O
with O
total O
gastrectomy O
with O
jejunal O
pouch O
interposition O
, O
suppresses O
postoperative O
inflammation B-NEG
following O
surgery O
for O
colorectal B-NEG
cancer I-NEG
, O
and O
controls O
radiation-induced O
enteritis B-NEG
. O

rikkunshito O
contributes O
to O
the O
amelioration O
of O
anorectic B-NEG
conditions I-NEG
in O
cancer B-NEG
cachexia-anorexia I-NEG
syndrome I-NEG
. O

goshajinkigan O
and O
shakuyakukanzoto O
reduce O
the O
neurotoxicity B-NEG
of O
patients O
with O
colorectal B-NEG
cancer I-NEG
who O
undergo O
oxaliplatin O
and O
folfox O
( O
5-fluorouracil/folinic O
acid O
plus O
oxaliplatin O
) O
therapy O
. O

hangeshashinto O
has O
the O
effect O
of O
preventing O
and O
alleviating O
diarrhea B-NEG
induced O
by O
cpt-11(irinotecan O
) O
and O
combination O
therapy O
with O
s-1/cpt-11 O
. O

o'rengedokuto O
significantly O
improves O
mucositis B-NEG
caused O
by O
anticancer B-POS
agents O
. O

-DOCSTART- O

miasma O
1 O
pestilential B-NEG
pathogene I-NEG
2 O
malaria B-NEG

-DOCSTART- O

blockade O
of O
dopaminergic O
d2 O
receptors O
in O
the O
limbic B-DNP
system I-DNP
alleviates O
positive O
symptoms O
of O
schizophrenia B-NEG
such O
as O
hallucinations B-NEG
, O
delusions B-NEG
, O
and O
erratic B-NEG
behavior I-NEG
and O
speech O
. O

blockade O
of O
serotonergic O
5-ht O
2 O
receptors O
in O
the O
mesocortical B-DNP
tract I-DNP
, O
causes O
an O
excess O
of O
dopamine O
and O
an O
increase O
in O
dopamine O
transmission O
, O
resulting O
in O
an O
increase O
in O
dopamine O
transmission O
and O
an O
elimination O
of O
core O
negative O
symptoms O
. O

dopamine O
receptors O
in O
the O
nigrostriatal O
pathway O
are O
not O
affected O
by O
risperidone O
and O
extrapyramidal O
effects O
are O
avoided O
. O

like O
other O
5-ht O
2 O
antagonists O
, O
risperidone O
also O
binds O
at O
alpha(1)-adrenergic O
receptors O
and O
, O
to O
a O
lesser O
extent O
, O
at O
histamine O
h1 O
and O
alpha(2)-adrenergic O
receptors O
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
absorption B-NEU
, O
lipid O
profile O
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
strength B-POS
and O
power B-POS
, O
others O
, O
motility B-NEU

-DOCSTART- O

promoting O
bile B-NEU
secretion I-NEU
. O

-DOCSTART- O

expel O
pus B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

angiotensin B-DNP
ii I-DNP
is O
a O
small O
hormone O
in O
the O
body O
and O
part O
of O
the O
ras B-DNP
. O

-DOCSTART- O

treatment O
of O
menstrual B-NEG
disorders I-NEG
, O
anemia B-NEG
, O
numbness B-NEG
and O
paralysis B-NEG
, O
rheumatic B-NEG
arthralgia I-NEG
. O

-DOCSTART- O

spitting B-NEG
pus I-NEG
and I-NEG
blood I-NEG

-DOCSTART- O

attack O
and O
expel O

-DOCSTART- O

disperse O
cold B-NEG

-DOCSTART- O

cough B-NEG
and O
asthma B-NEG
, O
fright O
epilepsy B-NEG
, O
wind-cold-damp B-NEG
impediment I-NEG
, O
dysentery B-NEG
, O
prolapse B-NEG
of I-NEG
rectum I-NEG
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

promote O
liquid O

-DOCSTART- O

pregnancy B-NEG
in I-NEG
diabetics I-NEG

-DOCSTART- O

treatment O
of O
epistaxis B-NEG
, O
spitting B-NEG
of I-NEG
blood I-NEG
, O
hematuria B-NEG
, O
hematochezia B-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
. O

-DOCSTART- O

cough B-NEG

-DOCSTART- O

phlegm-retention B-NEG
syndrome I-NEG
; O
congested O
fluids O
; O
retention B-NEG
of I-NEG
phlegm I-NEG
and O
fluid O
( O
1 O
) O
morbid B-NEG
conditions I-NEG
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, O
spleen B-DNP
md O
kidney B-DNP
or O
from O
disturbance B-NEG
of I-NEG
water I-NEG
circulation I-NEG
in O
the O
passage O
of O
triple O
ch'o O
. O

the O
thicker O
dampness B-NEG
is O
called O
phlegm O
, O
while O
the O
thinner O
fluid O
. O

retention B-NEG
of I-NEG
phlegm I-NEG
and O
fluid O
can O
give O
rise O
to O
various O
diseases B-NEG
, O
one O
of O
the O
four O
kinds O
of O
fluid B-NEG
retention I-NEG
. O

( O
2 O
) O
a O
morbid B-NEG
condition I-NEG
due O
to O
fluid B-NEG
retention I-NEG
in O
the O
stomach O
and O
intestines O
. O

-DOCSTART- O

inner O
impairment B-NEG

-DOCSTART- O

this O
is O
running O
a O
fever B-NEG
due O
to O
epidemic B-NEG
. O

-DOCSTART- O

simvastatin O
competitively O
inhibits O
hmg-coa O
reductase O
, O
lowers O
plasma O
cholesterol O
and O
lipoprotein O
levels O
, O
and O
modulates O
immune B-NEU
responses I-NEU
by O
suppressing O
mhc O
ii O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting B-DNP
cells I-DNP
such O
as O
human B-DNP
vascular I-DNP
endothelial I-DNP
cells I-DNP
. O
sitagliptin O
is O
a O
highly O
selective O
dpp-4 O
inhibitor O
, O
and O
increases O
insulin O
release O
and O
decreases O
glucagon O
levels O
in O
the O
circulation O
in O
a O
glucose-dependent O
manner O
. O

-DOCSTART- O

to O
have O
skin B-NEG
rashes I-NEG
due O
to O
epidemic B-NEG
febrile I-NEG

-DOCSTART- O

promoting O
phagocytosis B-NEU
of I-NEU
macrophage I-NEU
. O

-DOCSTART- O

painful O
urinary B-NEG
dysfunction I-NEG
; O
stranguria B-NEG
a O
syndrome O
characterized O
by O
frequent O
, O
painful B-NEG
and I-NEG
dripping I-NEG
urination I-NEG
. O

-DOCSTART- O

human B-NEG
immunodeficiency I-NEG
virus I-NEG
infection I-NEG

-DOCSTART- O

antiviral O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
b I-NEG

-DOCSTART- O

ulcer B-NEG

-DOCSTART- O

cyclandelate O
produces O
peripheral B-NEU
vasodilation I-NEU
by O
a O
direct O
effect O
on O
vascular B-DNP
smooth I-DNP
muscle I-DNP
. O

pharmacological O
action O
may O
be O
due O
to O
calcium-channel O
antagonism O
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
liver B-DNP
, O
liver B-DNP
health I-DNP

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
infectious B-NEG
and O
parasitic B-NEG
disease I-NEG
( O
unspecified O
) O
and O
pediatric O
indications O
. O

-DOCSTART- O

norepinephrine O
functions O
as O
a O
peripheral O
vasoconstrictor O
by O
acting O
on O
alpha-adrenergic O
receptors O
. O

it O
is O
also O
an O
inotropic O
stimulator O
of O
the O
heart B-DNP
and O
dilator O
of O
coronary B-NEG
arteries I-NEG
as O
a O
result O
of O
it's O
activity O
at O
the O
beta-adrenergic O
receptors O
. O

-DOCSTART- O

childhood B-NEG
acute I-NEG
erythroid I-NEG
leukemia I-NEG

-DOCSTART- O

1 O
inhibiting O
experimental O
arthritis B-NEG
in O
mice O
and O
decreasing O
capillary B-NEU
permeability I-NEU
. O

2 O
. O
anti-allergric B-NEU
. O

3 O
. O
inducing O
transient O
hypotensive B-NEG
effect I-NEG
. O

-DOCSTART- O

the O
target O
of O
lx6171 O
is O
a O
membrane B-DNP
protein I-DNP
that O
is O
expressed O
exclusively O
in O
the O
central B-DNP
nervous I-DNP
system I-DNP
. O

its O
activity O
is O
associated O
with O
synaptic B-DNP
vesicles I-DNP
and O
presynaptic B-DNP
membranes I-DNP
. O

-DOCSTART- O

enfuvirtide O
binds O
to O
the O
first O
heptad-repeat B-DNP
( O
hr1 O
) O
in O
the O
gp41 O
subunit O
of O
the O
viral O
envelope O
glycoprotein O
and O
prevents O
the O
conformational B-NEU
changes I-NEU
required O
for O
the O
fusion O
of O
viral O
and O
cellular B-DNP
membranes I-DNP
. O

it O
works O
by O
disrupting O
the O
hiv-1 B-NEG
molecular I-NEG
machinery I-NEG
at O
the O
final O
stage O
of O
fusion O
with O
the O
target O
cell O
, O
preventing O
uninfected B-DNP
cells I-DNP
from O
becoming O
infected O
. O

enfuvirtide O
is O
a O
biomimetic O
peptide O
that O
was O
rationally O
designed O
to O
mimic O
components O
of O
the O
hiv-1 B-NEU
fusion I-NEU
machinery O
and O
displace O
them O
, O
preventing O
normal O
fusion B-NEU
. O

-DOCSTART- O

toxoplasmosis B-NEG

-DOCSTART- O

treatment O
of O
jaundice B-NEG
caused O
by O
damp-heat B-NEG
, O
heat B-NEG
stroke I-NEG
with O
diarrhea B-NEG
, O
urolithiasis B-NEG
and O
hematuria B-NEG
, O
carbuncles B-NEG
and O
boils B-NEG
, O
traumatic B-NEG
injuries I-NEG
. O

-DOCSTART- O

distribution O
) O
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU

-DOCSTART- O

cold B-NEG
and O
heat B-NEG
; O

cold B-NEG
syndrome I-NEG
and O
heat B-NEG
syndrome I-NEG
two O
of O
the O
eight O
principles O
in O
analysing O
and O
differentiating O
pathological O
conditions O
; O

cold B-NEG
caused O
by O
excess O
of O
eum O
, O
and O
heat B-NEG
caused O
by O
excess O
of O
yang O
. O

chills B-NEG
and O
fever B-NEG

cold B-NEG
pathogene I-NEG
and O
heat B-NEG
pathogene I-NEG

-DOCSTART- O

treatment O
of O
mass B-NEG
in O
the O
abdomen O
, O
goitre B-NEG
with O
pain B-NEG
, O
epigastric B-NEG
pain I-NEG
and O
distension B-NEG
due O
to O
indigestion B-NEG
. O

-DOCSTART- O

to O
relieve O
cough B-NEG
and O
dyspnea B-NEG
, O
and O
eliminate O
retained O
phlegm B-NEG
. O

-DOCSTART- O

denosumab O
is O
designed O
to O
target O
rankl B-DNP
( O
rank B-DNP
ligand I-DNP
) O
, O
a O
protein O
that O
acts O
as O
the O
primary O
signal O
to O
promote O
bone B-NEG
removal/resorption I-NEG
. O

in O
many O
bone B-NEG
loss I-NEG
conditions O
, O
rankl B-DNP
overwhelms O
the O
body's O
natural O
defense O
against O
bone B-NEG
destruction I-NEG
. O

denosumab O
prevents O
rankl B-DNP
from O
activating O
its O
receptor O
, O
rank B-DNP
, O
on O
the O
surface O
of O
osteoclasts B-DNP
and O
their O
precursors O
. O

prevention O
of O
the O
rankl/rank B-DNP
interaction O
inhibits O
osteoclast B-DNP
formation O
, O
function O
, O
and O
survival O
, O
thereby O
decreasing O
bone B-NEG
resorption I-NEG
and O
increasing O
bone B-NEU
mass I-NEU
and O
strength O
in O
both O
cortical B-DNP
and I-DNP
trabecular I-DNP
bone I-DNP
. O

-DOCSTART- O

recurrent O
childhood B-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

anal B-NEG
fistula I-NEG
hemorrhoids I-NEG
complicated O
by O
anal B-NEG
fistula I-NEG
. O

-DOCSTART- O

pain B-NEG
and I-NEG
swelling I-NEG
of I-NEG
testis I-NEG

-DOCSTART- O

chest O
and O
hypochondriac O
pain O

-DOCSTART- O

to O
drain O
the O
pus B-NEG
and O
relieve O
swelling B-NEG
( O
external O
use O
for O
various O
kinds O
of O
severe O
skin B-NEG
lesions I-NEG
; O
oral O
use O
of O
crotonis O
fried O
yellow O
wax O
for O
bone B-NEG
tuberculosis I-NEG
and O
osteomyelitis B-NEG
) O
. O

-DOCSTART- O

regulate O
menstruation B-NEU

-DOCSTART- O

an O
inhibition O
of O
dna B-DNP
polymerase I-DNP
. O

-DOCSTART- O

to O
promote O
blood B-DNP
circulation I-DNP
, O
remove O
blood B-NEG
stasis I-NEG
, O
restore O
consciousness B-NEU
, O
remove O
obstruction B-NEG
in O
the O
channels O
, O
suppress O
the O
hyperfunction O
of O
liver-yang O
and O
stop O
endogenous B-NEG
wind I-NEG
to O
relieve O
convulsion B-NEG
. O

-DOCSTART- O

promote O
the O
intestine B-DNP

-DOCSTART- O

bone B-NEU
health I-NEU
and O
osteoporosis B-NEG
, O
woman O
, O
bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
menopausal B-NEG
woman I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
heat B-NEU
; O
heat-type B-NEG
stranguria I-NEG

-DOCSTART- O

tenesmus B-NEG

-DOCSTART- O

treatment O
of O
mass B-NEG
in O
the O
abdomen O
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
abdominal B-NEG
distension I-NEG
and O
pain B-NEG
caused O
by O
retention O
of O
undigested O
food O
. O

-DOCSTART- O

to O
benefit O
qi O
; O
to O
soothe O
stomach B-DNP
; O
to O
reduce O
lump B-NEG
; O
to O
stop O
vomiting B-NEG

-DOCSTART- O

this O
is O
a O
symptom O
with O
bleeding B-NEG
in O
the O
gum O
and O
root O
of O
tooth O
that O
comes O
out O
of O
the O
gums O
caused O
by O
a O
crack B-NEG
of I-NEG
the I-NEG
gum I-NEG
. O

-DOCSTART- O

ovarian B-NEG
hyperstimulation I-NEG
syndrome I-NEG

-DOCSTART- O

urinary B-NEG
incontinence I-NEG
; O
galacturia B-NEG
; O
stranguria B-NEG
with O
chyluria B-NEG
; O
stranguria B-NEG
marked O
by O
chyluria B-NEG

-DOCSTART- O

( O
1 O
) O
tangling O
up O
of O
intestine O
; O
accumulation O
of O
pathogenic O
factor O
in O
viscera O
( O
2 O
) O
accumulation O
of O
eum O
cold B-NEG
in O
viscera O
one O
of O
the O
symptoms O
in O
soeumin O
( O
marked O
by O
hard O
mass O
on O
the O
right O
side O
of O
the O
epigastrium O
. O
the O
prognosis O
is O
not O
hopeful O
. O

-DOCSTART- O

sore B-NEG
; O
pain B-NEG
; O
to O
ache B-NEG

-DOCSTART- O

yellowish B-NEG
complexion I-NEG

-DOCSTART- O

malaria B-NEG
infection I-NEG

-DOCSTART- O

milnacipran O
is O
used O
to O
treat O
moderate O
to O
severe O
clinical B-NEG
depression I-NEG
but O
this O
indication O
is O
not O
yet O
fda-approved O
in O
the O
usa O
. O

milnacipran O
is O
labelled O
for O
the O
treatment O
of O
fibromyalgia B-NEG
pain I-NEG
. O

-DOCSTART- O

delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O

treatment O
of O
chills B-NEG
, O
fever B-NEG
and O
headache B-NEG
in O
colds B-NEG
and O
influenza B-NEG
, O
vexation B-NEG
, O
oppressed B-NEG
feeling I-NEG
in O
the O
chest O
and O
insomnia B-NEG
. O

-DOCSTART- O

general O
anesthetic O
drug O
adverse O
reaction O

-DOCSTART- O

this O
is O
damp-arthritis B-NEG
caused O
by O
apoplectoid B-NEG
syndrome I-NEG
. O

-DOCSTART- O

saengmaeksan O
inhibits O
inflammatory O
mediators O
by O
suppressing O
rip-2 B-NEU
/ I-NEU
caspase-1 I-NEU
activation I-NEU
. O

-DOCSTART- O

hepatitis B-NEG
b I-NEG
infection I-NEG

-DOCSTART- O

cardiac B-NEG
output I-NEG
, I-NEG
low I-NEG

-DOCSTART- O

nepafenac O
is O
a O
prodrug O
. O

after O
penetrating O
the O
cornea O
, O
nepafenac O
undergoes O
rapid O
bioactivation O
to O
amfenac O
, O
which O
is O
a O
potent O
nsaid O
that O
uniformly O
inhibits O
the O
cox1 B-DNP
and I-DNP
cox2 I-DNP
activity I-DNP
. O

-DOCSTART- O

tourette B-NEG
disorder I-NEG

-DOCSTART- O

to O
eliminate O
toxic B-NEG
material I-NEG
, O
promote O
pus B-POS
drainage I-POS
and O
remove O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

hemiplegia B-NEG

-DOCSTART- O

amenorrhea B-NEG
; O
menstrual B-NEG
block I-NEG
absence I-NEG
or O
suppression B-NEG
of I-NEG
menstruation I-NEG
. O

-DOCSTART- O

retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
; O
dyspepsia B-NEG

-DOCSTART- O

adhd B-NEG

-DOCSTART- O

both O
acted O
at O
the O
same O
active O
site O
of O
penicillinbinding O
protein O
2a O
but O
at O
relatively O
high O
mics O
of O
32 O
g/ml O
. O

the O
relatively O
high O
mics O
make O
it O
less O
likely O
for O
both O
drugs O
to O
saturate O
target O
sites O
, O
thereby O
maintaining O
additive O
antibacterial B-POS
effect I-POS
. O

-DOCSTART- O

major O
cold B-NEG
and O
heat B-NEU

-DOCSTART- O

treatment O
of O
stroke B-NEG
with O
gurgling B-NEG
in I-NEG
the I-NEG
throat I-NEG
, O
deviation B-NEG
of I-NEG
the I-NEG
eye I-NEG
and I-NEG
the I-NEG
mouth I-NEG
, O
and O
impairment B-NEG
of I-NEG
speech I-NEG
, O
upward O
invasion O
of O
phlegm B-NEG
causing O
headache B-NEG
accompanied O
with O
dizziness B-NEG
, O
heaviness B-NEG
of I-NEG
the I-NEG
body I-NEG
, O
restlessness B-NEG
, O
fidgetness B-NEG
, O
nausea B-NEG
and O
cold B-NEG
extremities I-NEG
, O
or O
migraine B-NEG
, O
sore B-NEG
throat I-NEG
, O
tetanus B-NEG
, O
external O
use O
for O
scrofula B-NEG
, O
venomous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

to O
soothe O
the O
liver B-DNP
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-NEU
and O
toxic O
materials O
. O

-DOCSTART- O

pain B-NEG
from I-NEG
cramped I-NEG
tendons I-NEG
and I-NEG
bones I-NEG